=== МЕТАДАННЫЕ ===
{
  "original_filename": "ehac270.pdf",
  "converted_date": "2026-01-31T14:45:01.887211",
  "file_size_bytes": 7469860,
  "original_format": "pdf",
  "document_type": "Guidelines",
  "source_folder": "Guidelines",
  "full_path": "00_RAW_CARDIOLOGY/Guidelines/ehac270.pdf"
}

=== СОДЕРЖАНИЕ ===

--- Страница 1 ---
ESC GUIDELINES
EuropeanHeartJournal(2022)43,3826–3924
https://doi.org/10.1093/eurheartj/ehac270
2022 ESC Guidelines on cardiovascular
assessment and management of patients
undergoing non-cardiac surgery
Developed by the task force for cardiovascular assessment and
management of patients undergoing non-cardiac surgery of the
European Society of Cardiology (ESC)
Endorsed by the European Society of Anaesthesiology and
Intensive Care (ESAIC)
Authors/Task Force Members: Sigrun Halvorsen
*†
(Chairperson) (Norway),
Julinda Mehilli *† (Chairperson) (Germany), Salvatore Cassese** (Task Force
Coordinator) (Germany), Trygve S. Hall** (Task Force Coordinator) (Norway),
Magdy Abdelhamid (Egypt), Emanuele Barbato (Italy/Belgium), Stefan De Hert1
(Belgium),IngriddeLaval(Sweden),TobiasGeisler(Germany),LynneHinterbuchner
ł
(Austria), Borja Ibanez (Spain), Radosaw Lenarczyk (Poland), Ulrich R. Mansmann
(Germany), Paul McGreavy (United Kingdom), Christian Mueller (Switzerland),
ClaudioMuneretto(Italy),AlexanderNiessner(Austria),TatjanaS.Potpara(Serbia),
ć
Arsen Risti (Serbia), L. Elif Sade (United States of America/Turkey),
Henrik Schirmer (Norway), Stefanie Schüpke (Germany), Henrik Sillesen
(Denmark), Helge Skulstad (Norway), Lucia Torracca (Italy), Oktay Tutarel
(Germany), Peter Van Der Meer (Netherlands), Wojtek Wojakowski (Poland),
Kai Zacharowski1 (Germany), and ESC Scientifi c Document Group
*Correspondingauthors:SigrunHalvorsen,DepartmentofCardiology,OsloUniversityHospitalUlleval,Oslo,Norway,andUniversityofOslo,Oslo,Norway.Tel.:+4791317460.
E-mail:sigrun.halvorsen@medisin.uio.no.
JulindaMehilli,Department:MedizinischeKlinikI,Landshut-AchdorfHospital,Landshut,Germany,KlinikumderUniversitätMünchen,Ludwig-Maximilians-UniversitätandGermanCentre
forCardiovascularResearch(DZHK),partnersiteMunichHeartAlliance,Munich,Germany.Tel.:+498714042782.E-mail:Julinda.mehilli@lakumed.de
†Thetwochairpersonscontributedequallytothedocumentandarejointcorrespondingauthors.
**ThetwoTaskForceCoordinatorscontributedequallytothedocument
Author/TaskForceMemberaffiliations:listedinauthorinformation.
1RepresentingtheEuropeanSocietyofAnaesthesiologyandIntensiveCare(ESAIC)
ESCClinicalPracticeGuidelines(CPG)CommitteelistedintheAppendix.
ESCsubspecialtycommunitieshavingparticipatedinthedevelopmentofthisdocument:
Associations:AssociationforAcuteCardioVascularCare(ACVC),AssociationofCardiovascularNursing&AlliedProfessions(ACNAP),EuropeanAssociationofCardiovascular
Imaging(EACVI),EuropeanAssociationofPercutaneousCardiovascularInterventions(EAPCI),EuropeanHeartRhythmAssociation(EHRA),andHeartFailureAssociation(HFA).
Councils:CouncilofCardio-OncologyandCouncilonValvularHeartDisease.
WorkingGroups:AdultCongenitalHeartDisease,AortaandPeripheralVascularDiseases,CardiovascularPharmacotherapy,CardiovascularSurgery,andThrombosis.
PatientForum
ThecontentoftheseEuropeanSocietyofCardiology(ESC)Guidelineshasbeenpublishedforpersonalandeducationaluseonly.Nocommercialuseisauthorized.NopartoftheESC
GuidelinesmaybetranslatedorreproducedinanyformwithoutwrittenpermissionfromtheESC.PermissioncanbeobtaineduponsubmissionofawrittenrequesttoOxfordUniversity
Press,thepublisheroftheEuropeanHeartJournal,andthepartyauthorizedtohandlesuchpermissionsonbehalfoftheESC(journals.permissions@oup.com).
Downloaded
from
https://academic.oup.com/eurheartj/article/43/39/3826/6675076
by
guest
on
22
January
2026
--- Страница 2 ---
ESCGuidelines 3827
Document-Reviewers:JuhaniKnuuti,(CPGReviewCoordinator)(Finland),SteenDalbyKristensen,(CPG
ReviewCoordinator)(Denmark),VictorAboyans(France),IngoAhrens(Germany),SotirisAntoniou(United
Kingdom),RiccardoAsteggiano(Italy),DanAtar(Norway),AndreasBaumbach(UnitedKingdom),
HelmutBaumgartner(Germany),MichaelBöhm(Germany),MichaelA.Borger(Germany),HectorBueno
(Spain),JelenaČelutkienė(Lithuania),AlaideChieffo(Italy),MayaCikes(Croatia),HaraldDarius(Germany),
VictoriaDelgado(Spain),PhilipJ.Devereaux(Canada),DavidDuncker(Germany),VolkmarFalk(Germany),
LaurentFauchier(France),GilbertHabib(France),DavidHasdai(Israel),KurtHuber(Austria),BernardIung
(France),TinyJaarsma(Sweden),AleksandraKonradi(RussianFederation),KonstantinosC.Koskinas
(Switzerland),DipakKotecha(UnitedKingdom),UlfLandmesser(Germany),BasilS.Lewis(Israel),AlesLinhart
(CzechRepublic),Maja-LisaLøchen(Norway),MichaelMaeng(Denmark),StéphaneManzo-Silberman(France),
RichardMindham(UnitedKingdom),LisNeubeck(UnitedKingdom),JensCosedisNielsen(Denmark),
SteffenE.Petersen(UnitedKingdom),EvaPrescott(Denmark),AminaRakisheva(Kazakhstan),AnttiSaraste
(Finland),DirkSibbing(Germany),JolantaSiller-Matula(Austria),MartaSitges(Spain),IvanStankovic(Serbia),
RobF.Storey(UnitedKingdom),JurrientenBerg(Netherlands),MatthiasThielmann(Germany),and
RhianM.Touyz(Canada/UnitedKingdom)
Allexpertsinvolvedinthedevelopmentoftheseguidelineshavesubmitteddeclarationsofinterest.Thesehave
beencompiledinareportandsimultaneouslypublishedinasupplementarydocumenttotheguidelines.The
reportisalsoavailableontheESCwebsitewww.escardio.org/Guidelines
SeetheEuropeanHeartJournalonlineforsupplementarydatathatincludebackgroundinformationand
detaileddiscussionofthedatathathaveprovidedthebasisoftheguidelines.
ClickheretoaccessthecorrespondingESCCardioMedchapters.
Keywords Guidelines (cid:129) Non-cardiacsurgery (cid:129) Pre-operativecardiacriskassessment (cid:129) Pre-operativecardiactesting (cid:129)
Biomarkers (cid:129) Pre-operativecoronaryarteryrevascularization (cid:129) Peri-operativecardiacmanagement (cid:129)
Anti-thrombotictherapy (cid:129) Peri-operativebeta-blockers (cid:129) Pre-operativetreatmentofvalvulardisease (cid:129) Peri-operative
treatmentofarrhythmias (cid:129) Post-operativecardiacsurveillance (cid:129) Peri-operativemyocardialinjury/infarction
Table of contents 3.2.1.1.Vascularandendovascularprocedures ................... 3843
3.2.1.2.Video-assistednon-cardiacsurgery........................... 3843
1.Preamble........................................................................................................ 3832 3.3.Patient-relatedrisk............................................................................ 3843
2.Introduction ................................................................................................. 3834 3.3.1.Initialassessment....................................................................... 3843
2.1.Whatisnew ........................................................................................ 3834 3.3.1.1.Patientsaged,65yearswithoutahistoryof
2.2.Themagnitudeoftheproblem................................................... 3839 cardiovasculardiseaseorcardiovascularriskfactors ........ 3843
2.3.Changeindemographics................................................................ 3840 3.3.1.2.Patientsaged≥65yearsorwithcardiovascularrisk
2.4.Purpose.................................................................................................. 3840 factors .................................................................................................... 3843
2.5.Theoutcomeswewanttoprevent.......................................... 3841 3.3.1.3.Patientswithestablishedcardiovasculardisease. 3844
3.Clinicalriskevaluation.............................................................................. 3841 3.3.2.Patientswithmurmurs,chestpain,dyspnoea,or
3.1.Surgery-relatedrisk .......................................................................... 3841 peripheraloedema ............................................................................... 3845
3.1.1.Timingofsurgery...................................................................... 3842 3.3.2.1.Murmurs ............................................................................... 3845
3.2.Typeofsurgicalapproach ............................................................. 3842 3.3.2.2.Chestpain ............................................................................ 3845
3.2.1.Laparoscopy................................................................................ 3842 3.3.2.3.Dyspnoea.............................................................................. 3845
Disclaimer:TheESCGuidelinesrepresenttheviewsoftheESCandwereproducedaftercarefulconsiderationofthescientificandmedicalknowledgeandtheevidenceavailableatthe
timeoftheirpublication.TheESCisnotresponsibleintheeventofanycontradiction,discrepancy,and/orambiguitybetweentheESCGuidelinesandanyotherofficialrecommendations
orguidelinesissuedbytherelevantpublichealthauthorities,particularlyinrelationtogooduseofhealthcareortherapeuticstrategies.Healthprofessionalsareencouragedtotakethe
ESCGuidelinesfullyintoaccountwhenexercisingtheirclinicaljudgment,andinthedeterminationandtheimplementationofpreventive,diagnostic,ortherapeuticmedicalstrategies;
however,theESCGuidelinesdonotoverride,inanywaywhatsoever,theindividualresponsibilityofhealthprofessionalstomakeappropriateandaccuratedecisionsinconsiderationof
eachpatient’shealthconditionandinconsultationwiththatpatientand,whereappropriateand/ornecessary,thepatient’scaregiver.TheESCGuidelinesdonotexempthealthprofes-
sionalsfromtakingintofullandcarefulconsiderationtherelevantofficialupdatedrecommendationsorguidelinesissuedbythecompetentpublichealthauthorities,inordertomanage
eachpatient’scaseinlightofthescientificallyaccepteddatapursuanttotheirrespectiveethicalandprofessionalobligations.Itisalsothehealthprofessional’sresponsibilitytoverifythe
applicablerulesandregulationsrelatingtodrugsandmedicaldevicesatthetimeofprescription.
©TheEuropeanSocietyofCardiology2022.Allrightsreserved.Forpermissionspleasee-mail:journals.permissions@oup.com
Downloaded
from
https://academic.oup.com/eurheartj/article/43/39/3826/6675076
by
guest
on
22
January
2026
--- Страница 3 ---
3828 ESCGuidelines
3.3.2.4.Peripheraloedema ........................................................... 3845 5.3.2.2.6.Whentorestartnon-vitaminKantagonistoral
3.4.Timingofadequateriskevaluation............................................ 3846 anticoagulantsafterinterventions......................................... 3868
3.5.Avoidanceorallowanceforsurgeryintheindividualpatient 3846 5.3.2.3.Combinationtherapy(antiplateletand
3.6.Thepatientperspective.................................................................. 3846 anticoagulant)...................................................................................... 3868
4.Pre-operativeassessmenttools........................................................... 3847 5.4.Peri-operativethromboprophylaxis.......................................... 3869
4.1.Riskscores............................................................................................ 3847 5.5.Patientbloodmanagement........................................................... 3869
4.1.1.Generalriskcalculators.......................................................... 3847 5.5.1.Pre-operativeanaemia—diagnosisandtreatment ..... 3870
4.1.2.Frailty.............................................................................................. 3849 5.5.2.Bleedingandreductionofiatrogenicdiagnostic/
4.2.Functionalcapacity............................................................................ 3849 surgery-relatedbloodloss ................................................................ 3870
4.3.Electrocardiography ......................................................................... 3850 5.5.3.Optimalbloodcomponentusewithpatient-centred
4.4.Biomarkers ........................................................................................... 3850 clinicaldecisionsupport..................................................................... 3871
4.5.Non-invasiveandinvasiveprocedures..................................... 3851 6.Specificdiseases.......................................................................................... 3871
4.5.1.Restingtransthoracicechocardiography......................... 3851 6.1.Coronaryarterydisease................................................................. 3871
4.5.2.Stresstests................................................................................... 3852 6.1.1.Riskforpatientswithcoronaryarterydisease............ 3871
4.5.2.1.Exercisestresstest........................................................... 3852 6.1.2.Pre-operativeriskassessmentandmanagement........ 3872
4.5.2.2.Stressimaging ..................................................................... 3852 6.1.3.Revascularizationstrategies.................................................. 3872
4.5.3.Angiography ................................................................................ 3853 6.1.3.1.Chroniccoronarysyndromes...................................... 3872
4.5.3.1.Coronarycomputedtomographyangiography ... 3853 6.1.3.2.Acutecoronarysyndromes.......................................... 3872
4.5.3.2.Invasivecoronaryangiography .................................... 3853 6.2.Chronicheartfailure........................................................................ 3874
5.Generalrisk-reductionstrategies........................................................ 3854 6.2.1.Riskforpatientswithheartfailure.................................... 3874
5.1.Cardiovascularriskfactorsandlifestyleinterventions...... 3854 6.2.2.Pre-andpost-operativemanagementstrategies........ 3874
5.2.Pharmacological ................................................................................. 3854 6.2.3.Hypertrophicobstructivecardiomyopathy................... 3875
5.2.1.Beta-blockers.............................................................................. 3854 6.2.4.Patientswithventricularassistdevicesundergoing
5.2.2.Amiodarone................................................................................ 3855 non-cardiacsurgery.............................................................................. 3875
5.2.3.Statins ............................................................................................ 3855 6.3.Valvularheartdisease...................................................................... 3875
5.2.4.Renin–angiotensin–aldosteronesysteminhibitors ..... 3855 6.3.1.Riskforpatientswithvalvularheartdisease................. 3875
5.2.5.Calciumchannelblockers...................................................... 3855 6.3.2.Pre-operativemanagementstrategiesandrisk-
5.2.6.Alpha-2receptoragonists .................................................... 3856 reductionstrategy................................................................................. 3876
5.2.7.Diuretics ....................................................................................... 3856 6.3.2.1.Aorticvalvestenosis........................................................ 3876
5.2.8.Ivabradine..................................................................................... 3856 6.3.2.2.Mitralvalvestenosis ......................................................... 3877
5.2.9.Sodium–glucoseco-transporter-2inhibitors................ 3856 6.3.2.3.Aorticvalveregurgitation.............................................. 3878
5.3.Peri-operativehandlingofantithromboticagents............... 3857 6.3.2.4.Mitralvalveregurgitation ............................................... 3878
5.3.1.Antiplatelets ................................................................................ 3857 6.3.2.5.Patientswithprostheticvalve(s) ................................ 3878
5.3.1.1.Singleantiplatelettherapy ............................................. 3857 6.3.2.6.Prophylaxisofinfectiveendocarditis ........................ 3878
5.3.1.2.Dualantiplatelettherapy ............................................... 3860 6.4.Knownornewlydiagnosedarrhythmias ................................ 3879
5.3.1.3.De-escalationofantiplateleteffect............................ 3862 6.4.1.Peri-operativemanagement—generalmeasures........ 3879
5.3.1.4.Plateletfunctionguidedperi-operative 6.4.2.Supraventriculararrhythmias............................................... 3879
managementofantiplatelettherapy......................................... 3862 6.4.3.Atrialfibrillation/flutter........................................................... 3879
5.3.2.Oralanticoagulants .................................................................. 3863 6.4.4.Ventriculararrhythmias ......................................................... 3879
5.3.2.1.VitaminKantagonists...................................................... 3863 6.4.5.Bradyarrhythmias...................................................................... 3881
5.3.2.1.1.VitaminKantagonistsinpatientswith 6.4.6.Managementofpatientswithcardiacimplantable
mechanicalheartvalves............................................................. 3863 electronicdevices.................................................................................. 3881
5.3.2.1.2.VitaminKantagonistsforatrialfibrillation/ 6.5.Adultcongenitalheartdisease..................................................... 3882
venousthromboembolism....................................................... 3864 6.6.Pericardialdiseases ........................................................................... 3883
5.3.2.1.3.RestartingvitaminKantagonistsafterinvasive 6.7.Pulmonarydiseaseandpulmonaryarterialhypertension 3884
proceduresorsurgery............................................................... 3864 6.7.1.Pulmonarydisease.................................................................... 3884
5.3.2.1.4.ReversalofvitaminKantagonists...................... 3864 6.7.2.Pulmonaryarterialhypertension........................................ 3884
5.3.2.2.Non-vitaminKantagonistoralanticoagulants...... 3864 6.8.Arterialhypertension....................................................................... 3885
5.3.2.2.1.Unplannedsurgeryinpatientsonnon-vitamin 6.9.Peripheralarterydisease................................................................ 3886
Kantagonistoralanticoagulantsandreversalfor 6.9.1.Peripheralarterydiseaseandnon-vascularnon-cardiac
emergencyprocedures.............................................................. 3864 surgery....................................................................................................... 3886
5.3.2.2.2.Plannedinterventionsinpatientsonnon- 6.9.2.Peripheralarterydiseaseandvascularnon-cardiac
vitaminKoralanticoagulants.................................................. 3866 surgery....................................................................................................... 3886
5.3.2.2.3.Bridging ......................................................................... 3866 6.10.Cerebrovasculardisease.............................................................. 3887
5.3.2.2.4.Laboratorytestingbeforesurgery.................... 3866 6.11.Renaldisease..................................................................................... 3887
5.3.2.2.5.Considerationsforspecificprocedures.......... 3867 6.12.Obesity................................................................................................ 3888
Downloaded
from
https://academic.oup.com/eurheartj/article/43/39/3826/6675076
by
guest
on
22
January
2026
--- Страница 4 ---
ESCGuidelines 3829
6.13.Diabetes.............................................................................................. 3889 RecommendationTable9—Recommendationsforstressimaging 3853
6.14.Cancer................................................................................................. 3889 RecommendationTable10—Recommendationsforcoronary
6.15.Coronavirusdisease2019........................................................... 3889 angiography........................................................................................................ 3853
7.Peri-operativemonitoringandanaesthesia .................................... 3890 RecommendationTable11—Recommendationsforlifestyleand
7.1.Peri-operativemonitoring ............................................................. 3890 cardiovascularriskfactors........................................................................... 3854
7.2.Anaesthesia .......................................................................................... 3891 RecommendationTable12—Recommendationsfor
7.2.1.Intra-operativehaemodynamics......................................... 3891 pharmacologicaltreatment......................................................................... 3856
7.2.2.Choiceofanaestheticagent................................................. 3892 RecommendationTable13—Recommendationsforuseof
7.3.Locoregionaltechniques ................................................................ 3892 antiplatelettherapyinpatientsundergoingnon-cardiacsurgery 3862
7.4.Peri-operativegoal-directedhaemodynamictherapy ....... 3893 RecommendationTable14—Recommendationsfor
7.5.Post-operativemanagement......................................................... 3893 interruptionandresumptionofanticoagulantsinpatients
8.Peri-operativecardiovascularcomplications.................................. 3893 undergoingnon-cardiacsurgery............................................................... 3868
8.1.Peri-operativemyocardialinfarction/injury............................ 3894 RecommendationTable15—Recommendationsfor
8.2.Spontaneousmyocardialinfarction(afterday2) ................ 3897 thromboprophylaxis ...................................................................................... 3869
8.3.Takotsubosyndrome....................................................................... 3897 RecommendationTable16—Recommendationsforintra-and
8.4.Acuteheartfailure............................................................................ 3897 post-operativecomplicationsassociatedwithanaemia ................. 3870
8.5.Venousthromboembolism ........................................................... 3897 RecommendationTable17—Recommendationsforintra-and
8.6.Atrialfibrillationandotherrelevantarrhythmias................ 3897 post-operativecomplicationsassociatedwithbloodloss............. 3871
8.6.1.Preventionofpost-operativeatrialfibrillation............. 3897 RecommendationTable18—Recommendationsforintra-and
8.6.2.Managementofpost-operativeatrialfibrillation......... 3898 post-operativecomplicationsassociatedwithallogeneicblood
8.6.2.1.Rateand/orrhythmcontrol......................................... 3898 transfusion.......................................................................................................... 3871
8.6.2.2.Preventionofatrialfibrillation-related RecommendationTable19—Recommendationsforthetiming
thromboemboliccomplications.................................................. 3899 ofnon-cardiacsurgeryandrevascularizationinpatientswith
8.7.Peri-operativestroke....................................................................... 3899 knowncoronaryarterydisease................................................................ 3874
9.Keymessages............................................................................................... 3900 RecommendationTable20—Recommendationsfor
10.Gapsinevidence...................................................................................... 3900 managementofheartfailureinpatientsundergoingnon-cardiac
11.Sexdifferences ......................................................................................... 3901 surgery................................................................................................................. 3875
12.‘Whattodo’and‘whatnottodo’messagesfromthe RecommendationTable21—Recommendationsfor
Guidelines........................................................................................................... 3901 managementofvalvularheartdiseaseinpatientsundergoing
13.Qualityindicators.................................................................................... 3906 non-cardiacsurgery........................................................................................ 3878
14.Centralillustration.................................................................................. 3906 RecommendationTable22—Recommendations
15.Supplementarydata................................................................................ 3907 formanagementofknownornewlydiagnosedarrhythmias...... 3880
16.Dataavailabilitystatement................................................................... 3907 RecommendationTable23—Recommendationsfor
17.Authorinformation................................................................................ 3907 managementofbradyarrhythmiaandpatientscarryingcardiac
18.Appendix..................................................................................................... 3907 implantabledevices ........................................................................................ 3882
19.References.................................................................................................. 3908 RecommendationTable24—Recommendationsfor
managementofpatientswithadultcongenitalheartdisease
Tables of Recommendations undergoingnon-cardiacsurgery............................................................... 3883
RecommendationTable25—Recommendationsforpericardial
RecommendationTable1—Recommendationsforselectionof diseases................................................................................................................ 3884
surgicalapproachandimpactonrisk..................................................... 3843 RecommendationTable26—Recommendationsforpatients
RecommendationTable2—Recommendationsforallpatients withpulmonaryarterialhypertensionundergoingnon-cardiac
scheduledfornon-cardiacsurgery.......................................................... 3845 surgery................................................................................................................. 3885
RecommendationTable3—Recommendationsforpatients RecommendationTable27—Recommendationsfor
aged,65yearswithoutsigns,symptoms,orhistoryof pre-operativemanagementofhypertension ...................................... 3886
cardiovasculardisease ................................................................................... 3845 RecommendationTable28—Recommendationsfor
RecommendationTable4—Recommendationsfor managementofpatientswithperipheralarterydisease
pre-operativeassessmentinpatientswithpreviouslyunknown and/orabdominalaorticaneurysmundergoingnon-cardiac
murmur,angina,dyspnoea,orperipheraloedema .......................... 3845 surgery......................................................................................................... 3887
RecommendationTable5—Recommendationsforpatient RecommendationTable29—Recommendationsfor
information ........................................................................................................ 3847 managementofpatientswithsuspectedorestablishedcarotid
RecommendationTable6—Recommendationsfor arterydiseaseundergoingnon-cardiacsurgery ................................. 3887
pre-operativeassessmentoffrailtyandfunctionalcapacity......... 3849 RecommendationTable30—Recommendationsfor
RecommendationTable7—Recommendationsfor managementofpatientswithrenaldiseaseundergoing
pre-operativeriskassessment—electrocardiographyand non-cardiacsurgery........................................................................................ 3888
biomarkers......................................................................................................... 3851 RecommendationTable31—Recommendationsfor
RecommendationTable8—Recommendationsfor managementofpatientswithobesityundergoingnon-cardiac
transthoracicechocardiography ............................................................... 3852 surgery................................................................................................................. 3888
Downloaded
from
https://academic.oup.com/eurheartj/article/43/39/3826/6675076
by
guest
on
22
January
2026
--- Страница 5 ---
3830 ESCGuidelines
RecommendationTable32—Recommendationsfor Figure10Timingoflastnon-vitaminKantagonistoralanticoagulant
managementofpatientswithdiabetesmellitusundergoing dosebeforeelectiveNCSaccordingtorenalfunction...................... 3866
non-cardiacsurgery........................................................................................ 3889 Figure11Suggestedstrategyforpotentialreversalofnon-vitamin
RecommendationTable33—Recommendationsfor Koralanticoagulantseffect ........................................................................ 3867
peri-operativemonitoringandanaesthesia ......................................... 3893 Figure12Managementofpatientswithacuteorchroniccoronary
RecommendationTable34—Recommendationsfor syndromescheduledfornon-cardiacsurgery.................................... 3873
peri-operativecardiovascularcomplications....................................... 3899 Figure13Managementofpatientswithsevereaorticvalve
stenosisscheduledfornon-cardiacsurgery ........................................ 3876
List of tables Figure14Managementofpatientswithsecondarymitralvalve
regurgitationscheduledfornon-cardiacsurgery .............................. 3877
Table1Classesofrecommendations.................................................... 3833 Figure15Optimallocationofreturnelectrodeduringunipolar
Table2Levelsofevidence.......................................................................... 3833 electrosurgeryinpatientswithcardiacimplantableelectronic
Table3Newconceptsandsectionsinthecurrentguidelines... 3834 devices,dependingonthesurgerysite.................................................. 3882
Table4Whatisnew..................................................................................... 3834 Figure16Pathophysiologicalapproachtoaddressintra-operative
Table4ANewrecommendations........................................................... 3834 hypotension....................................................................................................... 3892
Table4BRevisedrecommendations...................................................... 3838 Figure17Factorsassociatedwithperi-operativecardiovascular
Table5Surgicalriskestimateaccordingtotypeofsurgeryor complications.SNS,sympatheticnervoussystem............................ 3894
intervention ....................................................................................................... 3842 Figure18Differentialdiagnosisofelevatedpost-operativecardiac
Table6Riskscorecalculators................................................................... 3848 troponinconcentrations.............................................................................. 3895
Table7Pharmacokineticandpharmacodynamiccharacteristicsof Figure19Systematicwork-up(aetiology)andtherapyof
antiplatelets........................................................................................................ 3857 peri-operativemyocardialinfarction/injury.......................................... 3896
Table8Pharmacokineticandpharmacodynamiccharacteristicsof Figure20Preventionandmanagementofpost-operativeatrial
oralanticoagulants.......................................................................................... 3858 fibrillation............................................................................................................ 3898
Table9Bleedingriskaccordingtotypeofnon-cardiacsurgery 3858 Figure21Centralillustration:thecomplexinterplaybetweenthe
Table10Laboratoryparametersforthediagnosisofabsolute intrinsicriskofsurgeryandthepatientriskofperi-operative
iron-deficiencyanaemia................................................................................ 3870 cardiovascularcomplications ..................................................................... 3906
Table11Peri-operativeapproachtopatientswithventricular
assistdevicesundergoingnon-cardiacsurgery................................... 3875 Abbreviations and acronyms
Table12Peri-operativemanagementofpatientswitharrhythmias 3880
Table13Riskstratificationfornon-cardiacsurgeryinadultswith AAA Abdominalaorticaneurysm
congenitalheartdisease ............................................................................... 3883 AAD Antiarrhythmicdrug
Table14Patient-relatedandsurgery-relatedfactorstobe ACEI Angiotensin-converting-enzyme
consideredwhenassessingperi-operativeriskinpatientswith inhibitor
pulmonaryarterialhypertension.............................................................. 3885 ACHD Adultswithcongenitalheartdisease
Table15Factorsthatcouldinfluenceperi-operativeriskduring ACS Acutecoronarysyndrome
cancersurgeryandpreventivestrategies ............................................. 3890 ACSNSQIP AmericanCollegeofSurgeryNational
SurgicalQualityImprovementProgram
List of fi gures AF Atrialfibrillation
AKI Acutekidneyinjury
Figure1Totalriskisaninteractionofpatient-relatedand aPTT Activatedpartialthromboplastintime
surgery-relatedrisk ........................................................................................ 3841 AR Aorticvalveregurgitation
Figure2Pre-operativeassessmentbeforenon-cardiacsurgery 3844 ARB Angiotensinreceptorblocker
Figure3Examplesofquestionsandconcernsexpressedby ARNI Angiotensinreceptorneprilysininhibitor
patients................................................................................................................ 3847 AS Aorticvalvestenosis
Figure4Recommendedmeasurementstoassessanddetectthe ASA Acetylsalicylicacid
riskofpost-operativecardiaccomplications ...................................... 3850 ASA–PS AmericanSocietyofAnesthesiology
Figure5Recommendationsformanagementofantiplatelet PhysicalStatus
therapyinpatientsundergoingnon-cardiacsurgery ....................... 3859 ASCVD Atheroscleroticcardiovasculardisease
Figure6P2Y inhibitorinterruptionafterpercutaneous AUB-HAS2 AmericanUniversityofBeirut
12
coronaryinterventionbeforeelectivenon-cardiacsurgery......... 3860 (AUB)-HAS2
Figure7Bridgingwithintravenousantiplateletagents.ASA, AUC Areaundercurve
acetylsalicylicacid;FU,follow-up;LD,loadingdose;NCS, AVR Aorticvalvereplacement
non-cardiacsurgery;o.d.,onceaday...................................................... 3861 BAV Balloonaorticvalvuloplasty
Figure8Recommendationsformanagementoforal BCSH BritishCommitteeforStandardsin
anticoagulationtherapyinpatientsundergoingnon-cardiac Haematology
surgery................................................................................................................. 3863 b.i.d. Bisindie(twiceaday)
Figure9Peri-operativemanagementofnon-vitaminKantagonist BTKi Brutontyrosinekinaseinhibitors
oralanticoagulantaccordingtotheperiproceduralriskofbleeding 3865 BMI Bodymassindex
Downloaded
from
https://academic.oup.com/eurheartj/article/43/39/3826/6675076
by
guest
on
22
January
2026
--- Страница 6 ---
ESCGuidelines 3831
BMS Baremetalstent EDKA Euglycaemicdiabeticketoacidosis
BNP B-typenatriureticpeptide eGFR Estimatedglomerularfiltrationrate
BP Bloodpressure EMI Electromagneticinterference
b.p.m. Beatsperminute EORP EURObservationalResearch
BSA Bodysurfacearea Programme
CABG Coronaryarterybypassgraft ESA EuropeanSocietyofAnaesthesiology
CAD Coronaryarterydisease ESC EuropeanSocietyofCardiology
CARP CoronaryArteryRevascularization ESH EuropeanSocietyofHypertension
Prophylaxis(trial) ESTS EuropeanSocietyofThoracic
CAS Carotidarterystenting Surgeons
CASS CoronaryArterySurgeryStudy ESVS EuropeanSocietyforVascularSurgery
CCB Calciumchannelblocker EuSOS EuropeanSurgicalOutcomesStudy
CCS Chroniccoronarysyndrome EVAR Endovascularabdominalaorticaneurysm
CCTA Coronarycomputedtomography repair
angiography FDA USFoodandDrugAdministration
CEA Carotidendarterectomy FFR Fractionalflowreserve
CHA DS -VASc Congestiveheartfailure,hypertension, FIIa FactorIIa
2 2
age≥75years,diabetesmellitus,stroke, FOCUS Focusedcardiacultrasound
vasculardisease,age65–74years,sex FXa FactorXa
category(female) GDMT Guideline-directedmedicaltherapy
CI Confidenceinterval GFR Glomerularfiltrationrate
CIED Cardiacimplantableelectronicdevice HbA1c Glycatedhaemoglobin
CK Creatininekinase HF Heartfailure
CKD Chronickidneydisease HIP-ATTACK HIPFractureAcceleratedSurgical
CKD-EPI ChronicKidneyDiseaseEpidemiology TreaTmentAndCaretracK(trial)
Collaboration HR Hazardratio
Cmax Maximumserumconcentration hs-cTn High-sensitivitycardiactroponin
CMR Cardiacmagneticresonance i.v. Intravenous
COAPT CardiovascularOutcomesAssessment ICA Invasivecoronaryangiography
oftheMitraClipPercutaneousTherapy ICD Implantablecardioverter–defibrillator
forHeartFailurePatientswith ICU Intensivecareunit
FunctionalMitralRegurgitation(trial) ID Irondeficiency
COPD Chronicobstructivepulmonarydisease IHD Ischaemicheartdisease
CORIDA Per-proceduralConcentrationofDirect INR Internationalnormalizedratio
OralAnticoagulants(trial) ISCHEMIA InternationalStudyofComparative
CoronaryCTAVISION CoronaryComputedTomographic HealthEffectivenesswithMedicaland
AngiographyandVascularEventsin InvasiveApproaches(trial)
NoncardiacSurgeryPatientsCohort iwFR Instantaneouswave-freeratio
Evaluation(trial) KDIGO KidneyDisease:ImprovingGlobal
COVID-19 Coronavirusdisease2019 Outcomes
CPET Cardiopulmonaryexercisetesting LD Loadingdose
CRF Cardiorespiratoryfitness LMWH Lowmolecularweightheparin
CRT Cardiacresynchronizationtherapy LOAD LoweringtheRiskofOperative
CT Computedtomography ComplicationsUsingAtorvastatin
cTnT/I CardiactroponinT/I LoadingDose(trial)
CTO Chronictotalocclusion LoE Levelofevidence
CV Cardiovascular LV Leftventricular
CVD Cardiovasculardisease LVEF Leftventricularejectionfraction
DAPT Dualantiplatelettherapy LVESD Leftventricularend-systolicdiameter
DASI DukeActivityStatusIndex LVESDi Leftventricularend-systolicdimension
DES Drug-elutingstent index
DM Diabetesmellitus MACE Majoradversecardiovascularevent
DSE Dobutaminestressechocardiography MET Metabolicequivalent
dTT Dilutedthrombintime METS MeasurementofExerciseTolerance
EACTS EuropeanAssociationfor beforeSurgery(trial)
Cardio-ThoracicSurgery MHV Mechanicalheartvalve
ECG Electrocardiographic/electrocardiogram MI Myocardialinfarction
Downloaded
from
https://academic.oup.com/eurheartj/article/43/39/3826/6675076
by
guest
on
22
January
2026
--- Страница 7 ---
3832 ESCGuidelines
MINS Myocardialinjuryfollowingnon-cardiac TTE Transthoracicechocardiography
surgery UFH Unfractionatedheparin
MR Mitralvalveregurgitation ULN Upperlimitofnormal
MS Mitralvalvestenosis VAD Ventricularassistdevice
NCS Non-cardiacsurgery VATS Video-assistedthoracicsurgery
NOAC Non-vitaminKantagonistoral VEGFi Vascularendothelialgrowfactor
anticoagulant inhibitor
NSAID Non-steroidalanti-inflammatorydrug VF Ventricularfibrillation
NSTE-ACS Non-ST-segmentelevationacute VHD Valvularheartdisease
coronarysyndrome VISION VascularEventsinNoncardiacSurgery
NT-proBNP N-terminalpro-B-typenatriuretic PatientsCohortEvaluation(trial)
peptide VKA VitaminKantagonist
NYHA NewYorkHeartAssociation VKORC1 VitaminKepoxidereductasecomplex1
OAC Oralanticoagulant VO Oxygenconsumption
2
o.d. Omniedie(onceaday) VT Ventriculartachycardia
OR Oddsratio VTE Venousthromboembolism
OSA Obstructivesleepapnoea WHA WorldHealthAssembly
PA Pulmonaryartery WPW Wolff–Parkinson–White
PAD Peripheralarterydisease
PAH Pulmonaryarterialhypertension 1. Preamble
PAUSE PerioperativeAnticoagulantUsefor
SurgeryEvaluation(trial) Guidelinessummarizeandevaluateavailableevidence,withtheaim
PBM PatientBloodManagement ofassistinghealthprofessionalsinproposingthebestmanagement
PCC Prothrombincomplexconcentrate strategies for an individual patient with a given condition.
PCI Percutaneouscoronaryintervention Guidelines and their recommendations should facilitate decision-
PE Pulmonaryembolism making of health professionals in their daily practice. Guidelines,
PMC Percutaneousmitralcommissurotomy however,arenotasubstituteforthepatient’srelationshipwiththeir
PMI Peri-operativemyocardialinfarction/ practitioner.Thefinaldecisionsconcerninganindividualpatientmust
injury be made by the responsible health professional(s), based on what
POISE PeriOperativeISchemicEvaluationTrial they consider to be the most appropriate in the circumstances.
PPC Prothrombincomplexconcentrate Thesedecisionsaremadeinconsultationwiththepatientandcare-
PT Prothrombintime giverasappropriate.
PVC Prematureventricularcontractions Guidelinesareintendedforusebyhealthprofessionals.Toen-
QI Qualityindicator sure that all users have access to the most recent recommenda-
RAAS Renin−angiotensin−aldosteronesystem tions, the European Society of Cardiology (ESC) makes its
RBC Redbloodcell guidelinesfreelyavailable.TheESCwarnsreadersthatthetechnical
RCRI RevisedCardiacRiskIndex languagemaybemisinterpretedanddeclinesanyresponsibilityin
RCT Randomizedcontrolledtrial thisrespect.
RF Radiofrequency Many guidelines have been issued in recent years by the ESC.
rHuEPO Recombinanthumanerythropoietin Becauseoftheirimpactonclinicalpractice,qualitycriteriaforthede-
RR Relativerisk velopmentofguidelineshavebeenestablishedinordertomakeall
RV Rightventricular decisionstransparenttotheuser.Therecommendationsforformu-
SAPT Singleantiplatelettherapy latingandissuingESCGuidelinescanbefoundontheESCwebsite
SARS-CoV-2 Severeacuterespiratorysyndrome (https://www.escardio.org/Guidelines). The ESC Guidelines re-
coronavirus2 presenttheofficialpositionoftheESConagiventopicandareregu-
SAVR Surgicalaorticvalvereplacement larlyupdated.
SCD Suddencardiacdeath InadditiontothepublicationofClinicalPracticeGuidelines,the
SGLT-2 Sodium–glucoseco-transporter-2 ESC carries out the EURObservational Research Programme of
SORT SurgicalOutcomeRiskTool international registries of cardiovascular diseases and interven-
SPAP Systolicpulmonaryarterypressure tions, which are essential to assess diagnostic/therapeutic pro-
STEMI ST-segmentelevationmyocardial cesses, use of resources, and adherence to guidelines. These
infarction registriesaimtoprovideabetterunderstandingofmedicalprac-
SVT Supraventriculartachycardia ticeinEuropeandaroundtheworld,andarebasedonhigh-quality
TAVI Transcatheteraorticvalveimplantation data collected during routine clinical practice. Furthermore, the
TEE Transoesophagealechocardiography ESC develops sets of quality indicators (QIs)—which are tools
TEER Transcatheteredge-to-edgerepair to evaluate the level of implementation of the guidelines and
TIA Transientischaemicattack may be used by the ESC, hospitals, healthcare providers, and
Downloaded
from
https://academic.oup.com/eurheartj/article/43/39/3826/6675076
by
guest
on
22
January
2026
--- Страница 8 ---
ESCGuidelines 3833
professionalstomeasureclinicalpractice,andineducationalpro- optionswereweighedandscoredaccordingtopre-definedscales,as
grammes—alongsidethekeymessagesfromtheguidelines,toim- outlinedbelow.TheTaskForcefollowedtheESCvotingprocedures.
provequalityofcareandclinicaloutcomes. Allrecommendationssubjecttoavoteachievedatleast75%among
ThemembersofthisTaskForcewereselectedbytheESCtore- votingmembers.
presentprofessionalsinvolvedwiththemedicalcareofpatientswith Theexpertsofthewritingandreviewingpanelsprovideddeclar-
thispathology.Theselectionprocedureaimedtoensurethatthereis ationofinterestformsforallrelationshipsthatmightbeperceivedas
a representative mix of members, predominantly from across the realorpotentialsourcesofconflictsofinterest.Theirdeclarationsof
whole of the ESC region and from relevant ESC Subspecialty interestwerereviewedaccordingtotheESCdeclarationofinterest
Communities. Consideration was given to diversity and inclusion, rulesandcanbefoundontheESCwebsite(http://www.escardio.org/
notablywithrespecttogenderandcountryoforigin.Acriticalevalu- Guidelines)andhavebeencompiledinareportandsimultaneously
ationofdiagnosticandtherapeuticprocedureswasperformed,in- publishedinasupplementarydocumenttotheguidelines.Thispro-
cluding assessment of the risk–benefit ratio. The level of evidence cessensurestransparencyandpreventspotentialbiasesinthedevel-
andthestrengthoftherecommendationofparticularmanagement opment and review processes. Any changes in declarations of
Table1 Classesofrecommendations
Definition Wording to use
Class I Evidence and/or general agreement Is recommended or is indicated
that a given treatment or procedure is
beneficial, useful, effective.
Class II Conflicting evidence and/or a divergence of opinion about the usefulness/
efficacy of the given treatment or procedure.
Class IIa Weight of evidence/opinion is in Should be considered
favour of usefulness/efficacy.
Class IIb Usefulness/efficacy is less well May be considered
established by evidence/opinion.
Class III Evidence or general agreement that the Is not recommended
given treatment or procedure is not
useful/effective, and in some cases
may be harmful.
Table2 Levelsofevidence
Level of Data derived from multiple randomized clinical trials
evidence A or meta-analyses.
Level of Data derived from a single randomized clinical trial
evidence B or large non-randomized studies.
Level of Consensus of opinion of the experts and/or small studies,
evidence C retrospective studies, registries.
snoitadnemmocerfosessalC
2202
CSE©
2202
CSE©
2202CSE©
2202CSE©
Downloaded
from
https://academic.oup.com/eurheartj/article/43/39/3826/6675076
by
guest
on
22
January
2026
--- Страница 9 ---
3834 ESCGuidelines
interest that arose during the writing period were notified to the 2. Introduction
ESCandupdated.TheTaskForcereceiveditsentirefinancialsup-
port from the ESC without any involvement from the healthcare 2.1. What is new
industry.
TheESCCPGCommitteesupervisesandcoordinatestheprepar-
ationofnewguidelines.TheCommitteeisalsoresponsibleforthe Table 3 New concepts and sections in the current
approval processoftheseguidelines. TheESC Guidelines undergo guidelines
extensivereviewbytheCPGCommitteeandexternalexperts,in- AnewflowchartforgeneralassessmentofpatientsbeforeNCS.
cludingamixofmembersfromacrossthewholeoftheESCregion
Anewsectiononpre-operativeassessmentofpatientswithnewly
and from relevant ESC Subspecialty Communities and National
detectedmurmurs,dyspnoea,oedema,orangina.
Cardiac Societies. After appropriate revisions, the guidelines are
Anewsectiononthepatientperspective.
signed-offbyalltheexpertsinvolvedintheTaskForce.Thefinalized
Anewsectiononassessmentoffrailty.
documentissigned-offbytheCPGCommitteeforpublicationinthe
ArevisedandexpandedfocusonuseofbiomarkersinNCS
European Heart Journal. The guidelines are developed after careful
consideration of the scientific and medical knowledge and the evi- Arevisedandexpandedsectiononperi-operativemanagementof
antiplatelettherapy.
denceavailableatthetimeoftheirwriting.
Arevisedandexpandedsectiononperi-operativemanagementof
ThetaskofdevelopingtheESCGuidelinesalsoincludescreating
oralanticoagulants.
educational toolsandimplementatingprogrammesforthe recom-
mendations, including condensed pocket guidelines versions, sum- Anewsectiononperi-operativethromboprophylaxis.
mary slides, summary cards for non-specialists, and an electronic Adedicatedsectiononpatientbloodmanagement.
version for digital applications (smartphones, etc.). These versions Anewsectiononmanagementofcardiovascularriskinpatientswith
areabridgedandthus,formoredetailedinformation,theusershould cancerundergoingNCS.
always access the full text version of the guidelines, which is AsmallsectiononNCSinpatientswithrecentCOVID-19.
freelyavailableviatheESCwebsiteandtheEuropeanHeartJournal. Anewsectionondiagnosisandmanagementofpost-operative
The National Cardiac Societies of the ESC are encouraged to complicationsduringNCS.
endorse, adopt, translate, and implement all ESC Guidelines.
COVID-19,coronavirus2019;NCS,non-cardiacsurgery
Implementationprogrammesareneededbecauseithasbeenshown
that the outcome of disease may be favourably influenced by the
thoroughapplicationofclinicalrecommendations.
HealthprofessionalsareencouragedtotaketheESCGuidelines
Table4 Whatisnew
fullyintoaccountwhenexercisingtheirclinicaljudgment,andinde-
termining and implementing preventive, diagnostic, or therapeutic
Table4A Newrecommendations
medical strategies. However, the ESC Guidelines do not override,
inanywaywhatsoever,theindividualresponsibilityofhealthprofes-
Recommendation Class
sionals to make appropriate and accurate decisions in considering
each patient’s health condition and in consulting with that patient Clinicalriskevaluation—Section3
orthepatient’scaregiverwhereappropriateand/ornecessary.Itis
PatientsscheduledforNCS
also the health professional’s responsibility to verify the rules and
InallpatientsscheduledforNCS,anaccuratehistory,and
regulations applicable in each country to drugs and devices at the I
clinicalexaminationarerecommended.
timeofprescriptionand,whereappropriate,torespecttheethical
Itisrecommendedtoperformapre-operativeriskassessment,
rulesoftheirprofession. I
ideallyatthesametimeastheNCSisproposed.
Off-labeluseofmedicationmaybepresentedintheseguidelines
ifasufficientlevelofevidenceshowsthatitcanbeconsideredmed- Iftimeallows,itisrecommendedtooptimize
icallyappropriatetoagivenconditionandifpatientscouldbenefit guideline-recommendedtreatmentofCVDandCVriskfactors I
fromtherecommendedtherapy.However,thefinaldecisionscon- beforeNCS.
Endovascularorvideo-assistedproceduresshouldbe
cerninganindividualpatientmustbemadebytheresponsiblehealth
consideredforpatientswithhighCVriskundergoingvascular IIa
professional,givingspecialconsiderationto:
orpulmonarysurgery.
(a) thespecificsituationofthepatient.Inthisrespect,itisspecified Patientsaged,65yearswithoutsigns,symptoms,orhistory
that,unlessotherwiseprovidedforbynationalregulations,off- ofCVD
labeluseofmedicationshouldbelimitedtosituationswhereit Inpatientswithafamilyhistoryofgeneticcardiomyopathy,itis
isinthepatient’sinteresttodoso,withregardtothequality, recommendedtoperformanECGandTTEbeforeNCS, I
safety,andefficacyofcare,andonlyafterthepatienthasbeen
regardlessofageandsymptoms.
informedandprovidedconsent; Inpatientsaged45–65yearswithoutsigns,symptoms,or
(b) and country-specific health regulations, indications by govern- historyofCVD,ECGandbiomarkersshouldbeconsidered IIa
mentaldrugregulatoryagencies,andtheethicalrulestowhich beforehigh-riskNCS.
healthprofessionalsaresubject,whereapplicable.
Continued
2202CSE©
2202CSE©
Downloaded
from
https://academic.oup.com/eurheartj/article/43/39/3826/6675076
by
guest
on
22
January
2026
--- Страница 10 ---
ESCGuidelines 3835
Pre-operativeassessmentinpatientswithanewlydetected Coronaryangiography
murmur,chestpain,dyspnoea,orperipheraloedema CCTAshouldbeconsideredtoruleoutCADinpatientswith
Inpatientswithanewlydetectedmurmurandsymptomsor suspectedCCSorbiomarker-negativeNSTE-ACSincaseof
I
signsofCVD,TTEisrecommendedbeforeNCS. low-to-intermediateclinicallikelihoodofCAD,orinpatients IIa
Inpatientswithanewlydetectedmurmursuggestingclinically unsuitablefornon-invasivefunctionaltestingundergoing
significantpathology,TTEisrecommendedbeforehigh-risk I non-urgent,intermediate-,andhigh-riskNCS.
NCS. Generalrisk-reductionstrategies—Section5
Inpatientswithanewlydetectedmurmur,butwithoutother
Cardiovascularriskfactorsandlifestyleinterventions
signsorsymptomsofCVD,TTEshouldbeconsideredbefore IIa
Smokingcessation.4weeksbeforeNCSisrecommendedto
moderateandhigh-riskNCS. I
reducepost-operativecomplicationsandmortality.
IfapatientscheduledforelectiveNCShaschestpainorother
ControlofCVriskfactors—includingbloodpressure,
symptomssuggestiveofundetectedCAD,furtherdiagnostic I I
dyslipidaemia,anddiabetes—isrecommendedbeforeNCS.
work-upbeforeNCSisrecommended.
Pharmacologicaltreatment
IfapatientinneedofacuteNCSalsohaschestpainorother
symptomssuggestiveofundetectedCAD,amultidisciplinary Forpatientsondiureticstotreathypertension,transient
I
assessmentapproachisrecommendedtochoosethe discontinuationofdiureticsonthedayofNCSshouldbe IIa
treatmentwithlowesttotalriskforthepatient. considered.
Inpatientswithdyspnoeaand/orperipheraloedema,anECG ItshouldbeconsideredtointerruptSGLT-2inhibitortherapy
IIa
andanNT-proBNP/BNPtestisindicatedbeforeNCS,unless I foratleast3daysbeforeintermediate-orhigh-riskNCS.
thereisacertainnon-cardiacexplanation. Antiplatelets
Inpatientswithdyspnoeaand/orperipheraloedemaand
I Forpatientsundergoinghighbleedingrisksurgery(e.g.
elevatedNT-proBNP/BNP,TTEisrecommendedbeforeNCS.
intracranial,spinalneurosurgery,orvitreoretinaleyesurgery),
I
Patientinformation itisrecommendedtointerruptaspirinforatleast7days
Itisrecommendedtogivepatientsindividualizedinstructions pre-operatively.
forpre-operativeandpost-operativechangesinmedication,in I Inhigh-riskpatientswitharecentPCI(e.g.STEMIpatientsor
verbalandwrittenformatswithclearandconcisedirections. high-riskNSTE-ACSpatients),aDAPTdurationofatleast3 IIa
Itshouldbeconsideredtosetupastructuredinformationlist monthsshouldbeconsideredbeforetime-sensitiveNCS.
(e.g.achecklisttohelpwithcommonissues)forpatientswith IIa Anticoagulants
CVDorathighriskofCVcomplicationsscheduledforNCS.
Whenanurgentsurgicalinterventionisrequired,itis
I
Pre-operativeassessmenttools—Section4 recommendedthatNOACtherapyisimmediatelyinterrupted.
Frailtyandfunctionalcapacity Innon-minorbleedingriskproceduresinpatientsusinga
NOAC,itisrecommendedtouseaninterruptionregimen
Inpatientsaged≥70years,beingscheduledtoundergo I
basedontheNOACcompound,renalfunction,andbleeding
intermediate-orhigh-riskNCS,frailtyscreeningshouldbe IIa
risk.
consideredusingavalidatedscreeningtool.
Inminorbleedingrisksurgeryandotherprocedureswhere
Adjustingriskassessmentsaccordingtoself-reportedabilityto
bleedingcaneasilybecontrolled,itisrecommendedto I
climbtwoflightsofstairsshouldbeconsideredinpatients IIa
performsurgerywithoutinterruptionofOACtherapy.
referredforintermediate-orhigh-riskNCS.
InpatientsusingNOACs,itisrecommendedthatminor
Transthoracicechocardiography
bleedingriskproceduresareperformedattroughlevels I
TTEisrecommendedinpatientswithpoorfunctionalcapacity (typically12–24hafterlastintake).
and/orhighNT-proBNP/BNP,orifmurmursaredetectedbefore I
LMWHisrecommended,asanalternativetoUFH,forbridging
I
high-riskNCS,inordertoundertakerisk-reductionstrategies. inpatientswithMHVsandhighsurgicalrisk.
TTEshouldbeconsideredinpatientswithsuspectednewCVD
IIa Forpatientswithmechanicalprostheticheartvalves
orunexplainedsignsorsymptomsbeforehigh-riskNCS.
undergoingNCS,bridgingwithUFHorLMWHshouldbe
TTEmaybeconsideredinpatientswithpoorfunctional
consideredifOACinterruptionisneededandpatientshave:(i)
capacity,abnormalECG,highNT-proBNP/BNP,or≥1clinical IIb IIa
mechanicalAVRandanythromboembolicriskfactor;(ii)
riskfactorbeforeintermediate-riskNCS.
old-generationmechanicalAVR;or(iii)mechanicalmitralor
Toavoiddelayingsurgery,aFOCUSexamperformedby tricuspidvalvereplacement.
trainedspecialistsmaybeconsideredasanalternativetoTTE IIb
Idarucizumabshouldbeconsideredinpatientsondabigatranand
forpre-operativetriage. requiringurgentsurgicalinterventionwithintermediatetohigh IIa
Stressimaging bleedingrisk.
Stressimagingshouldbeconsideredbeforehigh-riskNCSin Forinterventionswithaveryhighriskofbleeding,suchasspinal
asymptomaticpatientswithpoorfunctionalcapacity,and IIa orepiduralanaesthesia,interruptionofNOACsforuptofive IIa
previousPCIorCABG. half-livesandre-initiationafter24hshouldbeconsidered.
Continued Continued
Downloaded
from
https://academic.oup.com/eurheartj/article/43/39/3826/6675076
by
guest
on
22
January
2026
--- Страница 11 ---
3836 ESCGuidelines
Whenspecificreversalagentsareunavailable,PCCoractivated Specificdiseases—Section6
IIa
PCCshouldbeconsideredforreversingNOACeffects.
Coronaryarterydisease
Ifanurgentsurgicalinterventionisrequired,specific
Pre-operativeevaluationofpatientswithanindicationforPCI
coagulationtestsandassessmentofNOACplasmalevels
IIa byanexpertteam(surgeonandcardiologist)shouldbe IIa
shouldbeconsideredtointerpretroutinecoagulationtestsand
consideredbeforeelectiveNCS.
waningofanticoagulanteffect.
Heartfailure
Ifbleedingriskwithresumptionoffull-doseanticoagulation
outweighstheriskofthromboembolicevents,postponing InpatientswithHFundergoingNCS,itisrecommendedto
I
therapeuticanticoagulation48–72haftertheproceduremay IIb regularlyassessvolumestatusandsignsoforganperfusion.
beconsidered,usingpost-operativethromboprophylaxisuntil AmultidisciplinaryteamincludingVADspecialistsis
resumptionoffullOACdoseisdeemedsafe. recommendedforperi-operativemanagementofpatientswith I
BridgingofOACtherapyisnotrecommendedinpatientswith HFreceivingmechanicalcirculatorysupport. III
low/moderatethromboticriskundergoingNCS. Valvularheartdisease
Useofreduced-doseNOACtoattenuatetheriskof
III InpatientswithsymptomaticsevereARorasymptomatic
post-operativebleedingisnotrecommended. severeARandLVESD.50mmorLVESDi(LVESD/BSA)
Thromboprophylaxis .25mm/m2(inpatientswithsmallbodysize)orrestingLVEF I
Itisrecommendedthatdecisionsaboutperi-operative
≤50%,valvesurgeryisrecommendedpriortoelective
thromboprophylaxisinNCSarebasedonindividualand I intermediate-orhigh-riskNCS.
procedure-specificriskfactors. Inpatientswithmoderate-to-severerheumaticMSand
Ifthromboprophylaxisisdeemednecessary,itis
symptomsorSPAP.50mmHg,valveintervention(PMCor
I
recommendedtochoosethetypeanddurationof surgery)isrecommendedbeforeelectiveintermediate-or
thromboprophylaxis(LMWH,NOAC,orfondaparinux) I high-riskNCS.
accordingtotypeofNCS,durationofimmobilization,and InasymptomaticpatientswithsevereASwhoarescheduled
patient-relatedfactors. forelectivehigh-riskNCS,AVR(SAVRorTAVI)shouldbe IIa
Inpatientswithalowbleedingrisk,peri-operative consideredafterHeartTeamdiscussion.
thromboprophylaxisshouldbeconsideredforadurationofup IIa InpatientswithsymptomaticsevereprimaryMRor
to14or35days,fortotalkneeorhiparthroplasty,respectively. asymptomaticsevereprimaryMRwithLVdysfunction(LVESD
NOACsinthromboprophylaxisdosemaybeconsideredas
≥40mmand/orLVEF≤60%),valveintervention(surgicalor IIa
alternativetreatmentstoLMWHaftertotalkneeandhip IIb transcatheter)shouldbeconsideredpriortointermediate-or
arthroplasty. high-riskNCS,iftimeallows.
InpatientswithseveresecondaryMRwhoremain
Patientbloodmanagement
symptomaticdespiteguideline-directedmedicaltherapy
Itisrecommendedtomeasurehaemoglobinpre-operativelyin
I (includingCRTifindicated),valveintervention(transcatheter IIa
patientsscheduledforintermediate-tohigh-riskNCS.
orsurgical)shouldbeconsideredbeforeNCS,ineligible
ItisrecommendedtotreatanaemiainadvanceofNCSinorder
I patientswithanacceptableproceduralrisk.
toreducetheneedforRBCtransfusionduringNCS.
InpatientswithseveresymptomaticASinneedof
Inpatientsundergoingsurgerywithexpectedbloodlossof
I time-sensitiveNCSorinwhomtheTAVIandSAVRare
≥500mL,useofwashedcellsalvageisrecommended. IIb
unfeasible,BAVmaybeconsideredbeforeNCSasabridgeto
Itisrecommendedtousepoint-of-carediagnosticsfor I definitiveaorticvalverepair.
guidanceofbloodcomponenttherapy,whenavailable.
Arrhythmias
Theuseofanalgorithmtodiagnoseandtreatanaemicpatients
IIa
InAFpatientswithacuteorworseninghaemodynamic
beforeNCSshouldbeconsidered.
instabilityundergoingNCS,emergencyelectricalcardioversion I
InpatientsundergoingNCSandexperiencingmajorbleeding,
isrecommended.
administrationoftranexamicacidshouldbeimmediately IIa
Inpatientswithsymptomatic,monomorphic,sustainedVT
considered.
associatedwithmyocardialscar,recurringdespiteoptimal
Useofclosed-looparterialbloodsamplingsystemsshouldbe I
IIa medicaltherapy,ablationofarrhythmiaisrecommended
consideredtoavoidbloodloss.
beforeelectiveNCS.
Applicationofmeticuloushaemostasisshouldbeconsidereda
IIa ItisrecommendedthatallpatientswithCIEDsthatare
routineprocedure.
reprogrammedbeforesurgeryhaveare-checkandnecessary I
Afeedback/monitoringprogrammeorclinicaldecisionsupport
reprogrammingassoonaspossibleaftertheprocedure.
systemshouldbeconsideredtobeassessedbeforeblood IIa
Ifindicationsforpacingexistaccordingtothe2021ESC
transfusion.
Guidelinesoncardiacpacingandcardiacresynchronization
Beforeallogenicbloodtransfusion,itshouldbeconsidered IIa
therapy,NCSsurgeryshouldbedeferredandimplantationofa
toobtainanextensiveconsentaboutrisksassociatedwith IIa
permanentpacemakershouldbeconsidered.
transfusion.
Continued
Continued
Downloaded
from
https://academic.oup.com/eurheartj/article/43/39/3826/6675076
by
guest
on
22
January
2026
--- Страница 12 ---
ESCGuidelines 3837
Ablationshouldbeconsideredinsymptomaticpatientswith Diabetesmellitus
recurrentorpersistentSVT,despitetreatment,priorto IIa
Apre-operativeassessmentforconcomitantcardiac
high-risk,non-urgentNCS.
conditionsisrecommendedinpatientswithdiabeteswith
Inhigh-riskCIEDpatients(e.g.withICDorbeing suspectedorknownCAD,andthosewithautonomic I
pacing-dependant)undergoingNCScarryingahighprobability neuropathy,retinopathy,orrenaldiseaseandscheduledto
ofelectromagneticinterference(e.g.involvingunipolar
IIa undergointermediate-orhigh-riskNCS.
electrosurgeryabovetheumbilicalarea),CIEDcheck-upand
Peri-operativemonitoringandanaesthesia—Section7
necessaryreprogrammingimmediatelybeforetheprocedure
Itisrecommendedtoavoidpost-operativeacutepain.
shouldbeconsidered. I
Adultcongenitalheartdisease
Perioperativecardiovascularcomplications—Section8
InpatientswithACHD,aconsultationwithanACHDspecialist
I
Itisrecommendedtohavehighawarenessofperi-operative
isrecommendedbeforeintermediate-orhigh-risksurgery.
CVcomplicationscombinedwithsurveillanceforPMIin I
InpatientswithACHD,itisrecommendedthatintermediate-
patientsundergoingintermediate-orhigh-riskNCS.
andhigh-riskelectivesurgeryisperformedinacentrewith I
SystematicPMIwork-upisrecommendedtoidentifythe
experienceinthecareofACHDpatients. I
underlyingpathophysiologyandtodefinetherapy.
Pericardialdiseases
Itisrecommendedtotreatpost-operativeSTEMI,NSTE-ACS,
Inpatientswithacutepericarditis,deferringelectiveNCSuntil
acuteHF,andtachyarrhythmiasinaccordancewithguidelines
completeresolutionoftheunderlyingprocessshouldbe IIa I
forthenon-surgicalsetting,afterinterdisciplinarydiscussion
considered.
withthesurgeonaboutbleedingrisk.
AvoidingelectiveNCSproceduresundergeneralanaesthesia
Inpatientswithpost-operativePEofhighorintermediate
untilcolchicineortheimmunosuppressivetreatmentcourse IIb
clinicalprobability,initiationofanticoagulationis
I
forpericardialdiseaseiscompletedmaybeconsidered.
recommendedwithoutdelay,whilediagnosticwork-upisin
Pulmonaryarterialhypertension progress,ifbleedingriskislow.
Inodilatordrugs(dobutamine,milrinone,levosimendan), Post-operativeoralanticoagulationforPEisrecommendedto
I
whichincreasecardiacoutputandlowerpulmonaryvascular beadministeredforaperiodofatleast3months.
IIa
resistance,shouldbeconsideredperi-operativelyaccordingto Inpatientswithapost-operativeindicationforOAC,NOACs
I
thehaemodynamicstatusofthepatient. aregenerallyrecommendedoverVKA.
Peripheralarterydiseaseand/orabdominalaorticaneurysm Inpatientswithpost-operativeAFafterNCS,long-termOAC
therapyshouldbeconsideredinallpatientsatriskofstroke,
Routinereferralforcardiacwork-up,coronaryangiography,or IIa
CPETpriortoelectivesurgeryforPADorAAAisnot III
consideringtheanticipatednetclinicalbenefitofOACtherapy,
andinformedpatientpreferences.
recommended.
InpatientswithMINSandatlowriskofbleeding,treatment
Renaldisease
withdabigatran110mgorallyb.i.d.maybeconsideredfrom IIb
Inpatientswithknownriskfactors(age.65years,BMI.30,
about1weekafterNCS.
diabetes,hypertension,hyperlipidaemia,CVdisease,or
Routineuseofbeta-blockerforthepreventionofpost-
smoking)undergoingintermediate-orhigh-riskNCS,itis I III
operativeAFinpatientsundergoingNCSisnotrecommended.
recommendedtoscreenforpre-operativerenaldiseaseby
measuringserumcreatinineandGFR. AAA,abdominalaorticaneurysm;ACHD,adultswithcongenitalheartdisease;AF,atrial
fibrillation; AR, aortic valve regurgitation; AS, aortic valve stenosis; AVR, aortic valve
Inpatientswithrenaldiseaserequiringperi-operative
replacement;BAV,balloonaorticvalvuloplasty;b.i.d.,twiceaday;BMI,bodymassindex;
contrast-enhancedradiography,balancedhydrationwithi.v. BNP,B-typenatriureticpeptide;BSA,bodysurfacearea;CABG,coronaryarterybypass
isotonicfluids,theuseofaminimalvolumeofcontrastmedia, IIa graft;CAD,coronaryarterydisease;CCS,chroniccoronarysyndrome;CCTA,coronary
computedtomographyangiography;CIED,cardiacimplantableelectronicdevice;CPET,
andtheuseoflow-osmolaroriso-osmolarcontrastmedia
cardiopulmonary exercise testing; CRT, cardiac resynchronization therapy; CV,
shouldbeconsidered. cardiovascular; CVD, cardiovascular disease; DAPT, dual antiplatelet therapy; ECG,
IfacystatinCmeasurementassayisavailable,cystatinC
electrocardiogram;eGFR,estimatedglomerularfiltrationrate;ESC,EuropeanSocietyof
Cardiology; FOCUS, focused cardiac ultrasound; GFR, glomerular filtration rate; HF,
measurementshouldbeconsideredinpatientswithimpaired IIa
heartfailure;i.v.,intravenous;LMWH,lowmolecularweightheparin;LV,leftventricular;
eGFR(,45–59mL/min/1.73m2)toconfirmkidneydisease. LVEF, left ventricular ejection fraction; LVESD, left ventricular end-systolic diameter;
LVESDi, left ventricular end-systolic dimension index; MHV, mechanical heart valve;
Obesity
MINS,myocardialinjuryfollowingnon-cardiacsurgery;MR,mitralvalveregurgitation;MS,
Itisrecommendedtoassesscardiorespiratoryfitnessto mitralvalvestenosis;NCS,non-cardiacsurgery;NOAC,non-vitaminKantagonistoral
anticoagulant; NSTE-ACS, non-ST-segment elevation acute coronary syndrome;
estimateperi-operativeCVriskinobesepatients,with
I NT-proBNP,N-terminalpro-B-typenatriureticpeptide;OAC,oralanticoagulant;PAD,
particularattentiontothoseundergoingintermediate-and peripheralarterydisease;PCC,prothrombincomplexconcentrate;PCI,percutaneous
high-riskNCS. coronary intervention; PE, pulmonary embolism; PMC, percutaneous mitral
commissurotomy;PMI,peri-operativemyocardialinfarction/injury;RBC,redbloodcell;
Inpatientsathighriskofobesityhypoventilationsyndrome, SAVR, surgical aortic valve replacement; SGLT-2, sodium–glucose co-transporter-2;
additionalspecialistinvestigationbeforemajorelectiveNCS IIa SPAP, systolic pulmonary artery pressure; STEMI, ST-segment elevation myocardial
shouldbeconsidered. infarction; SVT, supraventricular tachycardia; TAVI, transcatheter aortic valve
implantation;TTE,transthoracicechocardiography;UFH,unfractionatedheparin;VAD,
Continued ventricularassistdevice;VKA,vitaminKantagonist;VT,ventriculartachycardia.
2202CSE©
Downloaded
from
https://academic.oup.com/eurheartj/article/43/39/3826/6675076
by
guest
on
22
January
2026
--- Страница 13 ---
3838 ESCGuidelines
Table4B Revisedrecommendations
Recommendationsin2014version Class Recommendationsin2022version Class
Preoperativeassessmenttools—Section4
Electrocardiographyandbiomarkers
Pre-operativeECGisrecommendedforpatientswhohaverisk InpatientswhohaveknownCVDorCVriskfactors(includingage
factor(s)andarescheduledforintermediate-orhigh-risksurgery. ≥65years),orsymptomsorsignssuggestiveofCVDitis
I I
recommendedtoobtainapre-operative12-leadECGbefore
intermediate-orhigh-riskNCS.
Assessmentofcardiactroponinsinhigh-riskpatients,bothbefore InpatientswhohaveknownCVD,CVriskfactors(includingage
and48–72haftermajorsurgery,maybeconsidered. ≥65years),orsymptomssuggestiveofCVD,itisrecommendedto
IIb I
measurehs-cTnTorhs-cTnIbeforeintermediate-andhigh-risk
NCS,andat24hand48hafterwards.
NT-proBNPandBNPmeasurementsmaybeconsideredfor InpatientswhohaveknownCVD,CVriskfactors(includingage
obtainingindependentprognosticinformationforperi-operative ≥65years),orsymptomssuggestiveofCVD,itshouldbe
IIb IIa
andlatecardiaceventsinhigh-riskpatients. consideredtomeasureBNPorNT-proBNPbeforeintermediate-
andhigh-riskNCS.
Universalpre-operativeroutinebiomarkersamplingforrisk Inlow-riskpatientsundergoinglow-andintermediate-riskNCS,it
stratificationandtopreventcardiaceventsisnotrecommended. III isnotrecommendedtoroutinelyobtainpre-operativeECG, III
hs-cTnT/I,orBNP/NT-proBNPconcentrations.
Coronaryangiography
Pre-operativeICAisnotrecommendedincardiac-stablepatients Routinepre-operativeICAisnotrecommendedinstableCCS
III III
undergoinglow-risksurgery. patientsundergoinglow-orintermediate-riskNCS.
Generalrisk-reductionstrategies—Section5
Pharmacologicaltreatment
TransientdiscontinuationofACEIsorARBsbeforeNCSin InpatientswithoutHF,withholdingRAASinhibitorsonthedayof
IIa IIa
hypertensivepatientsshouldbeconsidered. NCSshouldbeconsideredtopreventperi-operativehypotension.
Antiplatelets
Considerationshouldbegiventoperformingnon-urgentNCSin ItisrecommendedtodelayelectiveNCSuntil6monthsafter
patientswhohavehadrecentDESimplantationnosoonerthan12 electivePCIand12monthsafteranACS.
IIa I
monthsfollowingtheintervention.Thisdelaymaybereducedto6
monthsforthenew-generationDES.
Itisrecommendedthataspirinbecontinuedfor4weeksafterBMS AfterelectivePCI,itisrecommendedtodelaytime-sensitiveNCS
implantationandfor3–12monthsafterDESimplantation,unless untilaminimumof1monthofDAPTtreatmenthasbeengiven.
I I
theriskoflife-threateningsurgicalbleedingonaspirinis
unacceptablyhigh.
Continuationofaspirin,inpatientspreviouslythustreated,maybe InpatientswithapreviousPCI,itisrecommendedtocontinue
consideredintheperi-operativeperiod,andshouldbebasedonan aspirinperi-operativelyifthebleedingriskallows.
IIb I
individualdecisionthatdependsontheperi-operativebleeding
risk,weighedagainsttheriskofthromboticcomplications.
Discontinuationofaspirintherapy,inpatientspreviouslytreated InpatientswithoutahistoryofPCI,interruptionofaspirinatleast3
withit,shouldbeconsideredinthoseinwhomhaemostasisis IIa daysbeforeNCSmaybeconsideredifthebleedingriskoutweighs IIb
anticipatedtobedifficulttocontrolduringsurgery. theischaemicrisk,toreducetheriskofbleeding.
InpatientstreatedwithP2Y inhibitors,whoneedtoundergo IfinterruptionofP2Y inhibitorisindicated,itisrecommendedto
12 12
surgery,postponingsurgeryforatleast5daysaftercessationof withholdticagrelorfor3–5days,clopidogrelfor5days,and
ticagrelorandclopidogrel—andfor7daysinthecaseofprasugrel IIa prasugrelfor7dayspriortoNCS. I
—ifclinicallyfeasible,shouldbeconsideredunlessthepatientisat
highriskofanischaemicevent.
Specificdiseases—Section6
Coronaryarterydisease
IfPCIisindicatedbeforesemi-urgentsurgery,theuseof IfPCIisindicatedbeforeNCS,theuseofnew-generationDESis
new-generationDES,BMSorevenballoonangioplastyis I recommendedoverBMSandballoonangioplasty. I
recommended.
Continued
Downloaded
from
https://academic.oup.com/eurheartj/article/43/39/3826/6675076
by
guest
on
22
January
2026
--- Страница 14 ---
ESCGuidelines 3839
Arrhythmias
PatientswithICDs,whosedeviceshavebeenpre-operatively ItisrecommendedthatpatientswithtemporarilydeactivatedICDs
deactivated,shouldbeoncontinuouscardiacmonitorthroughout havecontinuousECGmonitoring,andduringtheperi-operative
theperiodofdeactivation.Externaldefibrillationequipment periodareaccompaniedbypersonnelskilledinearlydetectionand
shouldbereadilyavailable. I treatmentofarrhythmias.Inhigh-riskpatients(e.g. I
pacemaker-dependantorICDpatients),orifaccesstothetorso
willbedifficultduringtheprocedure,itisrecommendedtoplace
transcutaneouspacing/defibrillationpadspriortoNCS.
Hypertension
Largeperi-operativefluctuationsinbloodpressureinhypertensive InpatientswithchronichypertensionundergoingelectiveNCS,itis
patientsshouldbeavoided. recommendedtoavoidlargeperi-operativefluctuationsinblood
IIa I
pressure,particularlyhypotension,duringtheperi-operative
period.
CliniciansmayconsidernotdeferringNCSinpatientswithgrade1 ItisnotrecommendedtodeferNCSinpatientswithstage1or2
or2hypertension(systolicbloodpressure,180mmHg;diastolic IIb hypertension. III
bloodpressure,110mmHg).
Peripheralarterydisease
PatientswithPADshouldbeclinicallyassessedforischaemicheart Inpatientswithpoorfunctionalcapacityorwithsignificantrisk
diseaseand,ifmorethantwoclinicalriskfactorsarepresent,they factorsorsymptoms(suchasmoderate-to-severeanginapectoris,
shouldbeconsideredforpre-operativestressorimagingtesting. IIa decompensatedHF,valvulardiseaseandsignificantarrhythmia), I
referralforcardiacwork-upandoptimizationisrecommended
priortoelectivesurgeryforPADorAAA.
Diabetesmellitus
Inpatientsathighsurgicalrisk,cliniciansshouldconsiderscreening Inpatientswithdiabetesordisturbedglucosemetabolism,a
forelevatedHbA1cbeforemajorsurgeryandimproving pre-operativeHbA1ctestisrecommended,ifthismeasurement
pre-operativeglucosecontrol. IIa hasnotbeenperformedintheprevious3months.Incaseof I
HbA1c≥8.5%(≥69mmol/mol),electiveNCSshouldbe
postponed,ifsafeandpractical.
Peri-operativemonitoringandanaesthesia—Section7
Patientswithhighcardiacandsurgicalriskshouldbeconsideredfor InordertopreserveoptimalCVstability,itisrecommendedto
goal-directedtherapy. IIa applygoal-directedhaemodynamictherapyinpatientsundergoing I
high-riskNCS.
Avoidingarterialhypotension(meanarterialpressure Inordertominimizetheriskofpost-operativeorgandysfunction,
,60mmHg)forprolongedcumulativeperiods(.30min)maybe itisrecommendedtoavoidanintra-operativemeanarterial
IIb I
considered. pressuredecreaseof.20%frombaselinevaluesor,60–
70mmHgfor≥10min.
Avoidingnon-steroidalanti-inflammatorydrugs(especially Non-aspirinNSAIDsarenotrecommendedasfirst-lineanalgesics
cyclo-oxygenase-2inhibitors)asthefirst-lineanalgesicsinpatients IIb inpatientswithestablishedorhighriskofCVD. III
withIHDorstrokemaybeconsidered.
AAA,abdominalaorticaneurysm;ACEI,angiotensin-converting-enzymeinhibitor;ARB,angiotensinreceptorblocker;BNP,B-typenatriureticpeptide;BMS,baremetalstent;CCS,
chroniccoronarysyndrome;CV,cardiovascular;CVD,cardiovasculardisease;DAPT,dualantiplatelettherapy;DES,drug-elutingstent;ECG,electrocardiogram;HbA1c,glycated
haemoglobinA1c;HF,heartfailure;hs-cTn,high-sensitivitycardiactroponin;ICA,invasivecoronaryangiography;ICD,implantablecardioverter–defibrillator;IHD,ischaemicheart
disease; NCS, non-cardiac surgery; NSAID, non-steroidal anti-inflammatory drug; NT-proBNP, N-terminal pro-B-type natriuretic peptide; PAD, peripheral artery disease; PCI,
percutaneouscoronaryintervention;RAAS,renin−angiotensin−aldosteronesystem.
2.2. The magnitude of the problem had an overall population of 448 million in 2020 (27 countries),
Theannualvolumeofmajorsurgeryworldwideisestimatedtobe
thisfiguretranslatesintoacrudeestimateofnearly22millionmajor
morethan300millionpatients(about5%oftheworldpopulation),
proceduresannually.2
whichisa34%increasefrom2004to2012.1,2Nearly74%ofthese Nearly85%ofmajoroperationsarenon-cardiacsurgicalproce-
operationsareperformedincountriesspendingsubstantialamounts
dures.3InarecentreportfromtheUSANationalInpatientSample
onhealthcare.WhenappliedtoEuropeanUnioncountries,which
database,nearlyhalfofadultsaged≥45yearsundergoingmajornon-
2202CSE©
Downloaded
from
https://academic.oup.com/eurheartj/article/43/39/3826/6675076
by
guest
on
22
January
2026
--- Страница 15 ---
3840 ESCGuidelines
cardiac surgery (NCS) presented with at least two cardiovascular cardiovasculardisease(CVD)isapotentialsourceofcomplications
(CV) risk factors, 18% had coronary artery disease (CAD), 4.7% duringNCS.
had a history of stroke, and 7.7% had a modified Revised Cardiac
RiskIndex(RCRI)score≥3(range0–6)in2012–13.Thesepreva- 2.3. Change in demographics
lenceratesshowasubstantialincreasecomparedwiththeequivalent Withinthenext30years,theageingofthepopulationwillhaveama-
ratesin2008–09.4Inalargeregistryincluding37915consecutivepa- jorimpactonperi-operativepatientmanagement.Patientsundergoing
tientsundergoingpercutaneouscoronaryinterventions(PCIs)with NCSareolderthantherestofthepopulation.Furthermore,itises-
drug-eluting stent (DES), the rates of NCS after PCI were 11% timated that by 2030, one-fifth of individuals aged .75 years will
and 24%, 1 and 3 years after PCI respectively. The cut-off ages at undergosurgeryeachyear.Inaddition,between2018and2050,the
which NCS was more likely to occur within 1 and 3 years of PCI numberofpeopleinEuropeaged75–84yearsisprojectedtoincrease
were62and73yearsrespectively.5 by(cid:4)60%.Thetotalnumberofsurgicalproceduresmayincreaseeven
Theprevalenceofcomorbidities,theclinicalconditionofpatients fasterbecauseofthegreaterneedforinterventionswithincreasing
beforesurgery,andtheurgency,magnitude,type,anddurationofthe age. Demographics of patients undergoing surgery show trendsto-
surgical procedure determine the risk of peri-operative complica- wardsincreasingnumbersofelderlypatientsandincreasingnumbers
tions. In a recent cohort study of 40000 patients aged ≥45 years ofpatientswithcomorbidities,particularlyCVDs.Thus,adultsaged
undergoinginpatientNCS,oneofsevenexperiencedamajorcardiac ≥75yearshaveagreaterriskofperi-operativemajoradversecardio-
orcerebrovascularcomplicationat30days.6Cardiovascularcompli- vascular events (MACEs) (9.5% vs. 4.8% for younger adults [P,
cationscanparticularlyoccurinpatientswithdocumentedorasymp- 0.001]).9However,ageperseseemstoberesponsibleforasmallin-
tomatic coronary heart disease, left ventricular (LV) dysfunction, creaseintheriskofcomplications;greaterrisksareassociatedwithur-
valvularheartdisease(VHD),andarrhythmias,whoundergosurgical gencyandsignificantCV,pulmonary,andrenaldisease.
proceduresthatareassociatedwithprolongedhaemodynamicand
cardiac stress. In the case of peri-operative myocardial ischaemia, 2.4. Purpose
three mechanisms are important: (i) oxygen supply–demand mis- Asmanyyearshavepassedandnewevidencehasbecomeavailablesince
matchonthebackgroundofcoronaryarterystenosisthatmaybe- thepublication ofthe2014ESC/EuropeanSocietyofAnaethesiology
come flow-limiting by peri-operative haemodynamic fluctuations; (ESA) Guidelines on non-cardiac surgery: cardiovascular assessment
(ii)acutecoronarysyndrome(ACS)duetostress-inducederosion and management,10 the ESC has decided to revise the guidelines on
or rupture of a vulnerable atherosclerotic plaque in combination NCS.Thesenewguidelinesarebasedonthe2014edition,butallsec-
with pro-inflammatory andhypercoagulablestatesinduced bysur- tions have been revised or rewritten, and several new sections have
gery,andthehaemodynamicdistressresultingfromfluidshiftsand been added. Some of the old recommendations are unchanged or
anaesthesia;and(iii)surgery-associatedbleedingriskrequiringinter- havebeenrevised,andnewrecommendationshavebeenadded.
ruptionofantiplatelettherapies,whichmightleadtostentthrom- Theseguidelinesareintendedforphysicians,healthcareworkers,
bosisamongpatientsundergoingNCSafterrecentcoronarystent andcollaboratorsinvolvedinthepre-operative,operative,andpost-
placement.Leftventriculardysfunctionandarrhythmiasmayoccur operativecareofpatientsundergoingNCS.Theobjectiveistoen-
for various reasons at all ages. Because the prevalence of CAD, dorseastandardizedandevidence-basedapproachtoperi-operative
VHD, heart failure, and arrhythmias increases with age, peri- CVmanagement.Theguidelinesrecommendastepwiseevaluation
operative CV mortality and morbidity are predominantly an issue of the patient that integrates clinical risk factors and test results
intheadultpopulationundergoingmajorNCS. with the estimated stress of the planned surgical procedure and
InEurope,recentsystematicdataontheannualnumberandtype therisksinvolvedwiththediscontinuationofdrugs.Thisresultsin
of operations, and on patient outcomes are unfortunately lacking. an individualized riskassessment, with the opportunityofinitiating
Additionally, data definitions vary, as do data quantity and quality. medicaltherapy,coronaryinterventions,andspecificsurgicalandan-
Basedontheestimatesoutlinedabove,nearly6.6millionprocedures aesthetictechniques,orwithholdingmedicaltherapy,inordertoop-
areperformedannuallyinEuropeanpatientswithCAD,peripheral timize the patient’s peri-operative condition. Further, it should be
arterydisease(PAD),andcerebrovasculardiseasewhoareathigh discussedinwhichinstitutions(specializedsmallhospitalvs.tertiary
risk of CV complications. In a 7 day cohort study, the European care)theNCSwillbeperformed.Itisimportantthatpatients’values
SurgicalOutcomesStudy(EuSOS)groupinvestigatedtheoutcomes andpreferenceswithrespecttothebenefitsandrisksofsurgeryare
ofNCSin498hospitalsacross27EuropeannationsandtheUK;up takenintoconsideration,andthatpatientsareinvolvedinthedeci-
to8%ofpatientsundergoingNCSrequiredcriticalcareadmission, sions.Thisisparticularlyimportantwhenitcomestodecisionsabout
whilein-hospitalmortalityranged1.4–21.5%(mean4.0%),depend- undergoingelectivesurgeryornot,thetimingofsurgery,andchoice
ing on safety precautions.7 In a recent prospective study of 2265 ofsurgicalandanaesthetictechniques.
high-riskpatientsundergoingNCSinSwitzerland,oneoutoffivede- Comparedwithnon-surgicalsettings,randomizedcontrolledtrials
velopedmajoradverseeventswithin365days.8Whenappliedtothe (RCTs)arescarceinthisfield.However,sincethepublicationofthe
populationinEuropeanUnioncountries,thesefigurestranslateinto 2014ESC/ESAGuidelinesonnon-cardiacsurgery:cardiovascularas-
atleast660000majorcardiacorcerebrovascularcomplicationsoc- sessment and management there has been a significant increase in
curringannuallyduetoNCSprocedures. RCTsthatarerelevantinthissetting.Whennotrialsareavailable
The2022ESCGuidelinesoncardiovascularassessmentandman- on a specific CV management regimen in the surgical setting, data
agementofpatientsundergoingNCSfocusonthepre-operativeCV from the non-surgical setting may be extrapolated and similar re-
riskassessmentandperi-operativemanagementofpatientsinwhom commendationsmade,butwithdifferentlevelsofevidence.
Downloaded
from
https://academic.oup.com/eurheartj/article/43/39/3826/6675076
by
guest
on
22
January
2026
--- Страница 16 ---
ESCGuidelines 3841
These guidelines have the potential to improve peri- and post- takesplace(experienceofinstitution,electivevs.emergencyproced-
operativeoutcomesandhighlighttheexistenceofaclearopportunity ure).14Theriskmaybereducedbyanadequatepre-operativeevalu-
forimprovingthequalityofcare.Followingthepublicationofthese ation and proper selection of type and timing of the surgical
updatedguidelinesonNCS,theireffectsonoutcomesshouldbemon- procedure(Figure1).
itored.Theobjectiveevaluationsofthequalityoftheassessmentsand
theoutcomesaredescribedinqualityindicators(Section13). 3.1. Surgery-related risk
The surgery-related risk is determined by the type and duration
2.5. The outcomes we want to prevent
of the surgery, and the urgency of the procedure or intervention.
Therecommendations intheseguidelines areintended to prevent The type of anaesthesia and anaesthetic drugs may also influence
peri-operative CV morbidity and mortality, for example: peri-
theriskofcomplicationsinpatientsatintermediatetohighcardiac
operativemyocardialinfarction/injury(PMI),stentthrombosis,acute riskundergoingNCS(seeSection7).15Thesurgicalriskestimateis
heartfailure(HF),haemodynamicallyrelevantarrhythmias,pulmon-
abroadapproximationof30dayriskofCVdeath,MI,andstroke,
aryembolism(PE),ischaemicstroke,anddeath.Itisalsoimportant whichonlytakesintoaccountthespecificsurgicalinterventionwith-
topreventbleedingcomplications,especiallyassociatedwithantith- outconsideringthepatient’scomorbidities(Table5).10,16
rombotictreatment,sincebleedingisassociatedwithanincreased
Anysurgicalproceduremayincreasethelevelofcortisolandca-
riskofMIanddeath.6,11–13
techolaminesasstressresponsesduetotissueinjuryandinflamma-
tion,andneuro–endocrineandsympathovagalimbalance.Changesin
3. Clinical risk evaluation bodycoretemperature,bloodloss,andfluidshiftsmaycausearisein
vascularresistanceaswellashypotension,17leadingtoimbalancebe-
CardiovascularmorbidityandmortalityinpatientsundergoingNCS tweenmyocardialoxygendemandanddelivery.Bleeding,transfusion
aredeterminedbytwomainfactors:patient-relatedriskandtypeof ofbloodproducts,tissueinjury,andinflammatoryresponsemayaf-
surgery or procedure, including the circumstances under which it fectthecoagulationsystem,inducingaprothromboticstate.
Risk reduction
Patient-related risk
(Surgery)
Low risk Moderate risk High risk
Surgery-
related risk
Consider
Increased High
High risk postponing
attention attention
or avoiding
Increased High
Moderate risk Attention
attention attention
Increased
Low risk Attention Attention
attention
CV risk reduction
(Patient)
Figure1Totalriskisaninteractionofpatient-relatedandsurgery-relatedrisk.Ideally,thetotalriskshouldbeascloseaspossibletothelowerleft
corner,bychoosingsurgery/procedure/anaesthesia/institutionwiththelowestpossibleriskalongwitheffortstomitigatethepatient’sCVrisk.
Downloaded
from
https://academic.oup.com/eurheartj/article/43/39/3826/6675076
by
guest
on
22
January
2026
--- Страница 17 ---
3842 ESCGuidelines
Table5 Surgicalriskestimateaccordingtotypeofsurgeryorintervention
Lowsurgicalrisk(,1%) Intermediatesurgicalrisk(1–5%) Highsurgicalrisk(.5%)
(cid:129) Breast (cid:129) Carotidasymptomatic(CEAorCAS) (cid:129) Adrenalresection
(cid:129) Dental (cid:129) Carotidsymptomatic(CEA) (cid:129) Aorticandmajorvascularsurgery
(cid:129) Endocrine:thyroid (cid:129) Endovascularaorticaneurysmrepair (cid:129) Carotidsymptomatic(CAS)
(cid:129) Eye (cid:129) Headornecksurgery (cid:129) Duodenal-pancreaticsurgery
(cid:129) Gynaecological:minor (cid:129) Intraperitoneal:splenectomy,hiatalhernia (cid:129) Liverresection,bileductsurgery
(cid:129) Orthopaedicminor(meniscectomy) repair,cholecystectomy (cid:129) Oesophagectomy
(cid:129) Reconstructive (cid:129) Intrathoracic:non-major (cid:129) Openlowerlimbrevascularizationforacutelimb
(cid:129) Superficialsurgery (cid:129) Neurologicalororthopaedic:major(hipand ischaemiaoramputation
(cid:129) Urologicalminor:(transurethralresection spinesurgery) (cid:129) Pneumonectomy(VATSoropensurgery)
oftheprostate) (cid:129) Peripheralarterialangioplasty (cid:129) Pulmonaryorlivertransplant
(cid:129) VATSminorlungresection (cid:129) Renaltransplants (cid:129) Repairofperforatedbowel
(cid:129) Urologicalorgynaecological:major (cid:129) Totalcystectomy
CAS,carotidarterystenting;CEA,carotidendarterectomy;CV,cardiovascular;MI,myocardialinfarction;VATS,video-assistedthoracicsurgery.
Surgicalriskestimateisabroadapproximationof30dayriskofCVdeath,MI,andstrokethattakesintoaccountonlythespecificsurgicalintervention,withoutconsideringthepatient’s
comorbidities.
AdaptedfromdatainGlanceetal.,Mulleretal.,Bendixenetal.,andFalcozetal.18–23
3.1.1.Timingofsurgery an anaesthesiologist, in order to achieve optimized anaesthesia
Ingeneral,acuteprocedurescarryahigherriskofcomplicationsthan for each patient (see Section 7).
electiveprocedures.Uniformtimingdefinitionsareunfeasible,asthe
timespansmayvarybetweendiseases.Theseguidelinesusethetim- 3.2. Type of surgical approach
ingdefinitionsbelow. Newsurgicaltechniqueshavebeenintroducedtoreplaceopensur-
Immediate:surgery/interventionshouldbeperformedwithout geryandtoreducetheoverallriskforthepatient.
anydelaytosavelifeororganfunction.
Urgent:surgery/interventionshouldbeperformedwithoutun- 3.2.1.Laparoscopy
necessarydelaytosavelife,limb,ororganfunction. Laparoscopicprocedures,comparedwithopensurgicalprocedures,
Time-sensitive: surgery/intervention should be performed as havetheadvantageofcausinglesstissuetraumaandintestinalparalysis,
soonaspossibleasthereisatime-dependentriskoflosinglimbor resultinginlessincisionalpain,betterpost-operativepulmonaryfunc-
organ function, or increased risk of complications. Cancer surgery tion, significantly fewer wall complications, and diminished post-
istypicallytime-sensitive,asiscarotidsurgerytopreventstrokein operativefluidshiftsrelatedtobowelparalysis.25However,thepneu-
a symptomatic case. The time window for time-sensitive surgery moperitoneum required for these procedures results in elevated
willvarydependingontheunderlyingdisease. intra-abdominal pressure and a reduction in venous return. Typical
Elective:surgery/interventioncanbeperformedelectively(not physiological sequelae are secondary to increased intra-abdominal
furtherdefined)withoutsignificantriskoflosinglimb,ororganfunc- pressureandabsorptionofthegaseousmediumusedforinsufflation.
tion,orincreasedrisksofcomplications. Whilehealthyindividualsoncontrolledventilationtypicallytoler-
Many factors affect outcomes when comparing acute or time- ate pneumoperitoneum, patients with CVD, some types of adults
sensitive vs. elective surgery: the general condition of the patient withcongenitalheartdisease(ACHD),andobesepatientsmayex-
vs. the stage of the acute illness, and how far it has progressed. perience adverse consequences.26 Pneumoperitoneum and
The best interests of the patient should be considered before Trendelenburg position result in increased mean arterial pressure,
deciding on treatment, informed consent to management should centralvenouspressure,meanpulmonaryarterypressure,pulmon-
be obtained, if at all possible, and decisions should be clearly arycapillarywedgepressure,andsystemicvascularresistanceim-
recorded.24 pairing cardiac function.27,28 Therefore, compared with open
The degree of urgency should also be considered (i.e. does surgery,theCVriskinpatientswithCVDisnotnecessarilyreduced
the procedure need to be performed outside working hours inpatientsundergoinglaparoscopy,andbothshouldbeevaluatedin
or can it wait until the next day?). In general, competences thesameway.Thisisespeciallytrueinpatientsundergoinginter-
andsupportivefunctionsarenotalwayspresentintheevenings ventionsformorbidobesity,butalsoinothertypesofsurgery,con-
or during the night; thus, an overall evaluation of what best sideringtheriskofconversiontoanopenprocedure.29,30Superior
serves the patient is necessary. The optimal timing of NCS short-term outcomes of laparoscopic vs. open procedures have
should be discussed within the multidisciplinary team, including beenreported,dependingontypeofsurgery,operatorexperience,
2202CSE©
Downloaded
from
https://academic.oup.com/eurheartj/article/43/39/3826/6675076
by
guest
on
22
January
2026
--- Страница 18 ---
ESCGuidelines 3843
andhospitalvolume;however,fewstudiesprovidedirectmeasures 3.3. Patient-related risk
of cardiac complications.31–33 The benefit of laparoscopic proce-
3.3.1.Initialassessment
dures is probably greater in elderly patients, with reduced length Patient-relatedriskisdeterminedbypatient’sage,thepresenceor
of hospital stay, intra-operative blood loss, incidence of post-
absenceofCVriskfactors(e.g.smoking,hypertension,diabetes,dys-
operativepneumonia,timetoreturnofnormalbowelfunction,in- lipidaemia, family disposition)40 or established CV disease, and
cidence of post-operative cardiac complications, and wound comorbidities.41
infections.34
Identification of patients at risk of CV complications is of para-
mountimportancetochoiceoftherapywhennon-surgicaloptions
3.2.1.1.Vascularandendovascularprocedures are available, or when the type of surgery or anaesthesia impacts
Endovascularabdominalaorticaneurysmrepair(EVAR)isapro- theriskofcomplications.Whenemergencysurgeryisneeded,the
cedure using femoral artery access only, and is therefore asso- evaluation must necessarily be limited; however, most clinical cir-
ciated with lower operative mortality and morbidity than open cumstancesallowasystematicapproach.
repair. It minimizes the surgical risk in simultaneous surgery for Asaninitialassessment,itisrecommendedthatallpatientssched-
the treatment of abdominal aortic aneurysm (AAA) and a non- uledforNCSareevaluatedbyaccuratehistoryandphysicalexamin-
cardiacdisorder,andshortensthetimedelayfromthetreatment ation, with special emphasis on CV risk factors, established CV
ofAAAandthenon-cardiacdisorderinpatientsundergoingtwo- disease, and comorbidities.40 It is also recommended to measure
phasesurgery.35–37TheearlygaininmortalityfromEVARproce- standardlaboratorytests(e.g.haemoglobinandrenalfunction)inall
duresislostafter3–4years,comparedwithopensurgicaltreat- patientsundergoingintermediate-tohigh-risksurgery.Basedonthis
ment, due to general morbidity (especially CV mortality) of information, further assessment of patient-related risk can proceed
AAApatients. dependingonthesurgery-relatedrisk,asshowninFigure2.Itisrecom-
Variousvascularandnon-vascularNCSproceduresbeardifferent mendedtoperformanelectrocardiogram(ECG),assessthefunctional
operative risks. While aortic and infra-inguinal vascular surgical capacity, and/or measure biomarkers (cardiac troponins and/or
procedures are both regarded as high-risk procedures, their risk N-terminalpro-B-typenatriureticpeptide[NT-proBNP]/B-typenatri-
can be modified by adequate peri-operative measures.38 For uretic peptide [BNP]) depending on the patient-related and
patients undergoing treatment of femoropopliteal artery disease, surgery-relatedrisk(Figure2).Detailedinformationonavailabletools
anendovascular-firstapproachmaybeadvisableincaseofadditional forriskassessment,theirprognosticability,andindicationstoperform
significantcomorbidity.Ameta-analysisofstudiescomparingopen themisgiveninSection4.Moredetailsonpre-operativemanagement
surgerywithPCIforthetreatmentoffemoropoplitealarterialdis-
ofpatientswithspecificCVdiseasesaregiveninSection6.
easeshowedthatfemoralbypasssurgerywasassociatedwithhigher
morbidity(oddsratio[OR]2.93;95%confidenceinterval[CI],1.34– 3.3.1.1.Patientsaged,65yearswithoutahistoryof
6.41)butsimilarmortalityat30dayscomparedwithendovascular cardiovasculardiseaseorcardiovascularriskfactors
treatment.39 Patientsaged,65yearswithoutsigns,symptoms,orhistoryofCVD
orCVriskfactorsareconsideredtobeoflowrisk,andcanproceed
tolow-andmoderate-risksurgerywithoutadditionalpre-operative
3.2.1.2.Video-assistednon-cardiacsurgery
risk assessment.41 Before high-risk surgery, ECG and biomarkers
Video-assisted thoracic surgery (VATS) is supported by a trial
shouldbeconsidered(seeSections4.3and4.4).42
showing fewer peri-operative complications and a better quality
PatientswithoutsignsorsymptomsofCVD,butwithafamilyhis- oflifeinthefirstyearfollowingsurgeryforstage1lungcancercom-
toryofgeneticcardiomyopathy(i.e.dilatated,hypertrophic,arrhyth-
pared with anterolateral thoracotomy.20 Also, a large propensity
mic,orrestrictivecardiomyopathy,orLVnon-compaction)should
matched study conducted by the European Society of Thoracic
be evaluated with an ECG and an echocardiographic examination
Surgeons (ESTS) showed fewer post-operative complications fol-
to rule out the presence of the disease, irrespective of the age.43
lowing VATS compared with open thoracotomy.21 Overall, the
Nospecificdataareavailableintheliteratureregardingriskoffamily
benefits seem greatest in patients with reduced functional lung
memberswithoutthephenotype;however,theyareatriskofdevel-
capacity.
opingthedisease,whichmaybesubclinicalatthetimeoftheNCS.43
Recommendation Table 1 — Recommendations for 3.3.1.2.Patientsaged≥65yearsorwithcardiovascularrisk
selectionofsurgicalapproachandimpactonrisk factors
Patientswhoareaged≥65yearsandpatientswithriskfactorsfor
Recommendations Classa Levelb CVD—suchashypertension,dyslipidaemia,orsmoking—havean
Endovascularorvideo-assistedproceduresshould increased risk of having undetected CVD. The SCORE2 risk-
beconsideredforpatientswithhighCVrisk IIa B prediction tool can be used to estimate their 10 year CVD risk
undergoingvascularorpulmonarysurgery.21,35–39 outside the setting of NCS.40 Patients who are aged ≥65 years
and patients with risk factors for CVD also have an increased
CV,cardiovascular. risk of peri-operative complications during NCS.41,44 These
aClassofrecommendation.
bLevelofevidence. patients need additional assessment before intermediate- and
high-risksurgery(Figure2)andoptimaltreatmentofriskfactors.
2202CSE©
Downloaded
from
https://academic.oup.com/eurheartj/article/43/39/3826/6675076
by
guest
on
22
January
2026
--- Страница 19 ---
3844 ESCGuidelines
Management of patients befffore non-cardiac surgery (NCS)
Emergent or urgent NCS Y Cardiac testing notfffeasiblee
N
Multidisciplinary decision of
Time-sensitive NCS Y individualized cardiac testing.
If time,, manage as elective NCS
N
Elective NCS
Accurate history and clinical examination,, including standard lab tests (Class I)
Advise on stopping smoking,, optimize guideline-recommended medical therappy (Class I)
<65 years without any ≥65 years
Patients with established CVD
CVD/CV risk factorsa or with CV risk factorsa
Low-risk NCS Low-risk NCS Low-risk NCS
None None None (see section 6)
Intermediate-risk NCS Intermediate-risk NCS Intermediate-risk NCS
None ECG,, biomarkkkersb (Class I) ECG,, biomarkkkersb (Class I)
Functional capacityc (Class IIa) Functional capacityc (Class IIa)
(see section 6)
High-risk NCS High-risk NCS High-risk NCS
In patients >45 year,,consider:
ECG,, biomarkkkersb(Class I) ECG,, biomarkkkersb(Class I)
ECG,,biomarkkkersb
(Class IIa)
Functional capacityc (Class IIa) Functional capacityc (Class IIa)
+cardiology consultationd
(see section 6)
Multidisciplinary decision
Figure2Pre-operativeassessmentbeforenon-cardiacsurgery.CV,cardiovascular;CVD,cardiovasculardisease;ECG,electrocardiogram;N,no;NCS,
non-cardiacsurgery.Y,yes;aCVriskfactors:hypertension,smoking,dyslipidaemia,diabetes,familyhistoryofCVD.bBiomarkers:hs-cTnT/I(ClassI)and/
orBNP/NT-proBNP(ClassIIa).Ifpathological,consultacardiologist.cFunctionalcapacitybasedonDukeActivityStatusIndex(DASI)ortheabilityto
climbtwoflightsofstairs.dFordiagnosticandtherapeuticeffortstobeconsidered,seeSection6.eClosefollow-upafterinterventionandsubsequent
managementofheartdiseaseareadvised.
Thisisalsothecaseforpatientswithotherdiseasesknowntobe CVD.ThismaybepreventablebyimplementingappropriateCV
associatedwithahighriskofconcomitantundetectedorknown risk stratification prior to NCS and individually tailoring
CVD(Sections6.8and6.11–6.14). peri-operative therapy to reduce the risk.45 If time allows, it is
also recommended to optimize guideline-recommended treat-
3.3.1.3.Patientswithestablishedcardiovasculardisease ment of the disease before NCS. See Section 6 for a detailed
Thesurgicalprocedurehasthepotentialtoaggravatethedisease discussion of risk assessment and management of patients with
andincreasemorbidityandmortalityinpatientswithestablished knownCVD.
Downloaded
from
https://academic.oup.com/eurheartj/article/43/39/3826/6675076
by
guest
on
22
January
2026
--- Страница 20 ---
ESCGuidelines 3845
Recommendation Table 2 — Recommendations for increase the pre-test probability of haemodynamically significant
allpatientsscheduledfornon-cardiacsurgery but asymptomatic valvular disease. If the patient with the murmur
alsohassymptomsofCVD,anechocardiogramisindicatedbefore
Recommendations Classa Levelb
all NCS. The pre-operative setting is challenging, as the need for
InallpatientsscheduledforNCS,anaccurate NCSandtheriskofCVDhavetobeconsideredasindependentfac-
historyandclinicalexaminationare I C tors.Thus,anechocardiogrammaybeusefulinriskstratificationfor
recommended. somepatients,butwhetheritwouldimproveoutcomeisuncertain.
Itisimportanttobearinmindthatthetimedelaywhenperforming
Itisrecommendedtoperformapre-operative
riskassessment,ideallyatthesametimeasthe I B additional but unnecessaryexaminations may worsen thepatient’s
NCSisproposed.46–53 prognosis.57Ithasalsobeendiscussedthatafocusedcardiacultra-
sound (FOCUS) could replace auscultation in general in the pre-
Iftimeallows,itisrecommendedtooptimize
guideline-recommendedtreatmentofCVDand I C
operativeevaluationofpatients.58Whilecardiacauscultationhasse-
verelimitations,59,60thevalueofperformingaFOCUSasastandard
CVriskfactorsbeforeNCS.
pre-operative evaluation remains uncertain. Cardiac auscultation
CV,cardiovascular;CVD,cardiovasculardisease;NCS,non-cardiacsurgery. shouldnotbereplacedbyFOCUS.
aClassofrecommendation.
bLevelofevidence.
3.3.2.2.Chestpain
PatientsscheduledforNCSmayalsopresentwithpreviouslyunrec-
ognized symptoms suggestive of CAD. The disease leading to the
Recommendation Table 3 — Recommendations for needforNCSmayaggravateasubclinicalCAD,orthepatientmay
patientsaged,65yearswithoutsigns,symptoms,or
have a concomitant undetected CAD. In an elective setting, if the
historyofcardiovasculardisease
symptomsaresuggestiveofCAD,theguidelinesforCADpatients
Recommendations Classa Levelb in the non-surgical setting should be followed (see Sections 4.5.3
and 6.1.2). If immediate, urgent, or time-sensitive NCS is needed,
Inpatientswithafamilyhistoryofgenetic thetimeforandaccesstoadequatediagnostictoolsmaybelimited.
cardiomyopathy,itisrecommendedtoperform I C However,ECGandtroponinscanbeusedtodetectorexcludeACS
anECGandTTEbeforeNCS,regardlessofage (seeSections4.3and4.4).
andsymptoms.
Inpatientsaged45–65yearswithoutsigns,
3.3.2.3.Dyspnoea
symptoms,orhistoryofCVD,ECGand IIa C Dyspnoeaisasymptomofawiderangeofdiseasesandconditions.In
biomarkersshouldbeconsideredbeforehigh-risk a large series of patients, self-reported dyspnoea identified a sub-
NCS. groupofotherwiseasymptomaticpatientsatincreasedriskofdeath
fromCVDandanycause.61Inthediagnosticwork-uptofindtherea-
ECG, electrocardiogram; NCS, non-cardiac surgery; TTE, transthoracic
echocardiography. son for dyspnoea, spirometry, D-dimer, NT-proBNP/BNP, arterial
aClassofrecommendation.
blood gases, and transthoracic echocardiography (TTE) have diag-
bLevelofevidence.
nosticutility61butlimitedspecificity.IfNT-proBNP/BNPiselevated,
anechocardiogramshouldbeperformed.IfNT-proBNP/BNPisnot
3.3.2.Patientswithmurmurs,chestpain,dyspnoea, elevated,otherreasonsfordyspnoeashouldbeexplored.
orperipheraloedema
3.3.2.4.Peripheraloedema
Patients without known CVD and scheduled for elective or acute
NCS are often referred to a cardiologist because of symptoms or Increased hydrostaticpressureleading tooedemaisa featureofa
signsthatmaybecausedbyCVD.Murmurs,chestpain,dyspnoea, widerangeofCVdiseases,butanuprightpositionisalsoacommon
and oedema may suggest severe CVD, but may also be caused by causeofoedema.Thereisaspectrumofotherdiseasesthatcanre-
non-cardiac disease. Thus, the medical history, family history, and sultinperipheraloedemanotlistedhere.
riskfactorshavetobeobtainedandconsidered.Thepatient’sphys-
icalcapacityshouldbeassessed.Theneedforfurtherevaluationof Recommendation Table 4 — Recommendations for
thepatientshouldbedecidedaccordingtotheriskoftheplanned pre-operativeassessmentinpatientswithpreviously
procedureorsurgery. unknown murmur, angina, dyspnoea, or peripheral
oedema
3.3.2.1.Murmurs Recommendations Classa Levelb
Inapatientwithaheartmurmur,butwithoutanysymptomsofCVD,
Newlydetectedmurmur
the value of performing an echocardiogram is not well-established
andconsensusismissing.54–56However,ifaheartmurmursuggesting Inpatientswithanewlydetectedmurmurand
clinicallysignificantpathologyispresentbeforehigh-riskNCS,itisre- symptomsorsignsofCVD,TTEisrecommended I C
commendedtoperformanechocardiogram,eveninpatientswith- beforeNCS.
outanysymptomsofCVD.OldageorincreasedNT-proBNPmay Continued
2202CSE©
2202CSE©
Downloaded
from
https://academic.oup.com/eurheartj/article/43/39/3826/6675076
by
guest
on
22
January
2026
--- Страница 21 ---
3846 ESCGuidelines
Inpatientswithanewlydetectedmurmur Association [NYHA]class IV),cardiogenicshock,severepulmonary
suggestingclinicallysignificantpathology,TTEis I C hypertension, or patients with severe frailty (see Section 4.1.2 for
recommendedbeforehigh-riskNCS. frailtyassessment),high-riskNCSshouldprobablybeavoided.Lifeex-
pectancyandqualityoflifeshouldalsobetakenintoconsideration.
Inpatientswithanewlydetectedmurmur,but
withoutothersignsorsymptomsofCVD,TTE IIa C However, the decision should be made after discussions between
the surgeon, anaesthesiologist, cardiologist, and also a geriatrician
shouldbeconsideredbeforemoderate-riskNCS.
forelderlypatients,alongwiththepatientandrelatives.
Previouslyunknownangina
IfapatientscheduledforelectiveNCShaschest 3.6. The patient perspective
painorothersymptomssuggestiveofundetected
I C PatientswithestablishedCVDmayfaceconcernsabouttheirunder-
CAD,furtherdiagnosticwork-upbeforeNCSis
lyingdiseaseandcurrentCVmedication,co-ordinationbetweenthe
recommended.
surgicalteamandtheircardiologist(examplesprovidedinFigure3),
IfapatientinneedofacuteNCSalsohaschest and the potential excessive risk compared with the expected out-
painorothersymptomssuggestiveofundetected comeofthesurgery.Timeshouldbeallowedtoaddressconcerns
CAD,amultidisciplinaryassessmentapproachis I C and to provide evidence-based information on the risk–benefit
recommendedtochoosethetreatmentwith trade-offsandthesurgicaltreatmentoptions(includingnon-surgical
lowesttotalriskforthepatient. or‘donothing’alternatives)toensureinformedconsent,andtoal-
Dyspnoeaand/orperipheraloedema lowpatientstoengageinshareddecision-makingwiththeaimofsup-
Inpatientswithdyspnoeaand/orperipheral porting the best decision. The team needs to understand the
oedema,anECGandanNT-proBNP/BNPtestis
patient’sconcernsandexpectationsaboutthetreatmentandshort-
indicatedbeforeNCS,unlessthereisacertain
I C andlong-termgoals,astherisk-benefitsoftheinterventionmaynot
non-cardiacexplanation. be aligned with patientpreferences andwishes. Communicating in
plain language (oral and written) and targeting communication to
Inpatientswithdyspnoeaand/orperipheral
oedemaandelevatedNT-proBNP/BNP,TTEis I C fit the individual level of health literacy is pivotal. Several studies
recommendedbeforeNCS.c haveindicatedarelativelyhighprevalenceoflimitedhealthliteracy
inpatientswithCVD(e.g.withHF),62andlimitedhealthliteracyis
BNP,B-typenatriureticpeptide;CAD,coronaryarterydisease;CVD,cardiovascular associatedwithadverseoutcomes.63Anexampleofapatientinfor-
disease;ECG,electrocardiogram;NCS,non-cardiacsurgery;NT-proBNP,N-terminal
mationsheettobeusedinthecommunicationwithpatientsisgiven
pro-B-typenatriureticpeptide;TTE,transthoracicechocardiography.
aClassofrecommendation. intheSupplementarydata,TableS1.
bLevelofevidence.
Recent systematic reviews and meta-analyses have focused on
cIfBNP/NT-proBNPtestingisunavailable,TTEshouldbeconsidered.
shared decision-making in the field of surgery across disease
areas.64–67Ingeneral,shareddecision-makingpositivelyimpactsde-
3.4. Timing of adequate risk evaluation
cisionalconflicts,knowledgegained,satisfaction,anddecisionalanx-
iety(althoughculturalvariationsmayexist).67Inthebreastcancer/
Pre-operativeCVassessment should beperformed prior tosurgery,
endocrineandurologyspecialties,decision-makingandcommunica-
ideally at the time when the decision for NCS has been made.
Accurateestimatesoftherisksandbenefitsofsurgeryisaprerequisite
tionaidsappeartobeeffectivemethodsforsupportingpatients’in-
volvement in decision-making when undergoing elective surgery.
forinformeddecision-makingbybothphysiciansandpatientsaboutthe
Moreover, educational information, provided through interactive
appropriatenessofsurgery.Theseestimatesshouldalsohelpinguiding
multimedia,computer,oronDVD,usedpriortothesurgicalcon-
surgical(endovascular/endoscopicvs.openapproach)andmonitoring
sultationcouldenhancethedecision-makingprocessinadditionto
(intermediate care, screening for CV complications) approaches, and
helptodetectanunexpectedlyhighCVrisk.47Therefore,theprognos-
face-to-facecommunication.66
InEurope,theprevalenceofpre-operativeanxietyamongpatients
ticvalueofpre-operativeCVriskassessmentismuchhigherinelective
undergoing surgical procedures varies from 27–80%.68 Although a
vs. immediate or urgent surgery. Explicit communication of peri-
operativeCVrisk,onthebasisoftheexpectedeventrates,47andrisk certainlevelofanxietyinpatientsmustbeexpected,peri-operative
anxietyisassociatedwithworsesurgicaloutcomesandlongerrecov-
communicationtoolssuchastheAtoZInventoryofDecisionAids
ery,69–72whichhighlightstheimportanceofpre-surgicalassessment
(https://decisionaid.ohri.ca/AZinvent.php)arerecommended.
and,insomepatients,treatmentofanxiety.Factorsassociatedwith
pre-operativeanxietyarecomplexandinclude,amongothers,age,
3.5. Avoidance or allowance for surgery
sex, educational level, type of surgery, and fear of post-operative
in the individual patient complicationsortheoutcome.68Psychologicalreactionsinpatients
IntheclinicalsettingitcanbedifficulttodecidewhetherCVDrepre- undergoing high- or medium–high-risk procedures and/or patients
sentsacontraindicationtoNCS.Ingeneral,theriskforthepatientif withpreviousnegativeexperiencesofNCSmaywarrantparticular
not operated on must be considerably higher than the risk of the attention. Concerns and fears expressed by patients and relatives
treatment.Ideally,anunstablecardiacpatientshouldbestabilizedbe- shouldbetakenseriously.Anumberofreviewsandmeta-analyses
foreNCS,butwaitingcanbedetrimentalforacutesurgicaldisease. havesummarizedtheeffectsofinterventionsonsurgicaloutcomesin
Nodefinitelistcanbemadeforwhichcardiacdiseaseisaclearcontra- abdominal,cardiac,andorthopaedicsurgery,whichmayalsobeapplic-
indicationtoNCS,butinpatientswithsevereHF(NewYorkHeart
abletopatientswithCVconditionsinthesesettings.73–75
2202CSE©
Downloaded
from
https://academic.oup.com/eurheartj/article/43/39/3826/6675076
by
guest
on
22
January
2026
--- Страница 22 ---
ESCGuidelines 3847
Recommendation Table 5 — Recommendations for 4. Pre-operative assessment tools
patientinformation
4.1. Risk scores
Recommendations Classa Levelb
4.1.1.Generalriskcalculators
Itisrecommendedtogivepatientsindividualized Severalriskindiceshavebeendevelopedbasedonmultivariableanalyses
instructionsforpre-operativeandpost-operative I C of observational data and have been validated during the last decade
changesinmedication,inverbalandwritten (Table 6).47,49,76 Most risk calculators integrate both patient-related
formatswithclearandconcisedirections. andsurgery-relatedriskfactors,butnoneofthemincludebiomarkers
Itshouldbeconsideredtosetupastructured amongtheirvariables.Calculatorsformostofthecommonlyusedrisk
informationlist(e.g.achecklisttohelpwith IIa C indicesareavailableonline(Table6).Theriskcalculatorscanbeusedin
commonissues)forpatientswithCVDorathigh addition,orasanalternative,totheassessmentofsurgery-relatedand
riskofCVcomplicationsscheduledforNCS. patient-related risk factors described in Section 3.3. The Task Force
decidedagainstrecommendingonespecificriskscore.TheTaskForce
CV,cardiovascular;CVD,cardiovasculardisease;NCS,non-cardiacsurgery.
aClassofrecommendation. alsodecidedthattheselectioncriteriaforfurtherpre-operativetesting
bLevelofevidence. shouldbeclinicalcriteria,andnotbasedonaspecificscore.
Do I need to take any cardioprotective medication before surgery?
Who will inform my cardiologist about my surgery?
Do I need to pause or reduce any of my medications, and what are the risks if I do so?
Can my heart medications cause any problems during surgery?
Are there any interactions or contraindications between my medications and drugs given during surgery?
Who will take care of me and how will they communicate my history and needs during my hospital stay?
Can you give me information on how I will be monitored before, during, and after surgery?
How will the healthcare professionals involved in my care be informed about my heart condition?
Figure3Examplesofquestionsandconcernsexpressedbypatients.
2202CSE©
Downloaded
from
https://academic.oup.com/eurheartj/article/43/39/3826/6675076
by
guest
on
22
January
2026
--- Страница 23 ---
3848 ESCGuidelines
Table6 Riskscorecalculators
RevisedCardiac SurgicalRisk TheAmericanCollege Surgical TheAmerican
RiskIndex(RCRI) Calculator(2011) ofSurgeryNational Outcome UniversityofBeirut
(1999)a SurgicalQuality RiskTool (AUB)-HAS2
ImprovementProgram (SORT) CardiovascularRisk
(ACSNSQIP)(2013) (2014) Index(2019)b
Variables Ischaemicheart Age Age ASA–PSgrade HistoryofHeartdisease
disease ASA–PSgrade Sex Urgencyof SymptomsofHeart
Cerebrovascular Pre-operative Functionalstatus surgery disease(anginaor
disease dependentfunctional Emergencycase High-risk dyspnoea)
Historyofcongestive status ASAclass surgical Age≥75years
heartfailure Creatinine.1.5mg/dL Currentsteroiduse specialty Anaemia(haemoglobin
Insulintherapyfor Typeofsurgery Asciteswithin30days Surgicalseverity ,12g/dL)
diabetes Systemicsepsiswithin48h (fromminorto VascularSurgery
Serumcreatininelevel Ventilatordependence complexmajor) EmergencySurgery
≥2mg/dL Disseminatedcancer Cancer (2H,2Aand2S)
High-risksurgery Diabetes Age≥65years (eachassigned1point)
(eachassigned1point) Hypertensionontreatment orover
CongestiveHF
Dyspnoea
Currentsmoker
HistoryofsevereCOPD
Dialysis
Acuterenalfailure
Bodymassindex
Surgerycode
Scorerange Score1;risk6.0% Absoluterisk:0–100% Absoluterisk:0–100% Absoluterisk: Lowrisk(score0–1);(0.3
(4.9–7.4) 0–100% and1.6%)c
Score2;risk10.1% Intermediaterisk(score2–
(8.1–10.6) 3);(7.1and17%)c
Score≥3;risk15% Highrisk(score.3);
(11.1–20.0) (.17%)c
Outcome 30dayMI,cardiac Intra-operativeand30 Seriouscomplicationsand 30day 30daydeath,MI,orstroke
arrest,death dayMIorcardiacarrest anycomplicationsat30days mortality
Derivation 1422 211410 1414006 11219 3284
population
Validation Externallyvalidatedin 257385 Externallyvalidatedin 22631 1167414
population varioussurgical varioussurgicalpopulations
populations
Model 0.68–0.76 0.81–0.85 0.73 0.81–0.92 0.82
performance
(AUC)
Interactive https://www.mdcalc. http://www. https://riskcalculator.facs. http://www.
calculator com/revised-cardiac- surgicalriskcalculator. org sortsurgery.
risk-index-pre- com/miorcardiacarrest com
operative-risk
AUC,areaundercurve;ASA–PS,AmericanSocietyofAnesthesiologyPhysicalStatus;COPD,chronicobstructivepulmonarydisease;HF,heartfailure;MI,myocardialinfarction;RCRI,
RevisedCardiacRiskIndex.
aTheRCRIwasupdatedJanuary2019.
bDakiketal.2019,2020,and2022,andMsheiketal.49–51,81
cThepercentagesrelatetogeneralsurgeries.50
The RCRI estimates the risk of 30 day mortality, MI, or score of 1 indicates a 6% risk; a score of 2, 10%; and a score of
cardiac arrest, and is based on six variables.46,47 It has been ≥3,15%.47
validated in several countries and is easy to use.47 A score of The American College of Surgery National Surgical Quality
0indicatesa4%riskof30daymortality,MI,orcardiacarrest;a ImprovementProgram(ACSNSQIP)developedaninteractiverisk
2202CSE©
Downloaded
from
https://academic.oup.com/eurheartj/article/43/39/3826/6675076
by
guest
on
22
January
2026
--- Страница 24 ---
ESCGuidelines 3849
calculatorprovidinganestimateoftheabsolute30dayprobabilityof Oftheavailablescreeningtoolsforfrailty,theFrailtyIndexandthe
serious complications and any complications compared with the FrailPhenotypearethemostcommonlyrecommended.88,89Ofnote,
average patient.76 Evaluated in the US surgical database, the ACS the Frailty Index includes cognitive testing, while both scores assess
NSQIPmodelperformedbetterthantheRCRI,butanexternalval- physical function.90,91 A simpler approach is offered by the Clinical
idationinthePhilippinesfoundbothtohaveexcellentdiscriminative FrailtyScale,whichreliesoninformationfromthehistorytaking.The
abilitiesforpredictinganyMACE.48TheRCRIcanbeusedwithouta ClinicalFrailtyScalehasbeenvalidatedagainsttheFrailtyIndex.88For
webconnection,whereastheACSNSQIPisprocedure-specificand cognitive screening to incorporate with the Frailty Index, Mini-Cog©
isonlyavailableontheweb.Forclinicaluse,theRCRIismoreaccess- isasimpleandfastscreeningtoolvalidatedforpre-operativescreen-
ible,buttheACSNSQIPoffersprocedure-specificabsoluteriskes- ing92(Supplementarydata,FigureS1,andTablesS2andS3).
timates, which are valuable in patient-guided decision-making. In Onceadiagnosisoffrailtyisconfirmed,theprognosisofafrailpatient
vascularsurgery,bothriskcalculatorshaveshownmoderateaccur- canbeimprovedbyshareddecision-makingbetweenatleastatreating
acywithanareaundercurve(AUC)of0.64(95%CI,0.57–0.70)for physician(e.g.surgeon),anaesthesiologist,geriatrician,thepatient,and
ACSNSQIPand0.60(95%CI,0.54–0.65)forRCRI,duetounder- the patient’s relatives. During the shared decision-making process, a
estimation of the risk of MI.76a Attempts to generate procedure- careful discussion with a frail patient about goals of care could help
specificvascularcalculatorshavenotgivenbetterpredictionsinval- themtohaverealisticexpectationsandmakebetterinformeddecisions
idationcohorts.77 beforesurgery.AfterashareddecisiontogoaheadwithaplannedNCS,
TheSurgicalOutcomeRiskTool(SORT)estimates30daymortal- multimodalpre-habilitationprogrammes—includingexercise,nutrition,
ity after NCS based on the American Society of Anesthesiologists and psychological interventions—could potentially improve the peri-
PhysicalStatus(ASA–PS)grade,urgencyofsurgery,surgicalspeciality operative prognosis of frail patients by an individualized approach
andseverity,cancer,andage≥65years.Inthevalidationstudy,com- tailored tothepatient’s baselinefunctional status, comorbidities, and
biningsubjectiveassessmentwiththeSORTwassignificantlybetter cognitive/psychologicalfunction.90
thanusingeitheralone.78,79TheSurgicalRiskCalculatorisanother
toolthatpredictsintra-operativeand30dayriskofMIorcardiacar- 4.2. Functional capacity
restbasedonage,ASA–PSgrade,pre-operativedependentfunction- Quantifying functional capacity has been a pivotal step in pre-
alstatus,creatinine,andtypeofsurgery.80 operative cardiac risk assessment.10 Although the validity of
The American University of Beirut (AUB)-HAS2 Cardiovascular interview-based assessment of functional capacity has been ques-
Risk Index is the most recently developed index to assess 30 day tioned,93arecentlargeprospectivecohortstudyofhigh-riskpatients
eventrisk(death,MI,orstroke),andstratifiespatients undergoing undergoingNCSfoundself-reportedinabilitytoclimbtwoflightsof
NCSintolow (score0–1),intermediate(score2–3),andhighrisk stairsaddedincrementalvaluetothe30daycardiaceventratewhen
(score.3)basedonsixdataelements(seeTable6);scores.3de- addedtotheRCRI.94
noteapost-operativeeventrateof.10%.49TheAUB-HAS2Index Metabolicequivalents(METs),4havelongbeenconsideredto
hasbeentestedinabroadspectrumofsurgicalsubpopulationsand indicate poor functional capacity; however, studies using METs
demonstrated superior discriminatory power compared with the havebeenbasedonsubjectiveinterviewsandnotshownprovenva-
commonlyutilizedRCRI(Table6).50,51,81 lue. In the Measurement of Exercise Tolerance before Surgery
Thereissignificantvariabilityinthepredictedriskofcardiaccom- (METS)study,theDukeActivityStatusIndex(DASI)(https://www.
plicationsusingdifferentrisk-predictiontools;nonecanbedisquali- mdcalc.com/duke-activity-status-index-dasi#evidence) had a more
fiedwithcurrentevidence.82 preciseestimationofcardiacriskthansubjectivelyassessedfunction-
al capacity, improving risk estimation using RCRI.95 A DASI score
4.1.2.Frailty ,34 was associatedwith increased oddsof 30 day deathorMI.96
Frailtyisanage-related,multidimensionalstateofdecreasedphysio- FromtheDASIscore,METscanbecalculatedasVO max(maximal
2
logicalreservethatresultsindiminishedresiliency,lossofadaptive oxygen consumption)/3.5; where VO max (mL/kg/min)=0.43×
2
capacity, and increased vulnerability to stressors.83,84 The peri- DASI+9.6. Furthermore, cardiopulmonary exercise testing
operative evaluation of elderly patients (.70 years) who require (CPET)didnotpredict30daymortality,post-operativeMI,orcar-
electiveintermediate-orhigh-riskNCSshouldincludefrailtyscreen- diacarrest.94,95Itshouldbenotedthatarelativelylownumberofpri-
ing,whichhasproventobeanexcellentpredictorofunfavourable maryoutcomeeventslimitedthestatisticalpoweroftheanalysis.
healthoutcomesintheoldersurgicalpopulation.
FrailtyhasarelevantimpactonmortalityandMIriskbutdoesnot
Recommendation Table 6 — Recommendations for
addtoriskestimationderivedfromtheACSNSQIPcalculator,as
pre-operative assessment of frailty and functional
frailtyisassociatedwithvariablesalreadyinthemainmodel.Byadd- capacity
ingsixvariables,theACSNSQIPpredictstheriskofpost-operative
delirium,functionaldecline,needofanewmobilityaid,orpressure Recommendations Classa Levelb
ulcer.85Theuseofthisbroader-inclusivescoreidentifiescasesthat
Inpatientsaged≥70yearsandscheduledto
profit the most by involving a geriatrician in the pre- and post-
undergointermediate-orhigh-riskNCS,frailty
operativeteam.86,87Ameasureoffrailtyinformsthepatientandsur- IIa B
screeningshouldbeconsideredusingavalidated
geonaboutfurtherlifeexpectancyandthechanceofpost-operative
screeningtool.84–87,90,91
delirium,dependencyofmobilitysupport,andneedofnursinghome
Continued
orothercaresupportafterplannedsurgery.
Downloaded
from
https://academic.oup.com/eurheartj/article/43/39/3826/6675076
by
guest
on
22
January
2026
--- Страница 25 ---
3850 ESCGuidelines
Adjustingriskassessmentsaccordingto symptomssuggestiveofcardiacdisorders,andscheduledtoundergo
self-reportedabilitytoclimbtwoflightsofstairs intermediate-orhigh-risksurgery.Itisnotrecommendedtoroutine-
IIa B
shouldbeconsideredinpatientsreferredfor lyobtainapre-operativeECGinlow-riskpatientsundergoinglow-
intermediate-orhigh-riskNCS.94 riskNCS.100
Comparison with previous ECG recordings is helpful whenever
NCS,non-cardiacsurgery. relevant abnormalities are identified. Pre-operative recording of
aClassofrecommendation.
bLevelofevidence. ECG also enables identification of intra- and post-operative ECG
changes.
4.3. Electrocardiography 4.4. Biomarkers
The12-leadECGisawidelyavailable,simple,andinexpensivetool Astheperi-operativeriskforcardiaccomplicationsdependsonthe
thatisabletosemi-quantitativelyassesscardiacrisk(e.g.Qwavesin- presenceandextentofcardiacdisease,widelyavailableandsimple
dicativeofpreviousMI),anddetectunknownCVconditionsrequir- biomarkersthatdetectandquantifyessentialprognosticaspectsof
ing therapy (e.g. atrial fibrillation [AF] or AV-block).97–99 It is cardiacinvolvementmayaidintheevaluation.High-sensitivitycardiac
recommended to obtain a pre-operative 12-lead ECG in patients troponinT/I(Hs-cTnT/I)quantifiesmyocardialinjury,andBNPand
whoareaged≥65yearsorhaveknownCVD,CVriskfactors,or
NT-proBNP quantify haemodynamic cardiac wall stress (Figure 4).
STEP 1
Before NCS NCS After NCS
ECG
hs-cTn hs-cTn hs-cTn
0 1 2
Days
Δ hs-cTn
Δ hs-cTn
Δ hs-cTn If no measurements
available before NCS
STEP 2
If Δ hs-cTn ≥ ULN = PMI
STEP 3
Identify the cause
Clinical assessment ECG Echo
of PMI
PMI
+ +
Figure4Recommendedmeasurementstoassessanddetecttheriskofpost-operativecardiaccomplications.ECG,electrocardiogram;hs-cTn,high-
sensitivitycardiactroponin;PMI,peri-operativemyocardialinfarction/injury;ULN,upperlimitofnormal.Inpatientsscheduledtoundergointermediate-or
high-risksurgery,pre-operativeriskassessmentiscomplementedbyECG,hs-cTn,andBNP/NT-proBNP.Anabsoluteincreaseinhs-cTnconcentrationof
morethantheULNondays1or2aftersurgerycomparedtothepre-operativelevelisdefinedasPMI.109–111Intheabsenceofapre-operativehs-cTnT/I
concentration,averyhighhs-cTnT/Iconcentrationonday1(e.g.morethanfive-timestheULN)orarelevantchangefromday1today2(absoluteincrease
ordecreasemorethantheULNvs.day1)wouldalsoachieveareliablediagnosisofPMI.DetectionofPMIshouldtriggerECGrecordinganddetailedclinical
evaluationforPMIwork-upandtherapy.ThedifferentialdiagnosisofPMIaccordingtothefourthuniversaldefinitionofMIisdiscussedinSection8.TheESC
0/1/2halgorithmhasnotbeenvalidatedfortheperi-operativesettingandcannotbeusedhere.
2202CSE©
Downloaded
from
https://academic.oup.com/eurheartj/article/43/39/3826/6675076
by
guest
on
22
January
2026
--- Страница 26 ---
ESCGuidelines 3851
BothHs-cTnT/IandBNP/NT-proBNPcomplementclinicalassess- InpatientswhohaveknownCVD,CVriskfactors
mentandECGinriskprediction.9,52,53,101–103Hs-cTnT/Iand,toa
(includingage≥65years),orsymptomssuggestive
lesser extent, BNP/NT-proBNP concentrations are higher in pa- ofCVD,itshouldbeconsideredtomeasureBNP IIa B
tients with stress-induced myocardial ischaemia vs. those without, orNT-proBNPbeforeintermediate-andhigh-risk
andverylowhs-cTnT/Iconcentrationsachieveaveryhighnegative NCS.52,104,112–114
predictivevaluetoruleoutmyocardialischaemia.104–107
Inlow-riskpatientsundergoinglow-and
Severallargeprospectivestudieshaveshownthatbothhs-cTnT/I
intermediate-riskNCS,itisnotrecommended
III B
and BNP/NT-proBNP have high and incremental prognostic value
toroutinelyobtainpre-operativeECG,hs-cTnT/I,
forperi-operativecardiaccomplications,includingCVdeath,cardiac orBNP/NT-proBNPconcentrations.109,111,117–119
arrest,acuteHF,andtachyarrhythmias.Inacohortofnearly1000
subjects undergoing major elective NCS, individuals with pre- BNP,B-typenatriureticpeptide;CV,cardiovascular;CVD,cardiovasculardisease;ECG,
electrocardiogram;hs-cTnI,high-sensitivitycardiactroponin;hs-cTnT,high-sensitivity
operative hs-cTn T concentrations of .14ng/L had an in-hospital
cardiactroponinT;NCS,non-cardiacsurgery;NT-proBNP,N-terminalpro-BNP;ULN,
mortalityof6.9%vs.1.2%inpatientswithhs-cTnTconcentrations upperlimitofnormal.
≤14ng/L (P,0.001; AUC 0.81).53 In a large prospective cohort AbnormalECG:pathologicalQwave,ST-Twavechanges,non-sinusrhythm,leftbundle
branchblock.Abnormalpre-operativehs-cTnT/I:morethanULN.Age,sex,andknown
study including 10402 patients from 16 centres, NT-proBNP im-
cardiac disease should also be considered when interpreting the pre-operative
proved risk predication beyond the RCRI.52 Among 1923 patients concentration.98
undergoingNCS,NT-proBNPoutperformedbothRCRIandecho-
AbnormalBNP:≥35pg/mL;abnormalNT-proBNP:≥125pg/mL.BNP/NT-proBNP
should be interpreted as quantitative markers of heart failure, and also take into
cardiographic parameters in the prediction of peri-operative CV accountage,sex,obesity,andknowncardiacdisease.52,114Pleasenotethatage,renal
events.103 Overall, hs-cTn T/I and BNP/NT-proBNP seem to have dysfunction, and obesity are important confounders in the age group in which
comparable accuracy in the prediction of cardiac complica- measurementofBNP/NT-proBNPisrecommended,whilesexhaslessimpact.
tions.52,53,98–103,108However,Hs-cTnT/Ihas
fouradvantages over
a bC Lela vs es lo of fr ee vc ido em nm cee .ndation.
BNP/NT-proBNP:(i)itismorewidelyavailable;(ii)itislessexpen-
sive;(iii)ifnormal,itenablesacuteMItoberuledoutinthepreceding
days;and(iv)availabilityofpre-operativehs-cTnT/Iconcentration
4.5. Non-invasive and invasive
enables accurate diagnosis of PMI on Day 1 after
surgery.109–111
procedures
SeeSection8formoredetailsondiagnosisandtreatmentofPMI.
B-typenatriureticpeptide/NT-proBNPhastwoadvantages.First, 4.5.1.Restingtransthoracicechocardiography
ifelevated,evidencefromrandomizedcontrolledscreeningstudies Inlargeretrospectivecohorts,routinepre-operativeTTEbefore
performedoutsidetheperi-operativesettinghassupportedthecon- high-riskNCSdidnotreducetheriskofpost-operativeMACEor
ceptthatBNP/NT-proBNP-triggeredcardiacwork-upandintensifi- provide more information than clinical risk models.120–122 Poor
cation of therapy improve outcomes.112,113 Second, HF is a exercise tolerance, abnormal ECG, suspected new or significant
frequentlyundiagnosedconditionintheelderlypopulationmostof- CVDs without follow-up within the last 90 days, unexplained
ten undergoing NCS.47,114 Interpreting BNP/NT-proBNP concen- dyspnoea, or coexisting clinical risk factors are appropriate
trationsasquantitativemarkersofHFwithevolvingrule-incut-offs indications for TTE.123,124 Pre-operative TTE provides informa-
may facilitate detection of HF, optimal intra-operative monitoring, tiononthreemainriskmarkersforpost-operativecardiacevents:
andinitiationoroptimizationofHFtherapyaftersurgery.114 LV dysfunction, VHDs, and cardiomyopathies. Left ventricular
Todate,thereisinsufficientevidenceinsupportofotherCVbio- systolic dysfunction is an important predictor of post-operative
markersforthisspecificindication.115,116 HF.125 However, low ventricular ejection fraction is a
borderline independent predictor of major post-operative CV
complications.126–128
Recommendation Table 7 — Recommendations for
pre-operative risk assessment—electrocardiography
Pre-operativeFOCUSexamination—withahand-heldultrasound
andbiomarkers device for the assessment of murmurs, haemodynamic instability,
ventricularfunction,anddyspnea—mayimpactpatientmanagement
Recommendations Classa Levelb byimprovingthediagnosticaccuracyofclinicalassessment,andhelp
totriagecandidatesforstandardTTE,plansurgeryandanaesthesia
InpatientswhohaveknownCVDorCVrisk
technique, and with post-operative
monitoring.129–131
However,
factors(includingage≥65years),orsymptomsor
currentevidenceremainsmostlyconfinedtouncontrolledorretro-
signssuggestiveofCVDitisrecommendedto I C
spectiveobservationalstudieswithnoclearbenefitsontheoutcome,
obtainapre-operative12-leadECGbefore
intermediate-andhigh-riskNCS.97–99
despiteafavourableimpactonperi-operativemanagement.130,132In
amulticentrerandomizedtrial,preliminaryresultsshowedthatpre-
InpatientswhohaveknownCVD,CVrisk
operative FOCUS significantly reduced all-cause mortality.133
factors(includingage≥65years),orsymptoms
Notably, because of the lack of spectral Doppler capabilities, the
suggestiveofCVDitisrecommendedto
I B FOCUS examination is only accurate for assessing main structural
measurehs-cTnTorhs-cTnIbefore
andfunctionalabnormalities.
intermediate-andhigh-riskNCS,andat24hand
Patientswithdiastolicdysfunctionareusuallyold,morehyperten-
48hafterwards.53,105–107,109–111,117
sive,obese,diabetic,andlikelytohaveAForchronicrenaldisease.
Continued
Several studies with different clinical end-points have underlined
2202CSE©
Downloaded
from
https://academic.oup.com/eurheartj/article/43/39/3826/6675076
by
guest
on
22
January
2026
--- Страница 27 ---
3852 ESCGuidelines
theassociationofdiastolicdysfunctionwithpost-operativeadverse rhythm, Wolff–Parkinson–White [WPW] syndrome, ≥0.1mV
events, including pulmonary oedema, AF, and
mortality.134–138
A ST-segmentdepressiononrestingECG,ortakingdigitalis).Inadd-
meta-analysis including 3876 patients undergoing NCS found pre- ition,anexercisetestisunsuitableforpatientswithlimitedexercise
operativediastolicdysfunctiontobeanindependentriskfactorfor capacity, owing to their inability to reach their target heart rate.
pulmonary oedema, congestive HF, and MI after surgery.139 Therefore,anexercisestresstestaloneshouldonlybeconsidered
However, a recent retrospective study, including 7312 patients, a valuable alternative to diagnose obstructive CAD if non-invasive
showed no association between the degree of diastolic imaging tests are unavailable, or for assessing functional capacity
dysfunction and in-hospital mortality or hospital length of stay in whenclinicalhistoryisambiguous.146
NCSpatients.140AwarenessofdiastolicdysfunctionorhighLVfilling
pressure(e.g.pulmonaryhypertension,leftatrialvolume,E/e′ratio)
seems necessary to optimize peri-operative patient management; 4.5.2.2.Stressimaging
however, evidence does not support screening for diastolic Theuseofstressimaging isappropriate forriskassessment inpa-
dysfunction. tients with clinical risk factors and poor functional capacity.147,148
Thechoiceofthetestisdrivenbylocalexpertise.Selection,optimal,
andsafeperformanceofstressimagingshouldcomplywithrelated
Recommendation Table 8 — Recommendations for guidelinesandrecommendations.146,148,149Stressimagingisnotre-
transthoracicechocardiography
commended in patients undergoing urgent surgery or with an un-
stable clinical condition.Evidenceon therole ofstress imaging for Recommendations Classa Levelb
peri-operative risk prediction and patient management is largely
TTEisrecommendedinpatientswithpoor based on inducible ischaemia by pharmacological stress testing, al-
functionalcapacitycand/orhighNT-proBNP/ though no evidence indicates the superiority of pharmacological
BNP,dorifmurmursaredetectedbeforehigh-risk I B stresstoexercisestressimaginginpatientswhoareabletoperform
NCS,inordertoundertakerisk-reduction an adequate level of physical exercise. Several studies and
strategies.121,124,127,141–143 meta-analyseshaveconsistentlydefinedclinicalutilityofpharmaco-
TTEshouldbeconsideredinpatientswith logicalstress imaging forperi-operative riskassessment inpatients
suspectednewCVDorunexplainedsignsor IIa B undergoing NCS.150–154 Although RCTs related to post-operative
symptomsbeforehigh-riskNCS.59,124,125 outcomearelacking,therearelarge-scaleprospectivestudiesshow-
TTEmaybeconsideredinpatientswithpoor ing a risk-adjusted association of stress imaging results with peri-
functionalcapacity,abnormalECG,high
operativecardiaccomplications.155–157
IIb B
NT-proBNP/BNP,dor≥1clinicalriskfactor Studiesandmeta-analyseshavedemonstratedsimilarprognostic
beforeintermediate-riskNCS.126–128 valueofstressechocardiographyandmyocardialperfusionimaging
Toavoiddelayingsurgery,aFOCUSexam forperi-operativeriskassessmentwithslightlyhighernegativepre-
performedbytrainedspecialistsmaybe
dictivevalueofstressechocardiography,152buttheoverallaccuracy
IIb B
consideredasanalternativetoTTEfor varies with ischaemic heart disease (IHD) prevalence.151 A
pre-operativetriage.129,130,132,133,144 moderate-to-largeperfusiondefectoneithertestishighlysensitive
forpost-operativecardiacevents.152,158Normalstressimagingex-
Routinepre-operativeevaluationofLVfunctionis
III C
notrecommended.122,145 amswithoutrestingabnormalitieshavehighnegativepredictiveva-
lue.159,160 However, positive predictive value of stress imaging for
BNP,B-typenatriureticpeptide;CVD,cardiovasculardisease;ECG,electrocardiogram; peri-operativecardiaceventsisrelativelylowandrequiresconfirm-
FOCUS,focusedcardiacultrasound;LV,leftventricular;NCS,non-cardiacsurgery;
NT-proBNP, N-terminal pro-B-type natriuretic peptide; TTE, transthoracic
ationbyothertests.150,152,161
echocardiography. In a recent retrospective study including 4494 patients, dobuta-
aClassofrecommendation.
minestressechocardiography(DSE)providedmodestincremental
bLevelofevidence.
cSeeSection4.2. predictive value for peri-operative CV complications over clinical
d≥125pg/mL/35pg/mL. variablesandwasfoundtobeusefulaspartofastepwiseapproach
intheriskstratificationofpatientsundergoingintermediate-tohigh-
risk NCS.157 The strongest predictors of post-operative adverse
4.5.2.Stresstests eventsdeterminedsofararesignificantischaemia(morethanfour
4.5.2.1.Exercisestresstest ventricularsegments)duringDSE,ischaemicthreshold(60%ofage-
Physicalexercise,usingatreadmillorbicycleergometer,providesan predictedmaximalheartrate),andahistoryofcongestiveHF.162,163
estimate of functional capacity, evaluates blood pressure (BP) and AnegativeDSEwithoutrestingwallmotionabnormalityhasex-
heart rate response, and detects myocardial ischaemia through cellentnegativepredictivevalue,evenwhentargetheartratecannot
pathological ST-segment changes with poor sensitivity (61–73%) beachieveddespiteanaggressiveDSEregimen.164Inasymptomatic
and specificity (60–80%).146 An exercise stress test alone should patients if functionalcapacityisunknown,stress echocardiography
only be considered a valuable alternative to diagnose obstructive alsoenablesdynamicevaluationofLVsystolicanddiastolicfunction;
CAD if non-invasive imaging tests are unavailable.146 An exercise valvulardiseasessuchasaorticvalvestenosis(AS),mitralvalvesten-
stress test is of no diagnostic value in patients with pre-existing osis (MS), and hypertrophic obstructive cardiomyopathy; and pul-
ST-segment abnormalities (i.e. left bundle branch block, paced monary hypertension 165 However, the role of DSE for risk
2202CSE©
Downloaded
from
https://academic.oup.com/eurheartj/article/43/39/3826/6675076
by
guest
on
22
January
2026
--- Страница 28 ---
ESCGuidelines 3853
estimationinnon-ischaemicheartdiseasesbeforeNCShasyettobe InpatientsundergoingNCS,theroleofpre-operativeCCTAto
studied. ruleoutCADhasbeeninvestigatedinsmall-tomedium-sizedobser-
Myocardialperfusionimagingisparticularlysuitableifpatientshave vational studies. The Coronary Computed Tomographic
pooracousticwindowsforDSE.Meta-analysesofpatientsundergo- Angiography and Vascular Events in Noncardiac Surgery Patients
ing major NCS have demonstrated that, compared with fixed de- Cohort Evaluation (Coronary CTA VISION) trial prospectively in-
fects,reversibleperfusiondefectswereassociatedwithhigherrisk vestigatedtheincrementalpredictivevalueofCCTAoverRCRIin
ofcardiacdeathornon-fatalMI.Theriskofcardiaceventscorrelates 955patientswithahistoryoforriskfactorsforCAD,orahistory
withtheextentofreversibleperfusionabnormalities(severe:.20% ofcongestiveHFundergoingNCS.168Coronarycomputedtomog-
of myocardium). Normal myocardial perfusion imaging in high-risk raphyangiographyimprovedtheriskestimationfortheprimaryout-
patientsidentifiesalow-risksubgroupcomparablewiththosewith- comeofpost-operativeCVdeathandnon-fatalMIwithin30days,
outclinicalriskfactorsforadversecardiacoutcomes.154,159,160 althoughCCTAwasassociatedwithmorethanfivetimesinappro-
Stresscardiacmagneticresonance(CMR)imagingandlategado- priateriskoverestimationsamongpatientsnotexperiencingthepri-
linium enhancement are also accurate tools for detection of IHD mary outcome. The predictive value of CCTA further improved
andprognostication.166 whenassociatedwithnon-invasivefunctionaltesting,suchasmyo-
cardialperfusionimaging,withapositiveandnegativepredictiveva-
Recommendation Table 9 — Recommendations for lue of 50% (95% CI, 21–79) and 100% (95% CI, 79–100),
stressimaging respectively.161
Coronary computed tomography angiography associated with
Recommendations Classa Levelb
additionalfunctionalassessmentofcoronarystenosiswithfractional
Stressimagingisrecommendedbeforehigh-risk flow reserve (FFR) with computed tomography (CT) was able to
electiveNCSinpatientswithpoorfunctional identifyfunctionallyseverecoronarystenosisin57%oftheasymp-
I B
capacitycandhighlikelihoodofCADdorhigh tomatic patients with no history of cardiac disease undergoing ca-
clinicalrisk.e,146,156–158 rotidendarterectomy(CEA).169In135asymptomaticpatientswith
Stressimagingshouldbeconsideredbefore nohistoryofcardiacdiseaseundergoingperipheralvascularsurgery,
high-riskNCSinasymptomaticpatientswithpoor pre-operativeFFRwithCTfacilitatedtheidentificationoffunctional-
IIa C
functionalcapacity,dandpreviousPCIor ly severe coronary stenosis in 53% of the patients. These patients
CABG.147 benefited from further revascularization, with a 1 year lower rate
Stressimagingmaybeconsideredbefore
ofCVdeathandMI.170
intermediate-riskNCSwhenischaemiaisof
IIb B
concerninpatientswithclinicalriskfactorsand
4.5.3.2.Invasivecoronaryangiography
poorfunctionalcapacity.d,152,157,158
ThereisalackofinformationfromRCTsrelatingtotheusefulnessof
Stressimagingisnotrecommendedroutinely
III C ICAinpatientsscheduledforNCS.AdoptinganICAassessmentmay
beforeNCS.
also cause an unnecessary and unpredictable delay in an already
CABG, coronary artery bypass graft; CAD, coronary artery disease; ECG, plannedsurgicalintervention,andaddinganindependentprocedural
electrocardiogram;LV,leftventricular;NCS,non-cardiacsurgery;PCI,percutaneous risktotheoverallrisk.DespitethefactthatCADmaybepresentina
coronaryintervention. significant number of patients requiring NCS, indications for pre-
aClassofrecommendation.
bLevelofevidence. operativecoronaryangiographyandrevascularizationaresimilarto
cPhysicalcapacitybasedonDukeActivityStatusIndex(DASI)orinabilitytoclimbtwo angiography indications in the non-surgical setting.98,146,171
flightsofstairs.
Pre-operative treatment of patients with myocardial ischaemia, ei- dPre-testprobability.15%basedonage,sex,andnatureofsymptoms,ortwoormore
riskfactorsforCVD(dyslipidaemia,diabetes,hypertension,smoking,familyhistoryof thermedicallyorwithintervention,isrecommended.
CVD), or resting ECG changes (Q wave or ST-segment/T wave changes), or LV
dysfunctionsuggestiveofCAD.146 RecommendationTable10—Recommendationsfor
eOneormoreclinicalriskfactoraccordingtotheRevisedCardiacRiskIndex(ischaemic
coronaryangiography
heart disease, cerebrovascular disease, history of congestive heart failure, serum
creatininelevel.2mg/dL,diabetesrequiringinsulintherapy).46,47
Recommendations Classa Levelb
4.5.3.Angiography
Itisrecommendedtousethesameindicationsfor
4.5.3.1.Coronarycomputedtomographyangiography
ICAandrevascularizationpre-operativelyasinthe I C
Coronary computed tomography angiography (CCTA) is recom-
non-surgicalsetting.98,146
mended as an initial test for diagnosing CAD in stable patients
CCTAshouldbeconsideredtoruleoutCADin
withalowclinicallikelihoodornopreviousdiagnosisofCAD,and
patientswithsuspectedCCSor
characteristicsassociatedwithahighlikelihoodofgoodimagequal-
biomarker-negativeNSTE-ACSincaseof
ity.146Inaddition,CCTAisrecommendedasanalternativetoinva-
low-to-intermediateclinicallikelihoodofCAD,or IIa C
sive coronary angiography (ICA) for excluding non-ST-segment
inpatientsunsuitablefornon-invasivefunctional
elevation acute coronary syndrome (NSTE-ACS) when there is
testingundergoingnon-urgent,intermediate-,and
low-to-intermediatelikelihoodofCAD,andwhencardiactroponin
high-riskNCS.
and/or ECG are normal or inconclusive.98 The practical utility of
CCTAisreducedwhenahighcoronarycalciumscoreispresent.167 Continued
2202CSE©
Downloaded
from
https://academic.oup.com/eurheartj/article/43/39/3826/6675076
by
guest
on
22
January
2026
--- Страница 29 ---
3854 ESCGuidelines
5.2. Pharmacological
Pre-operativeICAmaybeconsideredinstable
IIb B
CCSpatientsundergoingelectivesurgicalCEA.172 5.2.1.Beta-blockers
Routinepre-operativeICAisnotrecommended Beta-blockersreducemyocardialoxygenconsumptionbyreducing
instableCCSpatientsundergoinglow-or III C contractileforceandheartrate.Beta-blockersarealsoeffectiveanti-
intermediate-riskNCS. arrhythmicagents.Inaddition,somebeta-blockerssuchasmetopro-
lol have an effect on acute inflammatory responses by inhibiting
CAD,coronaryarterydisease;CCS,chroniccoronarysyndrome;CCTA,coronary
computed tomography angiography; CEA, carotid endarterectomy; ICA, invasive neutrophil hyperactivation in acute settings.184 These properties
coronary angiography; NCS, non-cardiac surgery; NSTE-ACS, non-ST-segment mean that beta-blockers have been some of the most frequently
elevationacutecoronarysyndrome.
testedcardioprotectiveagentsinpatientsundergoingNCS.Several
aClassofrecommendation.
bLevelofevidence. RCTs have evaluated the effects of peri-operative beta-blockade
on clinical end-points in patients with different risk profiles (see
Supplementarydata,Section3.1.1.).Type,dosingandtitration,timing
5. General risk-reduction
ofinitiation,durationofbeta-blockertherapy,typeofsurgery,and
strategies risk profile of subjects significantly differ between studies, making
comparisonscomplex.
5.1. Cardiovascular risk factors and Thequestionaboutpre-surgeryinitiationofbeta-blockershasbeen
a matter of intense controversy (see Supplementary data, Section
lifestyle interventions
3.1.1.1). The largest and latest trial on the topic, the Perioperative
ControlofCVriskfactors—includingBP,dyslipidaemia,anddiabetes
Ischemic Evaluation (POISE-1) trial, enrolled 8351 patients with or
—is important before NCS. For pre-operative management of BP
at risk of atherosclerotic disease, and not on beta-blockers before
anddiabetes,seeSections6.8and6.13,respectively.
NCS.Patientswererandomizedtoextended-releasemetoprololsuc-
Whilelifestylemodificationsbeforeinterventionreducetheriskof
cinate 200mg daily or placebo 185 Treatment was initiated 2–4h
several peri-operative complications, the impact on CV complica-
before surgery and maintained for 30 days. The primary outcome
tionshasnotbeenadequatelyexplored.Ofthelifestylechangesre-
(composite of CV death, non-fatal MI, and non-fatal cardiac arrest)
commended before surgery, smoking cessation is the best
was significantly lower in the metoprolol arm (5.8% vs. 6.9% [P=
documented in RCTs. Smoking has been associated with a higher
0.04]).MetoprololwasassociatedwithsignificantreductionsinMIs,
rate of post-operative complications at 30 days.173,174 Reviews of
coronaryrevascularizations,andAF.However,theincidencesofall-
RCTs have shown an effect of smoking cessation up to 6 months
causedeath,stroke,andclinicallysignificanthypotensionorbradycar-
post-operatively,withaclearreductioninanypost-operativecom-
diaweresignificantlyhigherinthemetoprololarm.Posthocanalysis
plicationsbyhazardratio(HR)0.42(95%CI,0.27–0.65),particularly
showed that hypotension carried the greatest attributable risk of
wound infections (HR, 0.43; 95% CI, 0.21–0.85).173,175 Regarding
death and stroke 186 The high dose of extended metoprolol might
timingofcessation,reviewsofobservationalstudieshaveshowncon-
haveplayedaroleintheadverseeventsseenatfollow-up.
sistent associationswith bettersurgicaloutcomeforcessation.4
Severalmeta-analyses,systematicreviews,andobservationalstud-
weeksbeforesurgery,witheachadditionalweekresultinginafur- ieshavealsobeenreported(seeSupplementarydata,TableS4).187–
therimprovementof19%.176–178
189 Overall, initiation of beta-blockers before NCS was not asso-
Pre-operativeexerciseprogrammeshaveonlybeentestedinsmall
ciated with a net clinical benefit in most analyses, but they might
RCTs,andrecentreviewshaveshownarelativerisk(RR)reduction bebeneficialinpatientswithhighCVriskprofilesorwhoareunder-
in post-operative complications of 67% (RR, 0.33; 95% CI, 0.17–
going high-risk surgical interventions (including vascular interven-
0.61).179 Referral to a pre-operative exercise programme may be tions).188,190–192
When oral beta-blockade is initiated in CAD
consideredforpatientsscheduledformajororcomplexelectivesur-
patients who undergoNCS, theuseof atenololorbisoprolol asa gery.176,179,180Weightreductionofobesepatientsimmediatelyprior
firstchoicemaybeconsidered.190,193–195
tosurgeryisnotrecommended.
In patients who are on chronic beta-blocker therapy before
surgery,itisrecommendedtomaintaintheseintheperi-operative
RecommendationTable11—Recommendationsfor
period. Increased mortality following pre-operative beta-blocker
lifestyleandcardiovascularriskfactors withdrawal has been reported in five observational studies.190,196–199
Recommendations Classa Levelb
Interruptionofthistherapyfor.2dayspost-operativelymaydouble
theriskofAF.200
Smokingcessation.4weeksbeforeNCSis
Post-operativetachycardiashouldinitiallyleadtotreatmentofthe
recommendedtoreducepost-operative I B underlyingcause—suchashypovolaemia,pain,bloodloss,orinfec-
complicationsandmortality.181,182 tion—rather than simply increasing the beta-blocker dose. When
ControlofCVriskfactors—includingblood
beta-blockers are indicated, the optimal duration of the peri-
pressure,dyslipidaemia,anddiabetes—is I B operativebeta-blockadecannotbederivedfromrandomizedtrials.
recommendedbeforeNCS.173,176–178,183
Accordingto a meta-analysis of RCTs including 14967patients,
beta-blockers can reduce the risk of post-operative AF after
CV,cardiovascular;NCS,non-cardiacsurgery.
aClassofrecommendation. NCS;201 however, this comes at the cost of an increased risk of
bLevelofevidence. bradycardia,hypotension,andstroke.187
2202CSE©
2202CSE©
Downloaded
from
https://academic.oup.com/eurheartj/article/43/39/3826/6675076
by
guest
on
22
January
2026
--- Страница 30 ---
ESCGuidelines 3855
The ultra-short-acting beta-blockers esmolol and landiolol have 5.2.4.Renin–angiotensin–aldosteronesystem
thetheoreticaladvantagesofveryfastonsetofeffectsandshorthalf- inhibitors
lives. Notably, landiolol may lower BP to a lower extent than Dataonperi-operativeuseofrenin–angiotensin–aldosteronesystem
esmolol. Evidence of prevention of AF with landiolol after NCS is (RAAS)inhibitorsareinconclusive.Themajorityofstudiessuggest
less robust and inconsistent than in the context of cardiac sur- that continued use of RAAS inhibitors is associated with a higher
gery.202–205Thetimingoftheinitiationofbeta-blockerstoprevent
risk of peri-operative hypotension and, as a consequence, higher
AF remains unclear, with most prophylactic regimens using short- use of vasopressors and inotropes. Furthermore, intra-operative
actingagentsbeingstartedintra-operatively.187 hypotensionanditsdurationisassociatedwithend-organdamage,
includingkidneyinjury,myocardialdamage,andstroke.214Inasmall
trial of 275 subjects, randomized to either continuation of their
5.2.2.Amiodarone
angiotensin-converting-enzyme inhibitors (ACEIs) or omission of
Amiodarone is the most frequently used agent for prevention of
thefinalpre-operativeACEIdose,patientsrandomizedtoomission
post-operative AF,206 with a risk reduction of 58% in NCS in a
ofthelastdosebeforesurgeryexperiencedintra-operativehypoten-
meta-analysisevaluatingdifferentantiarrhythmicdrugs(AADs),but
sionlessfrequently(76/137[55%]vs.95/138[69%])andvasopressor
may induce relevant non-cardiac side effects.201 In another
usewaslesslikely.215Ontheotherhand,post-operativehyperten-
meta-analysis, amiodarone (oral or intravenous [i.v.]) and beta-
sionwasmorefrequentintheomissiongroup.Furthermore,inan
blockerswereequallyeffectiveinreducingpost-operativeAF.207In
observational cohort study consisting of 4802 patients undergoing
anotherprospectiveRCT,acombinationofbeta-blockerplusamio-
NCSandusinganACEIorangiotensinreceptorblocker(ARB),dis-
darone outperformed beta-blockers alone in reducing post-
continuationofthesedrugsinthe24hbeforesurgerywasassociated
operative AF.208 It should be noted that the two latter studies
withalowerriskofintra-operativehypotension(adjustedRR,0.80;
wereundertakeninpatientsundergoingcardiacsurgery.
95%CI,0.72–0.93;P,0.001),andassociatedwithareductioninthe
Overall, whilepreventiveamiodaroneseems toreduce theinci-
compositeend-pointconsistingofall-causemortality,stroke,andMI
denceofAF,theclinicalbenefitsassociatedwithitsroutineuseare
(adjusted RR, 0.82; 95% CI, 0.70–0.96; P=0.01);216 8% of the pa-
unclear.
tientsinthiscohortwerediagnosedwithHF,inwhomRAASinhibi-
tors are the cornerstone of medical therapy. A systematic review,
5.2.3.Statins includingninestudies(fiveRCTsandfourcohortstudies),revealed
Despitethewide-ranginguseofstatinsinpatientsundergoingsur- thatwithholdingACEI/ARBonthemorningofsurgerywasnotasso-
gery, RCTs assessing the effects of initiating statin therapy during ciatedwithmortalityorMACE;217however,itdidconfirmthatwith-
theperi-operativeperiodarescarce.Thisshouldbeviewedsepar- holdingtherapywasassociatedwithlessintra-operativehypotension
atelyfrompatientsalreadyonstatintherapy.Thelong-termuseof (OR,0.63;95%CI,0.47–0.85).IfanACEI/ARBiswithheldpriorto
statinsinpatientswithCVDorhighriskofCVDiswell-established.40 NCS,itshouldberestartedassoonaspossibleinordertoprevent
Observational data suggest a potential benefit of statins in the unintendedlong-termomission.Nodataonperi-operativeeffectsof
peri-operativephase.Inalarge,retrospective,andobservationalco- angiotensinreceptorneprilysininhibitors(ARNI)exist,buthypoten-
hort,whichincluded180000veteransundergoingNCS,theuseof sionismorecommoncomparedwithpatientsonACEI.218
statinsonthedayoforthedayaftersurgerywasassociatedwitha SomeimportantRCTsinthisfieldareongoing:theimpactofrenin–
reductioninmortality(RR,0.82;95%CI,0.75–0.89).209Similarre- angiotensinsysteminhibitorscontinuationvs.discontinuationonout-
sults were seen in a retrospective cohort study using hospital dis- come after major surgery trial STOPorNOT219 (NCT03374449),
charge and pharmacy records.210 Although both studies used and the POISE-3 trial (NCT03505723) are both assessing a
propensitymatchingtoreducebias,theseanalysesarepronetocon- hypotension-avoidancestrategyvs.ahypertension-avoidancestrategy
founding,especiallywhendischargeandpharmacyrecordsareused. ontheriskofvasculardeathandmajorvasculareventsinpatientswho
Assuch,RCTsgiveamorereliableeffectestimation,forexample:the arefollowedfor30daysafterNCS.
Lowering the Risk of Operative Complications Using Atorvastatin
Loading Dose (LOAD) trial studied 648 statin-naïve patients, of
whom24%hadahistoryofCVDand49%haddiabetes.211Inthis 5.2.5.Calciumchannelblockers
randomized, placebo-controlled trial, patients received a loading Theeffectsofcalciumchannelblockers(CCBs)onthebalancebe-
doseofatorvastatin80mgwithin18hbeforesurgeryfollowedby tweenmyocardialoxygensupplyanddemandmakesthemtheoret-
40mgdailyfor7days.Useofatorvastatindidnotreducetherisk ically suitable for risk-reduction strategies. The relevance of
of major events (all-cause mortality, non-fatal MI, or stroke at 30 randomized trials assessing the peri-operative effects of CCBs is
days [HR, 0.87; 95% CI, 0.60–1.26; P=0.46]). However, the trial limitedbytheirsmallsize,lackofriskstratification,andtheabsence
wasunderpoweredtodrawdefiniteconclusions.Inaddition,several of systematic reporting of cardiac death and MI. A meta-analysis
meta-analyseshaveshownambiguousresultsandmoststudiesareof pooled 11 randomized trials totalling 1007 patients.220 Treatment
alimitedsizewithlessthan100patients.212,213 with CCBs significantly reduced the number of episodes of
Therefore, routine peri-operative initiation of statin therapy is myocardialischaemiaandsupraventriculartachycardia(SVT)inthe
not recommended. However, in patients in whom statin use is al- pooledanalyses.However,thedecreaseinmortalityandMIreached
ready indicated, treatment should be considered peri-operatively, statistical significance only when both end-points were combined
particularlyinpatientsscheduledforhigh-risksurgery(e.g.vascular (RR,0.35;95%CI,0.08–0.83;P=0.02).Incontrast,amatchedcase-
surgery). control study of 1000 patients undergoing acute or elective
Downloaded
from
https://academic.oup.com/eurheartj/article/43/39/3826/6675076
by
guest
on
22
January
2026
--- Страница 31 ---
3856 ESCGuidelines
aorticaneurysmsurgerysuggestedthatdihydropyridineusewasin- therefore a possible alternative to beta-blockers. However, there
dependentlyassociatedwithanincreasedincidenceofperi-operative arefewstudiesaboutthevalueofivabradineforhigh-riskpatients
mortality.221 These observational data may be biased by the undergoing NCS.227 The small (78 patients) PeRi-OperaTivE
indications for the use of CCBs. In patients already on CCBs, CardioproTection With Ivabradine in Non-cardiac Surgery
particularlyinthosewithvasospasticangina,itisrecommendedto (PROTECTIN)(NCT04436016)trialisongoing.
continue CCBs during the peri-operative period, but withholding
the dose on the day of surgery in order to avoid post-operative
hypotension. 5.2.9.Sodium–glucoseco-transporter-2inhibitors
Theuseofsodium–glucoseco-transporter-2(SGLT-2)inhibitorsis
5.2.6.Alpha-2receptoragonists increasing,duetoprovenCVbenefitsforpatientswithtype-2dia-
Alpha-2 receptor agonists reduce post-ganglionic noradrenaline betesmellitus(DM)andabeneficialeffectonoutcomesforpatients
output and might therefore reduce catecholamine surge during with HF and renal insufficiency. Euglycaemic diabetic ketoacidosis
surgery.TheEuropeanMivazeroltrialrandomized1897patients (EDKA) is a rare but serious complication. While the incidence
with IHD who underwent intermediate- or high-risk NCS.222 wasnotsignificantlyincreasedwithSGLT-2inhibitorsinRCTs,sev-
Mivazerol did not decrease the incidence of death or MI in the eral case reports indicate that EDKA may occasionally occur after
wholepopulation.However,itdiddecreasetheincidenceofdeath (non-cardiac)surgeryinpatientsonSGLT-2inhibitors.228Asystem-
inasubpopulationof904patientsundergoingvascularsurgery.222
aticreviewindicatedthatprecipitatingfactorsincludediabetesmedi-
TheinternationalPeri-OperativeISchemicEvaluation2(POISE-2) cationchanges,dietmodifications,andintercurrentillnesses.229The
trial randomized 10010 patients undergoing NCS to clonidine USFoodandDrugAdministration(FDA)recommendsinterrupting
orplacebo.223Clonidinedidnotreducetherateofdeathornon- SGLT-2inhibitortherapyforatleast3–4daysbeforescheduledsur-
fatalMIingeneralorinpatientsundergoingvascularsurgery(RR, gery andtobe vigilantforsymptomsrelated toEDKA,prompting
1.08; 95% Cl, 0.93–1.26; P=0.29), but it did increase the risk measurementofketones.
ofclinicallyimportanthypotension(RR,1.32;95%Cl,1.24–1.40;
P,0.001) and non-fatal cardiac arrest (RR, 3.20; 95% Cl, 1.17–
8.73;P=0.02).
RecommendationTable12—Recommendationsfor
pharmacologicaltreatment
5.2.7.Diuretics
Recommendations Classa Levelb
DiureticsarefrequentlyusedinpatientswithhypertensionorHF.In
general,therapyfortreatmentofhypertensionshouldbecontinued Initiation
tothedayofsurgeryandresumedorallywhenpossible.However, Inpatientswithanindicationforstatins,itshould
IIa C
thebenefitforcontinuingdiureticsasantihypertensivetherapyisun-
beconsideredtoinitiatestatinsperi-operatively.
clear,andalternativeantihypertensiveagentsmaybeconsidered.In
Pre-operativeinitiationofbeta-blockersin
HF, the dosageof diureticsshouldbe adjusted wellin advancefor advancecofhigh-riskNCSmaybeconsideredin
anoptimalfluidbalancebeforesurgery,andtoavoidfluidretention
patientswhohavetwoormoreclinicalrisk IIb A
ordehydration. factors,dinordertoreducetheincidenceof
Thepossibilityofelectrolytedisturbanceshouldbeconsideredin peri-operativemyocardialinfarction.188,190–192
anypatientreceivingdiuretics.Hypokalaemiaisreportedtooccurin
Pre-operativeinitiationofbeta-blockerinadvance
up to 36% of patients undergoing surgery (mostly NCS).224,225 ofNCSmaybeconsideredinpatientswhohave IIb B
Specialattentionshouldbegiventopatientspronetodevelopingar- knownCADormyocardialischaemia.e,230–232
rhythmias. Any electrolyte disturbance, especially hypokalemiaand
Routineinitiationofbeta-blockerperi-operatively hypomagnesaemia,shouldbecorrectedinduetimebeforesurgery. III A
isnotrecommended.185,187,189,233,234
Acutepre-operativerepletioninasymptomaticpatientsmaybeas-
sociated with more risks than benefits; thus, minor asymptomatic Continuation
electrolytedisturbancesshouldnotdelayacutesurgery. Peri-operativecontinuationofbeta-blockersis
In the peri-operative period, volume status in patients with HF recommendedinpatientscurrentlyreceivingthis I B
should be carefully monitored and optimized by loop diuretics or
medication.190,196–199
fluids.However,retrospectivedatasuggestthatintra-operativepre- Inpatientsalreadyonstatins,itisrecommended
scription of diuretics may increase the risk of acute kidney injury tocontinuestatinsduringtheperi-operative I B
(AKI)afterNCS.226 period.235
InpatientswithstableHF,peri-operative
5.2.8.Ivabradine continuationofRAASinhibitorsmaybe IIb C
Heartrateisanindependentandmodifiableriskfactorforperipro- considered.
cedural MI (and maybe death) after NCS. Ivabradine is a negative Continued
chronotropic agent without associated hypotensive effect, and is
Downloaded
from
https://academic.oup.com/eurheartj/article/43/39/3826/6675076
by
guest
on
22
January
2026
--- Страница 32 ---
ESCGuidelines 3857
antithromboticdrugsinusemustbeconsidered(Tables7and8).The
Interruption
riskofbleedingassociatedwithdifferenttypesofinterventionsisshown
InpatientswithoutHF,withholdingRAAS
in Table 9. Risk estimation and decision-making in patients requiring
inhibitorsonthedayofNCSshouldbeconsidered IIa B
long-termantithrombotictherapyischallenging,sincerelevantassocia-
topreventperi-operativehypotension.215,216
tionsexistbetweenperi-operativeantithromboticmanagement,bleed-
Forpatientsondiureticstotreathypertension, ing,thromboticevents(MIandstroke),andmortality.6,11–13Thus,
transientdiscontinuationofdiureticsonthedayof IIa B
interdisciplinaryriskassessmentaheadoftheinterventioniscru-
NCSshouldbeconsidered.236
cial,inordertoclassifythepatient-relatedischaemicandbleeding
ItshouldbeconsideredtointerruptSGLT-2
risks(e.g.cardiologist,neurologist,vascularspecialist,andhaema-
inhibitortherapyforatleast3daysbefore IIa C
tologist), and the surgical risk (surgeon and anaesthesiologist).
intermediate-andhigh-riskNCS.
Informationontimingofinterventionbyindicateddurationofan-
b.p.m., beats per minute; CAD, coronary artery disease; HF, heart failure; NCS, tithrombotic therapy should be communicated with the patient
non-cardiac surgery; RAAS, renin–angiotensin–aldosterone system; RCRI, Revised andtreatinggeneralphysician.
CardiacRiskIndex;SGLT-2,sodium-glucoseco-transporter2.
aClassofrecommendation.
bLevelofevidence. 5.3.1.Antiplatelets
cIdeallyatleast1weekbeforesurgery,startingwithalowdosewithdosetitrationfor
5.3.1.1.Singleantiplatelettherapy
targetheartrate.185,197,230,237Thetargetisarestingheartrate60–70b.p.m.191witha
systolicbloodpressure.100mmHg.230,238 Inpatientstakingaspirinforprimaryprevention,theriskofischaemic
dIschaemic heart disease, cerebrovascular disease, renal insufficiency, or diabetes eventsislowandaspirincanbewithdrawnpriortoNCS.Permanent
mellitus,accordingtotheRCRIscore.239
discontinuation should be considered post-operatively in low- and
eTreatmentshouldideallybeinitiatedbetween30and(atleast)2daysbeforesurgery,
startingatalowdose,andshouldbecontinuedpost-operatively.197,230,237 moderate-riskatheroscleroticcardiovasculardisease(ASCVD)risk
patients and/or in patients with high bleeding risk based on
negative/neutraltrialsandtherecommendationsforprimarypreven-
5.3. Peri-operative handling of
tionofCVDinthe2021ESCGuidelinesoncardiovasculardisease
antithrombotic agents preventioninclinicalpractice.40,241
Managementofpatientstakingantithromboticagentsandneedingsur- Duetothebetterrisk–benefitratio,aspirinhasanestablishedrolefor
gery or an invasive procedure should consider patient- and thelong-termpreventionofnewcardiovasculareventsinpatientswith
procedure-relatedriskofbleedingandthrombosis.Furthermore,the establishedCVD.242ThePOISE-2trialisthelargest,randomized,placebo-
pharmacokinetic and pharmacodynamic characteristics of the controlledtrialofperi-operativeaspirininpatientsundergoingNCS.243
Table7 Pharmacokineticandpharmacodynamiccharacteristicsofantiplatelets
ASA Clopidogrel Prasugrel Ticagrelor Cangrelor Eptifibatide Tirofiban
Target COX-1 P2Y P2Y P2Y P2Y GPIIB/IIIa GPIIB/IIIa
12 12 12 12
(typeofblockade) (irreversible) (irreversible) (irreversible) (reversible) (reversible) (reversible) (reversible)
Application Oral Oral Oral Oral i.v. i.v. i.v.
TimetoC 0.5–1.0h 2h 0.5h 0.5h 2min 5min 5min max
(after600mgLD)a (after60mg (after180mg
LD)a LD)a
Prodrug No Yes Yes No No No No
Bioavailability(%) (cid:4)50 (cid:4)50 80 36 100 100 100
Druginteractions NSAIDs CYP3A4,CYP3A5, CYP3A4/A5 CYP3A4 None None None
(inparticular orCYP2C19 andCYP2B6 inducersor
ibuprofen+ inhibitorsor inhibitor inhibitors
naproxen) inducers
Plasmahalf-life 20min 0.5–1h(active 0.5–1h(active 6–12h 3–6min 2.5–2.8h 1.2–2h
metabolite) metabolite)
Durationofaction 7–10days 3–10daysb 7–10daysb 3–5days 1–2h 4h 8h
afterlastdose
Renalclearanceof NR NR NR NR 58 (cid:4)50 65
theactive
metabolite(%)
Doseregimen o.d. o.d. o.d. b.i.d. Bolus, Bolus, Bolus,
infusion infusion infusion
ASA,acetylsalicylicacid;b.i.d.,twiceaday;Cmax,maximumserumconcentration;i.v.,intravenous;LD,loadingdose;NR,non-relevant;o.d.,onceaday.
aTimetoCmaxformaybedelayedby8hormorefollowingadoseofopiate.
bDependingonresponsestatus.
2202CSE©
2202CSE©
Downloaded
from
https://academic.oup.com/eurheartj/article/43/39/3826/6675076
by
guest
on
22
January
2026
--- Страница 33 ---
3858 ESCGuidelines
Table8 Pharmacokineticandpharmacodynamiccharacteristicsoforalanticoagulants
Warfarin Phenprocoumon Apixaban Dabigatran Edoxaban Rivaroxaban
Target VKORC1 VKORC1 FXa FIIa FXa FXa
(typeof
blockade)
Application Oral Oral Oral Oral Oral Oral
TimetoC 2–6h 1.52h+1.52 3–4h 1.25–3h 1–2h 2–4h
max
Prodrug No No No Yes No No
Bioavailability(%) .95 100 50 6.5 62 80–100
Druginteractions CYP2C9, CYP2C9,CYP2C8, CYP3A4inhibitors P-glycoprotein P-glycoprotein CYP3A4inhibitors
CYP2C19, vitaminK orinductors, inhibitorsor inhibitors orinductors,
CYP2C8, P-glycoprotein inductors P-glycoprotein
CYP2C18, inhibitorsor inhibitorsor
CYP1A2, inductors inductors
CYP3A4,
vitaminK
Plasmahalf-life 36–48h (cid:4)100h 12h 12–14h 6–11h 7–11h(11–13hin
theelderly)
Durationofaction (cid:4)5days (cid:4)7days 24h 24h 24h 24h
afterlastdose
Renalclearance Non-renal Non-renal 27 85 37–50 33
oftheactive
metabolite(%)
Doseregimen Adjusted Adjustedaccording b.i.d. b.i.d. o.d. o.d./b.i.d.
accordingtoINR toINR
b.i.d.,twiceaday;Cmax,maximumserumconcentration;FIIa,factorIIa;FXa,factorXa;INR,Internationalnormalizedratio;LD,loadingdose;NOAC,non-vitaminKantagonistoral
anticoagulant;o.d.,onceaday;VKORC1,vitaminKepoxidereductasecomplex1.
Table9 Bleedingriskaccordingtotypeofnon-cardiacsurgery
Surgerywithminorbleedingrisk Surgerywithlowbleedingrisk Surgerywithhighbleedingrisk
(infrequentorwithlowclinical (frequentorwithsignificantclinical
impact) impact)
(cid:129) Cataractorglaucomaprocedure (cid:129) Abdominalsurgery:cholecystectomy, (cid:129) Abdominalsurgerywithliverbiopsy,
(cid:129) Dentalprocedures:extractions(1–3teeth),periodontal herniarepair,colonresection extracorporealshockwavelithotripsy
surgery,implantpositioning,endodontic(rootcanal) (cid:129) Breastsurgery (cid:129) Extensivecancersurgery(e.g.pancreas,
procedures,subgingivalscaling/cleaning (cid:129) Complexdentalprocedures(multiple liver)
(cid:129) Endoscopywithoutbiopsyorresection toothextractions) (cid:129) Neuraxial(spinalorepidural)anaesthesia
(cid:129) Superficialsurgery(e.g.abscessincision,smallskinexcisions/ (cid:129) Endoscopywithsimplebiopsy (cid:129) Neurosurgery(intracranial,spinal)
biopsy) (cid:129) Gastroscopyorcolonoscopywith (cid:129) Majororthopaedicsurgery
simplebiopsy (cid:129) Procedureswithvascularorganbiopsy
(cid:129) Large-boreneedlesprocedures(e.g. (kidneyorprostate)
bonemarroworlymphnodebiopsy) (cid:129) Reconstructiveplasticsurgery
(cid:129) Non-cataractophthalmicsurgery (cid:129) Specificinterventions(colonpolypectomy,
(cid:129) Smallorthopaedicsurgery(foot,hand lumbarpuncture,endovascularaneurysm
arthroscopy) repair)
(cid:129) Thoracicsurgery,lungresectionsurgery
(cid:129) Urologicalsurgery(prostatectomy,
bladdertumourresection)
(cid:129) Vascularsurgery(e.g.AAArepair,vascular
bypass)
AAA,abdominalaorticaneurysm.
AdaptedfromSteffeletal.240
2202CSE©
2202CSE©
Downloaded
from
https://academic.oup.com/eurheartj/article/43/39/3826/6675076
by
guest
on
22
January
2026
--- Страница 34 ---
ESCGuidelines 3859
Patients on dual antiplatelet therapppy
NCS-related bleeding risk
High bleeding risk
N
related to NCS
Y
Thrombotic risk
High thrombotic risk:
PCI <1 month or
N Y
ACS <3 months or
High risk of stent thrombosisa
Recommendations
Y Time-sensitive NCS
N
Interrupt P2Y
Continue aspirin 12 Bridge with GPI Defffer NCS
inhibitorb ContinueDDDAPT
(Class I) or cangrelorc (Class I)
(Class IIa/b)
Ticagrelor:: 3–5 daaays
Clopidogrel:: 5 daaays
Prasugrel:: 7 daaays
(Class I)
Figure 5 Recommendations for management of antiplatelet therapy in patients undergoingnon-cardiac surgery. ACS, acute coronary syndrome;
DAPT, dual antiplatelet therapy; GPI, glycoprotein IIb/IIIa inhibitors; PCI, percutaneous coronary intervention; N, no; NCS, non-cardiac surgery.
Y,yes;aHighriskofperi-operativestentthrombosisdefinedbyatleastoneofthefollowing:historyofstentthrombosisunderantiplatelettherapy,
reducedleftventricularejectionfraction(,40%),poorlycontrolleddiabetes,severelyimpairedrenalfunction/haemodialysis,recentcomplexPCI(i.e.
severelycalcifiedlesion,leftmainPCI,chronictotalocclusion,bifurcational/crushtechnique,bypassgraftPCI),orstentmalapposition/residualdissection.
bTimingofresumptionafterinterdisciplinaryriskassessmentassoonaspossible(within48h)aftersurgery.cFordosing,seeFigure7.
Thetrialrandomized10010patientsundergoingNCSwithestab- the perception that the ischaemic benefit of peri-operative aspirin
lishedCVD,orwhowereatincreasedCVrisk,toaspirinorplacebo. use outweighs the bleeding risk in patients with previous PCI.
Patientswerestratifiedaccordingtowhethertheyhadnotbeentak- Thus, among patients with previous PCI, in the absence of a very
ingaspirinbeforethestudyorwerealreadyonaspirin;33%ofthe highbleedingrisk,low-doseaspirinshouldbecontinuedduringthe
patientshadknownvasculardisease(23%CAD,9%PAD,and5% peri-operativeperiod.
stroke).Aspirindid not reduce theratesof death or non-fatal MI In patients undergoing transcatheter aortic valve implantation
at30days(7.0%vs.7.1%intheplacebogroup[HR,0.99;95%CI, (TAVI)whohavenootherindicationfororalanticoagulant(OAC)
0.86–1.15;P=0.92]).Majorbleedingwasmorecommonintheas- therapy,low-doseaspirinhasbeenrecommendedasstandardther-
piringroupthanintheplacebogroup(4.6%vs.3.8%[HR,1.23;95% apybyrecentguidelinesbasedonanRCT.245,246Therearenoran-
CI,1.01–1.49;P=0.04]).Theprimaryoutcomeresultsweresimilar, domizeddataavailableassessingthewithdrawalvs.continuationof
irrespectiveofwhetherornotpatientshadbeentakingaspirinbe- aspirininpatientsafterTAVIonaspirinaloneundergoingNCS.
forethestudy, andwerealso similarinpatientswithand without If the bleeding risk outweighs the potential CV benefit, aspirin
vasculardisease. shouldbediscontinued.Forpatientswithhighperi-operativebleed-
Inaposthocanalysisof470patients(,5%)whohadundergone ing risk (e.g. undergoing spinal surgery or certain neurosurgical or
previousPCI,aspirinusewasassociatedwithasignificantreduction ophthalmologicaloperations) aspirinshouldbe discontinuedforat
indeathorMI(HR,0.50;95%CI,0.26–0.95;P=0.036)andMIalone least7days.
(HR,0.44;95%CI,0.22–0.87;P=0.021),whiletheriskofmajoror On rare occasions, chronic coronary syndrome (CCS) patients
life-threatening bleeding was not significantly increased in this set- mightbeonclopidogrelmonotherapyduetotheresultsofrecent
ting.244Althoughtheanalysiscarriesseverallimitations,itsupports trials247andtherecommendationsofthe2020ESCGuidelinesfor
Downloaded
from
https://academic.oup.com/eurheartj/article/43/39/3826/6675076
by
guest
on
22
January
2026
--- Страница 35 ---
3860 ESCGuidelines
P2Y inhibitor interruption after PCI before elective non-cardiac surgerya
12
ACS at index PCI or other high ischaemic risk featuresb
N Y
Time from DAPT
initiation
Class IIIc
1 month Class IIIf
3 months Class IIad
Class IIbg
6 months
Class Ie
Class IIah
12 months
Class Ii
Figure6P2Y inhibitorinterruptionafterpercutaneouscoronaryinterventionbeforeelectivenon-cardiacsurgery.LoE,levelofevidence;MI,myo-
12
cardialinfarction;N,no;PCI,percutaneouscoronaryintervention.Y,yes;aAvailabilityof24hcath-labserviceissuggestedincaseofmajorsurgerywithin6
monthsinnon-ACS/non-high-riskpatientsandwithin12monthsinACS/high-riskpatients.bHighriskofperi-operativestentthrombosisdefinedbyat
leastoneofthefollowing:historyofrecurrentMI,historyofstentthrombosisunderantiplatelettherapy,reducedleftventricularejectionfraction
(,40%),poorlycontrolleddiabetes,severelyimpairedrenalfunction/haemodialysis,recentcomplexPCI(i.e.severelycalcifiedlesion,leftmainPCI,chronic
totalocclusion,bifurcational/crushtechnique,bypassgraftPCI),stentmalapposition/residualdissection.cClassIIILoEC.dClassIIaLoEB250,265,266,267.
eClassILoEA268,146.fClassIIILoEB269.gClassIIbLoEB270,271.hClassIIaLoEB272,273,274,275,276,277,278.iClassILoEA279,280,281,98.
themanagementofacutecoronarysyndromesinpatientspresenting missing.Itshouldberecognizedthattheeffectsofticagrelororclo-
withoutpersistentST-segmentelevation;98therefore,periprocedur- pidogrel monotherapy on haemostasis are considerably less than
al management of clopidogrel-based single antiplatelet therapy whentheyarecombinedwithaspirin.
(SAPT)isrequired.Consensushasbeenreachedthatashortinter-
ruptionofP2Y inhibitormonotherapyisrecommendedinpatients 5.3.1.2.Dualantiplatelettherapy
12
athighriskofbleeding. P2Y inhibitorsinadditiontoaspirinarerecommendedforpatients
12
PatientstreatedwithP2Y inhibitormonotherapyaspartofade- afterPCI.98,146ThefrequencyofmajorNCSinthefirstyearafterPCI
12
escalationstrategyafterPCI/ACS,orduetoarecentstroke,PAD,or is(cid:4)4%;mostfrequentlyorthopaedic,abdominal,andvascularsur-
aspirinintolerance,mightrequireperi-operativemanagementofthis gery.251 Other observational data report cumulative incidences of
monotherapy.248–250
A careful interdisciplinary evaluation of peri- NCS after PCI for 30 days, 6 months, and 1 year of 1%, 5%, and
operativebleedingvs.ischaemicriskiswarrantedinthesesituations, 9%,respectively.252
andindividualdecisionsbasedontheperi-operativebleedingandis- ObservationalstudieshavereportedasubstantialrateofMACE—
chaemicrisk(e.g.surgeryunderP2Y monotherapy,switchingtoas- includingcardiacdeath,MI,andstentthrombosis—rangingbetween
12
pirin,shortinterruption,orbridgingintheperi-operativephase)may 2–8%251,253,254inPCIpatients undergoingNCS,with a morethan
be applicable, although evidence for these different regimens is two-foldincreasedriskcomparedwithnon-stentedpatients.255,256
Downloaded
from
https://academic.oup.com/eurheartj/article/43/39/3826/6675076
by
guest
on
22
January
2026
--- Страница 36 ---
ESCGuidelines 3861
Low doseASA throughout
Clopidogrel
Prasugrel Clopidogrel/ NCS (LD 300 mg),
ticagrelor
followed by 75 mg o.d.
or restart tirofiban/eptifibatideb
Infusion tirooofffiiibbbaaannn///eeeptifibatidea
Day -7 -6 -5 -4 -3 -2 -1 -4–6 h 0 +4–6 h FU/
discharge
Low doseASA throughout
Clopidogrel
Prasugrel Clopidogrel/ NCS (LD 300 mg),
ticagrelor
followed by 75 mg o.d.
or restart cangrelorb
Infusiooonnn cccaaannngggrrrelorc
Day -7 -6 -5 -4 -3 -2 -1 -1–6 h 0 +4–6 h FU/
discharge
START STOP
Figure7Bridgingwithintravenousantiplateletagents.ASA,acetylsalicylicacid;FU,follow-up;LD,loadingdose;NCS,non-cardiacsurgery;o.d.,oncea
day.aTirofiban:0.1µg/kg/min;ifcreatinineclearance,50mL/min,adjustto0.05µg/kg/min.Eptifibatide:2.0µ/kg/min;ifcreatinineclearanceis,50mL/
min,adjustto1.0µg/kg/min.bUntiloralP2Y inhibitortherapyispossible.cInitiatewithin72hfromP2Y inhibitordiscontinuationatadoseof0.75μg/
12 12
kg/minforaminimumof48handamaximumof7days.
TheproportionofriskattributabletounderlyingCVDorstentim- be worse than for de novo coronary occlusion (and depends on
plantation remains uncertain.254 Risk factors for MACE after NCS the site of stent deployment), and premature interruption of
are:timefromPCItosurgery,withthehighestriskinthefirstmonth; DAPT in patients with recent coronary stent implantation is the
primaryPCIforST-segmentelevationmyocardialinfarction(STEMI); strongestpredictorforstentthrombosis.
dualantiplatelettherapy(DAPT)interruptions/discontinuation;and ThepreferredmanagementofpatientsonDAPTduetoPCIisto
lesion characteristics, including ostial and distal
lesions.252,257–259
delay elective NCS until completion of the full course of DAPT
Urgencyofsurgeryisafurtherriskfactor.TheESC/ESAclassification (6 months after elective PCI and 12 months after ACS).98,146
ofNCSisavalidatedtoolwithwhichtopredicttheimpactofthe However, several recent trials have indicated that shortening
typeofsurgeryonMACE.16 DAPT durationto 1–3 months after implantationof modern DES
A meta-analysis of observational data indicated that discontinu- isassociatedwithacceptableratesofMACEandstentthrombosis
ation of clopidogrel for at least 5 days reduced the risk of re- in low- and moderate-risk patients. Based on these newer data, it
operation for major bleeding by 50%, without increasing the risk is recommended to delay time-sensitive NCS until a minimum of
ofMACEordeath.260Otherobservationaldataindicateanincrease 1monthofDAPTtreatmenthasbeeneffectuated.Inhigh-riskCV
in MACE with brief DAPT interruptions.261 However, these non- patients, forexample due toan ACS,a DAPT duration ofatleast
randomizeddatamayhavebeenbiasedbythetypeandurgencyof 3 months should be considered before time-sensitive NCS.
surgery.260 Of note, theprognosis ofstent thrombosis appearsto See Figure 5 for the recommended duration of DAPT before
Downloaded
from
https://academic.oup.com/eurheartj/article/43/39/3826/6675076
by
guest
on
22
January
2026
--- Страница 37 ---
3862 ESCGuidelines
time-sensitiveNCS.OncetheP2Y inhibitorhasbeendiscontinued, bleeding;(ii)individualizedtimingofelectivesurgeryafterantiplatelet
12
surgeryshouldbeperformedwhilethepatientisstillonaspirin. therapy cessation; and (iii) guiding therapy in bleeding complica-
Indications for long-term DAPT have recently emerged.
tions.285–287However,neithertheoptimalassaynorauniversalcut-
Long-termDAPT(beyond1year)withclopidogrel,prasugrel,orti- offvalueassociatedwithbleedinghasbeendefinedandvalidatedin
cagrelorinadditiontoaspirinshouldbeconsideredinpatientswith patientsundergoingNCS.
highischaemicrisk,andmaybeconsideredinpatientswithmoderate
ischaemicrisk,bothintheabsenceofincreasedriskofmajororlife- RecommendationTable13—Recommendationsfor
threatening bleeding.98 When NCS is required, discontinuation of useofantiplatelettherapyinpatientsundergoingnon-
P2Y inhibitors is recommended for 3–7 days (depending on the cardiacsurgery
12
P2Y inhibitor)fortheseadditionalindicationsforDAPT.
12 Recommendations Classa Levelb
5.3.1.3.De-escalationofantiplateleteffect ItisrecommendedtodelayelectiveNCSuntil6
Themanagementofantiplatelettherapyinpatientswhohaveunder- monthsafterelectivePCIand12monthsafteran I A
gonerecentPCIandarescheduledforNCSshouldbediscussedby ACS.264,271
the surgeon and cardiologist, so that the balance between the risk AfterelectivePCI,itisrecommendedtodelay
of life-threatening surgical bleeding on antiplatelet therapy—best time-sensitiveNCSuntilaminimumof1monthof I B
understood by the surgeon—and the risk of life-threatening stent DAPTtreatmenthasbeengiven.266,271,288,289
thrombosis due to premature DAPT discontinuation—best under- InpatientswitharecentPCIscheduledforNCS,it
stoodbythecardiologist—canbeconsidered(Figure5andFigure6).
isrecommendedthatmanagementofantiplatelet
I C
An increased risk of MACE as a consequence of (major) bleeding
therapyisdiscussedbetweenthesurgeon,
alsoneedstobetakenintoconsiderationwhenbalancingrisk.
anaesthesiologist,andcardiologist.
When time-sensitive surgery cannot be postponed and be per-
Inhigh-riskpatientswitharecentPCI(e.g.STEMI
formed with the recommended DAPT on board, de-escalation or
patientsorhigh-riskNSTE-ACSpatients),aDAPT
shortening ofDAPT isrecommended.This mayencompasseither IIa C
durationofatleast3monthsshouldbe
aswitchfromthemorepotentP2Y inhibitorsprasugrelorticagre-
12 consideredbeforetime-sensitiveNCS.
lortoclopidogrel,orcessationofaspirinanduseofprasugrelorti-
Continuationofmedication
cagrelormonotherapy.Ifneitheroftheseoptionsisdeemedtobe
sufficient, premature discontinuation of the P2Y inhibitor may InpatientswithapreviousPCI,itisrecommended
12
beconsidered.Ifdiscontinuationisrequired,ticagrelorneedstobe tocontinueaspirinperi-operativelyifthebleeding I B
withheld for 3–5 days, clopidogrel for 5 days, and prasugrel for 7 riskallows.244
dayspriortosurgery.262–264
Recommendedtimeintervalfordruginterruptionbefore
Wheneverpossible,inpatientswithanindicationforDAPT,sur- NCS
geryshouldbeperformedwithoutdiscontinuationofaspirin.Aspirin IfinterruptionofP2Y inhibitorisindicated,itis
12
mightbediscontinuedasalastmeasureonlywithveryhighbleeding recommendedtowithholdticagrelorfor3–5
I B
risk and a comparably low ischaemic risk. However, such surgical days,clopidogrelfor5days,andprasugrelfor7
proceduresshouldbeperformedinhospitalswhere24/7catheter- dayspriortoNCS.262–264
izationlaboratoriesareavailablesoastotreatpatientsimmediately
Forpatientsundergoinghighbleedingrisksurgery
incaseofperi-operativeischaemicevents.
(e.g.intracranial,spinalneurosurgery,or
Although generally not recommended, bridging with i.v. com- vitreoretinaleyesurgery),itisrecommendedto I C
pounds (eptifibatide/tirofiban or cangrelor) might be applicable in
interruptaspirinforatleast7days
rarecaseswhenDAPTcannotbeinterruptedbeforeNCS(e.g.inpa-
pre-operatively.
tientswithveryhighriskofstentthrombosis,historyofrecurrentMI,
InpatientswithoutahistoryofPCI,interruption
recentPCI)(seeFigure5andFigure7).282
ofaspirinatleast3daysbeforeNCSmaybe
Forpatientsreceivingantiplatelettherapy,whohaveexcessiveor IIb B
consideredifthebleedingriskoutweighsthe
life-threateningperi-operativebleeding,transfusionofplateletsisre-
ischaemicrisk,toreducetheriskofbleeding.243
commendedasabail-outstrategy.However,ticagreloranditsactive
Resumptionofmedication
metabolite may also inhibit aggregation of transfused platelets.
Experimentaldataindicatethatadministrationofalbuminbindstica- Ifantiplatelettherapyhasbeeninterruptedbefore
grelorandreducesitsinhibitoryeffectonplateletaggregation.283A asurgicalprocedure,itisrecommendedtorestart
monoclonalantibodyfragment(PB2452)forneutralizingticagreloris therapyassoonaspossible(within48h) I C
indevelopmentbutisnotyetclinicallyavailable.284 post-surgery,accordingtointerdisciplinaryrisk
assessment.
5.3.1.4.Plateletfunctionguidedperi-operativemanagementof
ACS,acutecoronarysyndrome;DAPT,dualantiplatelettherapy;NCS,non-cardiac
antiplatelettherapy surgery; NSTE-ACS, non-ST-segment elevation acute coronary syndrome; PCI,
Platelet function testing has several theoretical advantages in the percutaneous coronary intervention; STEMI, ST-segment elevation myocardial
infarction.
peri-operativesetting,including:(i)theidentificationofpatientson
aClassofrecommendation.
antiplatelet therapy who are at increased risk of surgery-related bLevelofevidence.
2202CSE©
Downloaded
from
https://academic.oup.com/eurheartj/article/43/39/3826/6675076
by
guest
on
22
January
2026
--- Страница 38 ---
ESCGuidelines 3863
5.3.2.Oralanticoagulants medication,comorbidity,etc.Patientsrequiringareversalagent
Approximatelyoneinfourpatientstakinganticoagulanttherapywill need careful monitoring of haemostatic parameters and evalu-
require a surgical or invasive procedure within 2years.290 ation of thrombotic and bleeding risk in the peri-operative
Peri-operativemanagementoforalanticoagulant(OAC)therapyde- phase, as reversal might be insufficient or prothrombotic re-
pendsonsurgery-andpatient-relatedfactorsandthespecificOAC bound might occur. In the latter case, an interdisciplinary deci-
agent(vitaminKantagonist[VKA]oranon-vitaminKantagonistoral sion should be made with regard to early resumption of
anticoagulant[NOAC]).SeeFigure8forasummaryofrecommenda- anticoagulationtreatment.
tionsforthemanagementofOACsinpatientsundergoingNCS.
Surgery-related factors include urgency of the intervention and 5.3.2.1.VitaminKantagonists
theprocedure-relatedbleedingrisk(reflectingboththeriskofbleed- Threedrugsarecurrentlyused:warfarin(half-life36–48h),aceno-
ingoccurrenceandtheriskofadverseoutcomeifbleedingoccurs) coumarol(half-life12h),andphenprocoumon(half-life100h).
(seeTable8).Procedureswheremechanicalcompressionisunfeas-
iblecarryahighriskofseriousbleedingcomplications. 5.3.2.1.1.VitaminKantagonistsinpatientswithmechanicalheart
Patient-relatedfactorsincludeage,individualthromboticrisk, valves. Maintenance of therapeutic international normalized ratio
history of bleeding complications, renal function, concomitant (INR) is crucial for patients with mechanical heart valves (MHVs).
Patients on oral anticoagulation therapy
NCS-related
bleeding risk
N High bleeding risk NCS
Y
Thrombotic risk
High
N
thrombotic risk
Y
Selected patients
Mechanical
with very high
heart valvea
thromboembolic riskb
Recommendations
Possible
N
to defer NCS
VKA/
VKA Y
NOAC
VKA NOAC Bridgec Bridgec Defer NCSd
(Class IIa) (Class IIb) Interrupte
(Class I)
Continue with INR
in lower level or Short interruptione
short interruption (Class I)
Bridging is not
(Class I)
recommended
(Class III)
Bridging is not Bridging is not
recommended recommended
(Class III) (Class III)
Figure8Recommendationsformanagementoforalanticoagulationtherapyinpatientsundergoingnon-cardiacsurgery.CHA DS -VASc,congestive
2 2
heartfailure,hypertension,age≥75years,diabetesmellitus,stroke,vasculardisease,age65–74years,sexcategory(female);N,no;NCS,non-cardiac
surgery;NOAC,non-vitaminKantagonistoralanticoagulant;VKA,vitaminKantagonist;VTE,venousthromboembolism.Y,yes;aMechanicalaorticvalve
replacement(AVR)andanythromboembolicriskfactor(atrialfibrillation,previousthromboembolism,severeleftventriculardysfunction,hypercoagul-
ablestate),orolder-generationmechanicalAVR,oramechanicalmitralvalvereplacement.bRecentstroke,3months,highriskofVTErecurrences(e.g.
antithrombin3deficiencyorproteinCand/orSdeficiency),leftventricularapexthrombus,atrialfibrillationwithaveryhighstrokerisk.cBridgingwith
unfractionatedheparinorlowmolecularweightheparin.dE.g..3monthsafterstroke/VTE.eForNOACmanagementduringNCS,seeFigures9and10.
Downloaded
from
https://academic.oup.com/eurheartj/article/43/39/3826/6675076
by
guest
on
22
January
2026
--- Страница 39 ---
3864 ESCGuidelines
Minorsurgicalproceduresandprocedureswherebleedingiseasily Bridging therapy may be considered for patients with a high
controlled can be performed without VKA interruption. The INR thromboticrisk(i.e.AFwithCHA DS -VASc(congestiveheartfail-
2 2
shouldbemonitoredandmaintainedatthelowerlevelofthethera- ure,hypertension,age≥75years,diabetesmellitus,stroke,vascular
peutic range. Major surgical procedures needing INR ≤1.5require disease, age 65–74 years, sex category [female]) score .6, recent
VKA interruption, and heparin bridging should be considered. cardioembolic stroke ,3 months, or high risk of VTE recurrence,
However,theevidencetosupportbridgingtherapyislimitedandde- weighing the risk of bleeding against the risk of thromboembol-
rivedfromcohortstudieswithpoorornocomparatorgroups.291 ism291,294,300(seeSupplementarydata,FigureS3).
Furthermore, the current-generation mechanical prosthetic valves
intheaorticpositionareassociatedwithalowerriskofthrombo- 5.3.2.1.3. Restarting vitamin K antagonists after invasive proce-
embolismcomparedwiththeolderones.291Randomizedcontrolled
duresorsurgery. PatientswhohaveinterruptedVKAtreatmentbe-
trialsofbridgingvs.nobridgingtherapyforpatientswithAFwhodo fore surgery should restart the OAC 12–24h after the invasive
not have an MHV have shown higher risk of bleeding without a
procedure,ifthebleedingiswell-controlledandgastricandintestinal
changeinincidenceofthromboembolicevents,andincreasingcon-
reabsorptionhave been re-established.Therestarting dose should
cerns have been raised that bridging therapy exposes patients to
be the maintenance dose plus a boosting dose of 50% for 2 days.
higher bleeding risks without reducing the risk of thromboembol-
Patients managed with bridging therapy should start LMWH or
ism.292,293TherecentlypublishedPERI-OPtrialcomparedbridging
UFHtogetherwithVKA24haftersurgery,ifthebleedingiswell-
therapyvs.placeboinpatientswitheitheranMHV,AF,oratrialflut-
controlledandmaintained,untiltheINRhasreachedthetherapeutic
ter who required interruption of OAC therapy for surgery, and range.Inpatientsundergoingsurgerywithahighbleedingrisk,thera-
found no significant benefit for post-operative dalteparin bridging peuticdoseLMWHshouldbedelayedfor48–72hafterhaemostasis
topreventmajorthromboembolism.294Theresultswereconsistent
hasbeensecured.
fortheAF(n=1166)andMHVsgroups(n=350).Therefore,inpa-
tientswithMHVswithalowriskofthromboembolism(e.g.mechan-
5.3.2.1.4.ReversalofvitaminKantagonists. ReversalofVKAcan
icalbileafletaorticvalveinpatientswithsinusrhythm),bridgingmay
be managed with vitamin K, prothrombin complex concentrates
notbeneeded.InpatientswithMHVswithahighriskofthrombo-
(PPCs), and plasma administration. Vitamin K (from 2–10mg de-
embolism (mechanical aortic valve replacement [AVR] and any
pending on the INR value) can be used orally, with a predictable
thromboembolic risk factor, or an older-generation mechanical
reduction in INR in 18–24h or i.v. (in 25–50mL normal saline
AVR,oramechanicalmitralortricuspidvalvereplacement),bridging
over 15–30min) for more rapid INR reduction (4–6h). It should
with heparin should be considered during the peri-operative time
benotedthatcoagulationfactorscanstillbebelownormaldespite
intervalwhentheINRissubtherapeutic(Figure8).Inallsituations,
INR normalization, which means that bleeding risk might not yet
the risks of bleeding should be weighed against the benefits of
benormalized.Inpatientsneedingreversalforimmediatemajorsur-
thromboembolismprevention.
gery,PPCsorplasmashouldbeused.Four-factorPPCsarethepre-
Intravenousunfractionatedheparin(UFH)istheonlyheparintreat-
ferredoption301andaredosedonthebasisofINRandbodyweight
mentapprovedforbridginginpatientswithMHVs.Subcutaneouslow
(INR2–4at25U/kg,INR4–6at35U/kg,INR.6at50U/kg,witha
molecularweightheparin(LMWH),althoughusedoff-label,hassup-
maximumdose of 5000Uat 100kgof body weight).Whenfour-
plantedtheuseofUFHasabridgingtherapy,owingtothelowerin-
factor PPCs are unavailable, three-factor PPCs or plasma may be
cidenceofthrombocytopenia,greaterconvenience,morepredictable
used.Patientsrequiringareversalagentneedcarefulmonitoringof
dose–responserelationship,andsignificantcostsavingresultingfrom
haemostaticparametersandevaluationofthromboticandbleeding
outpatientadministration.Ameta-analysisofninestudiesof1042pa-
risks in the peri-operative phase, as reversal might be insufficient
tientswithMHVsshowednodifferencesbetweenLMWHandUFHin
oraprothromboticreboundmightoccur.Inthelattercase,aninter- the risks of thromboembolic events or major bleeding events.295
disciplinarydecisionshouldbemadewithregardtoearlyresumption
WhenLMWHisused,itshouldbegivenatatherapeuticdosetwice
ofanticoagulationtreatment.
adayandadjustedforrenalimpairment,whenapplicable.Anti-factor
Xa(FXa)activitymonitoringwithtargetlevelsfrom0.5–1.0U/mLmay
beusefulwhenthedosagemaybedifficulttodetermine(e.g.inpa- 5.3.2.2.Non-vitaminKantagonistoralanticoagulants
Fourdrugsarecurrentlyused:dabigatran(factorIIainhibitor),apix-
tientswithrenaldysfunctionorobesity).VitaminKantagonistbridging
strategiesareshowninSupplementarydata,FigureS2. aban,rivaroxaban,andedoxaban(FXainhibitors).Thepharmacoki-
neticandpharmacodynamiccharacteristicsofthesedrugsareshown
5.3.2.1.2. Vitamin K antagonists for atrial fibrillation/venous inTable8.
thromboembolism. In patients using VKA for AF or venous
thromboembolism (VTE), invasive procedures with a low bleeding 5.3.2.2.1.Unplannedsurgeryinpatientsonnon-vitaminKantag-
risk can be performed without VKA interruption.296–299 The INR onistoralanticoagulantsandreversalforemergencyprocedures.
shouldbemonitoredandmaintainedatthelowerlevelofthethera- Whenanurgentsurgicalinterventionisrequired,itisrecommended
peutic range. When interruption is necessary due to high bleeding thatNOACtherapyisimmediatelyinterrupted.Peri-operativeman-
risk procedures, the BRIDGE trial in AF patients showed that 3–5 agementofNOACtherapyinspecificproceduralsettingsandsug-
daysofwarfarininterruptionwithoutbridgingwassuperiortoheparin gested strategies for potential reversal of NOAC anticoagulant
bridging,havingthesameincidenceofarterialandvenousthrombo- effectareshowninFigures9–1199,240,302(seeSupplementarydata,
embolismandsignificantlylowerincidenceofmajorbleeding.292 TableS5).
Downloaded
from
https://academic.oup.com/eurheartj/article/43/39/3826/6675076
by
guest
on
22
January
2026
--- Страница 40 ---
ESCGuidelines 3865
Stopping and re-initiation of NOAC therapy in elective NCS according
to the periprocedural risk of bleeding in patients with normal renal function
NOAC type Frequency of NOAC administration
NCS
-3 -2 -1 1 2
Days
DDaabbiiggaattrraann Twice Twice MMaaaayy sskkiipp tthhee Twice Twice
Minor AAppiixxaabbaann daily daily eevveenniinngg ddoosseeaa daily daily
bleeding RReessttaarrtt
risk NCS RRiivvaarrooxxaabbaann Once Once Once NNOOAACC ≥≥66 hh Once Once
EEddooxxaabbaann daily daily dailyb aafftteerr ssuurrggeerryy daily daily
DDaabbiiggaattrraann Twice Twice Twice Twice
Low AAppiixxaabbaann daily daily daily daily
CCoonnssiiddeerr
bleeding
NNoo NNOOAACC rreessttaarrttiinngg
risk NCS RRiivvaarrooxxaabbaann Once Once NNNoo bbrriiddggiinnggcc NNOOAACC iinn tthhee Once Once
EEddooxxaabbaann daily daily eevveenniinngg daily daily
DDaabbiiggaattrraann Twice
High AAppiixxaabbaann daily
NNoo NNOOAACC RReessttaarrtt
bleeding NNoo NNOOAACC
CCoonnssiiddeerr pprroopphhyyllaaccttiicc NNOOAACC
risk NCS RRiivvaarrooxxaabbaann Once NNoo bbrriiddggiinnggcc ddoossee hheeppaarriinn ≥≥4488––7722 hh
EEddooxxaabbaann daily ppoosstt--ooppeerraattiivveellyy aaaafftteerr ssuurrggeerryyyyyy
START STOP
Figure9Peri-operativemanagementofnon-vitaminKantagonistoralanticoagulantaccordingtotheperiproceduralriskofbleeding.NCS,non-cardiacsur-
gery;NOAC,non-vitaminKantagonistoralanticoagulant.aInpatients/circumstancesfavouringNOACaccumulation(e.g.renaldysfunction,olderage,concomi-
tantmedication),theNOACshouldbepaused12–24hearlier.bInpatientsonrivaroxabanoredoxabantakingthedoseintheevening,theeveningdosemaybe
skipped.cNOACshavepredictableweaningoftheanticoagulanteffect.Owingtotheincreaseinbleedingriskassociatedwithbridging,itisgenerallynotre-
commendedtousebridginginpatientstakingNOACs.VeryfewcircumstanceswhenbridgingwithheparinmaybeconsideredinpatientstakingaNOAC
includehighthromboembolicriskconditions,suchas:1)patientswitharecent(within3months)thromboembolicevent(stroke,systemicembolism,or
VTE);2)patientswhoexperiencedathromboemboliceventduringpreviousinterruptionofNOACtherapy.
Whereastheopen-labelprospectivetrialtestingthespecificre- agentsareunavailable,prothrombincomplexconcentrate(PCC)or
versalagentidarucizumabinpatientsondabigatranenrolledpartici- activatedPCCshouldbeconsidered,althoughthereisalackofevi-
pantsexperiencingacutemajorbleedingorrequiringurgentsurgical denceontheirefficacyandsafetyforemergencyproceduresinpa-
intervention,303thetrialwiththereversalagentandexanetalphafor tients taking a NOAC.290,305 Performing immediate or urgent
FXainhibitorsincludedonlypatientswithacutemajorbleedingun- surgeryundergeneralratherthanspinalanaesthesiaisprudent,inor-
der therapy, but not those requiring urgent surgery.304 However, dertoreducetheriskofepiduralhaematoma.
theoff-labeluseofandexanetalphainlife-threateningsituationsre- Prior to unplanned surgery, the full panel of coagulation blood
quiring an immediate intervention may be considered, bearing in tests(seeSupplementarydata,TableS6)shouldbeobtainedinorder
mind that andexanetalpha non-specifically binds allFXa inhibitors, toassessthepatient’scoagulationstatus.Theindicationforreversal
whichmayhaveimportantimplicationsforfurthertreatment,includ- (and/ornon-specifichaemostatic)agentsisprimarilygovernedbythe
ingtheadministrationofUFHorLMWH.240Whenspecificreversal patient’s clinical presentation, but initial assessment of coagulation
Downloaded
from
https://academic.oup.com/eurheartj/article/43/39/3826/6675076
by
guest
on
22
January
2026
--- Страница 41 ---
3866 ESCGuidelines
Timing of last NOAC dose before elective NCS
according to renal function
Minor bleeding risk NCS
Perform intervention at NOAC through level (i.e. 12 h or 24 h after last intake for twice
or once daily regimens,respectively). Resume same day or latest next day.
Low and high bleeding risk NCS
Low bleeding High bleeding Low bleeding High bleeding
risk NCS risk NCS risk NCS risk NCS
Renal function
Dabigatran Apixaban, rivaroxaban, edoxaban
(estimated GFR, mL/min)
≥80 ≥24 h ≥48 h
50–79 ≥36 h ≥72 h ≥24 h
≥48 h
30–49 ≥48 h ≥96 h
15–29 Not indicated Not indicated ≥36 h
<15 NNoo ffffoorrmmaall iinnddiiccaattiioonn ffffoorr uussee
No peri-operative bridging with UFH/LMWH
Figure10Timingoflastnon-vitaminKantagonistoralanticoagulantdosebeforeelectiveNCSaccordingtorenalfunction.GFR,glomerularfiltrationrate;
LMWH,lowmolecularweightheparin;NCS,non-cardiacsurgery;NOAC,non-vitaminKantagonistoralanticoagulant;UFH,unfractionatedheparin.
statusmayhaveimportantimplicationsfortreatmentinthenextfew isnot recommended, except ina fewhighthrombotic riskcircum-
hours or days. Specific coagulation tests such as diluted thrombin stances(seeFigure9).However,post-operativethromboprophylaxis
time (dTT) or ecarin clotting assay for dabigatran and antiFXa withLMWHshouldbeconsideredinpatientsinwhomNOACther-
chromogenic assays for FXa inhibitors, and the assessment of apy cannot be quickly restarted. In patients receiving bridging with
NOAC plasma levels, may help in interpreting routine coagulation LMWH,monitoringofantiFXaactivityanddoseadjustmenttoatar-
testsandwaningofanticoagulanteffect.240 getlevelof0.5–1.0U/mLmaybeconsidered.
5.3.2.2.2.Plannedinterventionsinpatientsonnon-vitaminKoral 5.3.2.2.4.Laboratorytestingbeforesurgery. Pre-operativeassess-
anticoagulants. Invasivesurgicalinterventionsmayrequiretempor- mentofanticoagulationstatusinpatientsona NOACundergoing
arydiscontinuationofNOACtherapy,whilemanyless-invasivepro- plannedsurgeryprovidesadirectassessmentofresidualdrugcon-
cedureswitharelativelylowriskofbleedingmaybeperformedunder centration. Shorter NOAC interruption time intervals in patients
minimallyinterruptedoruninterruptedNOACtherapy(Figure9).240
undergoinglow-riskproceduresmayresultinmildlyormoderately
elevated NOAC levels, as seen in the Perioperative Anticoagulant
5.3.2.2.3.Bridging. InpatientstakingaNOAC,peri-operativebridg- UseforSurgeryEvaluation(PAUSE)trial,309whereascreatinineclear-
ing using heparin or LMWH was associated with increased risk of ance ,50mL/min,standardNOAC dose (comparedwith reduced
bleeding without reduction in thromboembolic events.290,306–308 dose),bodyweight,70kg,andfemalesexwereassociatedwithele-
Therefore,whenNOACinterruptionisrequiredforsurgery,bridging vated NOAC levels among patients undergoing high-risk surgery.
Downloaded
from
https://academic.oup.com/eurheartj/article/43/39/3826/6675076
by
guest
on
22
January
2026
--- Страница 42 ---
ESCGuidelines 3867
Strategy fffor potential reversal of non-vitamin K oral anticoagulants effffffect
Step 1
Urrgency
Degree of urgency
IMMEDIAAATE URGENT TIME-SENSITIVE
i.e..within minutes i.e.. within hoursa i.e.. within daaaysb
Step 2
Blood coagulation
Check fffor blood coagulation tests:
full coagulation panel (PTTT,, aPTTTT,, antiFXa,,dTTTT,,etc.)
Measurement of NOAC plasma levels,, if aaavailable
Step 3
Timing last NOOOAC
Last intakkke of NNOACs >12 hc
Step 4 N Y N Y N Y
NCS
Perffform NCS Perffform NCS Perffform NCS
Reversal of NOAC depending on:
Surgery-related bleeding risk Surgery deffferral fffor 12 h,c Surgery deffferral as fffor planned
and if safffe,,or after normalization procedures,, if safffe (see Figure 8)
agent aaavailabilityd of coagulation parameterse
Step 5
Recheck blood coagulation
Recheck coagulation panel if last NOAC intakkke <12 h,c
or initial coagulation tests pathological,
or clinically relevant bleeding situation
TTTargeted haemostatic measures
Figure11Suggestedstrategyforpotentialreversalofnon-vitaminKoralanticoagulantseffect.aPTT,activatedpartialthromboplastintime;dTT,diluted
thrombintime;FXa,factorXa;N,no;NOAC,non-vitaminKantagonistoralanticoagulant;PT,prothrombintime;UFH,unfractionatedheparin.Y,yes;
aConditionsthatarepotentiallylife-threateningorthatmaythreatenthesurvivaloflimbororgan.bConditionsthatcanbemanagedandprocedurede-
layedforseveraldays.c.24hincaseofsignificantlyreducedrenalfunction(i.e.eGFR,50mL/min).dIfspecificreversalagentisunavailable,consider
non-specifichaemostaticagents(prothrombincomplexconcentrate[PCC]oractivatedPCC[aPCCs]).Idarucizumabhasonlybeentestedinpatients
undergoingurgentsurgery.Andexanethasnotbeentestedinpatientsrequiringurgentsurgery.AndexanetbindsallFXainhibitors(includingUFH)non-
specifically.eUponre-check.
Theuseofamiodarone,verapamil,ordiltiazemwasalsoassociatedwith 5.3.2.2.5.Considerationsforspecificprocedures. Beforeinterven-
elevatedpre-operativeNOAClevelsintheprospectivePer-procedural tionsthatcarryaveryhighriskofbleeding—suchasspinalorepidural
Concentration of Direct Oral Anticoagulants (CORIDA) trial.310 anaesthesia,orlumbarpuncturerequiringintacthaemostasis-–interrup-
Importantly,elevatedNOAClevelswerenotfoundtobeindepend- tionofNOACsforuptofivehalf-lives(i.e.3daysforFXainhibitorsor
entlyassociatedwithbleedingcomplications.309,310 4–5daysfordabigatran)shouldbeconsidered,whereasNOACscan
The evidence base for modifying the duration of pre-operative usuallyberestarted24haftertheintervention.313,314
NOACinterruptiontimeintervalsaccordingtoresidualNOACplas- Dentalproceduresaregenerallyconsideredtobeassociatedwith
malevelsisunavailable,and‘safe’plasmalevelsofNOACsfordiffer- minorbleedingrisk,andadequatelocalhaemostasisisusuallyeasily
ent procedures are largely unknown. The time-based NOAC achieved. Hence, most dental procedures can be performed in an
interruption(Figure9)appearssafeinmostpatientsundergoingsur- outpatient setting, with uninterrupted NOAC (or a single skipped
gery.311,312WhenNOACsareinterruptedfor.72h,thelikelihood dose)andusingspecificlocalhaemostaticmeasures(suchastheap-
ofanyresidualNOACplasmalevelsisverylow.309,310 plicationofoxidizedcelluloseorabsorbablegelatinesponge,sutures,
Downloaded
from
https://academic.oup.com/eurheartj/article/43/39/3826/6675076
by
guest
on
22
January
2026
--- Страница 43 ---
3868 ESCGuidelines
tranexamic acid mouthwash or compressive gauze). Most profes- Innon-minorbleedingriskproceduresinpatients
sional statements on dental surgery advise uninterrupted NOAC, usingaNOAC,itisrecommendedtousean
I B
buttheserecommendationsaremostlybasedonexpertconsensus, interruptionregimenbasedontheNOAC
whilesomestudiesarecurrentlyongoing.315–317
compound,renalfunction,andbleedingrisk.310,311
Forinterventionswithaveryhighriskofbleeding,
5.3.2.2.6.Whentorestartnon-vitaminKantagonistoralanticoa- suchasspinalorepiduralanaesthesia,interruption
IIa C
gulants after interventions. In general, NOAC can be restarted ofNOACsforuptofivehalf-livesandre-initiation
6–8h after interventions with rapid and complete haemostasis. after24hshouldbeconsidered.
Whenthebleedingriskwithfull-doseanticoagulationresumption Whenspecificreversalagentsareunavailable,
outweighstheriskofthromboembolicevents,therapeuticantic- PCCoractivatedPCCshouldbeconsideredfor IIa C
oagulationmaybepostponedto.48–72haftertheprocedure, reversingNOACeffects.
using prophylactic post-operative thromboprophylaxis until the Ifanurgentsurgicalinterventionisrequired,
resumption of full-dose NOAC is deemed safe (Figure 9).240 specificcoagulationtestsandassessmentof
Post-operativeheparinadministrationshouldalsobeconsideredinpa- NOACplasmalevelsshouldbeconsideredto IIa C
tients unable to take oral therapy. Off-label use of reduced-dose interpretroutinecoagulationtestsandwaningof
NOACstoattenuatetheriskofpost-operativebleedingisnotrecom- anticoagulanteffect.
mended,asthereisnoevidenceinformingsuchanapproach. Continuationofmedication
Inminorbleedingrisksurgeryandother
5.3.2.3.Combinationtherapy(antiplateletandanticoagulant) procedureswherebleedingcanbeeasily
I B
Ingeneral,accordingtothe2020ESCGuidelinesforthediagnosis controlled,itisrecommendedtoperformsurgery
and management of atrial fibrillation developed in collaboration withoutinterruptionofOACtherapy.240,296–299
with the European Association for Cardio-Thoracic Surgery LMWHisrecommended,asanalternativeto
(EACTS), dual antithrombotic therapy should be adopted in most UFH,forbridginginpatientswithMHVsandhigh I B
patientswithAFandarecentPCI.99Electivesurgeryshouldbepost- surgicalrisk.295
poneduntiltheperiodwhenantiplatelettherapycanbesafelydis- InpatientsusingNOACs,itisrecommendedthat
continued in combination therapy (6 months after elective PCI or minorbleedingriskproceduresareperformedat I C
12monthsafterACS).268Peri-operativehandlingofNOACsshould troughlevels(typically12–24hafterlastintake).
follow the above recommendations (Figures 9 and 10). In urgent/ Forpatientswithmechanicalprostheticheart
emergencysurgerywithhighbleedingrisk,operativemeasurestore- valvesundergoingNCS,bridgingwithUFHor
ducebleedingand/orreversalstrategiesofanticoagulationmightbe LMWHshouldbeconsideredifOACinterruption
applied.Inpatientsreceivingcombinationtherapyforotherindica- isneededandpatientshave:(i)mechanicalAVR IIa C
tions(e.g.TAVIandAF),accordingtorecenttrialresults,antiplatelet andanythromboembolicriskfactor;(ii)
therapycanbesafelydiscontinuedbeforeNCS.318Inpatientsreceiv-
old-generationmechanicalAVR;or(iii)
inglow-doseOACsaspartofavascularprotectionstrategy,rivarox- mechanicalmitralortricuspidvalvereplacement.
abanshouldbepausedforatleast24hbeforesurgeryandresumed
BridgingofOACtherapyisnotrecommendedin
accordingtothepost-operativebleedingrisk. patientswithlow/moderatethromboticrisk III B
undergoingNCS.290,292,293,306–308,311
RecommendationTable14—Recommendationsfor Start/resumptionofmedication
interruption and resumption of anticoagulants in pa-
Ifbleedingriskwithresumptionoffull-dose
tientsundergoingnon-cardiacsurgery
anticoagulationoutweighstheriskof
Recommendations Classa Levelb thromboembolicevents,postponingtherapeutic
anticoagulation48–72haftertheproceduremay IIb C
Interruptionofanticoagulation beconsidered,usingpost-operative
Whenanurgentsurgicalinterventionisrequired, thromboprophylaxisuntilresumptionoffullOAC
itisrecommendedthatNOACtherapyis I C doseisdeemedsafe.
immediatelyinterrupted. Useofreduced-doseNOACtoattenuatetherisk
III C
Idarucizumabshouldbeconsideredinpatientson ofpost-operativebleedingisnotrecommended.
dabigatranandrequiringurgentsurgical
IIa B AVR,aorticvalvereplacement;OAC,oralanticoagulant;LMWH,lowmolecularweight
interventionwithintermediatetohighbleeding heparin;MHV,mechanicalheartvalve;NCS,non-cardiacsurgery;NOAC,non-vitamin
risk.303 Koralanticoagulant;PCC,prothrombincomplexconcentrate;UFH,unfractionated
heparin.
Continued aClassofrecommendation.
bLevelofevidence.
2202CSE©
Downloaded
from
https://academic.oup.com/eurheartj/article/43/39/3826/6675076
by
guest
on
22
January
2026
--- Страница 44 ---
ESCGuidelines 3869
5.4. Peri-operative thromboprophylaxis RecommendationTable15—Recommendationsfor
thromboprophylaxis
Trendsshowthatthecase-fatalityofperi-operativeVTEhasdeclined
overthepastfewdecades.319,320Itscausalrelationshipwithprevent-
Recommendations Classa Levelb
able mortality has been challenged by a recent meta-analysis.321
Thus, peri-operative VTE should be regarded as a marker of in- Itisrecommendedthatdecisionsabout
creased mortality risk rather than a causal factor. Careful pre- peri-operativethromboprophylaxisinNCSare
I A
operativeassessmentisessentialtoidentifypatientswithincreased basedonindividualandprocedure-specificrisk
VTE risk who might benefit from peri-operative thromboprophy- factors.328,332
laxis.Procedure-related(e.g.typeofsurgeryandlikelihoodofpost- Ifthromboprophylaxisisdeemednecessary,itis
operativeimmobilization)andpatient-relatedfactorscontributeto recommendedtochoosethetypeanddurationof
the risk of VTE. For non-orthopaedic surgical patients at low risk thromboprophylaxis(LMWH,NOAC,or
I A
of VTE, mechanical methods of VTE prophylaxis (graduated com- fondaparinux)accordingtotypeofNCS,duration
pressionstockings,intermittentpneumaticcompression,orvenous ofimmobilization,andpatient-related
footpump)ratherthanpharmacologicprophylaxisornoprophylaxis factors.328,332
arerecommended.PatientswithCVdisease(e.g.patientswithre- Inpatientswithalowbleedingrisk,peri-operative
cent MI or HF) have increased risk of peri-operative VTE.322 The thromboprophylaxisshouldbeconsideredfora IIa A
Capriniscorehasbeendevelopedforriskstratification,323andvali-
durationofupto14or35days,fortotalkneeor
dated in different surgical settings (see Supplementary data, hiparthroplasty,respectively.334–337
TableS7).324–327
NOACsinthromboprophylaxisdosemaybe
Thromboprophylaxis should be considered for patients with consideredasalternativetreatmentstoLMWH IIb A
moderate (i.e. 5–8 points) and high scores (i.e. ≥9 points). aftertotalkneeandhiparthroplasty.333
Thromboprophylaxisshouldbeinitiatedduringthehospitalstayuntil
LMWH,lowmolecularweightheparin;NCS,non-cardiacsurgery;NOAC,non-vitamin
12hbeforeNCSandcontinuedpost-operativelybasedonindividual
Koralanticoagulant.
risk assessment for bleeding. In most cases, thromboprophylaxis aClassofrecommendation.
shouldbecontinueduntilthepatientbecomesfullymobilizedoruntil bLevelofevidence.
hospitaldischarge(usuallyupto10days).Extendedpharmacological
VTEprophylaxisbeyonddischargeisnotroutinelyrecommendedin
5.5. Patient blood management
mostnon-orthopaedicsurgicalpatients.Althoughthereareinsuffi-
cientdataregardingthromboprophylaxisaftercancersurgery(par- Majorsurgeryisassociatedwithahighriskofperi-operativeblood
ticularly major abdominal and/or pelvic surgery for cancer), the loss.Preferredtreatmentofacuteanaemiarelatedtoperi-operative
consensus is to extend treatment duration with preferred use of blood loss is transfusion of allogenic blood products. However, a
LMWH for 3–4 weeks. Decisions on prophylaxis in populations large body of evidence indicates that inappropriate transfusion of
forwhichtheCapriniscorehasnotbeenvalidated(suchasortho- red blood cells (RBCs) may be associated with inherent complica-
paedicsurgery)shouldbebasedonindividualandprocedure-specific tions and impaired surgical outcome. Therefore, it is important to
riskfactors.Amongthose,apreviousVTEisthestrongestriskpre- identify at-risk patients pre-operatively and manage peri-operative
dictor(see Supplementarydata, TableS7).328Forspecialsituations bleedinginanypatientsundergoingmajorsurgery.
andpopulations(e.g.neurosurgery,elderly,obese),pleasereferto A hallmark study including .200000 major surgical patients
availablespecificpracticeguidelines.329–332 showed that even mild anaemia significantly increased the risk of
Large phase 3 and phase 4 studies comparing NOACs with morbidity—including respiratory, urinary, wound, septic, and
LMWHhaveshownsimilarresultsregardingefficacyandsafetyafter thromboembolic complications—and mortality across all age
majororthopaedicsurgery.333Theusualtimeperiodforthrombo- groups.345Moreover,Baronandcolleaguesanalysed.39000surgi-
prophylaxisaftertotalkneeandhiparthroplastywasupto14days cal patients and showed that anaemia was significantly associated
and35daysinRCTs,respectively,334–339butlarge-scaledatasuggest with increased mortality rate, hospital length of stay, and post-
safetyofforeshorteningthedurationrestrictedtothehospitalstay operative admission to intensive care.346 Up to 48% of surgical
after fast-track surgery.340 Recent practice guidelines and a patientssufferfromanaemia,andthereforeanaemiashouldbecon-
meta-analysissuggestarationalefortheuseofaspirinasthrombo- sidered to be a risk factor any time during hospitalization.347 Von
prophylaxisinmodernelectivetotalhipandkneearthroplasty.341,342 Heymann and colleagues analysed 4494 cardiac surgical patients
However,thereisaneedformoreadequatelypoweredclinicaltrials andshowedthatpre-operativeanaemiaandintra-operativetransfu-
withappropriateend-pointscomparingaspirinwithotherpharma- sion were independently associated with decreased long-term
cologicalmethods.Aspirinshouldnotbeusedasthesoleinitialagent
survival.348Inaddition,long-termsurvivalwasdecreasedby50%in
forVTEprophylaxis,butswitchingtoaspirinfollowingashortcourse anaemicpatientsreceiving bloodtransfusioncomparedwiththose
(e.g.5days)ofrivaroxabanmaybesuitableforselectedlow-riskpa- withoutbloodtransfusion.
tients.343Itisrecommendedtoimplementpatientcareprogrammes Anaemia may contribute to myocardial ischaemia, particularly if
—including post-operative mobilization, electronic prophylaxis re- CADispresent.Irondeficiency(ID)istheunderlyingcauseofan-
commendations,andteachingsessionsregardingdailyuseofthrom-
aemiain(cid:4)50%ofallcases.347ItwasrecentlyshownthatIDwasas-
boprophylaxis—as these have been shown to be beneficial in sociatedwithincreasedriskof90daymortalitybothinpatientswith
reducingtheriskofpost-operativeVTEcomplications.344 (4–14%)andwithout(2–5%)anaemia.349Inaddition,theincidence
2202CSE©
Downloaded
from
https://academic.oup.com/eurheartj/article/43/39/3826/6675076
by
guest
on
22
January
2026
--- Страница 45 ---
3870 ESCGuidelines
ofseriousadverseevents,majorcardiacandcerebrovascularevents, significantlyreducedby2.8daysforironsupplementedpatients.In
allogenicbloodtransfusionrequirements,andlengthofstaywerein- therecentPREVENTTtrialstudyingpatientswithanaemiaundergo-
creasedinpatientswithID. ingmajorabdominalsurgery,pre-operativeirontransfusionfailedto
Based on the possibility of preserving the patients’ own blood improveoutcomes;360however,duetoafaultinthestudydesign,all
resources and to enable safe handling of donor blood, the anaemicpatientsreceivedi.v.ironbutnotall((cid:4)50–70%)weresuf-
World Health Assembly (WHA) has endorsed the Patient feringfromID.
Blood Management (PBM) approach (WHA63.12). Patient Blood Recombinant human erythropoietin (rHuEPO) has frequently
Managementisapatient-centredandmultidisciplinaryapproachto been used together with iron supplementation to increase pre-
manage anaemia, minimize iatrogenic blood loss and bleeding, and operative haemoglobin concentrations. A recent Cochrane review
harness tolerance to anaemia in an effort to improve patient out- foundthattheadministrationofrHuEPO+irontoanaemicpatients
come.350–355AcomprehensivePBMprogrammeaddressingallthree
priortoNCS,comparedwithcontroltreatment,reducedtheneed
PBM pillars was associated with reduced transfusion need of RBC forRBCtransfusionandincreasedthe haemoglobinconcentration
units,andlowercomplicationandmortalityrates.350 pre-operatively; however, there were no important differences in
theriskofadverseeventsormortalitywithin30days,orinlength
ofhospitalstay.361Well-designed,adequatelypoweredRCTsarere-
5.5.1.Pre-operativeanaemia—diagnosisand
quired to more precisely estimate the impact of this combined
treatment treatment.
Aserumferritinlevel,30ng/mL,transferrinsaturation,20%,and/
Pre-operativemanagementofpatientswithanaemiacanbesimpli-
or microcytic hypochromic red cells (mean corpuscular volume fiedbymakinguseofstandardoperatingproceduresoralgorithmsin
,80fl,meancorpuscularhaemoglobin,27g/dL)areindicativeof whichthresholdsfordiagnosisandtreatmentaredepicted.362Anex-
ID. In the presence of inflammation or transferrin saturation ampleofsuchanalgorithmcanbefoundinthePBMprogramme363
,20%,aferritinlevelof,100ng/mLpointstofunctionalID(iron
(seeSupplementarydata,FigureS4)andintheBritishCommitteefor
sequestration)(Table10). StandardsinHaematology(BCSH)GuidelinesontheIdentification
Apartfromcompromisedbonemarrowfunction,mosttypesof andManagementofPre-OperativeAnaemia.364
anaemia are correctable within a period of 2–4 weeks. Oral and
i.v.irontherapycanbeusedtotreatID.Intravenousironproducts
consistofanironcoreembeddedinacarbohydrateshell,whichin- RecommendationTable16—Recommendationsfor
fluences the stability of the drug, for example: iron sucrose com- intra- and post-operative complications associated
withanaemia
prises a less stable shell, allowing a maximum dose of 200mg per
infusion, whereas ferric carboxymaltose, ferric derisomaltose, and
Recommendations Classa Levelb
ferumoxytol have a stable shell associated with slow iron release
and allowing a higher dose. Administration of i.v. iron has been Itisrecommendedtomeasurehaemoglobin
showntoeffectivelyreverseanaemiainIDpatients.356,357 pre-operativelyinpatientsscheduledfor I B
Intravenousironisefficaciousandsafe359andshouldbeusedin intermediate-tohigh-riskNCS.350,354
patientsinwhomoralironisnottolerated,orifsurgeryisplanned Itisrecommendedtotreatanaemiainadvanceof
inshortnoticeafterthediagnosisofID.Aprospectiveobservational NCS,inordertoreducetheneedforRBC I A
studyof1728majorsurgicalpatientsshowedthattheprevalenceof transfusionduringNCS.357,361
IDwas50%,46.3%,and52.7%inpatientswithhaemoglobin,8.0, Theuseofanalgorithmtodiagnoseandtreat
8.0–8.9,and9.0–9.9g/dL,respectively.357Furthermore,allironsup- anaemicpatientsbeforeNCSshouldbe IIa C
plemented iron-deficient anaemic patients required fewer RBC considered.
transfusions during the post-operative period, and a reduced
NCS,non-cardiacsurgery;RBC,redbloodcell.
intra-operativetransfusionratewasobservedifironwassupplemen-
aClassofrecommendation.
ted .7 days before surgery. In addition, the length of stay was bLevelofevidence.
5.5.2.Bleedingandreductionofiatrogenic
Table10 Laboratoryparametersforthediagnosisof
absoluteiron-deficiencyanaemia diagnostic/surgery-relatedbloodloss
Bloodlossassociatedwithlaboratorytestingcaneithercauseorag-
Parameter Normal Irondeficiency gravate hospital-acquired anaemia, which is associated with in-
creased length of stay and complications. In 1867 patients
Meancorpuscularhaemoglobin(g/dL) 28–33 ,27
undergoing cardiac surgery, an average of 115 tests per patient
Meancellularvolume(fL) 80–96 ,80 were performed, with a cumulative median volume of 454mL.365
Transferrinsaturation(%) 16–45 ,20
Areductioninblooddrawnforlaboratoryanalysescanbeachieved
Ferritin(ng/mL) 18–360 ,30a byloweringthefrequencyofsamplingandusingpaediatric-sizecol-
Reticulocyteshaemoglobin(ng/mL) 18–360 ,30 lectiontubesizes,forexample.Todecreasebloodloss,blood-saving
aIncasesofchronickidneydisease,chronicheartfailureorinfections,irondeficiencyis bundlescouldbeused(e.g.aclosed-looparterialbloodsamplingsys-
diagnosedwithferritinlevel,100ng/mLortransferrinsaturation,20%.358 tem, smaller sampling tubes, reduction of frequency of blood
2202CSE©
2202CSE©
Downloaded
from
https://academic.oup.com/eurheartj/article/43/39/3826/6675076
by
guest
on
22
January
2026
--- Страница 46 ---
ESCGuidelines 3871
drawings, and sample numbers). Such a strategy decreased mean InpatientsundergoingNCSandexperiencing
blood loss per intensive care unit (ICU) day from 43.3mL to majorbleeding,administrationoftranexamicacid IIa A
15.0mL (P,0.001),366 mainly due to the introduction of shouldbeimmediatelyconsidered.375,376,384–386
closed-loop arterial blood sampling systems. In addition, units of
Useofclosed-looparterialbloodsampling
transfused RBCs per 100 observation days decreased from 7 to systemsshouldbeconsideredtoavoidblood IIa B
2.3(P,0.001).366
loss.366,378,387,388
A reduction in surgery-related blood loss starts from the pre-
Applicationofmeticuloushaemostasisshouldbe
operativestage,withappropriatecessationstrategiesforanticoagu- IIa B
consideredaroutineprocedure.350,389
lationandantiplatelettherapy.Intra-operativeapproachestoavoid
blood loss include: (i) advanced anaesthetic; (ii) advanced surgical NCS,non-cardiacsurgery.
aClassofrecommendation.
techniqueswithmeticuloushaemostasis,suchasminimallyinvasive
bLevelofevidence.
surgeryandlaparoscopicsurgery;(iii)judicioususeofdiathermydis-
section;(iv)physician’smindfulnessregardinglimitingbloodloss;and
(v)applicationoftopicalhaemostaticagents.367–369
5.5.3.Optimalbloodcomponentusewith
Adequatecoagulationmanagementtominimizebloodlossneeds
patient-centredclinicaldecisionsupport
tobeapre-conditionbeforeRBCtransfusionisconsidered.Inthis
respect,theuseofacoagulationalgorithmisrecommended,370,371 Inordertooptimizeutilizationofallogeneicbloodproductsandto
encompassingpre-operativeassessment,372andensuringbasiccon- ensure guideline-adherent transfusion strategies, computerized
physicianorder-entrysystemsshouldbeconsidered.390,391Forex-
ditions for haemostasis, reversal of anticoagulants, point-of-care
ample,Kasererandcolleaguesevaluatedtheeffectivenessofamon-
diagnosticsinbleedingpatients,andoptimizedcoagulationmanage-
mentwiththeuseofclottingfactorconcentrates.373,374 itoringandfeedbackprogrammeandcomparedtransfusionratesof
Tranexamicacidisanantifibrinolyticagentthatiswidelyusedfor .210000 patients before and after implementation;392 overall,
prophylaxisandtreatmentofbleedingcausedbyhyperfibrinolysis.A transfusionofRBCswasreducedby40%.
Informedconsentshouldbeobtainedfrompatientspriortotrans-
meta-analysis including 129 trials encompassing more than 10000
fusionofallogeneicbloodproducts.Itisnecessarytoeffectivelycom-
patientstoassesstheeffectoftranexamicacidonbloodtransfusion
municatetherisksandbenefitsofthevariouspotentialinterventions
showed that administration of tranexamic acid reduced allogeneic
blood transfusion by 38% (P,0.001).375 In the recent POISE-3 tothepatient.Itmayfurtherberecommendedthatanytransfusion
ofallogeneicbloodproductsshouldbementionedinthedischarge
study,9535patientsundergoingNCSwererandomizedtotranex-
summary. In addition, the patient’s own preferences and values
amicacid(1gi.v.bolus)orplaceboatthestartandendofsurgery.
Theincidenceoftheprimaryefficacyoutcome(compositebleeding shouldbeconsideredwhendevelopingamedicalplan.
outcome) at 30 days was significantly lower with tranexamic acid
than with placebo (HR, 0.76; 95% CI, 0.67–0.87).376 With respect RecommendationTable18—Recommendationsfor
totheprimarysafetyoutcome(compositeCVoutcome),theresults intra- and post-operative complications associated
did not meet the non-inferiority criteria (HR, 1.02; 95% CI, withallogeneicbloodtransfusion
0.92–1.14;P=0.04fornon-inferiority).
Theuseof(washed)cellrecoveryishighlyrecommendedinsur- Recommendations Classa Levelb
gical settings where blood loss is routinely or anticipated to be
Afeedback/monitoringprogrammeorclinical
.500mL, as it reduces the rate of exposure to allogeneic RBCs, decisionsupportsystemshouldbeconsideredto IIa B
riskofinfection,andlengthofstay.Ameta-analysisincluding47trials beassessedbeforebloodtransfusion.392–396
encompassing3433patientsofallsurgicaldisciplinesshowedthatthe
Beforeallogenicbloodtransfusion,itshouldbe
useofwashedcellsalvagereducedtherateofexposuretoallogeneic consideredtoobtainanextensiveconsentabout IIa C
RBCtransfusionby39%(P,0.001),riskofinfectionby28%(P=
risksasssociatedwithtransfusion.
0.03),andlengthofstayby2.31days(P,0.001).377
aClassofrecommendation.
bLevelofevidence.
RecommendationTable17—Recommendationsfor
intra- and post-operative complications associated
withbloodloss 6. Specifi c diseases
Recommendations Classa Levelb
PatientswithCVDhaveanincreasedriskofperi-operativeCVcom-
Inpatientsundergoingsurgerywithexpected plications.45 Both the risk of complications and the peri-operative
bloodlossof≥500mL,useofwashedcellsalvage I A managementdependonthespecifictypeofCVD.
isrecommended.377,378
Itisrecommendedtousepoint-of-care
6.1. Coronary artery disease
diagnosticsforguidanceofbloodcomponent I A
therapy,whenavailable.370,379–383 6.1.1.Riskforpatientswithcoronaryarterydisease
Theperi-operativeriskofCVcomplicationsforpatientswithestab-
Continued
lished CADdependsonthe baselineCV risk,type ofsurgery,and
2202CSE©
2202CSE©
Downloaded
from
https://academic.oup.com/eurheartj/article/43/39/3826/6675076
by
guest
on
22
January
2026
--- Страница 47 ---
3872 ESCGuidelines
degreeofurgencyoftheNCS.Olderpatientshaveahigherriskthan treated did not differ in terms of acute MI after 30 days (8.4% vs.
youngerpatients,andpatientswitharecentACShaveahigherrisk 8.4%, respectively) and mortality after 2.7 years (22% vs. 23%, re-
thanthosewithCCS.Thepresenceofcomorbiditiesmayalsoinflu- spectively). Of note, this study excluded patients with significant
encetherisk. left main disease, while one-third of the patients presented with
three-vessel disease.399 In another randomized trial, 426 patients
6.1.2.Pre-operativeriskassessmentand withoutevidenceofCADandscheduledforCEAwererandomized
management toeitherroutinecoronaryangiographywithprovisionalrevascular-
Thediagnosticevaluationandpre-operativemanagementofpatients izationbeforeCEAorCEAwithoutpreviouscoronaryangiography.
withCCSundergoingNCSareoutlinedinSection4.Inparticular,the Therewerenosignificantdifferencesbetweenthetreatmentgroups
valueofCCTAandICAarediscussedinSections4.5.3.1.and4.5.3.2. inall-causemortality,acuteMI,andstrokeat30 days.172 Asubse-
InpatientsinneedofimmediateNCS,theoperationmustbeper- quentmeta-analysisincluding3949patientsshowednoclinicalbene-
formedwithoutfurtherdelayandthetimeforpre-operativeassess- fit associated with routine prophylactic revascularization before
mentislimited. NCS.400Arecentretrospectiveanalysison4414patientsundergoing
InpatientsscheduledforelectiveNCSwhopresentwithanACS, totaljointarthroplastyfoundthattheriskofadverseCVeventswas
the managementof ACSshouldfollow theguidelines forACSpa- increasedinpatientswithCAD,regardlessofcoronaryrevasculari-
tientsinthenon-surgicalsetting.98,171In suchsettings,itwouldbe zationbeforesurgery.However,inpatientsreceivingcoronaryre-
reasonabletoconsidertreatingtheculpritlesiononlybeforeNCS. vascularization, the risk of adverse CV events decreased, as the
Potentialchangesintimingofsurgeryandtheperi-operativemanage- interval between revascularization and total joint arthroplasty was
ment (e.g. type of surgery, anaesthesia, medical therapy, and peri- .2years.401
operativemonitoring)shouldbeconsidered. Thelackofevidenceinsupportofroutineprophylacticrevascular-
InpatientswithknownCAD,itisrecommendedtocollectinfor- ization in CCS does not preclude a decision-process based on
mation regarding previous invasive and non-invasive diagnostic ex- individual risk–benefit assessment in patients with a significant
aminations, and therapeutic interventions for CAD, within a amount of ischaemic myocardium (as in the case of left main
sufficienttimeintervalbeforetheNCS,ideallyatthetimethepro- disease)and/orwithrefractorysymptoms.TheInternationalStudy
posalforNCSismade. of Comparative Health Effectiveness with Medical and Invasive
Approaches(ISCHEMIA)trialrandomized5179patientswithstable
6.1.3.Revascularizationstrategies CADandmoderateorsevereischaemiatoaninitialinvasivestrategy
Theindicationforcoronaryrevascularizationdependsontheclinical (consistingofangiographyplusrevascularization,asappropriate)or
presentation of CAD (ACS vs. CCS), urgency, and cardiac risk of toaninitialstrategyofmedicaltherapyalone,withbail-outangiog-
NCS.Ingeneral,thereisclearevidencethatroutinerevascularization raphyifmedicaltherapyfailed.402Thistrialdidnotfindasignificant
improvesoutcomesinACSpatientsandlesssupportforsuchastrat- differenceintheprimarycompositeend-pointofdeathandMIbe-
egyinpatientswithCCS.Theprocessofdecision-makingrelatedto tweentreatmentgroups.Interestingly,theseneutralresultswerein-
revascularizationinCCSshouldbeindividualized,inordertopriori- applicable to patients with severe left main disease, since these
tizerevascularizationincaseofinvolvementofasignificantamountof patients were excluded after a pre-randomization CCTA. It has
ischaemicmyocardiumorrefractorysymptoms,whilemedicalman- yettobedemonstratedwhetherCCTArepresentsavaluabletool
agement is a valuable option in patients with less relevant CAD with which to select patients with stable CAD and/or moderate
manifestations. or severe ischaemia who might benefit from an initial invasive
strategy. A large angiography-based registry of 9016 CCS patients
6.1.3.1.Chroniccoronarysyndromes with high-risk coronary anatomy (three-vessel disease with ≥70%
TherationaleforcoronaryrevascularizationbeforeNCSistopre- stenosis in all three epicardial vessels or left main disease ≥50%
vent peri-operative myocardial ischaemia leading to acute MI, stenosis)showedimprovedoutcomes(all-causemortalityorMI)in
haemodynamicinstability,andarrhythmia.Datafromautopsystudies patients undergoing revascularization (both for PCI or CABG)
followingfatalperi-operativeMIshowedthatmorethantwo-thirds vs.conservativemedicaltherapy(HR,0.62;95%CI,0.58–0.66;P,
ofthepatientshadsignificantleftmainorthree-vesseldisease.397A 0.001).403
retrospectiveregistrybasedontheCoronaryArterySurgeryStudy The2018ESC/EACTSGuidelinesonmyocardialrevasculariza-
(CASS) studyfound that coronary artery bypass graft(CABG) re- tionandthe2019ESCGuidelinesforthediagnosisandmanage-
ducedtheriskofperi-operativemortalityandMIinpatientsunder- ment of chronic coronary syndromes generally apply to this
going majorNCS, particularly in subjects with three-vessel disease population of patients, as long as the NCS can be postponed
and reduced left ventricular ejection fraction (LVEF).398 However, long enough to allow safe discontinuation of DAPT.146,404
theevidenceinsupportofroutineprophylacticrevascularizationbe- Similarly, the choice between PCI and CABG should follow the
foreNCSisbasedonrelativelysmallclinicaltrialsandretrospective general rules outlined in the above-mentioned guidelines.268,404
registriesunrepresentativeofcurrentclinicalpractice. Theuseofintravascularimagingforplanningandoptimizationof
In the Coronary Artery Revascularization Prophylaxis (CARP) PCIisencouraged.405,406
trial,510patientswithCCSwererandomizedtoeitheroptimalmed-
icaltherapyorcoronaryrevascularization(surgicalorpercutaneous) 6.1.3.2.Acutecoronarysyndromes
beforemajorvascularsurgery.399Inthisstudy,patientsreceivingcor- Therearenotrialsspecificallyaddressingthestrategyofrevascular-
onary revascularization compared with those who were medically izationinACSpatientsscheduledforNCS.High-andveryhigh-risk
Downloaded
from
https://academic.oup.com/eurheartj/article/43/39/3826/6675076
by
guest
on
22
January
2026
--- Страница 48 ---
ESCGuidelines 3873
Management of patients withACS or CCS scheduled for NCS
ACS CCS
Optimize guideline-recommended Optimize guideline-recommended
medical therapy medical therapy
(Class I ) (Class I )
Diagnostic and therapeutic pathways Low-risk NCS
according toACS Guidelines and No further screening
individual basis
(Class I)
Intermediate-risk NCS
Clinical examination + ECG
+biomarkersa (Class I)
Functional capacityb (Class IIa)
Symptoms or abnormal ECG
Cardiologist–surgeon–anaesthesist
discussion regarding myocardial or poor exercise tolerance N
or elevated biomarkers
revascularization options and
antithrombotic strategy dependent
Y
on the options and acceptable
time interval to postpone NCS
±TTE ± stress imaging
Elevated hs-troponin or
ICAc ± iwFR/FFR Y N
stress-induced ischaemia
High-risk NCS
Clinical examination + ECG
+biomarkersa (Class I)
Functional capacityb (Class IIa)
±TTE ± stress imaging
Symptoms or abnormal ECG
Y or poor exercise tolerance N
or elevated biomarkers
Figure12Managementofpatientswithacuteorchroniccoronarysyndromescheduledfornon-cardiacsurgery.ACS,acutecoronarysyndrome;BNP,
B-typenatriureticpeptide;CABG,coronaryarterybypassgraft;CAD,coronaryarterydisease;CCS,chroniccoronarysyndrome;ECG,electrocardio-
gram;FFR,fractionalflowreserve;hs-cTn,high-sensitivitycardiactroponin;ICA,invasivecoronaryangiography;iwFR,instantaneouswave-freeratio;
N,no;NCS,non-cardiacsurgery;NT-proBNP,N-terminalproBNP;PCI,percutaneouscoronaryintervention;TTE,transthoracicechocardiography.
Y,yes;Thefigureprovidesaschematicrepresentationofdiagnostictoolsandtherapytobeimplementedaccordingtosurgicalriskandunderlyingcardiac
condition.aBiomarkers:hs-cTnT/I(ClassI)+BNP/NT-proBNP(ClassIIa).bFunctionalcapacitybasedonDukeActivityStatusIndex(DASI)ortheability
toclimbtwoflightsofstairs.cICA+PCI/CABGonacase-by-casebasisaccordingtotheHeartTeam.
patientsshouldbetreatedaccordingtothe2020ESCGuidelinesfor amenabletoaselectiveinvasivestrategy,thedecision-makingshould
themanagementofacutecoronarysyndromesinpatientspresenting beconsistentwiththeapproachforCCSpatients.
withoutpersistentST-segmentelevation,98withanearly(,24h)or In a post hoc analyses of the HIP-ATTACK (HIP Fracture
immediate(,2h)invasivestrategy,respectively.Inlow-riskgroups Accelerated Surgical TreaTment And Care tracK) trial, patients
Downloaded
from
https://academic.oup.com/eurheartj/article/43/39/3826/6675076
by
guest
on
22
January
2026
--- Страница 49 ---
3874 ESCGuidelines
with increased baseline troponin before randomization showed 6.2. Chronic heart failure
lower risk of mortality with accelerated surgery (within 6h
6.2.1.Riskforpatientswithheartfailure
from the diagnosis) vs. standard of care (HR, 0.38; 95% CI,
Heartfailureisanestablishedriskfactorforpost-operativemortality
0.21–0.66).57
acrossabroadrangeofsurgicalspecialties.410–412Severaltoolsfor
The selection of the type of revascularization (PCI or CABG)
riskcalculationsinpatientsundergoingNCSincludeHFasapredict-
shouldbebasedonthecoronaryanatomyandcomplexityofath- orofadversepost-operativeevents.411,413
erosclerosis,andthepresenceofdiabetes.268,404WhenPCIischo-
Theriskofadversepost-operativeeventsassociatedwithHFde-
sen, the use of a DES is recommended.407 In case of a
pendsonwhethertheLVsystolicfunctionispreservedorreduced,
life-threatening clinical condition requiring undeferrable NCS and
onthehaemodynamiccompensation,andonthepresenceofsymp-
concomitantACS-STEMIwithanindicationforcoronaryrevascu- toms.414,415InpatientsundergoingNCS,thereisariskofacutede-
larization, a minimalistic approach with plain balloon angioplasty
compensatedHF,withrapidonsetorworseningofsymptomsand/
and delayed stenting might be considered.408,409 Figure 12 shows orsignsofHF,precipitatedbyfluidaccumulationand/orcomorbid
a summary of diagnostic and therapeutic pathways in patients conditions.412
withCADscheduledforNCS.
Patientswithperi-operativeacuteorchronicHFareatincreased
riskofmortalityduringNCS.Inarecentlypublishedanalysisof21
560996hospitalizationsforNCS,thepresenceofanydiagnosisof
HFwasassociatedwithsignificantlyhigherin-hospitalall-causemor-
RecommendationTable19—Recommendationsfor
talitycomparedwithabsenceofHF(4.8%vs.0.78%;adjustedOR,
the timing of non-cardiac surgery and revasculariza-
tioninpatientswithknowncoronaryarterydisease
2.15;95%CI,2.09–2.22).416AmongpatientswithachronicHFdiag-
nosis,peri-operativemortalitywasgreaterinthosewithacuteex-
Recommendations Classa Levelb acerbation of chronic HF compared to those with compensated
chronicHF.Inarecentlarge-scalecohortstudyofindividualsunder-
PatientswithCCS
going ambulatory surgery, the crude 90 day mortality was 2.0%
IfPCIisindicatedbeforeNCS,theuseof among patients with HF and 0.4% among patients without HF.417
new-generationDESisrecommendedoverBMS I A The crude risk of 30 day post-operative complications was 5.7%
andballoonangioplasty.268 and2.7%,respectively.Ofnote,theriskofmortalityprogressivelyin-
Pre-operativeevaluationofpatientswithan creasedwithdecreasingsystolicfunction.Itisnotrecommendedto
indicationforPCIbyanexpertteam(surgeonand performelectiveNCSinpatientswithdecompensatedHF.
IIa C
cardiologist)shouldbeconsideredbeforeelective The value of pre-operative assessment of LV function with
NCS. TTE and measurement of natriuretic peptides (BNP or
Myocardialrevascularizationbeforehigh-risk NT-proBNP)isdiscussedinSection4.4.TheTTEshouldnotbeolder
electiveNCSmaybeconsidered,dependingon than6months,orperformedjustbeforeNCSinthecaseofclinical
theamountofischaemicmyocardium,refractory IIb B worsening.
symptoms,andfindingsatcoronaryangiography
(asinthecaseofleftmaindisease).399,402,403
6.2.2.Pre-andpost-operativemanagement
Routinemyocardialrevascularizationbeforelow-
strategies
andintermediate-riskNCSinpatientswithCCSis III B
Inordertoreducetheriskofacutedecompensationandtheriskof
notrecommended.399,400
mortality,optimalguideline-directedmedicaltreatmentofHFbefore
PatientswithACS scheduledNCSisrecommended.412Specialattentionshouldbegi-
IfNCScansafelybepostponed(e.g.atleast3 ventothefluidbalance,sincehigh-volumeinfusionisoftenneeded
months),itisrecommendedthatpatientswith in the peri-operative period. Invasive monitoring of the arterial
ACSbeingscheduledforNCSundergodiagnostic I A pressure aiming to obtain oximetric and metabolic parameters
andtherapeuticinterventionsasrecommended during NCS is frequently needed for intermediate- to high-risk
forACSpatientsingeneral.98,268 NCS among HF patients. Furthermore, dynamic variables derived
Intheunlikelycombinationofalife-threatening from the arterial pressure waveform (cardiac output, pulse
clinicalconditionrequiringurgentNCS,and pressure variation, stroke volume variation) are useful for guiding
NSTE-ACSwithanindicationfor protocolled goal-directed therapy. Use of more invasive tools,
IIa C
revascularization,theprioritiesforsurgeryona suchasrightheartcatheterizationortransoesophagealechocardiog-
case-by-casebasisshouldbeconsideredbythe raphy(TEE),mightbeconsideredonanindividualpatientlevel(see
expertteam.268 Section7.1).
Baseline medication should be continued throughout the peri-
ACS,acutecoronarysyndrome;BMS,baremetalstent;CAD,coronaryarterydisease;
CCS,chroniccoronarysyndrome;DES,drug-elutingstent;NCS,non-cardiacsurgery; operative period, in accordance with the recommendations pro-
NSTE-ACS,non-ST-segmentelevationacutecoronarysyndrome;PCI,percutaneous videdinSection5.2.ItisrecommendedtoperformECG,measure
coronaryintervention.
biomarkersofmyocardialinjury(cTnT/I),andperformechocardiog-
aClassofrecommendation.
bLevelofevidence. raphytotailortheoptimaltreatmentstrategyinpatientswithacute
decompensatedHFpost-operatively.
2202CSE©
Downloaded
from
https://academic.oup.com/eurheartj/article/43/39/3826/6675076
by
guest
on
22
January
2026
--- Страница 50 ---
ESCGuidelines 3875
Table11 Peri-operativeapproachtopatientswithventricularassistdevicesundergoingnon-cardiacsurgery
Pre-operative Intra-operative Post-operative
(cid:129) Multidisciplinaryteamidentified(primary (cid:129) StandardAmericanSocietyofAnesthesiologistsmonitors (cid:129) Standardpost-anaesthesiacare
surgicalandanaesthesiateams,cardiacsurgery, (cid:129) Cerebraltissueoxygenation,processed unitunlessICUisotherwise
HFcardiologist,VADpersonnel) electroencephalogram,arteriallinewithultrasoundguidance, indicated
(cid:129) Pre-operativemedicaloptimizationwhen centralvenouscatheteriffluidshiftsareexpected,PAcatheter (cid:129) Extubationcriteriaare
possibleornecessary onlyifseverepulmonaryhypertension,TEEavailable unchanged
(cid:129) Physicalexaminationfocusedonthesequelae (cid:129) MonitorVADcontrolconsole (cid:129) Avoidhypoventilation,optimize
ofHF (cid:129) Externaldefibrillatorpadsinplace oxygenation
(cid:129) BaselineECG,echocardiogram,andlaboratory (cid:129) Optimizepre-load,supportRVfunction,avoidincreasein (cid:129) Resumeheparininfusionwhen
values afterload post-opbleedingriskis
(cid:129) Managepacemaker/ICDsettingswhenindicated (cid:129) Gradualperitonealinsufflationsandpositionchanges acceptable
(cid:129) CTexaminationtoevaluatepossibledriveline
interferencewiththeoperativefield
(cid:129) Hold,bridge,orreverseanticoagulationwhen
indicated,afterVADteamconsultation
CT,computedtomography;ECG,electrocardiogram;HF,heartfailure;ICU,intensivecareunit;PA,pulmonaryartery;RV,rightventricular;TEE,transoesophagealechocardiography;
VAD,ventricularassistdevice.
AdaptedfromRobertsetal.421
Themanagementofpatientswithcardiacimplantableelectronic RecommendationTable20—Recommendationsfor
devices (CIEDs) undergoing NCS is discussed in Section 6.4.5. management of heart failure in patients undergoing
non-cardiacsurgery
In patients with resynchronization devices (cardiac resynchroniza-
tion therapy [CRT]), it is recommended to keep the device on to
Recommendations Classa Levelb
providebetterhaemodynamicstability.
InpatientswithsuspectedorknownHFscheduled
forhigh-riskNCS,itisrecommendedtoevaluate
6.2.3.Hypertrophicobstructivecardiomyopathy LVfunctionwithechocardiographyand I B
PatientswithhypertrophiccardiomyopathywithLVoutflowtract measurementofNT-proBNP/BNPlevels,unless
thishasrecentlybeenperformed.112,113,422,423
obstruction(HOCM)haveanincreasedriskofcomplicationsdur-
ingNCSandrequireadditionalattention.418Itisrecommendedto ItisrecommendedthatpatientswithHF
performTTEbeforeNCSinordertodeterminetheextentofthe undergoingNCSreceiveoptimalmedical I A
hypertrophy,obstruction,anddiastolicfunction.419Avoidanceof treatmentaccordingtocurrentESC
prolonged pre-operativefasting and dehydration is importantto
guidelines.412
maintainstrokevolumeandreducetheriskofincreasedobstruc- InpatientswithHFundergoingNCS,itis
tion.Furthermore,itisimportanttoavoidvasodilatinganaesthetic recommendedtoregularlyassessvolumestatus I C
agentsandmaintainneutralfluidbalanceduringtheperi-operative andsignsoforganperfusion.
period. The heart rate should be kept low (60–65 beats per AmultidisciplinaryteamincludingVADspecialists
minute [b.p.m.]) and AF should be avoided. Medication used isrecommendedforperi-operativemanagement
I C
to treat LV outflow tract obstruction should remain on board ofpatientswithHFreceivingmechanical
duringNCS. circulatorysupport.
BNP,B-typenatriureticpeptide;ESC,EuropeanSocietyofCardiology;HF,heartfailure;
LV,leftventricular;MCS,mechanicalcirculatorysupport;NCS,non-cardiacsurgery;
NT-proBNP,N-terminalpro-B-typenatriureticpeptide;VAD,ventricularassistdevice.
6.2.4.Patientswithventricularassistdevices
aClassofrecommendation.
undergoingnon-cardiacsurgery bLevelofevidence.
Ventricularassistdevices(VADs)playanimportantroleinthetreat-
mentofpatientswithend-stageHFwhorequireabridgetoheart
transplantationorasapermanentdestinationtherapy.Asthenum-
berofpatientsreceivingVADasdestinationtherapyincreases,420,421 6.3. Valvular heart disease
theneedforNCSinthisspecificsubsetofpatientsisexpectedtoin- 6.3.1.Riskforpatientswithvalvularheartdisease
creaseinyearstocome.Non-cardiacsurgeryshouldbeperformed Valvular heart disease increases the risk of peri-operative CV
insurgicalcentresthathaveaccesstoVADteams(Table11). complications during NCS. The magnitude of risk is highly
2202CSE©
2202CSE©
Downloaded
from
https://academic.oup.com/eurheartj/article/43/39/3826/6675076
by
guest
on
22
January
2026
--- Страница 51 ---
3876 ESCGuidelines
Management of patients with severe aortic valve stenosis scheduled for elective or time-sensitive NCS
Clinical examination + ECG + biomarkers +TTE ±TEE
(Class I)
AND
Optimal guideline-recommended medical treatmenta
(Class I)
AND
Multidisciplinary consultation
NCS without
additional
procedures
Y Symptoms N N
LV-dysfunction (LVEF <50%)
Y
Low-risk NCS Low- or intermediate-risk NCS
Patient risk for valve procedures
Low High
NCS without additional procedures
Individual decision about
NCS without
necessity of valve
additional procedures
procedure before NCS
Intermediate or high-risk NCS High-risk NCS
Patient risk for valve procedures Patient risk for valve procedures
Low High Low High
Consider BAV before Consider BAV before
HeartTeam HeartTeam
NCS if feasible, or NCS NCS if feasible, or NCS
(TAVI or SAVR) (TAVI or SAVR)
under strict monitoring under strict monitoring
(Class I) (Class IIa)
(Class IIb) (Class IIb)
Figure13Managementofpatientswithsevereaorticvalvestenosisscheduledfornon-cardiacsurgery.BAV,balloonaorticvalvuloplasty;ECG,elec-
trocardiogram;LV,leftventricular;LVEF,leftventricularejectionfraction;N,no;NCS,non-cardiacsurgery;SAVR,surgicalaorticvalvereplacement;TAVI,
transcatheteraorticvalveimplantation;TTE,transthoracicechocardiography;TEE,transoesophagealechocardiography.Y,yes;Thefigureprovidesa
schematicrepresentationofdiagnosticassessmentortherapytobeimplementedaccordingtosurgicalriskandunderlyingcardiaccondition.aThisapplies
totreatmentofcomplications(e.g.atrialfibrillation,heartfailure).Nomedicaltherapyisrecommendedforaorticstenosisperse.
variableanddependsontheseverityofVHDandtypeofNCS. and the risk of NCS-related complications should be estimated
It is particularly increased in patients with obstructive valve andcommunicatedtothepatientandthesurgicalteam.
pathology, for example symptomatic AS or MS, where peri-
operative volume shifts and arrhythmia may lead to rapid 6.3.2.1.Aorticvalvestenosis
decompensation.424
The peri-operative risk associated with AS during NCS depends
upon the presence of symptoms, stenosis severity, and coexisting
6.3.2.Pre-operativemanagementstrategiesand cardiac disease (e.g. CAD, mitral insufficiency, or reduced LVEF).
risk-reductionstrategy SeveresymptomaticASisasignificantriskfactorforpost-operative
Clinicalandechocardiographicevaluationisrecommendedinallpa- MIandHF,andapredictorfor30dayandlong-termmortalityafter
tientswithknownorsuspectedVHDwhoarescheduledforelective NCS.425,426 Careful peri-operative management is essential in pa-
intermediate-or-high-riskNCS.Patientsinwhommild-to-moderate tientsundergoingintermediate-andhigh-riskNCS,albeitthesignifi-
VHDwasdiagnosed.1yearearliershouldhaveclinicalandecho- canceofASinpatientsundergoinglow-riskNCSmighthavebeen
cardiographicre-assessment.Heartteamdiscussionmaybehelpful overemphasizedinstudiesthatpre-datethemorerecentadvances
in patients with significant VHD. The risks of valvular intervention in anaesthesia, surgical techniques, and post-operative management.
Downloaded
from
https://academic.oup.com/eurheartj/article/43/39/3826/6675076
by
guest
on
22
January
2026
--- Страница 52 ---
ESCGuidelines 3877
Management of severe secondary mitral valve regurgitation in patients scheduled for NCS
Elective NCS N Time-sensitive NCS
Y Y
Clinical examination + ECG + biomarkers +TTE ±TEE (Class I)
AND AND
Optimal GDMT including Optimal GDMT
CRT if indicated (Class I)
(Class I) AND
± Myocardial Multidisciplinary
revascularizationa consultation
NCS
N Persistent symptoms despite GDMT
under strict monitoring
Y
Low-risk NCS
No additional procedures
Intermediate-risk or high-risk NCS
TEER or surgery (repair when possible) depending
on eligibility and according to the decision of the
HeartTeam
(Class IIa)
Inoperable or at high procedural risk
Consider NCS under strict monitoring
Figure14Managementofpatientswithsecondarymitralvalveregurgitationscheduledfornon-cardiacsurgery.ECG,electrocardiogram;GDMT,
guideline-directedmedicaltherapy;N,no;NCS,non-cardiacsurgery;TTE,transthoracicechocardiography;TEE,transoesophagealechocardiography;
TEER,transcatheteredge-to-edgerepair.Y,yes;aCoronaryangiography+PCI/CABGonacase-by-caseaccordingtotheexpertteam.
Aorticvalvereplacementhasbeenassociatedwithreducedin-hospital AS and normal LVEF can safely undergo low- to intermediate-risk
and30daymortalityandmorbidityamongpatientswithASundergo- NCS,unlesstheNCSisassociatedwithlargevolumeshifts.245,428
ingintermediate-tohigh-riskNCS.425,426However,thedecisionre-
garding the timing of AVR in relation to NCS should be weighted 6.3.2.2.Mitralvalvestenosis
accordingtothebaselineriskprofileandtheriskassociatedwiththe Non-cardiacsurgerycanbeperformedwitharelativelylowriskof
NCS. The choice of surgical aortic valve replacement (SAVR) vs. complications in patients with mild MS (valve area .1.5cm2) and
TAVIshouldfollowthe2021ESC/EACTSGuidelinesforthemanage- in asymptomatic patients with moderate-to-severe MS (valve area
ment of valvular heart disease245 and patient’s informed preference ≤1.5cm2) and systolic pulmonary artery pressure (SPAP)
(Figure13). ,50mmHg on echocardiography.429 As transmitral gradients are
InpatientswithseveresymptomaticAS,inwhomNCScanbede- flow-sensitive, tachycardia and fluidoverload can cause pulmonary
ferred, aortic valve intervention (SAVR or TAVI) is recommended oedemaduring NCS.In thisregard,arterialvasodilators shouldbe
beforeNCS.Inpatientsrequiringtime-sensitiveNCS,TAVIisarea- avoidedandsurveillanceforperi-operativeAFisofparamountim-
sonableoption.427InpatientswithseveresymptomaticASinneedof portance. Management of anticoagulation for patients with high
time-sensitiveNCSinwhomTAVIorSAVRareunfeasible,balloon thromboticriskisdiscussedinSection5.3.2.Inasymptomaticpatients
aorticvalvuloplasty(BAV)maybeconsideredbeforeNCSasabridge with moderate-to-severe MSand SPAP .50mmHg, and in symp-
todefinitiveaorticvalverepair.Asymptomaticpatientswithsevere tomaticpatients, theperi-operativeriskofCV eventsisincreased.
Downloaded
from
https://academic.oup.com/eurheartj/article/43/39/3826/6675076
by
guest
on
22
January
2026
--- Страница 53 ---
3878 ESCGuidelines
Inthiscase,apercutaneousmitralcommissurotomy(PMC)should InasymptomaticpatientswithsevereASwhoare
beconsideredbeforehigh-riskNCS.Otherwise,amultidisciplinary scheduledforelectivehigh-riskNCS,AVR(SAVR
IIa C
team should manage patients with moderate-to-severe MS who orTAVI)shouldbeconsideredafterHeartTeam
areineligibleforPMC,andNCSshouldbeperformedonlyifneces- discussion.
sary.Intermediate-riskNCSmaybeperformedinasymptomaticpa-
InpatientswithseveresymptomaticASinneedof
tients with severe MS with appropriate intra-operative and
time-sensitiveNCSorinwhomtheTAVIand
post-operativehaemodynamicmonitoring,ifvalvemorphologyisun- SAVRareunfeasible,BAVmaybeconsidered IIb C
suitableforPMC. beforeNCSasabridgetodefinitiveaorticvalve
repair.
6.3.2.3.Aorticvalveregurgitation Aorticvalveregurgitation
In patients with mild-to-moderate aortic valve regurgitation (AR),
InpatientswithsymptomaticsevereARor
NCScanbeperformedwithoutadditionalrisk.Patientswithsevere asymptomaticsevereARandLVESD.50mmor
ARinwhomvalvularinterventionisneededshouldbetreatedbe- LVESDi(LVESD/BSA).25mm/m2(inpatients
foreintermediate-or-high-riskelectiveNCS(see Recommendation withsmallbodysize)orrestingLVEF≤50%,valve I C
Table21andthe2021ESC/EACTSGuidelinesforthemanagement
surgeryisrecommendedpriortoelective
ofvalvularheartdisease).245
intermediate-orhigh-riskNCS.
Mitralvalvestenosis
6.3.2.4.Mitralvalveregurgitation
Inpatientswithmoderate-to-severerheumatic
Inpatientswithseveresymptomaticmitralvalveregurgitation(MR),
MSandsymptomsorSPAP.50mmHg,valve
the type of valve disease (primary or secondary) and LV function I C
intervention(PMCorsurgery)isrecommended
should be assessed. Patients with secondary MR, especially of
beforeelectiveintermediate-orhigh-riskNCS.
ischaemic aetiology, are at increased risk of CV complications
during NCS.430 Patients with severe symptomatic MR fulfilling the Mitralvalveregurgitation
intervention criteria should be referred for valve treatment InpatientswithsymptomaticsevereprimaryMR
before intermediate- or high-risk elective NCS. In case of orasymptomaticsevereprimaryMRwithLV
symptomatic moderate-to-severe secondary MR, patients meeting
dysfunction(LVESD≥40mmand/orLVEF
IIa C
the Cardiovascular Outcomes Assessment of the MitraClip
≤60%),valveintervention(surgicalor
Percutaneous Therapy for Heart Failure Patients With Functional transcatheter)shouldbeconsideredpriorto
Mitral Regurgitation (COAPT) criteria should be considered intermediate-orhigh-riskNCS,iftimeallows.
for transcatheter edge-to-edge treatment before NCS InpatientswithseveresecondaryMRwhoremain
(Figure14).245,431InpatientswithsevereprimaryMRwithsymptoms symptomaticdespiteguideline-directedmedical
or asymptomatic with LV dysfunction, valve repair is the recom- therapy(includingCRTifindicated),valve
IIa C
mendedtherapy(seeRecommendationTable21andthe2021ESC/ intervention(transcatheterorsurgical)shouldbe
EACTSGuidelinesforthemanagementofvalvularheartdisease245). consideredbeforeNCS,ineligiblepatientswithan
In patients with reduced LVEF and concomitant AR or MR, acceptableproceduralrisk.
intra-operative haemodynamic monitoring, heart rate control, and AS,aorticvalvestenosis;AR,aorticvalveregurgitation;AVR,aorticvalvereplacement;
careful fluid balance are crucial to avoid haemodynamic deterior- BAV, balloon aortic valvuloplasty; BSA, body surface area; CRT, cardiac
ation,especiallyduringhigh-risksurgery. resynchronizationtherapy;LV,leftventricular;LVEF,leftventricularejectionfraction;
LVESD, left ventricular end-systolic diameter; LVESDi, left ventricular end-systolic
dimensionindex;MR,mitralvalveregurgitation;MS,mitralstenosis;NCS,non-cardiac
RecommendationTable21—Recommendationsfor surgery; PMC, percutaneous mitral commissurotomy; SAVR, surgical aortic valve
replacement; SPAP, systolic pulmonary artery pressure; TAVI, transcatheter aortic
management of valvular heart disease in patients
valveimplantation;VHD,valvularheartdisease.
undergoingnon-cardiacsurgery aClassofrecommendation.
bLevelofevidence.
Recommendations Classa Levelb
Clinicalandechocardiographicevaluation(ifnot
6.3.2.5.Patientswithprostheticvalve(s)
recentlyperformed)isrecommendedinall
PatientswhohaveundergoneprevioussurgicalcorrectionofVHD
patientswithknownorsuspectedVHDwhoare I C
andhaveaprostheticvalvecanundergoNCS providedthatthere
scheduledforelectiveintermediate-orhigh-risk
is no evidence of valve dysfunction. In current practice, the main
NCS. problemistheneedforamodificationoftheanticoagulationregimen
Aorticvalvestenosis intheperi-operativeperiod;thisisdiscussedindetailinSection5.3.
AVR(SAVRorTAVI)isrecommendedin
symptomaticpatientswithsevereASwhoare
I C 6.3.2.6.Prophylaxisofinfectiveendocarditis
scheduledforelectiveintermediate-orhigh-risk
ProphylaxisagainstinfectiveendocarditisinpatientsrequiringNCS
NCS.
shouldbeconsistentwiththe2015ESCGuidelinesforthemanage-
Continued mentofinfectiveendocarditis.432
2202CSE©
Downloaded
from
https://academic.oup.com/eurheartj/article/43/39/3826/6675076
by
guest
on
22
January
2026
--- Страница 54 ---
ESCGuidelines 3879
6.4. Known or newly diagnosed ofsurgery(seeSection5.3.2).99,240SometimesAFisasymptomatic442
arrhythmias
andmaybefirstdetectedonadmissionforsurgery,ormayfirstoccur
ArrhythmiasposeasignificantburdentopatientsundergoingNCS, inthepre-operativeperiod.Theinitialmanagementofnewlydiagnosed
AFincludespreventionofthromboembolism,andsymptomcontrol,
contributingtoexcessivemorbidityandmortality.433,434
andshouldnotbedeferredawaitingconsultationwithacardiologist.99
InpatientswithnewlydiagnosedAFwhorequiresystemicOACther-
6.4.1.Peri-operativemanagement—general
apy for stroke prevention, the choice of anticoagulant in the pre-
measures
operativeperioddependsonthetypeofsurgery(seeSection5.3.2).
Arrhythmias—namely, supraventricular tachycardia (SVT) and ven- Optimalratecontrol(i.e.restingheartrate,110b.p.m.)99ismanda-
triculartachycardia(VT)—mayaccompanyacutesurgicalillness,but
tory in all patients with AF, whereas rhythm control (i.e. achieving
should notdeferurgentsurgical procedures, unless thearrhythmia
and maintenance of sinus rhythm) in the pre-operative period may
is life-threatening. All patients with known arrhythmia undergoing
beconsideredonlyifsymptomspersistdespiteoptimalratecontrol.
elective surgery should have a 12-lead ECG performed pre-
Rate control can be achieved using beta-blockers or non-
operativelyandundergoacardiologycheck-up.Preventionofpoten-
dihydropyridine CCBs (verapamil, diltiazem). Amiodarone can be
tialarrhythmictriggersiscrucial:electrolyteandacid-baseimbalance, usedasfirst-linetherapyinpatientswithHF,whereasdigoxinisusu-
myocardial ischaemia (also caused by excessive blood loss and an-
ally ineffective in high adrenergic conditions such as surgery.
aemia),andlargevolumeshifts,whichcanprovokesubsequentauto-
Pharmacological cardioversion of symptomatic recent-onset AF
nomic hyperactivity, should be avoided in the pre-, intra-, and canbeattemptedusingflecainideorpropafenone;inpatientswith-
post-operativeperiods.PatientswithasystolicHFshouldreceiveop- out significant LV hypertrophy, LV systolic dysfunction, or IHD,
timaltreatment,assuchtherapyreducestheriskoftotalmortality theuseofflecainideorpropafenoneresultsinprompt(3–5h)and
and sudden cardiac death (SCD).435 Patients already taking AADs safe restoration of sinus rhythm in .50% of patients. Intravenous
shouldgenerallynotstoptakingthesedrugs.Patientsathigh-riskof
amiodaroneadministrationhasalimitedanddelayedeffectbutcan
malignant arrhythmias should have continuous ECG monitoring
slowtheheartratewithin12h;i.v.vernakalantisthemostrapidly
through the whole peri-operative period, with particular emphasis
cardioverting drug, including patients with mild HF and/or
placedonpatientswhohavehadimplantablecardioverter–defibrilla-
IHD.99,443DofetilideisnotusedinEurope,andibutilideiseffective
tors(ICDs)deactivatedduringNCS. to convert atrial flutter to sinus rhythm.99,444 In patients with AF
andhaemodynamicinstability,emergencycardioversion(mostcom-
6.4.2.Supraventriculararrhythmias monly electrical direct current cardioversion) is indicated.99
Supraventricular arrhythmias do not usually cause deferral of sur- Alternatively,pharmacologicalcardioversionusingi.v.AADsshould
gery.Inrarecases,presenceofpre-excitationandAFconductedrap- be attempted, if consistent with the patient’s clinical status.
idlyoveranaccessorypathwayflagapatientatriskofSCDandmay
Systemic OACtherapytopreventthromboemboliceventsshould
indicatetheneedforablation,ifsurgeryisnotemergent. be started as soon as possible.99 Post-operative AF is discussed in
Supraventricularprematurebeatsusuallydonotrequiretherapy. Section8.6.
Identification and correction of potential triggers (electrolyte and ManagementofatrialflutterfollowsthesameprinciplesasAFwith
acid-base imbalance, volume overload, etc.) are highly recom- respecttoOACtherapy.Ratecontrolisusuallyaninitialapproachin
mended. Peri-operative SVT typically responds well to vagal man- patientswithatrialflutter;436however,drugsthatslowatrioventricu-
oeuvres,ortoa bolusofadenosine ifunsuccessful.IfSVTpersists lar conduction (digoxin, beta-blockers, or non-dihydropyridine
orreoccurs,i.v. beta-blockers,verapamil,or diltiazemcan be used CCBs)areusuallylesseffectivethaninAF.Inpatientswithahighven-
forrhythmconversionortemporalslowingofatrioventricularcon- tricular rate, electrical cardioversion is frequently needed.445–448
duction.436Promptcardioversionshouldbeperformedinrarecases
Amiodaronemay be analternative usedtocontrol rate,especially
ofhaemodynamicallyunstableSVT.Ifprophylactictherapyisneeded inHForcriticallycompromisedpatients.449Dofetilideandibutilide
to prevent recurrent SVT, beta-blockers or non-dihydropyridine areeffectiveinconvertingatrialfluttertosinusrhythm,whereasclass
CCBs(verapamil,diltiazem)canbeused,andflecainide/propafenone IAandICdrugsandamiodaronearelessefficientandshouldnotbe
oramiodaronecanbeconsideredifineffective.Rarely,whenSVT used.450–453
recurs despite therapy or becomes incessant, ablation should be
considered in patients undergoing high-risk, non-emergent sur- 6.4.4.Ventriculararrhythmias
gery.RecentlypublishedresultsofanRCTconfirmedthesuperior-
Prematureventricularcontractions(PVC)andnon-sustainedVTare
ity of radiofrequency (RF) ablation over AADs for persistent frequent in the general population and patients undergoing NCS.
atrioventricular nodal re-entry tachycardia. Large registries and Specificclinicalfeatureshavebeensuggestedaspredictorsofincreas-
meta-analyses have demonstrated efficacy and safety of RF abla- ing incidence of PVC.454 These arrhythmias have historically been
tioninWPWsyndromeandotherSVTs,withasingle-procedure considered benign; however, recent studies have suggested that
successrateof.90.437–441
theymaybeassociatedwithanadverseoutcome,eveninpatients
with apparently normal hearts, especially if frequent (e.g. .10–
6.4.3.Atrialfibrillation/flutter 20%).455–459
In patients with heart disease, the prognostic impact
ThemajorityofpatientswithAFreceivelifelongOACtherapyfor of PVC and non-sustained VT depends on type and extent of
the prevention of stroke and systemic embolism,99 and the peri- heart damage.460–466 In patients undergoing urgent NCS, they
operative management of OAC therapy will depend on the type do not require treatment unless frequent and symptomatic.
Downloaded
from
https://academic.oup.com/eurheartj/article/43/39/3826/6675076
by
guest
on
22
January
2026
--- Страница 55 ---
3880 ESCGuidelines
Table12 Peri-operativemanagementofpatientswitharrhythmias
Typeof SVT IdiopathicVTinstructurally/functionally VTinstructuralheart
arrhythmia normalheart disease
Diagnostics (cid:129) ECG+TTEa (cid:129) ECG+TTE (cid:129) ECG+TTE+
biomarkersb
(cid:129) +Coronaryangiography
(cid:129) +CardiacCT/MRI
Acute (cid:129) Vagalmanoeuvres (cid:129) Vagalmanoeuvres (cid:129) Treatmentofunderlying
management (cid:129) I.v.adenosine,beta-blocker,CCB (cid:129) I.v.beta-blockers/verapamil heartdisease
(cid:129) Electricalcardioversionifunstable (cid:129) Electricalcardioversionifunstable (cid:129) I.v.beta-blocker
(uptitration),amiodarone
(cid:129) Electricalcardioversionif
unstable
Preventionof (cid:129) Peroralbeta-blocker,CCB (cid:129) Notreatmentor (cid:129) Peroralbeta-blocker,
recurrence (cid:129) Catheterablationifrecurrentdespite (cid:129) Peroralbeta-blocker,CCB,classIAAD amiodarone
OMT(onlybeforehigh-riskNCS) (cid:129) Catheterablationincaseofrecurrencedespite (cid:129) Catheterablationif
AADsordrug-intolerancebeforehigh-riskNCS recurrentdespiteOMT
AAD,antiarrhythmicdrug;CCB,calciumchannelblocker;CT,computertomography;ECG,electrocardiogram;MRI,magneticresonanceimaging;NCS,non-cardiacsurgery;OMT,
optimalmedicaltherapy;SVT,supraventriculartachycardia;TTE,transthoracicechocardiography;VT,ventriculartachycardia.
aBeforehigh-risksurgery.
bHigh-sensitivitycardiactroponinT/I,and/orBNP/N-terminalpro-BNP.
Ifhaemodynamicallycompromising,up-titrationofbeta-blockersisre- myocardiumwithnoreversiblecauses,despiteoptimaltherapy,inva-
commended;amiodarone(300mgi.v.bolus)shouldbeconsideredif sive electrophysiological study and ablation should be performed
beta-blockersare nottolerated or contraindicated.467Further diag- pre-operatively,ifNCScanbedeferred.Afterextensiveendocardial
nostics to rule out significant heart disease is necessary in patients VT ablation, treatment with an OAC for a limited period of time
awaitingelectiveNCS,especiallyiffrequent,complex(non-sustained mightbereasonable.470,471Asummaryofdiagnosticandtherapeutic
VT),symptomatic,orinthosewithapositivefamilyhistoryofSCD. pathwaysinpatientswithSVTorVTisshowninTable12.
PolymorphicVTandventricularfibrillation(VF)canbeprovoked
byischaemia,electrolyteimbalance,ormaybemanifestationsofpri-
Recommendation Table 22 — Recommendations
mary electrical disease, such as long-QT or Brugada syndrome.
for management of known or newly diagnosed
MonomorphicVTisoftenassociatedwiththepresenceofscarred arrhythmias
myocardium.Hence,peri-operative VTorVFinapatientawaiting
surgeryshouldleadtoadiagnosticwork-uptoexcludesevereven- Recommendations Classa Levelb
triculardysfunction(seeSection4.5.1),andtoruleoutCADrequiring
Supraventriculararrhythmias
promptrevascularization(seeSection6.1)andotherpotentialcauses
of arrhythmia (primary electrical disease, dyselectrolytaemia). InpatientswithSVTcontrolledbymedication,itis
MonomorphicVTinpatientswithoutovertstructuralorelectrical recommendedthatAADsarecontinuedduring I C
heartdisease(idiopathicVT,mostcommonlyarisingfromoutflow theperi-operativeperiod.
tract)isassociatedwithgoodprognosisandmaybeleftuntreated Ablationshouldbeconsideredinsymptomatic
or, if symptomatic, may be treated with beta-blockers, verapamil, patientswithrecurrentorpersistentSVT, IIa B
orsodiumchannelblockers.Patientswithhaemodynamicallycom- despitetreatment,priortohigh-risk,non-urgent
promisingVTshouldundergoelectricalcardioversion(afteri.v.sed-
NCS.437–441
ation, if conscious) and VF should be terminated with prompt AFwithhaemodynamicinstabilityinpatientsundergoing
defibrillation.RecurrentVTandVFinthesettingofacuteischaemia
NCS
maybeeffectivelytreatedwithbeta-blockersandamiodarone,and
InAFpatientswithacuteorworsening
myocardial revascularization in case of obstructive CAD.468
haemodynamicinstabilityundergoingNCS,
Up-titration of beta-blockers to the maximal tolerated doses can I B
emergencyelectricalcardioversionis
preventarrhythmiarecurrence.469
recommended.99,472,473
Haemodynamicallystable,sustainedVTshouldbecardiovertedas
InAFpatientswithhaemodynamicinstability,
afirst-linetreatment;i.v.procainamideorflecainidemaybeconsid-
amiodaronemaybeconsideredforacutecontrol IIb B
ered in patients without HF or myocardial ischaemia. In cases in
ofheartrate.99
whichthesedrugsareunavailable,i.v.amiodaronecanbeused.Inse-
Continued
lectedcases,whenmonomorphicVTrecursinpatientswithscarred
2202CSE©
Downloaded
from
https://academic.oup.com/eurheartj/article/43/39/3826/6675076
by
guest
on
22
January
2026
--- Страница 56 ---
ESCGuidelines 3881
pacing may lead to pacing on the T wave, which can provoke VT/
Ventriculararrhythmias
VF. However, the risk of clinically significant EMI is low487–489 and
Inpatientswithsymptomatic,monomorphic,
apracticalsolutionwouldbetomonitorthepatientviaplethysmo-
sustainedVTassociatedwithmyocardialscar,
graphyoranarterialline,andlimittheuseofelectrocauteryifpauses
recurringdespiteoptimalmedicaltherapy, I B
occurduringECGmonitoring.
ablationofarrhythmiaisrecommendedbefore
Patients with leadless pacemakers may safely undergo surgery,
electiveNCS.474–480
withprecautionssimilartopatientswithconventionalpacemakers,
Itisnotrecommendedtoinitiatetreatmentof
III C avoiding EMI and after reprogramming the pacemaker into non-
asymptomaticPVCduringNCS.
sensingmodeinpacing-dependentpatients(duetoitsintracardiac
AAD, antiarrhythmic drug; AF, atrial fibrillation; NCS, non-cardiac surgery; PVC, locationandlackofaHall-effectsensor/reedswitch,thisdevicecan-
prematureventricularcontractions;SVT,supraventriculartachycardia;VT,ventricular notbetemporarilyreprogrammedtoanasynchronousmodewitha
tachycardia. magnetappliedoverthebodyofthepacemaker).490,491
aClassofrecommendation.
bLevelofevidence. InpatientswithICDsundergoingNCSwithanticipatedriskofEMI,
arrhythmiadetectionorantiarrhythmictherapiesthroughthedevice
shouldbeswitchedoffbeforeNCS,492oramagnetshouldbeput
overthedevice.488,489,492AllmodernICDswillrespondtomagnet
6.4.5.Bradyarrhythmias
applicationbyinhibitingantitachycardiatherapy,whilethebradypa-
Temporary cardiac pacing during the peri-operative period should
cingisleftintact.Deactivationbyprogrammingmandatestelemetry
be limited to patients undergoing urgent NCS, if bradycardia is
and cardioversion equipment until reactivation, which may be im-
haemodynamically compromising despite i.v. chronotropic drugs,
practical.Furthermore,thereisariskthatthepatientisdischarged
orprovokesepisodesofventriculartachyarrhythmia.481Inpatients
without the device being reactivated. These factors would favour
undergoing elective NCS, surgery should be deferred if possible,
theuseofamagnetinsteadofdeactivation.Insomepatientswhere
andpermanentpacemakershouldbeimplanted,ifindicationsforpa-
thedeviceisinaccessibleformagnetapplication,amagnetcannotbe
cingarefulfilled.481Prophylacticpacinginthesettingsofasymptom-
used and reprogramming is mandatory. From this point onwards,
aticbifascicular block,with or withoutfirst-degree atrioventricular
throughoutthewholeprocedureuntilreactivationoftheICD,the
block,isgenerallynotindicated,andchronotropicdrugs(atropine,
patient should have continuous ECG monitoring, and personnel
isoprenaline, adrenaline, or, alternatively, aminophylline, dopamine,
skilledinearlydetectionofarrhythmias,defibrillation,andcardiopul-
orglucagoninbeta-blockerorCCBoverdosing)areusuallyeffective.
monary resuscitation manoeuvres should be present. As soon as
Patients with bifascicular bundle branch block or prolonged
possible after NCS, it is recommended that the ICD is checked
His-ventricularintervalareatanincreasedriskofdevelopingcom-
andtherapiesswitchedon.485
plete heart block.482,483 Equipment needed to perform emergent
PatientswithsubcutaneousICDcanundergosurgeryafterswitch-
transcutaneouspacingandpersonnelabletoperformsuchaproced-
ingofftheantiarrhythmictherapyormagnetapplication;however,if
ureshouldbeimmediatelyavailableduringNCSinpatientswithbi-
thoracicsurgeryisplanned,especiallywithamediansternotomy,the
fascicular block; alternatively, a permanent pacemaker may be
surgeon should be aware of the presence of the ICD and the
implanted.481
courseofthesubcutaneouselectrode.Thiscanpreventmechanical
damageofthelead,thedirectuseofelectrocauteryontheelectrode,
6.4.6.Managementofpatientswithcardiac ortheplacementofsternalwiresincloseproximitytothesensing
implantableelectronicdevices electrodes.493
Patients with CIEDs can undergo NCS, pending adequate peri- In pacing-dependent patients, patients with CRT, and ICD pa-
operative device management. A pre-operative check should have tients, EMI with the device should be avoided (e.g. with electro-
beenperformedatleastoncewithinthe12monthsprecedingsur- cautery). Use of bipolar electrocautery, short bursts of impulses
geryforpacemakerpatientsandwithin6monthsforpatientswith limitedtoseveralseconds(,5s),withthelowesteffectiveenergy,
ICD, in the absence of any malfunction (remote monitoring can andoperatingwithapenorstylusawayfromthedevice(.15cm)
alsobeusedforcheck-ups).484,485Inpacing-dependentpatients,pa- can minimize the risk of interference with the device. In the case
tientswithbiventricularpacingforCRT,andICD-recipientsunder- of unipolar electrocoagulation, the electrosurgical unit should be
going elective NCS associated with risk of electromagnetic connected in a way that keeps the current circuit away from the
interference(EMI)(e.g.involvingtheuseofunipolarelectrocoagula- CIEDcanandelectrodes.However,themanufacturer’srecommen-
tion,especiallyabovetheumbilicus),CIEDcheckandreprogramming dationsshouldbeconsidered(usuallyrecommendingplacementof
should be performed immediately before surgery. In pacemaker- the indifferent electrode on the opposite site of the body to the
dependent patients, devices should be reprogrammed to non- oneoperatedon,butpossiblyclosetothesurgicalsite,onawell-
sensingorasynchronouspacingmodetoprotectagainstinhibition vascularized, muscular area). Consequently, the indifferent return
ofthepacemaker. Thiscan beperformed inthe majority ofpace- padshouldbeplacedasfarawayfromtheCIEDaspossible,keeping
maker models by placing a magnet over the pacemaker can.486,487 the surgical site between the CIED and the return electrode
However,magnetmodeinmodernpacemakers,exceptMedtronic
(Figure15).494–497
and Sorin/Livanova/Microport, is programmable and may not be Inpatientswithimplantablelooprecorders(especiallythosenot
asynchronouspacing;thus,magnetapplicationisnotauniversalrem- undergoing remote monitoring and regular downloads of the
edy against EMI-induced malfunction. Furthermore, asynchronous CIEDmemory),thedevicememorydownloadistobeconsidered
2202CSE©
Downloaded
from
https://academic.oup.com/eurheartj/article/43/39/3826/6675076
by
guest
on
22
January
2026
--- Страница 57 ---
3882 ESCGuidelines
A B C
Electric knife
CIED
Return
electrode
Figure15Optimallocationofreturnelectrodeduringunipolarelectrosurgeryinpatientswithcardiacimplantableelectronicdevices,dependingonthe
surgerysite.CIED,cardiacimplantableelectronicdevice.Useofbipolarelectrocautery,short(,5s)burstsofimpulses,withthelowesteffectiveenergy,
operatingwithpenorstylusaway(.15cm)fromthedevicecanminimizetheriskofinterferencewiththedevice.(A)Surgerysiteonipsilateralsiteabove
CIED.(B)SurgeryonipsilateralsitebelowCIED.(C)Surgeryoncontralateralsite.494
beforeproceduresassociatedwithpossibleEMI,orinvolvingtheana-
Inhigh-riskCIEDpatients(e.g.withICDorbeing
tomicallocationclosetothedevice,toavoidmisrecognizingandre-
pacing-dependant)undergoingNCScarryinga
cordingnoiseasarrhythmiaorerasingthememory.498,499
highprobabilityofelectromagneticinterference
(e.g.involvingunipolarelectrosurgeryabovethe IIa C
RecommendationTable23—Recommendationsfor
umbilicalarea),CIEDcheck-upandnecessary
management ofbradyarrhythmia and patientscarry-
reprogrammingimmediatelybeforethe
ingcardiacimplantabledevices
procedureshouldbeconsidered.
Recommendations Classa Levelb CIED,cardiacimplantableelectronicdevice;ECG,electrocardiogram;ICD,implantable
cardioverter–defibrillator;NCS,non-cardiacsurgery.
Ifindicationsforpacingexistaccordingtothe aClassofrecommendation.
2021ESCGuidelinesoncardiacpacingand bLevelofevidence.
cardiacresynchronizationtherapy,481NCS IIa C
surgeryshouldbedeferredandimplantationofa
permanentpacemakershouldbeconsidered.
Itisrecommendedthatpatientswithtemporarily 6.5. Adult congenital heart disease
deactivatedICDshavecontinuousECG Adultswithcongenitalheartdisease(ACHD)accountfor.60%of
monitoring,andduringtheperi-operativeperiod the population with congenital heart disease (CHD).500,501
areaccompaniedbypersonnelskilledinearly Accordingly,ACHDrepresentanincreasingproportionofNCSad-
detectionandtreatmentofarrhythmias.In
I C
missions502andmightbeathighriskofCVevents.
high-riskpatients(e.g.pacemaker-dependantor Pre-operative risk assessment in ACHD needs to focus on the
ICDpatients),orifaccesstothetorsowillbe underlying disease, type of surgery, residua, and sequelae.503
difficultduringtheprocedure,itisrecommended
Coexistence of HF, pulmonary hypertension, arrhythmia, hypox-
toplacetranscutaneouspacing/defibrillationpads
aemia,damagetootherorgans,andendocarditismayconsiderably
priortoNCS. influencethebaselineriskofthesepatientsfromnoadditionalrisk
ItisrecommendedthatallpatientswithCIEDs to very high risk of worse prognosis.503,504 Thus, original medical
thatarereprogrammedbeforesurgeryhavea and surgical reports should be obtained along with current data,
I C
re-checkandnecessaryreprogrammingassoonas which should include symptoms, exercise capacity, oxygen satur-
possibleaftertheprocedure. ation, laboratory values (BNP, haemoglobin, creatinine, etc.), and
Continued medication.
2202CSE©
Downloaded
from
https://academic.oup.com/eurheartj/article/43/39/3826/6675076
by
guest
on
22
January
2026
--- Страница 58 ---
ESCGuidelines 3883
Table13 Riskstratificationfornon-cardiacsurgery right-to-left shunts, air filters must be used for venous access.
inadultswithcongenitalheartdisease Ventilatormanagementand extubationcanbe complicatedby the
presence of restrictive lung disease.507 Antibiotic prophylaxis for
Minorrisk Patientswithsmall,uncorrecteddefects,andno
endocarditisshouldbegivenaccordingtothe2015ESCGuidelines
needformedicationoranyothertreatment
forthemanagementofinfectiveendocarditis.432Furthermore,post-
PatientswithsuccessfullycorrectedCHDwithno
operativecareinanICUwithexperienceinhandlingACHDpatients
symptoms,norelevantresidua,andnoneedfor
isoftennecessary.
medication
Aprolongedmonitoringperiodinthissettingshouldbeconsid-
Intermediate Patientswithcorrectedoruncorrected
ered, with a special focus on arrhythmias and an optimal volume
risk conditionswithresidualhaemodynamic
management,asithasbeenshownthatupto50%ofadverseevents
abnormality,withorwithoutmedication
were attributable to lapses in the post-operative monitoring and
Severerisk Patientswithuncorrectedcyanoticheartdisease,
care.508Twogroupsatspecialriskarepatientswithchroniccyanosis
pulmonaryhypertension,othercomplexCHD,
andthoseaftertheFontanprocedure.Chroniccyanosisisassociated
ventriculardysfunctionrequiringmedication,and
with multiorgan involvement. Furthermore, bleeding risk is higher
patientslistedforhearttransplantation
due to multiple collaterals, platelet dysfunction, and alterations in
CHD,congenitalheartdisease. thecoagulationcascade.509InpatientswithEisenmengersyndrome,
conditionsthatincreasepulmonaryvascularresistancesuchashypo-
thermia,metabolicacidosis,hypercapnia,andhypovolaemiamustbe
avoided.509ThisisalsotrueforpatientsaftertheFontanprocedure,
Inarecentreport,absolutemortalityinACHDpatientsundergo- where venous return relies on low pulmonary pressures. If
ing NCS exceeded 4%.502 Mortality and peri-operative morbidity intra-abdominalpressurerisestoohighinthesepatients,venousre-
weregreaterinACHDcomparedwithamatchedcomparisonco- turnisdrasticallyreduced,withasubsequentdropincardiacoutput.
hort, and patients with severe ACHD had the highest mortality Thesehaemodynamicaspectsshouldbecarefullyconsideredincases
rate. It is well known that patients with pulmonary hypertension oflaparoscopicoropenNCS.
and with Eisenmenger syndrome have a higher risk of complica-
tions.505Alargeregistryconfirmedthesefindings:patientswithse-
vere CHD had an increased risk of 30 day mortality, overall RecommendationTable24—Recommendationsfor
mortality,andreintubation,while patients with intermediateCHD management of patients with adult congenital heart
had a moderate increase in overall mortality and risk of reintuba- diseaseundergoingnon-cardiacsurgery
tion.506Basedonthisstudyandrecentguidelines,503theclassification
inTable13isproposedforriskstratification. Recommendations Classa Levelb
AconsultationbyanACHDspecialistisnecessary,especiallyinpa- InpatientswithACHD,aconsultationwithan
tients with intermediate or severe ACHD scheduled for ACHDspecialistisrecommendedbefore I C
intermediate-orhigh-riskNCS.Itisrecommendedthatelectivesur- intermediate-orhigh-risksurgery.
gery in intermediate- and severe-risk ACHD patients should take InpatientswithACHD,itisrecommendedthat
placeincentresexperiencedinthemanagementofACHDpatients. intermediate-andhigh-riskelectivesurgeryis
I C
It is generally recommended to perform the least invasive proce- performedinacentrewithexperienceinthecare
duresandanaesthesiawithaslowanimpactonhaemodynamicsas ofACHDpatients.
possible.
ACHD,adultswithcongenitalheartdisease.
Optimal peri-operative care in ACHD undergoing NCS starts
aClassofrecommendation.
withaproperpre-operativeevaluation.Adultswithcongenitalheart bLevelofevidence.
diseasecanpresentwithmultiorganinvolvement(kidneys,liver,lung,
andendocrinesystem),whichshouldbeconsideredduringthediag-
nosticwork-up.503Inmanycases,patientswithACHDhavealifelong
indicationforOACtherapyorantithrombotictreatment,mainlydue 6.6. Pericardial diseases
to arrhythmias or increased thromboembolic risk associated with ActivepericardialdiseaseisinfrequentatthetimeofNCS,butpo-
specific ACHD. Oral anticoagulant therapy in the peri-operative tentially life-threatening. The clarification of underlying aetiology is
phase should be re-evaluated on a case-by-case basis. The ofutmostimportanceforperi-operativemanagement(viralorbac-
CHA DS -VASc score has not been validated in ACHD patients terialinfection,malignant,systemicautoimmune,metabolic,orauto-
2 2
andshouldnotbeusedinthisgroup. reactivedisease). Thetreatmentoftheseconditionsshouldfollow
Continuous haemodynamic monitoring can be necessary in pa- the recommendations provided in the 2015 ESC Guidelines for
tientswithACHDandshouldincludeinvasiveBPmonitoring,espe- thediagnosisandmanagementofpericardialdiseases.510
ciallyin caseswith ACHD ofmoderate orsevere complexity. It is Acutepericarditisisaclearindicationtopostponeanelectivesur-
worthmentioningthat,accordingtothetypeofACHDorsurgery gicalprocedure.However,incasesofundeferrableNCS,attentionis
(e.g.coarctationoftheaortaorfollowingaBlalock-Taussigshunt), required regarding drug-to-drug interactions. The frequently used
thelocationofthearteriallineforcontinuousBPandgasexchange colchicineispredominantlymetabolizedthroughtheliver,whilere-
monitoring requires careful attention. In patients with persistent nal excretion accounts for only 10–20%. Colchicine may increase
2202CSE©
2202CSE©
Downloaded
from
https://academic.oup.com/eurheartj/article/43/39/3826/6675076
by
guest
on
22
January
2026
--- Страница 59 ---
3884 ESCGuidelines
sensitivitytocentralnervoussystemdepressantsandexertarespira- effectisanincreaseintheriskofpost-operativepulmonarycompli-
tory depressant effect.511 Adverse events of peri-operative signifi- cations. These complications particularly occur after abdominal or
cance include diarrhoea, worsening renal failure, and, very rarely, thoracic surgery, and the risk seems to be increased in smokers.
bone marrow suppression, hepatotoxicity, paralysis, convulsions, Certain respiratory conditions are associated with CV pathology
and cardiopulmonary collapse. Immunosuppressive drugs such as and may require special cardiac risk assessment and management,
steroids and interleukin-1 receptor antagonist agents suppress the in addition to dealing with the pulmonary disease per se. Three
immune system, and may increase the risk of infection and delay such conditions are chronic obstructive pulmonary disease
woundhealingintheperi-operativephase.511 (COPD),obesityhypoventilationsyndrome,andpulmonaryarterial
Imminentcardiactamponadeisanabsolutecontraindicationforall hypertension(PAH).
surgical procedures, especially when a general anaesthesia is re-
quired.510,512BeforeNCS,pericardialeffusionshouldfirstbepercu-
taneously drained, under local anaesthesia. In cases of small or 6.7.1.Pulmonarydisease
moderate chronic pericardial effusion and constrictive pericarditis, Chronicobstructivepulmonarydiseaseisasamajorcauseofmor-
attentionshouldbepaidtotakemeasurementstoincreasecardiac bidityandmortality.513AlthoughpatientswithCOPDhaveanin-
pre-load. The pre-load should be optimized peri-operatively with creasedriskofCVD,thereisnoevidencethatCOPDisrelatedto
i.v.fluidspriortogeneralanaestheticinductiontofacilitateventricu- a higher risk of peri-operative cardiac complications. However,
larfilling.Manipulationandmedicationdiminishingvenousreturnto post-operativepulmonarycomplicationsresultinsignificantmor-
theheartshouldbeavoidedorminimized.Positivepressureventila- talityandmorbidity.Pre-operativeevaluation,usingspecificpost-
tion might cause a dramatic decline in pre-load and should be operative pulmonary complication tools, can be used to stratify
avoided. If spontaneous breathing is not possible, ventilation with at-risk patients and enable optimal pre-operative and peri-
minimal inspiratory pressures (low tidal volumes, high respiratory operative management.514 In patients with COPD undergoing
rate) should be considered. Anaesthetics that minimize changes in NCS,thepre-operativetreatmentgoalsaretooptimizepulmon-
heartrate,systemicvascularresistance,venousreturn,andmyocar- ary function and minimize post-operative respiratory complica-
dial contractility should be selected.189 Ketamine, a sympathetic tions;thisincludesusingthepre-operativeperiodforeducation,
stimulantthatpreservesspontaneousventilation,isthedrugoffirst includingpossiblecessationofsmoking(2monthsbeforesurgery),
choice.Combinationsofopiates,benzodiazepines,andnitricoxide, instruction concerning chest physiotherapy and lung expansion
with or without low doses of volatile anaesthetics, are acceptable manoeuvres,muscularendurancetraining,andre-nutritionifre-
formaintenanceofanaesthesia.Musclerelaxantswithminimalcircu- quired.Beta-adrenergicagonistsandanticholinergicagentsshould
latoryeffectsshouldbepreferred,althoughthemodestincreasein becontinueduntilthedayofsurgeryinallsymptomaticCOPDpa-
heart rate observed with administration of pancuronium is also tientswithbronchialhyper-reactivity.Insomecases,short-term
acceptable. systemic/inhaledsteroidsmaybeconsidered.Wherethereisac-
tivepulmonaryinfection,appropriateantibioticsshouldbeadmi-
nisteredforatleast10daysand,ifpossible,electiveNCSshould
bedeferred.515
RecommendationTable25—Recommendationsfor Obesityhypoventilationsyndromeisdefinedasthetriadofobes-
pericardialdiseases
ity, daytime hypoventilation, and sleep-disordered breathing.
Although distinct from simple obesity and sleep apnoea, it is esti-
Recommendations Classa Levelb
mated that 90% patients with obesity hypoventilation syndrome
Inpatientswithacutepericarditis,deferring alsohaveobstructivesleepapnoea(OSA).Theprevalenceofobesity
electiveNCSuntilcompleteresolutionofthe IIa C hypoventilationsyndromeis0.15–3%ofadultsand7–22%inpatients
underlyingprocessshouldbeconsidered. undergoingbariatricsurgery.516Obesityhypoventilationsyndromeis
AvoidingelectiveNCSproceduresundergeneral associated with even higher morbidity, including HF (and
anaesthesiauntilcolchicineorthe obesity-relatedcardiomyopathy),anginapectoris,pulmonaryhyper-
immunosuppressivetreatmentcoursefor IIb C tension(30–88%)andcorpulmonale,andincreasedperi-operative
pericardialdiseaseiscompletedmaybe mortality.516 Patients at high risk of obesity hypoventilation syn-
considered. dromewhoareundergoingNCSshouldbereferredforadditional
specialistinvestigationofsleep-disorderedbreathingandpulmonary
NCS,non-cardiacsurgery.
aClassofrecommendation. hypertension, with pre-operative initiation of appropriate
bLevelofevidence. positive airway pressure therapy, and planning of peri-operative
techniques(anaestheticandsurgical)andpost-operativepositiveair-
way pressure management within an appropriate monitored
environment.516,517
6.7. Pulmonary disease and pulmonary
arterial hypertension
Thecoexistenceofpulmonarydiseaseincardiacpatientsundergoing 6.7.2.Pulmonaryarterialhypertension
NCSmayincreasetheoperativerisk.Pre-existingpulmonarydisease Pulmonary arterial hypertension is associated with increased
hasasignificantimpactonperi-operativerisk,butthemostcommon morbidity and mortality in patients undergoing NCS.518
2202CSE©
Downloaded
from
https://academic.oup.com/eurheartj/article/43/39/3826/6675076
by
guest
on
22
January
2026
--- Страница 60 ---
ESCGuidelines 3885
Table 14 Patient-related and surgery-related fac- RecommendationTable26—Recommendationsfor
tors to be considered when assessing peri-operative patientswithpulmonaryarterialhypertensionunder-
riskinpatientswithpulmonaryarterialhypertension goingnon-cardiacsurgery
Patient-related Surgery-related Recommendations Classa Levelb
peri-operativeriskfactors peri-operativeriskfactorsin
Itisrecommendedtocontinuechronictherapy
inpatientswithPAH patientswithPAH I C
forPAHintheperi-operativephaseofNCS.
(cid:129) Functionalclass.II (cid:129) Emergencysurgery Itisrecommendedthathaemodynamic
(cid:129) Reducedsix-minutewalk (cid:129) Durationofanaesthesia.3h monitoringofpatientswithseverePAHcontinues I C
distance (cid:129) Intra-operativerequirementfor foratleast24hinthepost-operativeperiod.
(cid:129) Coronaryheartdisease vasopressors InthecaseofprogressionofrightHFinthe
(cid:129) Previouspulmonaryembolism post-operativeperiodinpatientswithPAH,itis
(cid:129) Chronicrenalinsufficiency
recommendedthatthediureticdosebe
I C
(cid:129) Severerightventricular optimizedand,ifnecessary,i.v.prostacyclin
dysfunction analoguesbeinitiatedundertheguidanceofa
physicianexperiencedinthemanagementofPAH.
PAH,pulmonaryarterialhypertension.
AdaptedfromOlssonetal.522 Inodilatordrugs(dobutamine,milrinone,
levosimendan),whichincreasecardiacoutputand
lowerpulmonaryvascularresistance,shouldbe IIa C
consideredperi-operativelyaccordingtothe
Ameticulouspre-operativediagnosticwork-upinthissubsetof
haemodynamicstatusofthepatient.
patients should include assessment of functional status and se-
verity of disease, in addition to comorbidities and the type of HF,heartfailure;i.v.,intravenous;NCS,non-cardiacsurgery;PAH,pulmonaryarterial
hypertension.
NCS.Echocardiographyandrightheartcatheterization(ifclinic- aClassofrecommendation.
allyindicated)arekeycomponentsinthepre-operativework-up. bLevelofevidence.
The morbidity and mortality associated with PAH derive from
the haemodynamic response of the right ventricle to acute in-
creasesinafterload.519
In patients with severe PAH, peri-operative mortality ranging who develop worsening pulmonary hypertension post-
between 3–18% has been reported, depending on the operatively to maintain right ventricular (RV) function and
severityoftheunderlyingdisease,andthenatureandurgencyof
haemodynamicstability.526
thesurgicalprocedure.Emergencyproceduresarealsoassociated
with a high risk of complications.520,521 Patient-related and 6.8. Arterial hypertension
surgery-relatedfactorsshouldbeconsideredwhenassessingperi- The prevalence of arterial hypertension in adults in Europe is
operative risk in patients with PAH (Table 14).522 Owing to the (cid:4)30–45%.527 Of these patients, ,40% have well-controlled BP
potentialforanaesthesiaandsurgerytobecomplicatedbyacute (,140/90mmHg).Alargeobservationalstudyhasshownthatpa-
right HF and pulmonary hypertensive crisis, elective NCS in pa- tientswithuntreatedhypertension1monthbeforesurgeryhada
tientswithPAHshouldbeadequatelydiscussedinamultidisciplin- 69%increasedriskof90daypost-operativemortality.183Further,
aryteam.Ideally,patientswithPAHundergoingNCSshouldhave overallCVriskassessment,includingthesearchforhypertension-
optimal medical treatment before surgery and be managed in a mediatedorgandamage,isofparamountimportanceinhyperten-
centre experienced in PAH. Patients scheduled for NCS should sive patients, and mandatory when there is newly detected BP
be discussed by a pneumologist, cardiologist, surgeon, and an elevation.528
anaesthesiologist.523 The management of patients with PAH in Postponingsurgeryisusuallynotadvisedinpatientswithgrade
the peri-operative setting should follow the recommendations 1 or 2 hypertension. In contrast, in subjects with a systolic BP
provided in the 2022 ESC/ERS Guidelines for the diagnosis and ≥180mmHg and/or diastolic BP ≥110mmHg, deferring the
treatmentofpulmonaryhypertension.524 intervention until BP is under control is advisable, except for
Severalnoveltherapiesaimedatreducingpulmonarypressures emergencysurgery.236,527,529,530Italsoseemsimportanttoavoid
are used pre-operatively in patients undergoing NCS. Of these largeperi-operativeBPfluctuations.Inarecentrandomizedtrial
therapies, endothelin receptor antagonists, phosphodiesterase among patients undergoing abdominal surgery, an individualized
inhibitors, and prostacyclin analogues are the most used.525 intra-operative treatment strategy with systolic BP values kept
This medication should be continued during the peri-operative within a 10% difference from the pre-operative office measure-
phasebecausetherapydisruptionmayleadtoacriticalrebound mentresultedinareducedriskofpost-operativeorgandysfunc-
ofthePAH.Inhalednitricoxideallowsselectivepulmonaryvaso- tion.528 Ina meta-analysisincluding130862 patientsundergoing
dilatation with rapidity of action and it can be given to patients surgery, intra-operative hypotension was associated with
2202CSE©
2202CSE©
Downloaded
from
https://academic.oup.com/eurheartj/article/43/39/3826/6675076
by
guest
on
22
January
2026
--- Страница 61 ---
3886 ESCGuidelines
increasedriskofmorbidity(OR,2.08;95%CI,1.56–2.77),mortal- RecommendationTable27—Recommendationsfor
ity (OR, 1.94; 95% CI, 1.32–2.84), cardiac complications (OR, pre-operativemanagementofhypertension
2.44; 95% CI, 1.52–3.93), and AKI (OR, 2.68; 95% CI, 1.31–
5.55).531Inpatientswithhypertension,hypoperfusionmayoccur Recommendations Classa Levelb
at higher BP levels and peri-operative BP control should be tai- Inpatientswithchronichypertensionundergoing
loredtopre-operativelevels.528
electiveNCS,itisrecommendedtoavoidlarge
In patients referred for elective NCS, control of BP should be peri-operativefluctuationsinbloodpressure, I A
prioritized, especially in patients with systolic BP .160mmHg. particularlyhypotension,duringthe
Themanagementofpatientswithhypertensioninthepre-operative peri-operativeperiod.528,531
setting should follow the recommendation provided in the 2018
Itisrecommendedtoperformpre-operative
ESC/European Society of Hypertension (ESH) Guidelines for the
screeningforhypertension-mediatedorgan
managementofarterialhypertension.529Theseguidelinesadvocate
damageandCVriskfactorsinnewlydiagnosed I C
anapproachusingRAASinhibitors(inpatientsaged,70years)or
hypertensivepatientswhoarescheduledfor
CCBs(inpatientsaged.70years)assingletherapyinmoderate
electivehigh-riskNCS.
hypertension and both in combination where dual therapy is
ItisnotrecommendedtodeferNCSinpatients
III C
needed,addingadiureticandanaldosteroneantagonistifaddition-
withstage1or2hypertension.
almedicationisneededforadequatecontrol.Beta-blockersarere-
strictedtopatientswhereitisspecificallyindicated.529Inpatients CV,cardiovascular;NCS,non-cardiacsurgery.
aClassofrecommendation.
with hypertension and a clear indication for beta-blocker, third- bLevelofevidence.
generationbeta-blockers—suchascarvedilol,celiprolol,labetolol,
and nebivolol—have superior antihypertensive effects compared
6.9. Peripheral artery disease
with other beta-blockers and fewer adverse effects, but there
are no RCTs reporting outcomes in hypertensive patients.529 In Patientswithperipheral artery disease (PAD)usually haveadvanced
a large observational study, a beta-blocker prescription prior to atheroscleroticdiseaseaffectingmultiplevascularbedsinvaryingde-
NCSwasassociatedwithlower30daymortalityinpatientswith grees and have a worse prognosis compared with patients without
three or four cardiac risk factors.188 However, for patients with
PAD.534–538PatientswithPADgenerallydifferintheirriskprofiles,ac-
nocardiacriskfactors,theriskofdeathwassignificantlyincreased cordingtowhethertheyundergovascularornon-vascularNCS.
withbeta-blockers.188,532
Mostpatientswithstage3hypertensiononthedayofsurgery 6.9.1.Peripheralarterydiseaseandnon-vascular
will be classified as hypertensive urgencies. In these cases, the non-cardiacsurgery
2018ESC/ESHGuidelinesforthemanagementofarterialhyper- Decisionsonpre-operativetreatmentofpre-existingPADandAAA
tension recommend ACEIs, CCBs, or diuretics. Neither ACEIs inpatientsscheduledfornon-vascularNCSshouldbemadeonan
nor diuretics are recommended on the day of surgery. The use individualbasis,takingintoaccountsymptomsandrisksofsurgery.
ofCCBsissupportedbyameta-analysisof11studiesofCCBsdur- Non-cardiacsurgeryshouldbeprioritizedinpatientsneedingrevas-
ingNCS.220Further,astudyof989well-controlledpatientswith cularizationforPAD,butcarefulperi-operativemonitoringofdeteri-
hypertensionwithouthypertension-relatedorgandamage,testing oration in lower extremity perfusion is warranted, particularly in
the use of fast-acting nasal nifedipine when stage 3hypertension thosepatientswithchroniclimb-threateningischaemia(e.g.periph-
(systolicBP.180and/ordiastolicBP.110mmHg)wasdiagnosed eral BP of ≤50–70mmHg in the foot joint and ≤30–50mmHg in
thedayofNCS,foundnodifferenceinoutcomebetweenadmin- the toes).539 For patients with AAA, pain control is essential to
istrationofnifedipineandsurgeryonthesamedaycomparedwith ensure stableBP,minimizingrupturerisk. PatientswithlargeAAA
deferral for hypertension control before resuming surgery.533 (i.e. .5cm in diameter for women and .5.5cm for men) should
Immediatenifedipinetreatmentwasassociatedwithshorterhos- be evaluated for aortic aneurysm repair (preferably
EVAR)540–542
pitalstays.Asthiswasthefirststudytestingtheneedfordeferral before non-vascular NCS is planned, particularly in the case of
ofstage3hypertension,itchallengedtheneedforthispractice.For malignanttumours,dependingonthestageofmalignantdisease.
patientswithhypertensiveemergencies(systolicBP.180and/or
diastolicBP.110mmHgandorgandamage),the2018ESC/ESH 6.9.2.Peripheralarterydiseaseandvascular
Guidelines for the management of arterial hypertension recom- non-cardiacsurgery
mend labetolol, nitroglycerin, nitroprusside, etc., according to The2017ESCGuidelinesonthediagnosisandtreatmentofperiph-
theaffectedorgan.529 eral arterial diseases535 and the European Society for Vascular
The timing of administration of the antihypertensive drugs, and Surgery(ESVS)2019ClinicalPracticeGuidelinesonthemanagement
their continuation or discontinuation in the peri-operative period ofabdominalaorto-iliacarteryaneurysms35providedetailedevidence
isdiscussedinSection5.2. andrecommendationsonthescreeningofpatientsbeforevascular
2202CSE©
Downloaded
from
https://academic.oup.com/eurheartj/article/43/39/3826/6675076
by
guest
on
22
January
2026
--- Страница 62 ---
ESCGuidelines 3887
NCSandtheirtreatmentmodalityselection.Notably,thereisrando- debate.Importantly,thepurposeofcarotidrevascularizationinthis
mized evidence against prophylactic coronary revascularization be- setting is more the long-term prevention of stroke than peri-
fore major vascular surgery in CCS patients due to lack of benefit operativestrokeriskreduction;therefore,ifcarotidrevascularization
inimprovementofperi-operativeandlong-termoutcomes(2.7years isindicated,thismaybeperformedbeforeoraftertheplannedNCS.
mean follow-up).399 Assessment of functional capacity might offer Independentoftherevascularization strategy, patients with carotid
guidancetoselectcandidatesforcardiacassessmentpriortomajor artery stenosis benefit from aggressive CV risk-factor modification
NCS, although severe walking impairment may challenge this test. topreventperi-operativemyocardialischaemia.
Thepreviouslyestablishedriskpredictivemodeltodetectmortality
in patients undergoing elective AAA repair may be helpful.543
RecommendationTable29—Recommendationsfor
Low-doserivaroxabanplusaspirininitiatedwithin10daysafteralow-
managementofpatientswithsuspectedorestablished
erlimbrevascularizationprocedurereducespost-operativethrom-
carotidarterydiseaseundergoingnon-cardiacsurgery
botic events (acute limb ischaemia, amputation, MI, ischaemic
stroke,andCVdeath)inpatientsundergoinglowerlimbrevascular- Recommendations Classa Levelb
ization,whetheritiscarriedoutusinganendovascularoropensur-
gical approach.544 Handling of other co-drugs should follow the Pre-operativecarotidarteryandcerebralimaging
isrecommendedinpatientswithahistoryofTIA
recommendationsdetailedinSection5.2. I C
orstrokeintheprevious6monthsandwhohave
notundergoneipsilateralrevascularization.
RecommendationTable28—Recommendationsfor
Forpatientswithcarotidarterydisease
management of patients with peripheral artery dis-
ease and/or abdominal aortic aneurysm undergoing undergoingNCS,thesameindicationsforcarotid
IIa C
non-cardiacsurgery revascularizationshouldbeconsideredasfor
otherpatientswithcarotidstenosis.
Recommendations Classa Levelb
Pre-operativecarotidarteryimagingisnot
III C
Inpatientswithpoorfunctionalcapacityor recommendedroutinelyinpatientsundergoingNCS.
significantriskfactorsorsymptoms(suchas
NCS,non-cardiacsurgery;TIA,transientischaemicattack.
moderate-to-severeanginapectoris, aClassofrecommendation.
decompensatedHF,valvulardisease,and I C bLevelofevidence.
significantarrhythmia),referralforcardiac
work-upandoptimizationisrecommendedprior
6.11. Renal disease
toelectivesurgeryforPADorAAA.
Routinereferralforcardiacwork-up,coronary Renaldiseaseisassociatedwithseveralcardiaccomorbidities,including
angiography,orCPETpriortoelectivesurgeryfor III C hypertension,HF,CAD,andarrhythmias.546Consistently,renaldisease
PADorAAAisnotrecommended.
portendsasignificantincreaseinthepost-operativeriskofCVevents,
includingMI,stroke,andprogressionofHFinpatientsundergoingNCS.
AAA,abdominalaorticaneurysm;CPET,cardiopulmonaryexercisetesting;HF,heart Forthisreason,mostriskindicesforthequantificationofpre-operative
failure;PAD,peripheralarterydisease.
aClassofrecommendation. riskinpatientsundergoingNCSincluderenalfunction.
bLevelofevidence. Chronickidneydisease(CKD)isdefinedasimpairedkidneyfunc-
tionorraisedproteinuria,confirmedontwoormoreoccasionsat
least3monthsapart.Thekidneyfunctioncanbeassessedthrough
6.10. Cerebrovascular disease theestimatedglomerularfiltrationrate(eGFR)calculatedusingthe
PatientsundergoingNCSshouldbequestionedaboutpreviousneuro- ChronicKidneyDiseaseEpidemiologyCollaboration(CKD-EPI)for-
logicalsymptoms,andthosewithsymptomssuggestiveoftransientis- mula,includingsex,age,ethnicorigin,andserumcreatinineconcen-
chaemic attack (TIA) or stroke in the preceding 6 months should tration.Acut-offglomerularfiltrationrate(GFR)value,60mL/min/
undergopre-operativeneurologicalconsultationandneurovascularand 1.73m2significantlycorrelateswithMACEs.Identificationofcardiac
brainimaging,ifappropriate.Intheabsenceofdedicatedstudiesaddres- patientsatriskofworseningofrenalfunctionintheperi-operative
singthisissue,thecriteriaforcarotidrevascularizationinsymptomaticand phaseofNCSisofparamountimportance,inordertoinitiatesup-
asymptomaticpatientsisdescribedindetailinthe2017ESCGuidelines portivemeasuressuchasmaintenanceofadequateintravascularvol-
onthediagnosisandtreatmentofperipheralarterialdiseases,incollabor- umeforrenalperfusionanduseofvasopressors.547
ationwiththeESVS;theseguidelinesshouldalsoguidethemanagement PatientswithcardiaccomorbiditiesarepronetodevelopAKIafter
ofpatientswithcarotiddiseasewhoareundergoingNCS.535 major NCS, due to worsening of haemodynamic status associated
Inpatientswithsymptomaticcarotiddisease,thebenefitofcarotid with fluids or blood loss, and withdrawal or continuation of
revascularization is particularly high in patients with recent (,3 cardio-activetherapies.Theperi-operativemanagementofpatients
months)TIAorstroke,and≥70%carotidarterystenosis.Thus,ca- undergoingNCSandtreatedwithcardio-activedrugshasbeendis-
rotidrevascularizationshouldbeperformedfirstandelectiveNCS cussedinSection5.2.Acutekidneyinjuryreduceslong-termsurvival
shouldbepostponed.545 in patients with normal baseline renal function.548 Of interest,
Thequestionastowhetherpatientswithsevereasymptomaticca- (cid:4)30–40%ofallcasesofAKIoccuraftersurgeryandtheincidence
rotidocclusivediseasewhoareundergoingelectivemajorNCSre- ofpost-operativeAKIranges18–47%.Riskfactorsforthedevelop-
quire pre-operative carotid revascularization remains a matter of ment of post-operative AKI following NCS include cardiac
2202CSE©
2202CSE©
Downloaded
from
https://academic.oup.com/eurheartj/article/43/39/3826/6675076
by
guest
on
22
January
2026
--- Страница 63 ---
3888 ESCGuidelines
(decompensated orchronicHF,hypertension,cardio-activedrugs) second leading cause of preventable death following tobacco
and non-cardiac triggers (age, sex, emergent, and/or intraperito- use.558Obesityisdefinedasabodymassindex(BMI)of≥30kg/m2,
neal surgery, mild pre-operative renal insufficiency, pre-operative morbidobesityasaBMI≥35kg/m2,andsuper-morbidobesityasa
creatinine elevation, CKD, and DM).549,550 The combination of a BMI ≥50kg/m2. Obese individuals have a higher prevalence of CV
lowcardiacoutput/highvenouspressureand/ortheadministration riskfactorsandahigherriskofdeath,559andareapopulationwho
ofiodinatedcontrastmediaduringdiagnosticandoperativeproce- areatincreasedriskofadverseeventsinthecaseofsurgicalproce-
duresrepresentthemostfrequentcausesofAKIinhospitalizedcar- dures. There are specific recommendations for the pre-operative
diac patients, regardless of pre-existing impaired renal function. riskassessmentofobesepatientsundergoingNCS,regardlessofthe
Contrast-induced AKI is defined as a rise in serum creatinine of presenceofpre-existingcardiacconditions.560However,whileobes-
44mmol/L(0.5mg/dL)ora25%relativerisefrombaselineat48h ityacceleratesthepropensityforCVD,itseemsthatmanytypesof
(or 5–10% at 12h) following contrast administration. It occurs in CVDmayhaveabetterprognosisintheoverweightpopulationcom-
upto15%ofpatientswithCKDwhoareundergoingradiographic paredwiththeirleanercounterparts,aphenomenonthatisknownas
procedures.551 Although most cases of contrast-induced AKI are the‘obesityparadox’.561,562Similarly,incasesofNCS,mildlyobesepa-
self-limiting, with renal function returning to normal within 7 days tientspresentlowermortalityriskcomparedwithunderweightand
oftheprocedure,thesepatientsoccasionally(0.5–12%ofcases)de- normal weight patients, both post-operatively and at long-term
velop overt renal failure associated with increased morbidity and follow-up.563Thisfindingmayberelatedtothelowerprevalenceof
mortality.Toreducetheriskofcontrast-inducedAKIinsubjectsre- PMIinmildlyobesepatientsundergoingNCS.564
quiring contrast-enhanced radiography, the Kidney Disease: Ithasbeensuggestedthatcardiorespiratoryfitness(CRF),rather
Improving Global Outcomes (KDIGO) Clinical Practice Guidelines thanBMI,shouldbeusedtoassessCVriskinobesepatients.While
recommend: pre-operative hydration with i.v. isotonic fluids; the the classification based on BMI is simple, highly reproducible, and
useoftheminimumvolumeofcontrastmedia;andtheuseoflow- widelyadoptedinclinicalpractice,itdoesnotreflectfatdistribution
osmolaroriso-osmolarcontrastmedia,regardlessofpre-existingre- andbodycomposition.Cardiorespiratoryfitnessreferstotheability
naldisease.547Inthepost-operativephase,kidneyfunctionshouldbe ofthecirculatoryandrespiratorysystemstosupplyoxygentoskel-
monitored by applying established AKI scoring systems to raise etalmusclesduringsustainedphysicalactivity,whichisofparamount
awarenessandenableearlyintervention.552 importance,especiallyinpatientswithcardiacdiseases.Theprimary
measureofCRFisVO max.565Acohortstudyofnearly10000pa-
2
tients with CAD followed for almost 15 years showed that those
RecommendationTable30—Recommendationsfor with relatively good CRF had favourable prognosis regardless of
managementofpatientswithrenaldiseaseundergoing body composition;566 however, a lower CRF was found to be a
non-cardiacsurgery major predictor of mortality, regardless of BMI.561,567 Whether
specific optimization and/or treatment strategies might have a
Recommendations Classa Levelb
positive impact on the outcome of obese patients with pre-
Inpatientswithrenaldiseaserequiring existingornewlydiagnosedcardiaccomorbiditiesandscheduled
peri-operativecontrast-enhancedradiography, for NCS is a matter of ongoing controversy. Studies assessing
balancedhydrationwithi.v.isotonicfluids,theuse the effect of weight loss interventions (low-energy diets with or
IIa B
ofaminimalvolumeofcontrastmedia,andthe withoutanexercisecomponent)onclinicaloutcomesinpatients
useoflow-osmolaroriso-osmolarcontrastmedia undergoing NCS found inconsistent results in terms of peri-
shouldbeconsidered.547,553–555 operativemorbidityormortality.568,569
Inpatientswithknownriskfactors(age.65
years,BMI.30kg/m2,diabetes,hypertension,
hyperlipidaemia,CVdisease,orsmoking)
I C
undergoingintermediate-orhigh-riskNCS,itis
RecommendationTable31—Recommendationsfor
managementofpatientswithobesityundergoingnon-
recommendedtoscreenforpre-operativerenal
cardiacsurgery
diseasebymeasuringserumcreatinineandGFR.
IfacystatinCmeasurementassayisavailable, Recommendations Classa Levelb
cystatinCmeasurementshouldbeconsideredin
IIa C
patientswithimpairedeGFR(,45–59mL/min/ Itisrecommendedtoassesscardiorespiratory
1.73m2)toconfirmkidneydisease.556 fitnesstoestimateperi-operativeCVriskinobese
I B
patients,withparticularattentiontothose
BMI,bodymassindex;CV,cardiovascular;eGFR,estimatedglomerularfiltrationrate;
undergoingintermediate-andhigh-riskNCS.565,570
GFR,glomerularfiltrationrate;i.v.,intravenous;NCS,non-cardiacsurgery.
aClassofrecommendation. Inpatientsathighriskofobesityhypoventilation
bLevelofevidence.
syndrome,additionalspecialistinvestigation
IIa C
beforemajorelectiveNCSshouldbe
considered.516
6.12. Obesity
CV,cardiovascular;NCS,non-cardiacsurgery.
The prevalence of people being overweight and having obesity is aClassofrecommendation.
reaching epidemic proportions in Western countries557 and is the bLevelofevidence.
2202CSE©
2202CSE©
Downloaded
from
https://academic.oup.com/eurheartj/article/43/39/3826/6675076
by
guest
on
22
January
2026
--- Страница 64 ---
ESCGuidelines 3889
6.13. Diabetes
Apre-operativeassessmentforconcomitant
Duetotheprogressiveageingofthepopulationundergoingsur- cardiacconditions(seeSections3and4)is
gicalproceduresandtheincreasingprevalenceofobesityworld- recommendedinpatientswithdiabeteswith
wide, the prevalence of diabetes among patients undergoing suspectedorknownCAD,andthosewith I C
NCS is expected to increase in years to come.4,571 Several autonomicneuropathy,retinopathy,orrenal
studies have demonstrated that diabetic patients undergoing diseaseandscheduledtoundergointermediate-
NCShaveahigherprevalenceofCADthannon-diabeticpatients. orhigh-riskNCS.
Furthermore,patientswithdiabetesaremorelikelytohavesilent
CAD, coronary artery disease; HbA1c, glycated haemoglobin; NCS, non-cardiac
ischaemiabecauseofalteredneuralpainpathwaysintheheart.572
surgery.
For this reason, patients with diabetes appear to have a greater aClassofrecommendation.
riskofpost-operativemyocardialischaemia.Differentreasonsex-
bLevelofevidence.
istbehindtherelationbetweenDMandincreasedperi-operative
mortalityinpatientsundergoingNCS.First,patientswithdiabetes
are known to have more comorbidity and/or advanced CAD at 6.14. Cancer
the time of intervention. Second, diabetes is a clear risk factor
Duetotheirgenerallyolderage,cancerpatientshaveahighpreva-
forstroke.Diabetesisassociatedwithpost-operativecongestive
lenceofCVriskfactorsandCVD,beingapopulationatincreased
HF and wound infections. Many patients with diabetes have im- riskofadverseeventsincasesofNCS.Itisthereforeimportantto
pairedrenalfunction.Thepresenceoranewdiagnosisofimpaired
optimize treatment of CV risk factors and known CVD before
glucosemetabolisminpatientsscheduledforNCSshouldfollow NCS, following the general and disease-specific recommendations
the recommendations provided for the general population in provided in other sections of these guidelines. Furthermore, NCS
the2019ESCGuidelinesondiabetes,pre-diabetes,andcardiovas-
maybeparticularlychallengingincancerpatientsbecauseofprevious
cular diseases,573 including increased awareness regarding pos- administration of potentially cardiotoxic chemotherapy or fibrosis
siblesubclinicalorgandamage. due to previous radiation. For example, the widely used anthracy-
Theglycatedhaemoglobin(HbA1c)testshouldbeperformedin
clines have a dose-dependent relation with the incidence of HF
allpatientswithdiabetesorimpairedglucosemetabolismscheduled
and the use of trastuzumab can lead to important cardiotoxicity
forNCS,ifthismeasurementhasnotbeenperformedintheprevi- andshouldbetakenintoaccountinthepre-operativeassessment.
ous3months.Thereisevidencetosupportthatpre-admissionop-
Furthermore, radiation therapy to areas that included the heart
timaltreatmentofhyperglycaemiainpatientsscheduledforelective
mayleadtoprematureCADandVHD;previousthoracicradiother-
NCSiseffectiveinreducingthepost-operativeriskofCVevents,in-
apy may predispose younger patients to heart disease who would
cludingMI,stroke,andprogressionofHF.574Incontrast,noclearas-
otherwisenothaveanelevatedrisk.Post-operativeAFisfrequently
sociation has been shown between intra-operative blood glucose
observedinpatientsundergoingcancersurgery,withthehighestin-
levelsand the subsequentrisk of surgical site infection, MI, stroke,
cidence reportedforlungsurgery.Patientswithcancer areatele-
anddeathinpatientsundergoingNCS.575Theriskofacidosisasso-
vatedriskofthrombosisduetoboththediseaseitselfandpatient-
ciatedwithmetforminuseisalsodebated.576Nevertheless,repeated
andtreatment-relatedfactors.Inasmallstudyofpatientsundergoing
blood glucose monitoring on the day of surgery is recommended, planned open surgery for abdominal or pelvic cancer, enoxaparin
with a general consensus to maintain peri-operative glucose levels prophylaxis for 4 weeks compared with 1 week reduced the inci-
,10.0mmol/L without causing hypoglycaemia (target level 5.6– dence of thrombosis (4.8% in the enoxaparin group vs.12.0% in
10.0mmol/L).Thiscanbeachievedeitherwithsubcutaneousdoses theplacebogroup;P=0.02).582Althoughlaterstudieshaveshown
of rapid-acting insulin analogues or with i.v. insulin.577 Handling somewhat conflicting results, the consensus is to recommend ex-
of SGLT2 inhibitors in relation to surgery has been discussed in
tending thromboprophylaxis after major abdominal and/or pelvic
Section5.2. surgeryforcancerto4–5weeks,withpreferreduseofLMWH.583
A summary of patient-related and cancer therapy-related factors
that could influence peri-operative risk is shown in Table 15.
Furtherinformationisavailableinthe2022ESCGuidelinesoncar-
RecommendationTable32—Recommendationsfor dio-oncology.584
managementofpatientswithdiabetesmellitusunder-
goingnon-cardiacsurgery
6.15. Coronavirus disease 2019
Recommendations Classa Levelb Coronavirus disease 2019 (COVID-19) is an infectious disease
caused by the severe acute respiratory syndrome coronavirus 2
Inpatientswithdiabetesordisturbedglucose
(SARS-CoV-2).Inarecentobservationalstudy,among140231pa-
metabolism,apre-operativeHbA1ctestis
tientsscheduledforNCS,2.2%ofpatientshadapre-operativediag-
recommended,ifthismeasurementhasbeennot
I B nosisofSARS-CoV-2infection.585Patientsundergoingsurgerywith
performedintheprevious3months.Incaseof
HbA1c≥8.5%(≥69mmol/mol),electiveNCS peri-operativeorrecentSARS-CoV-2appeartobeatincreasedrisk
shouldbepostponed,ifsafeandpractical.578–581 ofpost-operativeVTEandmortalitycomparedwithpatientswithno
historyofSARS-CoV-2infection.586Furthermore,thepossiblemyo-
Continued
cardialinjuryassociatedwithCOVID-19infectionmightincreasethe
2202CSE©
Downloaded
from
https://academic.oup.com/eurheartj/article/43/39/3826/6675076
by
guest
on
22
January
2026
--- Страница 65 ---
3890 ESCGuidelines
Table15 Factorsthatcouldinfluenceperi-operativeriskduringcancersurgeryandpreventivestrategies
Factorsthatcouldinfluenceperi-operativeriskduringcancer Preventivestrategies
surgery
(cid:129) Patient-related (cid:129) Lifestyleriskfactors—smoking,obesity,sedentarylifestyle (cid:129) OptimalmanagementofCVriskfactorsand
factors (cid:129) PoorlycontrolledCVriskfactors—hypertension,diabetes CVD
(cid:129) Pre-existingCVD,includingcancertherapy-relatedcardiovascular (cid:129) Optimizepreventivestrategieswithrespect
toxicity toVTEandarterialthromboembolicevents
(cid:129) Cardiacmedicationincreasingperi-operativebleedingrisk(e.g. (cid:129) ECGmonitoringforarrhythmias
antiplateletsandanticoagulants) (cid:129) Correctionofallproarrhythmicconditions
(cid:129) Historicalprimarymalignancy
(cid:129) Currentcancertype,stage,andlocation
(cid:129) Arrhythmias(duetomyocardialcancerinvasion,induced
QT-prolongation,AF,orimbalanceofautonomicnervoussystem)
(cid:129) Neoadjuvantcancer (cid:129) Previouscardiotoxiccancertreatments(especiallyanthracycline (cid:129) EnsureoptimalCVmonitoringof
therapy chemotherapyand/ortrastuzumab;immunecheckpointinhibitors, neoadjuvanttherapy
VEGFi,fluoropyrimidineandthoracicradiotherapy) (cid:129) Optimizepreventivestrategieswithrespect
(cid:129) Cancertreatmentsincreasingperi-operativebleedingrisk(e.g. toVTEandarterialthromboembolicevents
antiangiogenics,BTKi)
(cid:129) Cancertreatmentsincreasingriskofarrhythmias
AF,atrialfibrillation;BTKi,Brutontyrosinekinaseinhibitors;CV,cardiovascular;CVD,cardiovasculardisease;ECG,electrocardiogram;VEGFi,vascularendothelialgrowfactorinhibitor;
VTE,venousthromboembolism.
intrinsicperi-operativeriskofadversecardiaceventsassociatedwith timeofsurgery.TheclinicalcourseofCOVID-19infection,presence
surgicalprocedures.587,588 and intensity of cardiopulmonary symptoms during the acute and
Todate,thereisnospecificCVscreeningtobeperformedafter latephases,andpre-existingcomorbiditiesshouldbetakenintocon-
COVID-19 infection in patients scheduled for NCS. The pre- sideration.Inaddition,persistenceofCOVID-19symptoms—such
operativeevaluationofCVriskassociatedwithNCSinthisspecific asfatigue,shortnessofbreath,andchestdiscomfort—shouldbegi-
subset of patients should incorporate, beyond the general risk as- ven attention, as this condition is associated with higher post-
sessmentoutlinedintheseguidelines,theseverityofCOVID-19dis- operativemortalityindependentofthetimingofCOVID-19diagno-
ease,historyofCVcomplicationsduringCOVID-19infection,and sis.588,589Theevidenceiscurrentlyinsufficienttomakerecommen-
functionalcapacityafterrecovery.Thisinformationisdeemedofim- dationsforthosewhobecomeinfectedaftervaccination.
portancetofurtheroptimizetimingofsurgeryandthetreatmentof
COVID-19-associated cardiovascular conditions affecting the peri-
7. Peri-operative monitoring and
operativeriskofNCS.589
anaesthesia
TheoptimaltimingofNCSinpatientswithahistoryofCOVID-19
infectionislargelyunknown.Generally,electiveNCSshouldbepost-
poned until complete recovery and optimization of coexisting co- 7.1. Peri-operative monitoring
morbidities. Registry data of patients undergoing NCS after DespitetheabsenceofprospectiveRCTsinvestigatingtheprognos-
COVID-19infectionreportincreasedrisksofmortalityandmorbid- ticrelevanceofperi-operativemonitoring,previousevidenceclearly
ityupto7weekspost-COVIDdiagnosis.586Anotherstudyhasre- indicatesthattheroutineuseofmonitoringimprovessafetyofsur-
portedgreaterriskofpost-operativecomplicationsupto8weeks gical procedures. Mandatory intra-operative monitoring of the CV
post-diagnosis.590However,itshouldbenotedthatalmostallavail- andrespiratorysystems,temperature,neuromusculartransmission,
abledatacomefromstudyperiodswithzerotolowprevalenceof anddepthofanaesthesiaisrecommended.592,593
vaccination, and no robust data exist on patients recovering from RoutineCVmonitoringincludesECG,automatednon-invasiveBP
themorerecentDeltaandOmicronvariants. measurementatregularintervals,andperipheraloxygensaturation
Ajointstatementonelectivesurgeryandanaesthesiaforpatients withpulseoximetry.Near-infraredspectroscopyhasrecentlybeen
after COVID-19 infection from the American Society of introducedtoassessregionaltissueperfusionandoxygenation.Inse-
Anaesthesiologists and Anaesthesia Patient Safety Foundation591 lected cases, more invasive monitoring techniques can be applied
suggestsdelayingelectivesurgeryfor7weeksafteraSARS-CoV-2 suchascontinuousarterialBPmeasurementviaanarterialcatheter
infection in unvaccinated patients who are asymptomatic at the andmonitoringofcardiacoutput.Meanarterialpressureandheart
2202CSE©
Downloaded
from
https://academic.oup.com/eurheartj/article/43/39/3826/6675076
by
guest
on
22
January
2026
--- Страница 66 ---
ESCGuidelines 3891
rateremainstable,evenwithvariationofupto30%oftotalblood patient outcome. A recent systematic review identified 42 studies
volume.594Rightheartcatheterizationcanbeusedtocontinuously looking at associations between various absolute and relative
measurecentralvenouspressureand/orpulmonaryarterypressure, intra-operativehypotensiondefinitionsandpost-operativeadverse
pulmonary artery wedge pressure (as a reflection of LV diastolic outcomesafterNCS.214Thereportedassociationssuggestthator-
pressure), and cardiac output. However, these are static variables gan injury (myocardial injury, stroke, AKI) might occur when the
thatdonotreliablyreflecttheCVfillingstatus,andhavebeenshown meanarterialpressuredecreasesto,80mmHgfor≥10min,and
toaccuratelyguidefluidtherapyin50%ofpatients.595 that this risk increases with BP becoming progressively lower.
While routine use of pulmonary catheterization is discouraged However,mostoftheincludedstudieshadaretrospectiveobserva-
duringNCS,usingdynamicvariables,suchasstrokevolumevariation tionaldesignwithalargevariabilityinpatientcharacteristics.Inadd-
orpulsepressurevariation,hasbecomethegoldstandard.Inadd- ition, the definitions of intra-operative hypotension varied widely
ition,TEEisincreasinglybeingusedasanintra-operativemonitoring across included studies. A recent study on the incidence of
techniqueinmajorsurgeryincardiaccompromisedpatientsanddur- intra-operativehypotensionasafunctionofthechosencut-offdef-
ingcardiacsurgery.Decisionsontheextentofperi-operativemon- initiondescribed48differentdefinitionsofintra-operativehypoten-
itoringandimplementationofspecificstrategiesduringNCSshould sion. When applying these definitions to a cohort of 15509
alwaysbebasedonanindividualpatient-directedassessment,taking consecutiveadultpatientsundergoingNCSundergeneralanaesthe-
intoconsiderationtheseverityofsurgeryandthepatient’sphysical sia,anyepisodeofsystolicBP,80mmHgwasfoundin41%ofthe
condition.Basicperi-operativemonitoringoftherespiratorysystem patients,and93%ofthepatientshadatleastoneepisodeofsystolic
consistsofpulseoximetryandcapnography;bothmethodsarenon- BP .20% below baseline. The relation between threshold values
invasiveandeasilyapplicable.Pulseoximetryenablesinvivomeasure- from the literature and incidence of intra-operative hypotension
mentofarterialoxygensaturation,andcapnometrymeasuresend- showed a sigmoidal shaped cumulative incidence curve, with
tidalcarbondioxideconcentrationduringinspirationandexpiration; intra-operative hypotension occurrence frequencies varying from
these monitors also provide information about the global haemo- 5–99%.600 It seems that no universal target BP to define
dynamicstatus. intra-operative hypotension can currently be defined. In addition,
Patients,independentoftheanaesthetictechniqueandinforma- instudiesonintra-operativehypotension,boththethresholdtode-
tionprovidedbythedifferentmonitoringsystems,mustberegularly finehypotensionandthemethodchosentomodelintra-operative
controlled.596 In addition, blood loss and urine output should be hypotensionaffectedtheassociationofintra-operativehypotension
checked,whenappropriate,andoverallclinicalstatus.597Specialat- with outcome.601 As a consequence, different studies on
tentionisrequiredfortheactivationandsettingofaudiblealarms, intra-operative hypotension are uncomparable and clinical conclu-
as inadequate use or failure to respond to intra-operative alarms sionsonreportedresultsremainhazardous.Arecentexpertcon-
mayresultinpatienthazardandundesirableoutcomes.598 sensus statement concluded that intra-operative mean arterial
pressures ,60–70mmHg are associated with myocardial injury,
7.2. Anaesthesia AKI,anddeath.Thesecomplicationsareafunctionofhypotension
Thedecisionontheoptimalperi-operativestrategyshouldbebased severityandduration.602Itremainstobeestablishedwhethercorrec-
oncloseexchangeofclinicalinformationbetweenanaesthesiologists, tionofintra-operativehypotensionisalsoassociatedwithimproved
cardiologists,surgeons,andotherrelevantspecialists.Inaddition,itis post-operativeoutcome.Todate,onlyonestudyhasspecificallyad-
mandatorythatanyproposedstrategyispresentedtoanddiscussed dressed the question of whether an individualized BP management
withthepatient.Aninformeddiscussionwiththepatientdescribing strategyreducespost-operativecomplicationsinamulticentreRCT
theplannedpatientpathwayandexpectationsduringthepre-,peri-, including292patients.Anindividualizedmanagementstrategyoftar-
andpost-operativephasesofcare,andwhattoexpectfromstaffand getingasystolicBPwithin10%ofthepatient’snormalrestingvaluere-
surroundings,shouldbegivenusingaclear,concise,andsimplede- sultedinsignificantlylowerratesofpost-operativeorgandysfunction
scription. The ESA published Pre-operative evaluation of adults comparedwithstandardpractice(38.1%vs.51.7%,respectively).528
undergoing elective noncardiac surgery: updated Guideline from These findings support the benefits of personalizing care, especially
the European Society of Anaesthesiology in 2018.560 This current insurgicalpatientsathigh-riskofcardiaccomplications.Itisimportant
sectionfocusesonissuesthatarespecificallyimportanttopatients tounderscoretheimportanceofaphysiopathologicalapproachinun-
withCVriskfactorsanddiseases,takingintoaccountthemostre- derstanding the underlying mechanisms of intra-operative hypoten-
centdevelopmentsinperi-operativemanagementofthesepatients. sion, taking into account the extent and severity of the patient’s
comorbidities;onlythenwillatailoredtreatmenttargetingthecause
7.2.1.Intra-operativehaemodynamics ofintra-operativehypotensionbepossible(Figure16).
Mostanaesthetictechniquesreducesympathetictone,leadingtoa Theseverityofintra-operativehypotensionisdefinedbothbythe
decreaseinvenousreturnduetoincreasedcomplianceoftheven- thresholddecreasefrombaselineandthedurationofthehypoten-
oussystem, vasodilatation, and decreased BP. Therefore, mainten- siveepisode.Theunderlyingmechanismsforintra-operativehypo-
ance of adequate organ flow and perfusion pressure is of key tension need to be identified: sympathicolysis with vasodilation,
importance in anaesthesiological management, especially in the hypovolaemia,orothermorecomplexcausessuchasperi-operative
CV-compromised patient. The importance of keeping stable peri- myocardialfailure.Oncetheunderlyingmechanismsareidentified,a
operativehaemodynamicshasbeenrecognizedformanyyears.599 targetedtherapeuticstrategycanbeapplied.Thisincludesconsidering
Inthepastfewyears,severalstudieshavefocusedontherelation- whetheradministrationofspecificchronicvasoactivemedicationsuch
ship between intra-operative hypotension and post-operative asACEIsorARBsshouldbeinterrupted24hpriortosurgery.216
Downloaded
from
https://academic.oup.com/eurheartj/article/43/39/3826/6675076
by
guest
on
22
January
2026
--- Страница 67 ---
3892 ESCGuidelines
Patients with intra-operativehypotension
Defineseverity:
(i)mean blood pressure decrease >20% from baseline
(ii)the duration of thehypotensive episode
Underlying mechanism
Sympathicolysis with Other more
Hypovolaemia
vasodilatation complex causesa
Smooth induction Exclude impaired venous return Advanced diagnosis
AAAvoid‘too deep’ anaesthesia Restore circulating volume Appropriate treatment
positioning (TTTrendelenburg,
legs up)
VVVasoconstriction
(caaave organ perfusion)
Figure16Pathophysiologicalapproachtoaddressintra-operativehypotension.aE.g.peri-operativemyocardialfailure.
A detailed analysis of the strategies for the different chronic CV advisable to consider intra-operative tachycardia as an indicator of
medicationisdiscussedinSection5.Ofnote,post-operativeout- haemodynamicimpairment.
come is not only negatively influenced by the occurrence of
intra-operativehypotension,butalsobyhypotensiveeventsduring 7.2.2.Choiceofanaestheticagent
theinitialfourpost-operativedays.603Foradultnon-cardiacsurgi- Thechoiceoftheanaestheticagenthasbeenconsideredtobeoflit-
calpatients,thereisinsufficientevidencetorecommendageneral tleimportanceintermsofpatientoutcome,providedthatvitalfunc-
upper limit of arterial pressure at which therapy should be in- tions areadequatelysupported. Evidence from surgicalmyocardial
itiated, although pressures .160 mmHg have been associated revascularization studies indicates that a volatile vs. i.v. anaesthetic
withmyocardialinjuryandMI.602 regimenisassociatedwithlesspost-operativetroponinreleasewith-
Intra-operative tachycardia may adversely affect the myocar- out impact on clinical outcomes.599,608 A recent large multicentre
dialoxygenbalanceandthusresultinperi-operativemyocardial randomizedtrialfoundaneutraleffecton12monthmortalityasso-
injury. A retrospective analysis of 41140 patients found that a ciatedwithvolatilevs.i.v.anaestheticregimen.609InNCS,incidence
heart rate ≥90b.p.m. was associated with an increased risk of ofpost-operativecardiaceventsisnotinfluencedbythechoiceofa
myocardialinjury.604Thesefindingsweresimilartoobservations volatileorani.v.anaestheticregimen.610
in the Vascular Events in Noncardiac Surgery Patients Cohort
Evaluation(VISION)trial.605Ananalysisofhigh-risksurgicalpa- 7.3. Locoregional techniques
tients found that an HR .87b.p.m., recorded at rest before Theanalgesiceffectsofneuraxialanalgesiaarewell-established.The
pre-operativecardiopulmonaryexercisetesting,wasstronglyas- mainperi-operativeindicationsforepiduralanalgesiaincludemajor
sociatedwithdistinctCVphenotypes,whichmayexplaintheunin- openabdominalsurgeryandthoracotomy.Possibleadditionalbene-
tended, adverse consequences of non-personalized treatments fitsofepiduralanalgesia,suchasacceleratedrecoveryanddecreased
aimedatreducingintra-operativetachycardiainisolationfromother post-operativecomplications,remainamatterofdebate.611,612
haemodynamicfactors.606Finally,arecentstudyevaluatedtheasso- Neuraxialanalgesiamayinducesympatheticblockade.Whenreach-
ciation between intra-operative tachycardia and a composite of ingthethoracicdermatomelevel4,areductionincardiacsympathetic
post-operativemyocardialinjuryandall-causemortality.Themajor drivemayoccur,withsubsequentreductioninmyocardialcontractil-
finding of this study was the lack of an association between ity,heartrate,andchangeincardiacloadingconditions.Thereareno
intra-operativeheartrate.90b.p.m.andthecompositeoutcome; studies specifically investigating the changes in outcomes related to
HR .80b.p.m. or .100b.p.m. were also not associated with the neuraxial anaesthetic techniques in patients with cardiac disease.
composite outcome.607 Taken together, the assumed association Cardiac patients often take various types of drugs that interfere
betweenintra-operativetachycardiaandadverseperi-operativeout- withcoagulation;therefore,careshouldbetakentoensuresufficient
comeremainsasubjectofongoingcontroversy.However,itseems coagulationabilitywhenneuraxialblocksareapplied.613
Downloaded
from
https://academic.oup.com/eurheartj/article/43/39/3826/6675076
by
guest
on
22
January
2026
--- Страница 68 ---
ESCGuidelines 3893
Currentresearchisfocusingonalternativesforneuraxialanalgesia NSAID use and post-operative MI.632 In contrast, another
with similar effects on peri-operative pain control in patients with meta-analysisofthree randomizedtrialsincluding 2604major sur-
cardiaccomorbiditiesundergoingNCS;theseincludealternativean- gery patients detected a 2.3-fold increase in MACEs in the group
algesic techniques such as i.v. analgesia, continuous wound infiltra- with COX-2 inhibitors. In a position paper, The ESC Working
tion,paravertebralbloc,andselectivenerveblocks. GrouponCardiovascularPharmacotherapyadvisesthatnon-aspirin
NSAIDsshouldgenerallynotbeusedinpatientswithestablishedor
7.4. Peri-operative goal-directed
athighriskofCVD.633
haemodynamic therapy
Goal-directedtherapyaimstooptimizeCVperformance,inorderto
achievenormalorevensupranormaloxygendeliverytotissues,by RecommendationTable33—Recommendationsfor
optimizingpre-loadandinotropicfunctionusingpre-definedhaemo-
peri-operativemonitoringandanaesthesia
dynamic targets. In contrast to clinical signs or arterial
pressure-orientatedstandardtherapy,goal-directedtherapyisbased Recommendations Classa Levelb
onfloworfluidresponsivenessofhaemodynamicvariables,suchas
InordertopreserveoptimalCVstability,itis
strokevolume,responsetofluidchallenges,strokevolumeorpulse
recommendedtoapplygoal-directed
pressure variation, or similar optimization of cardiac output. I A
haemodynamictherapyinpatientsundergoing
Goal-directedtherapywasinitiallybasedontheuseofapulmonary high-riskNCS.614–618
arterycatheter.Less-invasivetechniqueshaverecentlybeendevel-
Itisrecommendedtoavoidpost-operativeacute
oped,including:transoesophagealDoppler,transpulmonarydilution I B
pain.614
techniques, and advanced pressure waveform analysis. Early goal-
directedfluidtherapy—intherightpatientcohortandwithaclearly Inordertominimizetheriskofpost-operative
definedprotocol—hasbeenshowntodecreasepost-operativemor- organdysfunction,itisrecommendedtoavoidan
talityandmorbidity.614–618 intra-operativemeanarterialpressuredecreaseof I B
.20%frombaselinevaluesor,60–70mmHgfor
≥10min.214,600–602,634
7.5. Post-operative management
Non-aspirinNSAIDsarenotrecommendedas
Severalstudieshavedemonstratedthatitispossibletostratifythe first-lineanalgesicsinpatientswithestablishedor III B
riskofpost-operativecomplicationsandmortalitywithasimplesur- highriskofCVD.633,635
gicalApgarscore.Thispost-eventstratificationmightenablepatients
to be redirected to higher-intensity care units. The importance of CV,cardiovascular;CVD,cardiovasculardisease;NCS,non-cardiacsurgery;NSAID,
non-steroidalanti-inflammatorydrug.
such risk stratification is underscored by the results of the EuSOS aClassofrecommendation.
group.Inthis7daycohortstudy,46539consecutiveadultNCSpa- bLevelofevidence.
tients in 498 hospitals across 28 European nations were included:
1855patients(4%)diedbeforehospitaldischargeand1358(73%)
ofthosepatientswerenotadmittedtocriticalcareatanystageafter
8. Peri-operative cardiovascular
surgery.7Thisconceptoffailure-to-rescuehasgainedalotofatten-
tioninperi-operative medicineinthelast fewyearsand strategies complications
havebeenproposedtoaddressthisissue.619–622
Severepost-operativepainoccursin5–10%ofpatients,increases SpecificchallengesapplytodetectingCVcomplicationsthatoccur
sympatheticdrive,anddelaysrecovery.623,624Arecentstudydemon- peri-operatively.First,duetoanaesthesiaandanalgesia,PMI,which
stratedthattime-weightedaveragepainscoreswithin72haftersur- isthemostcommonCVcomplication,islargelyasymptomaticin
geryweresignificantlyassociatedwithmyocardialinjuryinpatients (cid:4)90%ofpatientsandisthereforemissedinroutineclinicalprac-
undergoingNCS;625thisfindingunderscorestheimportanceofef- tice in the absence of surveillance for PMI.41,101,111,413,636–641
fectivepost-operativeanalgesiatoreducepost-operativeCVrisk. Second, post-operative pain, nausea, surgical wounds, and drains
The place ofnon-steroidal anti-inflammatory drugs (NSAIDs) in mayinterferewiththeearlyidentificationofacutecardiacdisor-
thetreatmentofpost-operativepainincardiacpatientsundergoing ders, such as PMI, Takotsubo syndrome, tachyarrhythmias, and
NCSisapointofdebate.Diclofenachasbeenshowntocarrythe acute HF. Third, cardiologists are usually not directly involved in
highestCVriskofanyofthenon-selectiveNSAIDs.626,627TheCV post-operativecare;therefore,theearlydetectionandearlytreat-
riskofibuprofenseemstobecomparablewiththatofcelecoxib.628 mentofcardiaccomplicationsisperformedbynon-cardiologists,
NaproxenhasabetterCVsafetyprofilethandiclofenacandibupro- sometimeswithlittletrainingintheearlydetectionofacutecar-
fen.629,630Onerandomizedtrialfoundthatparecoxibandvaldecoxib diacdisorders.Giventherelativelyhighprevalenceofcardiaccom-
did not increase thromboembolic events in patients undergoing plications,theirhighmorbidityandmortality,andtheavailabilityof
NCS. A meta-analysis of 32 randomized trials did not find an in- effective therapy, high awareness combined with surveillance for
creased CV risk when comparing parecoxib/valdecoxib with pla- PMI in high-risk patients (known CAD, PAD, insulin-dependent
cebo,631 and a single-centre observational study with .10000 DM, or symptoms suggestive of cardiac disorders) undergoing
patients undergoing arthroplasty found no association between intermediate- or high-risk NCS is recommended to overcome
2202CSE©
Downloaded
from
https://academic.oup.com/eurheartj/article/43/39/3826/6675076
by
guest
on
22
January
2026
--- Страница 69 ---
3894 ESCGuidelines
Factors associated with peri-operative cardiovascular complications
Patient-related factors
Chronic: (Sub)-Acute:
Age >75 years Acute coronary syndrome
Coronary artery disease Acute aortic syndrome
Heart failure Acute stroke
Severe aortic stenosis Acute trauma (e.g. hip fracture)
Peripheral arterial disease
Cerebrovascular disease
Renal insufficiency
Diabetes, anaemia
Procedure-related factors (surgery and anaesthesia):
Urgency of the procedure,hypotension,hypercoagulability,
bleeding inflammation, tachycardia,hypothermia, SNS stimulation
Post-operative factors:
Hypotension, bleeding,
hypoxaemia, tachycardia, pain
Cardiovascular complications:
Type 1 myocardial infarction
Type 2 myocardial infarction
Acute heart failure, arrhythmias
Pulmonary embolism
Stroke
Cardiovascular death
Figure17Factorsassociatedwithperi-operativecardiovascularcomplications.SNS,sympatheticnervoussystem.
these
challenges.41,101,109–111,118,413,636–639,642,643
All measures rapidly detected using PMI surveillance with hs-cTn T/I measure-
needtobecarefullyalignedwiththeresponsiblesurgeon. ments before and serially after surgery (e.g. 24 and 48h post-
Chroniccardiacdisorders,suchasCAD,seemtoprovideasub- operatively). In the BASEL-PMI study, circa 15% of patients with
strateforcardiaccomplicationsduringandaftersurgery.41,413,636,637 pre-existingCAD/PADoraged.65yearsundergoingmajorNCS
Several related chronic conditions (e.g. diabetes and renal insuffi- developedPMI.8AsmostPMIoccursduringtheoperationitselfor
ciency),whicharelikelytobesurrogatesforundiagnosedcardiacdis- in the immediate post-operative period, during which high doses
ease, are also strongly associated with peri-operative cardiac of anaesthetics and/or analgesics are required, (cid:4)90% of patients
complications(Figure17).41,413,636,637 with PMI do not report typical symptoms and are therefore
Acuteconditionssuchastrauma,surgery,andanaesthesiaitselfin-
missedinroutineclinicalpractice.41,101,111,413,636–639Thisisofmajor
duce activation of the sympathetic nervous system, inflammation, concern, as the mortality risk associated with PMI is also high in
stress,hypercoagulable,andcatabolicstates,allofwhichmaytrigger patients without
symptoms.41,101,111,413,636–639
Similarly, the
cardiac complications.41,413,636,637 While the risk of CV complica- mortality risk associated with PMI is high in patients without add-
tions after NCS is highest in the immediate peri-operative period, itional ECG and/or imaging evidence of myocardial ischae-
itseemstoremainincreasedforaprolonged‘vulnerableperiod’of mia.8,41,101,109–111,118,413,564,636–639,641 Overall, 30 day mortality in
3–5months.8 patients developing PMI is (cid:4)10%.8,41,101,109–111,118,413,564,636–639,641
No single intervention has yet been proven to be unequivocally
beneficialinthepreventionofPMI.185,644
8.1. Peri-operative myocardial
ItisimportanttohighlightthatPMIisnotahomogenousdisease.
infarction/injury Several different pathophysiologies and clinical phenotypes may
Peri-operative MI (PMI) is defined as acute cardiomyocyte injury underliePMI(Figure18).Atleastoneadditionalcriterion(ischaemic
(post-operative hs-cTn T/I release) with or without accompanying pain;ischaemicECGchanges;imagingevidenceofnewlossofviable
symptoms,andwithorwithoutECGorimagingevidenceofacute myocardium,ornewregionalwallmotionabnormalityinapattern
myocardial ischaemia. Peri-operative MI can only be reliably and consistent with an ischaemic aetiology; and thrombus in coronary
Downloaded
from
https://academic.oup.com/eurheartj/article/43/39/3826/6675076
by
guest
on
22
January
2026
--- Страница 70 ---
ESCGuidelines 3895
Myocardial injury cTnT
cTn l
CK
Day 1 or 2 after the NCS
Cardiac troponin
Chronic cardiac troponin Acute cardiac troponin = PMI
Primarily Cardiac cause
non-cardiac
Tachy- Acute heart Likely
Type 1 MI Type 2 MI
cause arrhythmia failure type 2 MI
Severe sepsis Athero- Supply demand Supply demand Multiple Missed
Pulmonary embolism thrombosis mismatch with mismatch mechanisms type 1 MI
Stroke obvious type 2 Undocumented
trigger hypotension
(hypotension, Mild
anaemia) hypotension
Figure18Differentialdiagnosisofelevatedpost-operativecardiactroponinconcentrations.CK,creatininekinase;cTnl,cardiactroponinI;cTnT,
cardiactroponinT;MI,myocardialinfarction;PMI,peri-operativemyocardialinfarction/injury.Pleasebeawarethattheaccuracyofphysicians’judgement
intheclassificationoftype-1vs.type-2MIintheperi-operativesettingmaybelowervs.thenon-operativesetting.647
angiography)isrequiredforpatientswithPMItoalsomeetthedef- ischaemia (i.e. secondary to supply–demand mismatch or throm-
inition of peri-operative myocardial infarction, according to the bosis), in the absence of an atypical surgical physiological stress,
fourth universal definition.643 Because is often initially unclear andnoevidenceofacardiacnon-CADaetiology,e.g.rapidAF,acute
whether the patient will end up fulfilling the criteria for peri- HF).101,109,638,641,642,645,646Inapproximatelyhalfofallpatientswith
operativemyocardialinfarction,thebroadtermPMIispreferredin PMI,theunderlyingpathophysiologycannotbereliablyascertained
the initial assessment. In order to properly interpret the aetiology based on the commonly available documentation and is assumed
ofelevatedpost-operativehs-cTnT/Iconcentrations,abaselinepre- tobelikelytype-2MIduetoundocumentedorrelativehypotension,
operativeconcentrationisnecessarytodeterminewhetherthein- butmayalsoincludemissedtype-1MI,ormissedPEincasesinwhich
creaseisacuteorchronic(seeSection4).643Toidentifytheunder- CTangiographyhasnotyetbeenperformedpost-operatively.110,647
lying pathophysiology and define causal therapy, systematic ItisthereforeimportanttohighlightthatPMIsurveillancealsofacil-
work-up and early differentiation of primarily non-cardiac causes itatesthedetectionofprimarilynon-cardiacdisorderswithimmedi-
(e.g. severe sepsis, PE) vs. the different cardiac causes—including atetherapeuticconsequences,suchasPE,thatwouldotherwisehave
type-1MI,type-2MI,tachyarrhythmia,andacuteHF—isofmajorim- beenmissed.
portance (Figures 18 and 19). Transthoracic echocardiography is The prevalence of PMI depends on patient-related, procedural-
helpfulinthework-upofmostpatientswithPMI. related,andpost-operativefactors,andtherequiredminimumextent
ThetermmyocardialinjuryfollowingNCS(MINS)hasbeenused of acute myocardial injury, quantified by absolute increase in
foraselectedsubsetofpatientswithcardiacPMI,inwhomcardio- hs-cTn T/I (e.g. the 99th percentile ULN) above the pre-operative
myocyteinjurywasdeemedmostlikelyduetoCADwithmyocardial hs-cTn T/I
concentration.8,41,101,109–111,118,413,564,636–639,641,648
Downloaded
from
https://academic.oup.com/eurheartj/article/43/39/3826/6675076
by
guest
on
22
January
2026
--- Страница 71 ---
3896 ESCGuidelines
Systematic work-up and treatment of peri-operative myocardial injury/infarction
Step 1
12-lead ECG, symptoms, and haemoglobin
Immediate transfusion
ST or ST or
Y Severe anaemiaa Y Type 2 MI followed by
typical chest pain
reassessment for ICA
N ICA, aspirin,c
N Type 1 MI statin, monitoring
(Class I)
Step 2
Transthoracic
echocardiography
Tachyarrhythmia (type 2 MI)
Other cardiac cause Y Acute heart failure (injury) Treat cause
Aortic valve stenosis (injury)
N
Step 3
Non-cardiac cause Y Sepsis, pulmonary embolism, stroke (injury) Treat cause
N
Step 4
Severe anaemiaa
(Hb <80 g/L)
Y Type 2 MI Treat cause
Severe (documented)
hypotensionb
N
Step 5
Relative or
Aspirin,d statin,
undocumented Y Type 2 MI or missed type 1 MI
stress imaging/CCTA/ICA
hypotensionb
Figure19Systematicwork-up(aetiology)andtherapyofperi-operativemyocardialinfarction/injury.CCTA,coronarycomputedtomographyangi-
ography; ECG, electrocardiogram; Hb, haemoglobin; ICA, invasive coronary angiography; MI, myocardial infarction; N, no; ST, ST-segment. Y, yes;
Mostpatientswithtype-2MIandsilenttype-1MIshouldbescheduledforstressimagingorCCTA/ICAasoutpatientsafterdischarge,dependingon
symptomspriortooraftersurgeryandknownCAD.aOractivebleeding.bOrothertype-2MItriggersuchashypoxaemia,tachycardia,hypertension.
cDualantiplatelettherapyaftercoronarystenting.dPossiblyincombinationwithdabigatran110mgb.i.d.
An absolute increase in more than the ULN above pre-operative lowermortality.649Mortalitysubstantiallydiffersamongthedifferent
concentrations has consistentlybeen shown to be associated with phenotypes:30dayall-causemortalityandthecompositeof30day
arelevantincreasein30dayandlong-termmortality,andothernon- CVdeath,life-threateningarrhythmia,acuteMIoccurringafterday3,
fatal post-operative cardiac complications, and can easily be and cardiac decompensation are highest in patients with acute HF
determined for each hs-cTn T/I assay. This threshold is therefore andprimarilyextra-cardiacPMI,suchasseveresepsisorPE,inter-
recommended for clinical
use.8,41,101,109–111,118,413,564,636–639,641,648
mediatefortype-1MIandtachyarrhythmias,andmodestlyelevated
However, further studies are warranted regarding optimal thresh- inlikelytype-2MI.110Type-2MIpatientsareusuallytreatedasfor
olds. Emerging data suggest that surveillance for PMI is type-1MI,althoughtheevidenceforthisislimited.
cost-effective.117,119 Inarandomized,placebo-controlledtrial,1754patients(meanage
Identificationofthemostlikelypathophysiologyiscriticalforse- 70years)whohaddevelopedMINSafterNCS(mainlyorthopaedic,
lectionofthemostappropriatetherapy.Evidencefromalargesingle- general,andvascularsurgery) were randomlyassigned (1:1) tore-
centreretrospectivecohortsuggeststhatinvolvementofacardiolo- ceivedabigatran110mgorallyb.i.d.ormatchedplacebowithin35
gistinthework-upandtherapyofthesepatientswasassociatedwith days of MINS;650 60% of patients were already on aspirin or a
Downloaded
from
https://academic.oup.com/eurheartj/article/43/39/3826/6675076
by
guest
on
22
January
2026
--- Страница 72 ---
ESCGuidelines 3897
P2Y inhibitor. The median peak measured hs-cTn concentration renal insufficiency, MI, and post-operative infection.322
12
associated with the diagnosis of MINS was 82 ng/L. More than Stratification of the extent of embolism (e.g. massive, submassive,
90% of MINS events occurred without a clinical symptom or sign and subsegmental; high risk, intermediate high/low risk, and low
of cardiac ischaemia. Dabigatran/placebo was initiated a median of risk) is important to predict mortality and guide therapeutic strat-
6daysaftertheoperationandtheaveragetimeonstudydrugwas egy.652 Pulmonary embolism should be suspected in patients with
(cid:4)9 months. Among patients with MINS randomly assigned to re- PMI without a clear cause. Close haemodynamic monitoring and
ceivedabigatran(n=877)orplacebo(n=877),thecompositepri- monitoringofRVfunction(echocardiography,CT)isessentialtode-
maryefficacyoutcomeofamajorvascularcomplication—including terminewhichPEpatientsrequireaggressivetherapy.Thereiscur-
vascularmortality,MI,non-haemorrhagicstroke,peripheralarterial rentlyalackofevidenceregardingadequateantithrombotictherapy
thrombosis,amputation,andsymptomaticVTE—occurredinfewer in patients with post-operative PE, since recent major surgery or
patientsrandomizedtodabigatranthanplacebo(97[11%]of877pa- traumawasacontraindicationinprevioustrialsofthrombolyticor
tientsassignedtodabigatranvs.133[15%]of877patientsassigned anticoagulant therapy.653 Small case series support the use of sys-
to placebo; HR, 0.72; 95% CI, 0.55–0.93; P=0.0115). There was temicthrombolysis,surgicalthrombectomy,654orcatheter-directed
noincreaseinmajorbleeding.Basedonthesedata,inpatientswith therapies in massive PE. In general, anticoagulation, preferably
MINSandatlowriskofbleeding,initiationofdabigatran110mgor- LMWHorfondaparinux,shouldbeinitiatedasearlyaspossible.652
allyb.i.d.maybeconsideredabout1weekafterNCS. Oral anticoalgulant therapy, preferably NOAC due to the lower
bleedingrisk,shouldbeinitiated,dependingonpost-operativerenal
8.2. Spontaneous myocardial infarction function and bleeding risk, as early as possible for at least 3
(after day 2)
months.652
Rescue thrombolytic therapyisrecommendedfor patients with
Theincidenceofpost-operativespontaneousMIafterday2seemstobe
about0.5%within30days,and1–2%within365daysforpatientsunder- PE and haemodynamic deterioration on anticoagulation treatment
goingmajorNCSwithestablishedCAD,PAD,oraged.65years.8 in the post-operative phase, if possible, according to bleeding
Intheimmediatepost-operativeperiod(,5days),bleedingisama-
risk.652AsanalternativetothrombolytictherapyformassivePE,sur-
gical embolectomy or percutaneous catheter-directed treatment
jorconcernandlimitstheuseofantiplateletandanticoagulantther-
shouldbeconsideredforpatientswithhaemodynamicdeterioration
apy, depending on the site and extent of surgery. Otherwise, the
onanticoagulationtreatment,particularlyinpatientswithhighbleed-
sameprinciplesasforMItherapyshouldgenerallybeappliedfollow-
ingrisk.
ingtherecommendationsofspecialityguidelines.98,171
8.3. Takotsubo syndrome 8.6. Atrial fibrillation and other relevant
The incidence of peri-operative Takotsubo syndrome remains un- arrhythmias
known,asnoneofthestudieswithPMIscreeningusedechocardiog- Post-operativeAFisdefinedasnew-onsetAFintheimmediatepost-
raphyinallpatientsduringPMIwork-up.Increasedawarenessinthe operativeperiod;itsincidencerangesbetween2–30%,withpeakin-
non-operativesettinghasledtoasubstantialincreaseinthedetec- cidence2–4dayspost-operatively.655,656
tion of Takotsubo syndrome, and the use of TTE in the work-up Although many post-operative AF episodes are self–terminating
ofPMI is stronglyencouraged. Anecdotal evidence suggeststhat it andsomeareasymptomatic,post-operativeAFhasbeenassociated
islikelythattheincidenceisalsohigherthanexpectedintheperi- withafour-tofive-foldriskofAFrecurrenceinthe5yearsfollowing
operativesetting.8,41,101,109–111,118,413,564,636–639,641,644
cardiacsurgery,whiletheriskofrecurrenceafterNCSislesswellde-
scribed.656–660
Importantly, post-operative AF is a risk factor for
8.4. Acute heart failure stroke, MI, and death compared with non-post-operative AF pa-
Theincidenceofpost-operativeacuteHFseemstobe1–2%within tients.656,658,661Post-operativeAFmayalsoleadtohaemodynamic
30daysand4–6%within365daysinpatientswithestablishedCAD, instability, prolonged hospital stay, infections, renal complications,
PAD,oraged.65yearsundergoingmajorNCS.8Pre-existingdiag- bleeding, increased in-hospital death, and greater healthcare
nosed or undiagnosed chronic HF and volume loading in the peri-
costs.662–664Theessentialprinciplesofthepreventionandmanage-
operative and post-operative periods are important contributors. mentofpost-operativeAFareoutlinedinFigure20.
In the absence of studies specifically investigating acute HF post-
operatively, the general principles of acute HF diagnostic work-up 8.6.1.Preventionofpost-operativeatrial
andtherapyshouldbeapplied.651 fibrillation
Pre-operativeuseofbeta-blockersisassociatedwithreducedin-
8.5. Venous thromboembolism cidence of post-operative AF,204,665–667 but not major adverse
The incidence of VTE in the peri-operative phase is currently un- events such as death, stroke, or AKI.668 Importantly, in a large
known and likely underreported due to the lack of systematic RCT, peri-operative metoprolol was associated with increased
screening methods and the limited validity of diagnostic tools (e.g. mortality risk.185 In a meta-analysis, amiodarone (oral or i.v.)
D-dimer, typical pain symptoms) in this setting. It is associated was equally effective in reducing post-operative AF as beta-
withhighperi-operativemortality((cid:4)17%).322Riskfactorsforpost- blockers,207 whereas their combination was better than beta-
operativeVTE/PEincludetypeofsurgery(e.g.high-riskhiparthro- blockers alone.208 Lower cumulative doses of amiodarone
plasty, open prostatectomy, open surgery for malignancy), acute
(,3000mg)maybeeffective,withfeweradverseevents.669–671
Downloaded
from
https://academic.oup.com/eurheartj/article/43/39/3826/6675076
by
guest
on
22
January
2026
--- Страница 73 ---
3898 ESCGuidelines
Pre-operative
Optimize haemodynamics
prevention ofAF
Correct electrolyte imbalance
Identify patients at increased risk for post-operativeAF
PharmacologicalAF prophylaxis:
Continue beta-blockers (if chronic therapy)
OtherAADs in selected patients
Peri-operatively
Management of patients with intra- and post-operative AF
Haemodynamic Emergency
Y
instability cardioversion
N
Systemic
Rate control |Target
anticoagulationa
restingHR <110 b.p.m.
Rhythm control AADs(optional)
Preserved LVEF: (electrical or
Normal LVEF:
beta-blocker, CCB Symptomatic or pharmacological
and/or digoxinb N difficultrate control Y cardioversion) Class I or III
Reduced LVEF:
Reduced LVEF:
Amiodarone
beta-blocker
and/or digoxinb
Optimize fluid balance,oxygenation, and pain control
Minimize inotropes and vasopressors
Continue pre-operative pharmacological prophylaxis
Discharge
Individualized follow-up planc
Re-assessment for rhythm andAADs
Long-term OAC in patients at risk of stroke (balanced with bleeding risk)
considering the anticipated net clinical benefit of OAC and informed patient preferences
(Class IIa)
Figure20Preventionandmanagementofpost-operativeatrialfibrillation.AAD,antiarrhythmicdrug;AF,atrialfibrillation;b.p.m.,beatsperminute;
CCB,calciumchannelblocker;HR,heartrate;LVEF,leftventricularejectionfraction.N,no;Y,yes.aDependingontheCHA DS VASC-score,andpost-
2 2
operativebleedingrisk.bIntheacutepost-operativephase,unlessbloodpressureishigh,combinationoflow-dosebeta-blockerandloadingwithdigoxinis
preferred to avoid hypotension. cShould include a cardiology visit before month 3. Adapted from the 2020 ESC Guidelines on the Diagnosis and
ManagementofAtrialFibrillation.99
Data for other interventions—such as statins,672,673 magnesium,674 patients with post-operative AF, ensuring optimal ventricular rate
sotalol,666colchicine,675orcorticosteroids676—arenotrobust.677,678 controlduringthearrhythmiaismandatory(using,forexamplebeta-
blockersorverapamil,asneeded).Aspost-operativeAFisoftenself-
8.6.2.Managementofpost-operativeatrial terminating, non–emergent cardioversion may not be needed. If
fibrillation performedinpatientswithAFlasting≥48h,non-emergencycardi-
8.6.2.1.Rateand/orrhythmcontrol oversionofpost-operativeAFshouldfollowtheprinciplesofperi-
In haemodynamically unstable patients with post-operative AF, an cardioversion thromboprophylaxis (that is, can be performed only
emergentelectricalorpossiblypharmacological(i.e.i.v.administra- after the left atrial thrombosis is excluded by TEE or postponed
tionofamiodarone666orvernakalant,679ifconsistentwiththeclinical for3weeksoftherapeuticOACtherapy).Ofnote,aRCTofpatients
situation) cardioversion is indicated.99 In haemodynamically stable withpost-operativeAFaftercardiacsurgeryshowednonetclinical
Downloaded
from
https://academic.oup.com/eurheartj/article/43/39/3826/6675076
by
guest
on
22
January
2026
--- Страница 74 ---
ESCGuidelines 3899
advantageofrhythm(i.e.achievingandmaintenanceofsinusrhythm) hypotension and/or severe stenosis ofthe cervicocranial vessels—
vs.ratecontrolstrategy.680Therefore,rateorrhythmcontroltreat- isanunusualcauseofperi-operativestroke.690Rarely,peri-operative
ment decisions in patients with haemodynamically stable post- strokemaybeduetoair,fat,orparadoxicalembolisms.
operativeAFshouldbebasedonpatient’ssymptomsandsharedin- Inanattempttoattenuatetheriskofperi-operativestroke,anti-
formedtreatmentdecision-making.99 platelet/anticoagulant treatments should be continued whenever
possible throughout the peri-operative period. Alternatively, the
8.6.2.2.Preventionofatrialfibrillation-relatedthromboembolic
periodofdrugwithdrawalshouldbekeptasshortaspossible,while
complications weightingthromboembolicandhaemorrhagicrisks(seeSection5.2).
Inallpatientswithpost-operativeAF,itshouldbeconsideredtoini- Adequateselectionoftheanaesthetictechnique(regionalvs.neurax-
tiate therapeutic anticoagulation as soon as possible during in- ialvs.generalanaesthesia),preventionandtreatmentofAF,euglycae-
hospital treatment, depending on the individual stroke risk miccontrol(avoidingbothhyperglycaemiaandhypoglycaemia),and
(CHA DS -VASc) and the bleeding risk after surgery. In a large meticulousperi-operativecontrolofBPmayallcontributetoredu-
2 2
meta-analysis,patientswithpost-operativeAFhad62%higherrisk cingtheriskofperi-operativestroke.
ofearlystrokeand37%higherriskoflong-termstrokecompared Ifpost-operativestrokeoccurs,itmusttriggerimmediateaction:
with patients without post-operative AF (long-term stroke rates angio-CT and neurology/neurosurgical consultation with the goal
were 2.4% in post-operative AF vs. 0.4% in patients without AF), torestoreflowinthecaseofacutethromboticocclusion.
anda44%and37%higherriskofearlyandlong-termmortality,re-
spectively.661Importantly,post-operativeAFwasmorestronglyas-
sociatedwiththelong-termstrokeriskinpatientsundergoingNCS RecommendationTable34—Recommendationsfor
(HR, 2.00; 95% CI, 1.70–2.35) than in patients undergoing cardiac peri-operativecardiovascularcomplications
surgery(HR,1.20;95%CI,1.07–1.34;P,0.0001).661
Evidenceontheeffectsoflong-termOACtherapyforthepre- Recommendations Classa Levelb
vention of stroke or systemic embolism in patients with post-
Itisrecommendedtohavehighawarenessof
operative AF is from observational
studies.664,681–685
In a recent
peri-operativeCVcomplications,combinedwith
study,post-operativeAFfollowingNCSwasassociatedwithsimi- surveillanceforPMIinpatientsundergoing I B
lar long-term thromboembolic risk as common, non-surgical AF, intermediate-orhigh-riskNCS.41,101,109–
and OAC use was associated with comparable lower risk of 111,118,413,636–639
thromboembolism and all–cause mortality in both groups (mean
SystematicPMIwork-upisrecommendedto
CHA 2DS 2-VASc-score3.0+1.7).686 identifytheunderlyingpathophysiologyanddefine I B
Basedontheavailableevidence,long-termOACshouldbeconsid- therapy.41,101,109–111,118,413,636–639
eredinallpatientswithpost-operativeAFatriskofstroke.Ifantic-
Itisrecommendedtotreatpost-operativeSTEMI,
oagulation is parenterally initiated, LMWH or fondaparinux is
NSTE-ACS,acuteHF,andtachyarrhythmiasin
recommended(overUFH)formostpatients.Non-vitaminKantag-
accordancewithguidelinesforthenon-surgical I C
onist oral anticoagulants should be preferred over VKA for long-
setting,afterinterdisciplinarydiscussionwiththe
termtreatment.Re-evaluationofthecontinuationofOACmaybe
surgeonaboutbleedingrisk.98,99,171,651,652
performed after a period of 3 months. A small RCT (ASPIRE-AF;
Inpatientswithpost-operativePEofhighor
NCT03968393)ontheoptimallong-termOACuseamongNCSpa-
intermediateclinicalprobability,initiationof
tientsdevelopingpost-operativeAFisongoing.
anticoagulationisrecommendedwithoutdelay, I C
8.7. Peri-operative stroke whilediagnosticwork-upisinprogress,ifbleeding
riskislow.650,652
With respect to NCS, peri-operative stroke has been reported in
0.08–0.70%ofpatientsundergoinggeneralsurgery,0.2–0.9%ofpa- Post-operativeoralanticoagulationforPEis
tients requiring orthopaedic surgery, 0.6–0.9% of lung operations, recommendedtobeadministeredforaperiodof I C
and0.8–3.0%ofsurgeriesinvolvingtheperipheralvasculature.687,688
atleast3months.99,650
Theassociatedmortalityrangesfrom18–26%.687,688Amorerecent Inpatientswithapost-operativeindicationfor
OAC,NOACisgenerallyrecommendedover I A
analysisof523059patientsundergoingNCSreportedalowerinci-
VKA.99
dence of peri-operative stroke (0.1%), although the occurrence of
thisadverseeventwasassociatedwithaneight-foldincreaseinperi- Inpatientswithpost-operativeAFafterNCS,
operativemortalitywithin30days,correspondingtoanabsoluterisk long-termOACtherapyshouldbeconsideredin
increase of .20%.689 Peri-operative stroke is mainly ischaemic or allpatientsatriskofstroke,consideringthe IIa B
cardioembolic, and AF is often the leading underlying condition.
anticipatednetclinicalbenefitofOACtherapy,
Triggersincludewithdrawalofanticoagulationandthehypercoagul-
andinformedpatientpreferences.99,682,683,685,686
able state related to surgery. Additional aetiologies include ather- InpatientswithMINSandatlowriskofbleeding,
oembolism, originating from the aorta or the supra-aortic vessels, treatmentwithdabigatran110mgorallyb.i.d.may IIb B
andlocalatherothrombosisinthepresenceofintracranialsmallves-
beconsideredfrom(cid:4)1weekafterNCS.650
sel disease. Hypoperfusion—related to peri-operative arterial Continued
Downloaded
from
https://academic.oup.com/eurheartj/article/43/39/3826/6675076
by
guest
on
22
January
2026
--- Страница 75 ---
3900 ESCGuidelines
Routineuseofbeta-blockerforthepreventionof (cid:129) Itisimportanttoclearlyandconciselycommunicatewithpatients,
post-operativeAFinpatientsundergoingNCSis III B withsimpleverbalandwritteninstructions,aboutchangesinmedi-
notrecommended.185,201 cationinthepre-andpost-operativephases.
(cid:129) Management in the peri-operative phase of NCS aims to avoid
AF, atrial fibrillation; b.i.d., twice a day; CV, cardiovascular; HF, heart failure; MI, haemodynamicimbalance,whileensuringsufficientcardioprotec-
myocardial infarction; MINS, myocardial injury following non-cardiac surgery; NCS,
non-cardiacsurgery;NOAC,non-vitaminKantagonistoralanticoagulant;NSTE-ACS, tiveaction.
non-ST-elevationacutecoronarysyndrome;OAC,oralanticoagulant;PE,pulmonary (cid:129) Healthcareprovidersarerecommendedtohavehighawarenessof
embolism; PMI, peri-operative myocardial infarction/injury; STEMI, ST-segment
peri-operative CV complications combined with surveillance for
elevationmyocardialinfarction;VKA,vitaminKantagonist.
aClassofrecommendation. PMI in high-risk patients undergoing intermediate- or high-risk
bLevelofevidence. NCS.
(cid:129) Routine assessment of treatmentqualitythrough specificindica-
torsisimportantto documentandmeasure thesuccessofpre-
9. Key messages ventiveandtherapeuticstrategiesinpatientsundergoingNCS.
(cid:129) TheoccurrenceofCVcomplicationsintheperi-operativephase
10. Gaps in evidence
ofNCShasadramaticimpactonprognosis.
(cid:129) TheriskofCVcomplicationsinpatientsundergoingNCSisdeter- (cid:129) Theagecut-offforindividuals(consideredtobecardiovascularly
minedbypatient-relatedfactors,typeofsurgeryorprocedure,and healthy)benefitingfromriskstratificationwork-outbeforeNCS
thecircumstancesunderwhichsurgerytakesplace(electivevs.emer- needstobeevaluated.
gencyprocedure;localortertiaryhospital). (cid:129) Furtherstudiesareneededtocharacterizeoutcomedifferencesin
(cid:129) Specificpatient-relatedriskfactorsmaybereducedbyadequate NCSbetweenmenandwomen,andbetweendifferentcountries,
pre-operativeriskassessmentandinitiationofeffectiverisk-reduction inordertoindividualizeperi-operativemanagementandimprove
strategies. patientsafety.
(cid:129) Thequantificationofsurgicalriskaslow,intermediate,andhighis (cid:129) Evidence on the additive value of cardiac biomarkers, hand-held
helpfulinidentifyingthegroupofpatientswhoshouldmostbenefit ultrasound,problemFOCUS,andstressechocardiographyforcar-
frompreventive,diagnostic, andtherapeuticapproachesto con- diac risk stratification of patients scheduled for NCS presenting
comitantCVconditions. with previously unknown cardiac murmur, dyspnoea, oedema,
(cid:129) Properselectionoftypeandtimingofthesurgicalproceduremay andchestpainisstilllacking.TheimpactofFOCUSonoutcomes
reducetheriskofcomplications. ofurgentortime-sensitivesurgeryneedsfurtherinvestigation.
(cid:129) Itisimportantthatpatients’values,qualityoflife,andpreferences (cid:129) The impact of stress imaging (echocardiography or MRI) before
regardingthebenefitsandrisksofsurgeryaretakenintoconsider- NCS on reduction of peri-operative CV complications in non-
ation,andthatwell-informedpatientsareinvolvedinthedecisions. ischaemicheartdiseasesneedsfurtherresearch.
Riskshouldbecommunicatedtothepatientinabsoluteterms(e.g. (cid:129) Theroleofrightheartcatheterizationinpatientswithadvanced
1outof100). HF or patients with severe pulmonary hypertension undergoing
(cid:129) Clinical examination, patient-reported functional capacity, and NCSisunknown.
non-invasivetestsrepresentthecornerstoneofpre-operativecar- (cid:129) Itisunknownwhetherartificialintelligence-basedsystemsfacilitate
diacassessment. prompt detection and response to imminent adverse events in
(cid:129) Instrumental and functional cardiac examination tools should be high-riskcardiacpatientsundergoinghigh-riskNCS.
selectedinviewofthesurgicalrisk,relativediagnosticproficiency, (cid:129) Systematic and structured research to investigate pathophysi-
andhealthcareresourceutilizationandcosts. ology, causes, and time distribution of serious peri-operative ar-
(cid:129) The peri-operative evaluation of elderly patients who require rhythmiceventsamongpatientsundergoingNCSisstillneeded.
electivemajorNCSshouldincludefrailtyscreening,whichhaspro- (cid:129) Strategiesfortimingofpre-operativeCIEDcontroldependenton
ventobeanexcellentpredictorofunfavourablehealthoutcomes devicetype,urgency,andtypeofNCS,andriskofEMIduringNCS
intheoldersurgicalpopulation. needtobedevelopedtoensuremaximalpatientsafety.
(cid:129) Treatmentofpre-existingornewlydiagnosedCVconditions(e.g. (cid:129) Benefit of routine myocardial revascularization of high-risk CCS
coronary and peripheral vascular disease, rhythm disorders, and patients(exceptleftmainorthree-vesselCAD,reducedLVfunc-
HF) should be individualized according to the pre-operative risk tion) before elective intermediate- and high-risk NCS is not
of NCS, and considering the recommendations of speciality well-established.
guidelines. (cid:129) Moreevidenceregardingtheneedforbridgingofanticoagulation
(cid:129) Amultidisciplinaryapproachtoevaluatewhetherthetreatment inpatientswithMHVsisneeded.
of concomitant cardiac conditions before scheduled NCS im- (cid:129) Thereisalackofevidenceregardingtheoptimalstrategiesbefore
proves peri-operative safety without unnecessary delay is emergent or time-sensitive NCS for patients on antithrombotic
encouraged. treatment at high risk of thromboembolic events, including the:
(cid:129) Efficientperi-operativemanagementofantithrombotictherapies (i) use of extracorporeal haemoperfusion or NOAC antidotes
inpatientsscheduledforNCSaimstoofferthepotentialbenefit (ongoingtrialNCT04233073);(ii)useofalbumin,extracorporeal
of preventing thrombotic events without excessive bleeding haemoperfusion,orPB2452-specificantidotetoantagonizedtica-
complications. grelor (ongoing trial NCT04286438 for PB2452); and (iii)
2202CSE©
Downloaded
from
https://academic.oup.com/eurheartj/article/43/39/3826/6675076
by
guest
on
22
January
2026
--- Страница 76 ---
ESCGuidelines 3901
premature cessation or bridging during interruption of oral womenthanmen,andtheriskofundetecteddiseasecouldtherefore
P2Y12-receptorinhibitors(glycoproteinIIb/IIIareceptorinhibitors belowerinwomen.However,nodataexistonsex-specificassess-
orcangrelor). mentstrategies.
(cid:129) Thereislackofwell-poweredstudiestoevaluatetheroleofplate- Thein-hospitalmortalityduringsurgerywasrecentlyreportedto
letfunctiontestingtoguidethestrategyfortreatmentofNCSpa- belowerinwomenthanmen.41,691Incontrast,among609735pa-
tientsonantiplatelettherapy. tients who underwent elective NCS between 2009 and 2016, the
(cid:129) Evidenceregardingtheneedforandbenefitofanticoagulationin oddsofpost-operative90daymortalitywerehigheramongwomen
NCS patients with post-operative AF is still lacking (ongoing withHFthanmenwithHF.692Furtherstudiesareneededtoprovide
ASPIRE-AFtrial:NCT03968393). moreinformationaboutoutcomedifferencesbetweenmenandwo-
(cid:129) Prophylacticstrategiestoreducetheincidenceofpost-operative meninNCS.
AFinNCSpatientsadditionaltobeta-blockermaintenanceinpa- Some studieshave reporteda higher riskofbleeding inwomen
tientsalreadyonthistreatmentneedtobeevaluated. thanmen,butotherstudiescouldnotconfirmthis.Notrialshave
(cid:129) The optimal cardiac work-up and therapy for patients with PMI systematicallyinvestigatedtheimpactofsexdifferencesregardingef-
withinandoutsidehospitalsettingsneedtobeevaluated. ficacyandsafetyofcontinuationvs.interruptionofantithrombotic
(cid:129) Studiesareneededtoinvestigatetheimpactofthetreatmentof therapyinpatientsundergoingNCS.
peri-operativehypotensiononpost-operativeoutcomes,theuse Theprevalenceofanaemiainwomenofreproductiveageisashigh
of new HF drug classes (SGLT2 inhibitors and vericiguat), and as30%(WHOGlobalAnaemiaestimates),693resultinginmillionsof
the use of NSAIDs as a temporary treatment for acute post- womenundergoingsurgeryeveryyeardespitepre-operativeanaemia.
operativepain. Furthermore, since women have lower blood volumes and lower
(cid:129) Prospectivestudiesareneededtoinvestigatetheincrementalvalue haemoglobinvaluesthanmen,butfacethesamesurgicalbloodloss
ofanaemiaalgorithmsandblood-sparingstrategies(useofblood- asmen,theyareexposedtofarhigherriskofpost-operativecompli-
sparingbloodtubes)toreducetheriskofanaemia-associatedad- cations. Also, higher transfusion rates and volumes have been re-
verseoutcomesamongCVpatientsundergoingNCS. ported in women compared with men in elective surgery.694 It is
therefore of particular importance that clinicians follow the Patient
11. Sex differences BloodManagementprograminwomenundergoingNCS.Othersex-
relateddifferencesinphysiology,andpharmacokineticsandpharma-
Sex and gender may significantly affect the management and out- codynamicsofanaestheticdrugsmayinfluencetheanaesthesiaplan,
comes of patients with specific diseases undergoing NCS. There painmanagement,post-operativerecovery,andpatientsatisfaction.
aresex-andgender-dependentclinicalphenotypesofcomorbidities Sex differences regarding presentation, electrophysiological sub-
andriskfactors,whichmayhaveanimpactonperi-operativemor- strate, complications, or long-term outcomes have been reported
bidityandmortality.However,thereisapaucityofdataspecifically in patients undergoing CIED implantation,695,696 and female sex is
addressingtheinterplaybetweensex,age,andcomorbiditiesinpa- a well-known risk factor for stroke in patients with AF.697
tientsscheduledforNCS. However,nospecificdataexistthatsuggestsexdifferencesinrisk
The pre-operative assessment before NCS might take sex into profile or outcomes of patients with CIEDs or arrhythmias who
consideration,sincetheage-adjustedincidenceofCVDislowerin undergoNCS.
‘ ’ ‘ ’
12. What to do and what not to do messages from the Guidelines
Recommendations Classa Levelb
Recommendationsforclinicalriskevaluation
InallpatientsscheduledforNCS,anaccuratehistoryandclinicalexaminationarerecommended.
I C
Itisrecommendedtoperformapre-operativeriskassessment,ideallyatthesametimeastheNCSisproposed.
I B
Iftimeallows,itisrecommendedtooptimizeguideline-recommendedtreatmentofCVDandCVriskfactorsbeforeNCS.
I C
Inpatientswithafamilyhistoryofgeneticcardiomyopathy,itisrecommendedtoperformanECGandTTEbeforeNCS,regardlessof
I C
ageandsymptoms.
InpatientswithanewlydetectedmurmurandsymptomsorsignsofCVD,TTEisrecommendedbeforeNCS.
I C
Inpatientswithanewlydetectedmurmursuggestingclinicallysignificantpathology,TTEisrecommendedbeforehigh-riskNCS.
I C
Continued
Downloaded
from
https://academic.oup.com/eurheartj/article/43/39/3826/6675076
by
guest
on
22
January
2026
--- Страница 77 ---
3902 ESCGuidelines
IfapatientscheduledforelectiveNCShaschestpainorothersymptomssuggestiveofundetectedCAD,furtherdiagnosticwork-up
I C
beforeNCSisrecommended.
IfapatientinneedofacuteNCSalsohaschestpainorothersymptomssuggestiveofundetectedCAD,amultidisciplinaryassessment
I C
approachisrecommendedtochoosethetreatmentwithlowesttotalriskforthepatient.
Inpatientswithdyspnoeaand/orperipheraloedema,anECGandanNT-proBNP/BNPtestisindicatedbeforeNCS,unlessthereisa
I C
certainnon-cardiacexplanation.
Inpatientswithdyspnoeaand/orperipheraloedemaandelevatedNT-proBNP/BNP,TTEisrecommendedbeforeNCS.
I C
Recommendationsforpatientinformation
Itisrecommendedtogivepatientsindividualizedinstructionsforpre-operativeandpost-operativechangesinmedication,inverbaland
I C
writtenformatswithclearandconcisedirections.
Recommendationsforuseofriskassessmenttools
InpatientswhohaveknownCVDorCVriskfactors(includingage≥65years),orsymptomsorsignssuggestiveofCVDitis
I C
recommendedtoobtainapre-operative12-leadECGbeforeintermediate-andhigh-riskNCS.
InpatientswhohaveknownCVD,CVriskfactors(includingage≥65years),orsymptomssuggestiveofCVDitisrecommendedto
I B
measurehs-cTnTorhs-cTnIbeforeintermediate-andhigh-riskNCS,andat24hand48hafterwards.
TTEisrecommendedinpatientswithpoorfunctionalcapacityand/orhighNT-proBNP/BNP,orifmurmursaredetectedbefore
I B
high-riskNCS,inordertoundertakerisk-reductionstrategies.
Stressimagingisrecommendedbeforehigh-riskelectiveNCSinpatientswithpoorfunctionalcapacityandhighlikelihoodofCADor
I B
highclinicalrisk.
ItisrecommendedtousethesameindicationsforICAandrevascularizationpre-operativelyasinthenon-surgicalsetting.
I C
Inlow-riskpatientsundergoinglow-andintermediate-riskNCS,itisnotrecommendedtoroutinelyobtainpre-operativeECG,hs-cTn
III B
T/I,orBNP/NT-proBNPconcentrations.
Routinepre-operativeevaluationofLVfunctionisnotrecommended.
III C
StressimagingisnotrecommendedroutinelybeforeNCS.
III C
Routinepre-operativeICAisnotrecommendedinstableCCSpatientsundergoinglow-andintermediate-riskNCS.
III C
RecommendationsforCVriskfactorsandlifestyleinterventions
Smokingcessation.4weeksbeforeNCSisrecommendedtoreducepost-operativecomplicationsandmortality.
I B
ControlofCVriskfactors—includingbloodpressure,dyslipidaemia,anddiabetes—isrecommendedbeforeNCS.
I B
Recommendationsforpharmacologicalrisk-reductionstrategies
Beta-blockers
Peri-operativecontinuationofbeta-blockersisrecommendedinpatientscurrentlyreceivingthismedication.
I B
Routineinitiationofbeta-blockerperi-operativelyisnotrecommended.
III A
Statins
Inpatientsalreadyonstatins,itisrecommendedtocontinuestatinsduringtheperi-operativeperiod.
I B
Recommendationsforperi-operativehandlingofantithromboticagents
Antiplatelets
ItisrecommendedtodelayelectiveNCSuntil6monthsafterelectivePCIand12monthsafteranACS.
I A
AfterelectivePCI,itisrecommendedtodelaytime-sensitiveNCSuntilaminimumof1monthofDAPTtreatmenthasbeengiven.
I B
InpatientswitharecentPCIscheduledforNCS,itisrecommendedthatmanagementofantiplatelettherapyisdiscussedbetweenthe
I C
surgeon,anaesthesiologist,andcardiologist.
Continued
Downloaded
from
https://academic.oup.com/eurheartj/article/43/39/3826/6675076
by
guest
on
22
January
2026
--- Страница 78 ---
ESCGuidelines 3903
InpatientswithapreviousPCI,itisrecommendedtocontinueaspirinperi-operativelyifthebleedingriskallows.
I B
IfinterruptionofP2Y inhibitorisindicated,itisrecommendedtowithholdticagrelorfor3–5days,clopidogrelfor5days,andprasugrel
12 I B
for7dayspriortoNCS.
Forpatientsundergoinghighbleedingrisksurgery(e.g.intracranial,spinalneurosurgery,orvitroretinaleyesurgery),itisrecommended
I C
tointerruptaspirinforatleast7dayspre-operatively.
Ifantiplatelettherapyhasbeeninterruptedbeforeasurgicalprocedure,itisrecommendedtorestarttherapyassoonaspossible(within
I C
48h)post-surgery,accordingtointerdisciplinaryriskassessment.
Oralanticoagulants
Whenanurgentsurgicalinterventionisrequired,itisrecommendedthatNOACtherapyisimmediatelyinterrupted.
I C
Inminorbleedingrisksurgeryandotherprocedureswherebleedingcaneasilybecontrolled,itisrecommendedtoperformsurgery
I B
withoutinterruptionofOACtherapy.
Innon-minorbleedingriskproceduresinpatientsusingaNOAC,itisrecommendedtouseaninterruptionregimenbasedonthe
I B
NOACcompound,renalfunction,andbleedingrisk.
InpatientsusingNOACs,itisrecommendedthatminorbleedingriskproceduresareperformedattroughlevels(typically12–24hafter
I C
lastintake).
LMWHisrecommended,asanalternativetoUFH,forbridginginpatientswithMHVsandhighsurgicalrisk.
I B
BridgingofOACtherapyisnotrecommendedinpatientswithlow/moderatethromboticriskundergoingNCS.
III B
Useofreduced-doseNOACtoattenuatetheriskofpost-operativebleedingisnotrecommended.
III C
Recommendationsforperi-operativethromboprophylaxis
Itisrecommendedthatdecisionsaboutperi-operativethromboprophylaxisinNCSarebasedonindividualandprocedure-specificrisk
I A
factors.
Ifthromboprophylaxisisdeemednecessary,itisrecommendedtochoosethetypeanddurationofthromboprophylaxis(LMWH,
I A
NOAC,orfondaparinux)accordingtotypeofNCS,durationofimmobilization,andpatient-relatedfactors.
RecommendationsforpatientbloodmanagementinNCS
Itisrecommendedtomeasurehaemoglobinpre-operativelyinpatientsscheduledforintermediate-tohigh-riskNCS.
I B
ItisrecommendedtotreatanaemiainadvanceofNCSinordertoreducetheneedforRBCtransfusionduringNCS.
I A
Inpatientsundergoingsurgerywithexpectedbloodlossof≥500mL,useofwashedcellsalvageisrecommended.
I A
Itisrecommendedtousepoint-of-carediagnosticsforguidanceofbloodcomponenttherapy,whenavailable.
I A
RecommendationsformanagementofpatientswithspecificdiseasesundergoingNCS
A)PatientswithCAD
IfPCIisindicatedbeforeNCS,theuseofnew-generationDESisrecommendedoverBMSandballoonangioplasty.
I A
IfNCScansafelybepostponed(e.g.atleast3months),itisrecommendedthatpatientswithACSbeingscheduledforNCSundergo
I A
diagnosticandtherapeuticinterventionsasrecommendedforACSpatientsingeneral.
Routinemyocardialrevascularizationbeforelow-andintermediate-riskNCSinpatientswithCCSisnotrecommended.
III B
B)Patientswithheartfailure
InpatientswithsuspectedorknownHFscheduledforhigh-riskNCS,itisrecommendedtoevaluateLVfunctionwithechocardiography
I B
andmeasurementofNT-proBNP/BNPlevels,unlessthishasrecentlybeenperformed.
ItisrecommendedthatpatientswithHFundergoingNCSreceiveoptimalmedicaltreatmentaccordingtocurrentESCGuidelines.
I A
InpatientswithHFundergoingNCS,itisrecommendedtoregularlyassessvolumestatusandsignsoforganperfusion.
I C
Continued
Downloaded
from
https://academic.oup.com/eurheartj/article/43/39/3826/6675076
by
guest
on
22
January
2026
--- Страница 79 ---
3904 ESCGuidelines
AmultidisciplinaryteamincludingVADspecialistsisrecommendedforperi-operativemanagementofpatientswithHFreceiving
I C
mechanicalcirculatorysupport.
C)PatientswithVHD
Clinicalandechocardiographicevaluation(ifnotrecentlyperformed)isrecommendedinallpatientswithknownorsuspectedVHD
I C
whoarescheduledforelectiveintermediate-orhigh-riskNCS.
AVR(SAVRorTAVI)isrecommendedinsymptomaticpatientswithsevereASwhoarescheduledforelectiveintermediate-orhigh-risk
I C
NCS.
InpatientswithsymptomaticsevereARorasymptomaticsevereARandLVESD.50mmorLVESDi(LVESD/BSA).25mm/m2(in
I C
patientswithsmallbodysize)orrestingLVEF≤50%,valvesurgeryisrecommendedpriortoelectiveintermediate-orhigh-riskNCS.
Inpatientswithmoderate-to-severerheumaticMSandsymptomsorSPAP.50mmHg,valveintervention(percutaneousmitral
I C
commissurotomyorsurgery)isrecommendedbeforeelectiveintermediate-orhigh-riskNCS.
D)PatientswithACHD
InpatientswithACHD,aconsultationwithanACHDspecialistisrecommendedbeforeintermediate-orhigh-risksurgery.
I C
InpatientswithACHD,itisrecommendedthatintermediate-andhigh-riskelectivesurgeryisperformedinacentrewithexperiencein I C
thecareofACHDpatients.
E)Patientswitharrhythmias
InpatientswithSVTcontrolledbymedication,itisrecommendedthatAADsarecontinuedduringtheperi-operativeperiod.
I C
InAFpatientswithacuteorworseninghaemodynamicinstabilityundergoingNCS,emergencyelectricalcardioversionisrecommended.
I B
Inpatientswithsymptomatic,monomorphic,andsustainedVTassociatedwithmyocardialscar,recurringdespiteoptimalmedical
I B
therapy,ablationofarrhythmiaisrecommendedbeforeelectiveNCS.
ItisrecommendedthatpatientswithtemporarilydeactivatedICDshavecontinuousECGmonitoring,andduringtheperi-operative
periodareaccompaniedbypersonnelskilledinearlydetectionandtreatmentofarrhythmias.Inhigh-riskpatients(e.g.
I C
pacemaker-dependantorICDpatients),orifaccesstothetorsowillbedifficultduringtheprocedure,itisrecommendedtoplace
transcutaneouspacing/defibrillationpadspriortoNCS.
ItisrecommendedthatallpatientswithCIEDsthatarereprogrammedbeforesurgeryhaveare-checkandnecessaryreprogrammingas
I C
soonaspossibleaftertheprocedure.
ItisnotrecommendedtoinitiatetreatmentofasymptomaticPVCduringNCS.
III C
F)Patientswithpulmonaryhypertension
ItisrecommendedtocontinuechronictherapyforPAHintheperi-operativephaseofNCS.
I C
ItisrecommendedthathaemodynamicmonitoringofpatientswithseverePAHcontinuesforatleast24hinthepost-operativeperiod.
I C
InthecaseofprogressionofrightHFinthepost-operativeperiodinpatientswithPAH,itisrecommendedthatthediureticdosebe
optimizedand,ifnecessary,i.v.prostacyclinanaloguesbeinitiatedundertheguidanceofaphysicianexperiencedinthemanagementof I C
PAH.
G)Patientswithhypertension
InpatientswithchronichypertensionundergoingelectiveNCS,itisrecommendedtoavoidlargeperi-operativefluctuationsinblood
I A
pressure,particularlyhypotension,duringtheperi-operativeperiod.
Itisrecommendedtoperformpre-operativescreeningforhypertension-mediatedorgandamageandCVriskfactorsinnewly
I C
diagnosedhypertensivepatientswhoarescheduledforelectivehigh-riskNCS.
ItisnotrecommendedtodeferNCSinpatientswithstage1or2hypertension.
III C
H)PatientswithPAD
Inpatientswithpoorfunctionalcapacityorwithsignificantriskfactorsorsymptoms(suchasmoderate-to-severeanginapectoris,
decompensatedHF,valvulardiseaseandsignificantarrhythmia),referralforcardiacwork-upandoptimizationisrecommendedpriorto I C
electivesurgeryforPADorAAA.
Routinereferralforcardiacwork-up,coronaryangiography,orCPETpriortoelectivesurgeryforPADorAAAisnotrecommended.
III C
Continued
Downloaded
from
https://academic.oup.com/eurheartj/article/43/39/3826/6675076
by
guest
on
22
January
2026
--- Страница 80 ---
ESCGuidelines 3905
I)Patientswithcerebrovasculardisease
Pre-operativecarotidarteryandcerebralimagingisrecommendedinpatientswithahistoryofTIAorstrokeintheprevious6months
I C
andwhohavenotundergoneipsilateralrevascularization.
Pre-operativeroutinecarotidarteryimagingisnotrecommendedinpatientsundergoingNCS.
III C
J)Patientswithrenaldisease
Inpatientswithknownriskfactors(age.65years,BMI.30kg/m2,diabetes,hypertension,hyperlipidaemia,CVdisease,orsmoking)
undergoingintermediate-orhigh-riskNCS,itisrecommendedtoscreenforpre-operativerenaldiseasebymeasuringserumcreatinine I C
andGFR.
K)Patientswithobesity
Itisrecommendedtoassesscardiorespiratoryfitnesstoestimateperi-operativeCVriskinobesepatients,withparticularattentionto
I B
thoseundergoingintermediate-andhigh-riskNCS.
L)Patientswithdiabetesmellitus
Apre-operativeassessmentforconcomitantcardiacconditionsisrecommendedinpatientswithdiabeteswithsuspectedorknown
I C
CAD,andthosewithautonomicneuropathy,retinopathy,orrenaldiseaseandscheduledtoundergointermediate-andhigh-riskNCS.
Inpatientswithdiabetesordisturbedglucosemetabolism,apre-operativeHbA1cisrecommended,ifthismeasurementhasbeennot
I B
performedintheprevious3months.IncaseofHbA1c≥8.5%(≥69mmol/mol),electiveNCSshouldbepostponed,ifsafeandpractical.
Recommendationsforperi-operativemonitoringandanaesthesia
InordertopreserveoptimalCVstability,itisrecommendedtoapplygoal-directedhaemodynamictherapyinpatientsundergoing
I A
high-riskNCS.
Itisrecommendedtoavoidpost-operativeacutepain.
I B
Inordertominimizetheriskofpost-operativeorgandysfunction,itisrecommendedtoavoidanintra-operativemeanarterialpressure
I B
decreaseof.20%frombaselinevaluesor,60–70mmHgfor≥10min.
Non-aspirinNSAIDsarenotrecommendedasfirst-lineanalgesicsinpatientswithestablishedorhighriskofCVD.
III B
Recommendationsfortreatmentofpost-operativecardiovascularcomplications
Itisrecommendedtohavehighawarenessofperi-operativeCVcomplications,combinedwithsurveillanceforPMIinpatients
I B
undergoingintermediate-orhigh-riskNCS.
SystematicPMIwork-upisrecommendedtoidentifytheunderlyingpathophysiologyanddefinetherapy.
I B
Itisrecommendedtotreatpost-operativeSTEMI,NSTE-ACS,acuteHF,andtachyarrhythmiasinaccordancewithguidelinesforthe
I C
non-surgicalsetting,afterinterdisciplinarydiscussionwiththesurgeonaboutbleedingrisk.
Inpatientswithpost-operativePEofhighorintermediateclinicalprobability,initiationofanticoagulationisrecommendedwithout
I C
delay,whilediagnosticwork-upisinprogress,ifbleedingriskislow.
Post-operativeoralanticoagulationforPEisrecommendedtobeadministeredforaperiodofatleast3months. I C
Inpatientswithapost-operativeindicationforOAC,NOACisgenerallyrecommendedoverVKA.
I A
Routineuseofbeta-blockerforthepreventionofpost-operativeAFinpatientsundergoingNCSisnotrecommended.
III B
AAA,abdominalaorticaneurysm;AAD,antiarrhythmicdrug;ACHD,adultswithcongenitalheartdisease;ACS,acutecoronarysyndrome;AF,atrialfibrillation;AR,aorticvalve
regurgitation;AS,aorticvalvestenosis;AVR,aorticvalvereplacement;BMI,bodymassindex;BNP,B-typenatriureticpeptide;BMS,baremetalstent;BSA,bodysurfacearea;CAD,
coronary artery disease; CCS, chronic coronary syndrome; CIED, cardiac implantable electronic device; CPET, cardiopulmonary exercise testing; CV, cardiovascular; CVD,
cardiovasculardisease;DAPT,dualantiplatelettherapy;DES,drug-elutingstent;ECG,electrocardiogram;ESC,EuropeanSocietyofCardiology;GFR,glomerularfiltrationrate;
HbA1c,glycatedhaemoglobin;HF,heartfailure;hs-cTn,high-sensitivitycardiactroponin;ICA,invasivecoronaryangiography;ICD,implantablecardioverter–defibrillator;LMWH,
low molecular weight heparin; LV, left ventricular; LVEF, left ventricular ejection fraction; LVESD, left ventricular end-systolic diameter; LVESDi, left ventricular end-systolic
dimensionindex;MHV,mechanicalheartvalve;MS,mitralvalvestenosis;NCS,non-cardiacsurgery;NOAC,non-vitaminKantagonistoralanticoagulant;NSAID,non-steroidal
anti-inflammatorydrug;NSTE-ACS,non-ST-segmentelevationacutecoronarysyndrome;NT-proBNP,N-terminalpro-B-typenatriureticpeptide;OAC,oralanticoagulant;PAD,
peripheralarterydisease;PAH,pulmonaryarterialhypertension;PCI,percutaneouscoronaryintervention;PE,pulmonaryembolism;PMI,peri-operativemyocardialinfarction/injury;
PVC,prematureventricularcontractions;RBC,redbloodcell;SAVR,surgicalaorticvalvereplacement;SPAP,systolicpulmonaryarterypressure;STEMI,ST-segmentelevation
myocardialinfarction;SVT,supraventriculartachycardia;TAVI,transcatheteraorticvalveimplantation;TIA,transientischaemicattack;TTE,transthoracicechocardiography;UFH,
unfractionatedheparin;VAD,ventricularassistdevice;VHD,valvularheartdisease;VKA,vitaminKantagonist;VT,ventriculartachycardia.
2202CSE©
Downloaded
from
https://academic.oup.com/eurheartj/article/43/39/3826/6675076
by
guest
on
22
January
2026
--- Страница 81 ---
3906 ESCGuidelines
13. Quality indicators EvaluationandRandomizedTrials(EuroHeart)project705toprovide
‘real-world’dataaboutthepatternsandoutcomesofcareforCVdis-
Qualityindicators(QIs)aretoolsthatmaybeusedtoevaluatecare easeacrossEurope.
quality,includingstructural,process,andoutcomesofcare.698They InparallelwiththewritingofthisClinicalPracticeGuidelinedocu-
mayalsoserveasamechanismforenhancingadherencetoguideline ment,aprocesshasbeeninitiatedtodevelopQIsforpatientsunder-
recommendations, through associated quality improvement initia- going NCS using the ESC methodology and through collaboration
tives and the benchmarking of care providers.699,700 As such, the withpatientrepresentativesanddomainexperts.SuchQIsmaybe
roleofQIsinimprovingcareandoutcomesforCVdiseaseisincreas- usedforevaluationofthequalityofcareforthisgroupofpatients
inglybeingrecognizedbyhealthcareauthorities,professionalorgani- andenablecaptureofimportantaspectsofcaredelivery.TheQIs,
zations,payers,andthepublic.698 alongside their measurement specifications and development pro-
TheESCunderstandstheneedformeasuringandreportingquality cess,willbepublishedinaseparatepaper.
andoutcomesofCVcareandhasestablishedmethodsforthedevel-
opmentoftheESCQIsforthequantificationofcareandoutcomesfor
CVdiseases.698Todate,theESChasdevelopedQIsuitesforanumber 14. Central illustration
ofCVdiseases701–703andembeddedtheseinrespectiveESCClinical
PracticeGuidelines(2020ESCGuidelinesforthediagnosisandman- Thereisacomplexinterplaybetweentheintrinsicriskofsurgeryand
agement of atrial fibrillation; 2021 ESC Guidelines for the diagnosis thepatient-relatedriskofperi-operativeCVcomplications.Thislat-
and treatment of acute and chronic heart failure; and 2021 ESC terriskdependsonthebaselinegeneralandCVstatusofpatients
Guidelines on cardiac pacing and cardiac resynchronization ther- scheduledforNCS.Foreachpatient,theproperquantificationand
apy).99,412,481,704Furthermore,theESCaimstointegrateitsQIswith communication of the surgical risk require close cooperation be-
clinicalregistriessuchastheEURObservationalResearchProgramme tween cardiologists, surgeons, anaesthesiologists, general practi-
(EORP) and the European Unified Registries On Heart Care tioners,andotherhealthcareproviders(Figure21).
Comorbidityy risk Thrombotic/bleeding risk
Ageing/metabolic and autonomic
dysregulation/hypertension/
chronic kidney diseaassee
Acute/chronniicc
coronary syndrome
Withdrawal/continuation
antithrombotic drugs
Low
Intermediate
High
Surgical
risk
Central/systemic
gas-eeeeexxxxxcccchhhhaaaannnnggggeeee bbbbaaaallllaaannnccceee Rhythm disooooo
device theeeeerrr
Fluid/blood loss
O
2 CCCCCCOOOOOO
22222
Vaallvvvvvuuuuuulllaaarr hheeaarrtt dddiissseeeaassse DDDDDDDDDiiiiiaaaaaaaaassssstttttttttttttooooollllliiiiiccccc/////sssssyyyyyyssssstttttooooollllllllliiiiiiiiiiiicccccccc
dddyyyssfffuunction and
pppppppuuulllmmmooooonnnary congestion
Hypoxic/hypotensive/ HHHaaaeeemmmooodddyyyynnamic/
hypovolaemic risk arrhythmic risk
Figure 21 Central illustration: the complex interplay between the intrinsic risk of surgery and the patient risk of peri-operative cardiovascular
complications.
Downloaded
from
https://academic.oup.com/eurheartj/article/43/39/3826/6675076
by
guest
on
22
January
2026
--- Страница 82 ---
ESCGuidelines 3907
15. Supplementary data Alliance, DZHK (German Center for Cardiovascular Research),
Munich, Germany; Henrik Sillesen, Vascular Surgery,
SupplementarydataisavailableatEuropeanHeartJournalonline. Rigshospitalet, University of Copenhagen, Copenhagen, Denmark,
Clinical Medicine, University of Copenhagen, Copenhagen,
Denmark; Helge Skulstad, Department of Cardiology, Clinic of
16. Data availability statement
heart-, lung- and vessel disease, Oslo University Hospital, Oslo,
Norway, Institute of Clinical Medicine, University of Oslo, Oslo,
Nonewdataweregeneratedoranalysedinsupportofthisresearch.
Norway; Lucia Torracca, Cardiac Surgery, IRCCS Humanitas
Research Hospital, Milano, Italy; Oktay Tutarel, Department of
17. Author information Congenital Heart Disease and Paediatric Cardiology, German
Heart Centre Munich, TUM School of Medicine, Technical
Author/Task Force Member Affiliations: Salvatore University of Munich, Munich, Germany, DZHK (German Centre
Cassese, Klinik für Herz- und Kreislauferkrankungen, Deutsches for Cardiovascular Research), partner site Munich Heart Alliance,
Herzzentrum München, Munich, Germany; Trygve S. Hall, Munich, Germany; Peter Van der Meer, Cardiology, University
DepartmentofCardiology,OsloUniversityHospital,Ullevål,Oslo, Medical Center Groningen, Groningen, Netherlands; Wojtek
Norway; Magdy Abdelhamid, Cardiology Department, Faculty Wojakowski, Division of Cardiology and Structural Heart
of Medicine, Kase Al Ainy, Cairo University, Cairo, Egypt; Diseases, Medical University of Silesia, Katowice, Poland; and Kai
Emanuele Barbato, Advanced Biomedical Sciences, University Zacharowski, Anaesthesiology, Intensive Care Medicine & Pain
Federico II, Naples, Italy, Cardiovascular Center Aalst, OLV Therapy, University Hospital Frankfurt, Goethe University,
Hospital, Aalst, Belgium; Stefan De Hert, Department of Frankfurt,Germany.
Anesthesiology and Perioperative Medicine, Ghent University
Hospital/Ghent University, Ghent, Belgium; Tobias Geisler,
Department of Cardiology and Angiology, University Hospital 18. Appendix
Tübingen, Tübingen, Germany; Lynne Hinterbuchner,
Department of Cardiology, Clinic of Internal Medicine II, ESC Scientific Document Group: includes Document
ParacelsusMedicalUniversityofSalzburg,Salzburg,Austria;Borja ReviewersandESCNationalCardiacSocieties.
Ibanez, Clinical Research Department, Centro Nacional de Document Reviewers: Juhani Knuuti (CPG Review
Investigaciones Cardiovasculares (CNIC), Madrid, Spain, Coordinator) (Finland), Steen Dalby Kristensen (CPG Review
CardiologyDepartment,FundaciónJiménezDíazHospital,Madrid, Coordinator) (Denmark), Victor Aboyans (France), Ingo Ahrens
Spain, CIBERCV Centro Investigacion Biomedica en Red, Madrid, (Germany), Sotiris Antoniou (United Kingdom), Riccardo
Spain; Ingrid de Laval (Sweden), ESC Patient Forum, Sophia Asteggiano(Italy),DanAtar(Norway),AndreasBaumbach(United
Antipolis, France; Radosław Lenarczyk, Department of Kingdom), Helmut Baumgartner (Germany), Michael Böhm
Cardiology, Congenital Heart Diseases and Electrotherapy, The (Germany), Michael A. Borger (Germany), Hector Bueno (Spain),
Medical University of Silesia, Division of Medical Sciences in Jelena Čelutkienė (Lithuania), Alaide Chieffo (Italy), Maya Cikes
Zabrze,Zabrze,Poland,SilesianCenterforHeartDisease,Zabrze, (Croatia), Harald Darius (Germany), Victoria Delgado (Spain),
Poland; Ulrich R. Mansmann, Institute for Medical Data Philip J. Devereaux (Canada), David Duncker (Germany), Volkmar
Processing, Biometry, and Epidemiology, Ludwig-Maximilian’s Falk(Germany),LaurentFauchier(France),GilbertHabib(France),
University,Munich,Germany;PaulMcGreavy(UnitedKingdom), DavidHasdai(Israel),KurtHuber(Austria),BernardIung(France),
ESCPatientForum,SophiaAntipolis,France;ChristianMueller, Tiny Jaarsma (Sweden), Aleksandra Konradi (Russian Federation),
Cardiovascular Research Institute Basel, University Heart Center, Konstantinos C. Koskinas (Switzerland), Dipak Kotecha (United
University Hospital Basel, Basel, Switzerland, University of Basel, Kingdom), Ulf Landmesser (Germany), Basil S. Lewis (Israel), Ales
Basel, Switzerland; Claudio Muneretto, Cardiothoracic, Linhart (Czech Republic), Maja-Lisa Løchen (Norway), Michael
University of Brescia Italy, Brescia, Italy; Alexander Niessner, Maeng (Denmark), Stéphane Manzo-Silberman (France), Richard
DepartmentofInternalMedicineII,DivisionofCardiology,Medical Mindham (United Kingdom), Lis Neubeck (United Kingdom), Jens
University of Vienna, Vienna, Austria; Tatjana S. Potpara, CosedisNielsen(Denmark),SteffenE.Petersen(UnitedKingdom),
School of Medicine, Belgrade University, Belgrade, Serbia, Eva Prescott (Denmark), Amina Rakisheva (Kazakhstan), Antti
Cardiology Clinic, University Clinical Center of Serbia, Belgrade, Saraste (Finland), Dirk Sibbing (Germany), Jolanta M. Siller-Matula
Serbia;ArsenD.Ristić,FacultyofMedicine,BelgradeUniversity, (Austria), Marta Sitges (Spain), Ivan Stankovic (Serbia), Rob
Belgrade, Serbia, Department of Cardiology, University Clinical F. Storey (United Kingdom), Jurrien ten Berg (Netherlands),
Center of Serbia, Belgrade, Serbia; L. Elif Sade, Heart and Matthias Thielmann (Germany), and Rhian M. Touyz (Canada/
Vascular Institute, University of Pittsburgh Medical Center, UnitedKingdom).
Pittsburgh,PA,UnitedStatesofAmerica,Cardiology,Universityof ESCNationalCardiacSocietiesactivelyinvolvedinthere-
Baskent, Ankara, Turkey; Henrik Schirmer, Department of viewprocessofthe2022ESCGuidelinesonassessmentandman-
Cardiology, Akershus University Hospital, Lørenskog, Norway, agementofpatientsundergoingnon-cardiacsurgery
Institute of Clinical Medicine, Campus Ahus, University of Oslo, Algeria: Algerian Society of Cardiology, Mohammed Amine
Lørenskog, Norway; Stefanie Schüpke, ISAResearch Center, Bouzid; Armenia: Armenian Cardiologists Association, Hamayak
Deutsches Herzzentrum München, Munich, Germany, Heart Sisakian; Austria: Austrian Society of Cardiology, Bernhard
Downloaded
from
https://academic.oup.com/eurheartj/article/43/39/3826/6675076
by
guest
on
22
January
2026
--- Страница 83 ---
3908 ESCGuidelines
Metzler; Belarus: Belorussian Scientific Society of Cardiologists, Jean-Philippe Collet (France), Volkmar Falk (Germany), Laurent
Vadim Shumavets; Belgium: Belgian Society of Cardiology, Agnès Fauchier (France), Chris P. Gale (United Kingdom), Sigrun
Pasquet;BosniaandHerzegovina:AssociationofCardiologists Halvorsen (Norway), Bernard Iung (France), Tiny Jaarsma
of Bosnia and Herzegovina, Elnur Smajic; Bulgaria: Bulgarian (Sweden), Aleksandra Konradi (Russian Federation), Konstantinos
Society of Cardiology, Maria Milanova; Croatia: Croatian Cardiac C. Koskinas (Switzerland), Dipak Kotecha (United Kingdom), Ulf
Society, Boško Skorić; Cyprus: Cyprus Society of Cardiology, Landmesser (Germany),Basil S.Lewis(Israel),Ales Linhart(Czech
Maria Karakyriou; Czechia: Czech Society of Cardiology, Hana Republic), Maja-Lisa Løchen (Norway), Richard Mindham (United
Skalicka;Denmark:DanishSocietyofCardiology,MichaelMaeng; Kingdom), Jens Cosedis Nielsen (Denmark), Steffen E. Petersen
Egypt: Egyptian Society of Cardiology, Bassem Abd Elhamid; (United Kingdom), Eva Prescott (Denmark), Amina Rakisheva
Estonia: Estonian Society of Cardiology, Arno Ruusalepp; (Kazakhstan), Marta Sitges (Spain), and Rhian M. Touyz (Canada
Finland: Finnish Cardiac Society, Kati Valtola; France: French /UnitedKingdom).
SocietyofCardiology,ArielCohen;Georgia:GeorgianSocietyof
Cardiology, Archil Chukhrukidze; Germany: German Cardiac
Society, Ilka Ott; Greece: Hellenic Society of Cardiology, Nikos
19. References
Kafkas; Hungary: Hungarian Society of Cardiology, Zoltán Járai;
Iceland: Icelandic Society of Cardiology, Thórdís Jóna
1.WeiserTG,RegenbogenSE,ThompsonKD,HaynesAB,LipsitzSR,BerryWR,
Hrafnkelsdóttir; Ireland: Irish Cardiac Society, Patricia Campbell;
etal.Anestimationoftheglobalvolumeofsurgery:amodellingstrategybased
Israel:IsraelHeartSociety,AlonEisen;Italy:ItalianFederationof onavailabledata.Lancet2008;372:139–144.
Cardiology, Stefano Urbinati; Kazakhstan: Association of 2.WeiserTG,HaynesAB,MolinaG,LipsitzSR,EsquivelMM,Uribe-LeitzT,etal.
Estimateoftheglobalvolumeofsurgeryin2012:anassessmentsupportingim-
Cardiologists of Kazakhstan, Nazipa Aidargaliyeva; Kosovo
provedhealthoutcomes.Lancet2015;385:S11.
(Republic of): Kosovo Society of Cardiology, Arlind Batalli; 3.Eurostat.EUpopulationin2020:almost448million.https://ec.europa.eu/eurostat/
Kyrgyzstan: Kyrgyz Society of Cardiology, Olga Lunegova; documents/2995521/11081093/3-10072020-AP-EN.pdf/d2f799bf-4412-05cc-
a357-7b49b93615f1(31March2022).
Latvia: Latvian Society of Cardiology, Andrejs Erglis; Lebanon:
4.SmilowitzNR,GuptaN,GuoY,BeckmanJA,BangaloreS,BergerJS.Trendsincar-
Lebanese Society of Cardiology, Georges Saade; Lithuania: diovascularriskfactoranddiseaseprevalenceinpatientsundergoingnon-cardiac
Lithuanian Society of Cardiology, Andrius Macas; Luxembourg:
surgery.Heart2018;104:1180–1186.
5.LeeOH,HongSJ,AhnCM,KimJS,KimBK,KoYG,etal.Theincidenceofnon-
LuxembourgSocietyofCardiology,CristianaBanu;Malta:Maltese
cardiac surgery in patients treated with drug-eluting stents according to age.
Cardiac Society, Tiziana Felice; Moldova: Moldavian Society JInvasiveCardiol2019;31:E9–E14.
of Cardiology, Aurel Grosu; Montenegro: Montenegro Society 6.Vascular Events in Noncardiac Surgery Patients Cohort Evaluation Study
Investigators,SpenceJ,LeManachY,ChanMTV,WangCY,SigamaniA,etal.
of Cardiology, Mihailo Vukmirovic; Morocco: Moroccan
Associationbetweencomplicationsanddeathwithin30daysafternoncardiacsur-
Society of Cardiology, Aida Soufiani; Netherlands: Netherlands gery.CMAJ2019;191:E830–E837.
Society of Cardiology, Eric Dubois; North Macedonia: North 7.PearseRM,MorenoRP,BauerP,PelosiP,MetnitzP,SpiesC,etal.Mortalityafter
surgeryinEurope:a7daycohortstudy.Lancet2012;380:1059–1065.
Macedonian Society of Cardiology, Hristo Pejkov; Norway:
8.SazgaryL,PuelacherC,LuratiBuseG,GlarnerN,LampartA,BolligerD,etal.
Norwegian Society of Cardiology, Erlend Aune; Poland: Polish Incidence of major adverse cardiac events following non-cardiac surgery. Eur
Cardiac Society, Stanisław Bartuś; Portugal: Portuguese Society HeartJAcuteCardiovascCare2020;10:550–558.
9.SmilowitzNR,BergerJS.Perioperativecardiovascularriskassessmentandmanage-
of Cardiology, Mário Santos; Romania: Romanian Society of mentfornoncardiacsurgery:areview.JAMA2020;324:279–290.
Cardiology, Elisabeta Badila; Russian Federation: Russian 10.KristensenSD,KnuutiJ,SarasteA,AnkerS,BotkerHE,HertSD,etal.2014ESC/
Society of Cardiology, Olga Irtyuga; San Marino: San Marino ESAGuidelinesonnon-cardiacsurgery:cardiovascularassessmentandmanage-
ment: the Joint Task Force on non-cardiac surgery: cardiovascular assessment SocietyofCardiology,LucaBertelli;Serbia:CardiologySocietyof
and management of the European Society of Cardiology (ESC) and the
Serbia, Branko Beleslin; Slovakia: Slovak Society of Cardiology, EuropeanSocietyofAnaesthesiology(ESA).EurHeartJ2014;35:2383–2431.
MartinDúbrava;Slovenia:SlovenianSocietyofCardiology,Zlatko 11.KamelH,JohnstonSC,KirkhamJC,TurnerCG,KizerJR,DevereuxRB,etal.
AssociationbetweenmajorperioperativehemorrhageandstrokeorQ-wavemyo-
Fras; Spain: Spanish Society of Cardiology, José Luis Ferreiro; cardialinfarction.Circulation2012;126:207–212.
Sweden: Swedish Society of Cardiology, Claes Held; 12.CRASH-2TrialCollaborators,ShakurH,RobertsI,BautistaR,CaballeroJ,CoatsT,
Switzerland: Swiss Society of Cardiology, Philippe Meyer; etal.Effectsoftranexamicacidondeath,vascularocclusiveevents,andbloodtrans-
fusionintraumapatientswithsignificanthaemorrhage(CRASH-2):arandomised,
SyrianArabRepublic:SyrianCardiovascularAssociation,Walid placebo-controlledtrial.Lancet2010;376:23–32.
Bsata; Tunisia: Tunisian Society of Cardiology and 13.KougiasP,SharathS,BarshesNR,ChenM,MillsJL,Sr.Effectofpostoperativean-
Cardio-Vascular Surgery, Afef Ben Halima; Turkey: Turkish emiaandbaselinecardiacriskonseriousadverseoutcomesaftermajorvascular
interventions.JVascSurg2017;66:1836–1843.
Society of Cardiology, Murat Biteker, United Kingdom of
14.CohnSL.Thecardiacconsultforpatientsundergoingnon-cardiacsurgery.Heart
Great Britain and Northern Ireland: British Cardiovascular 2016;102:1322–1332.
Society, Andrew Archbold; Ukraine: Ukrainian Association of 15.GuayJ,ChoiP,SureshS,AlbertN,KoppS,PaceNL.Neuraxialblockadeforthe
prevention of postoperative mortality and major morbidity: an overview of
Cardiology, Maksym Sokolov; and Uzbekistan: Association of
Cochranesystematicreviews.CochraneDatabaseSystRev2014:2014:CD010108.
CardiologistsofUzbekistan,NodirZakirov. 16.Norderud K, Egholm G, Thim T, Olesen KKW, Madsen M, Jensen LO, et al.
ESC Clinical Practice Guidelines (CPG) Committee: Validation of the European Society of Cardiology and European Society of
Anaesthesiologynon-cardiacsurgeryriskscoreinpatientstreatedwithcoronary
ColinBaigent(Chairperson)(UnitedKingdom),MagdyAbdelhamid drug-elutingstentimplantation.EurHeartJQualCareClinOutcomes2019;5:22–27.
(Egypt), Victor Aboyans (France), Sotiris Antoniou (United 17.ManganoDT.Perioperativemedicine:NHLBIworkinggroupdeliberationsandre-
Kingdom), Elena Arbelo (Spain), Riccardo Asteggiano (Italy),
commendations.JCardiothoracVascAnesth2004;18:1–6.
18.GlanceLG,LustikSJ,HannanEL,OslerTM,MukamelDB,QianF,etal.TheSurgical
Andreas Baumbach (United Kingdom), Michael A. Borger
MortalityProbabilityModel:derivationandvalidationofasimpleriskprediction
(Germany), Jelena Čelutkienė (Lithuania), Maja Cikes (Croatia), rulefornoncardiacsurgery.AnnSurg2012;255:696–702.
Downloaded
from
https://academic.oup.com/eurheartj/article/43/39/3826/6675076
by
guest
on
22
January
2026
--- Страница 84 ---
ESCGuidelines 3909
19.MullerMD,LyrerP,BrownMM,BonatiLH.Carotidarterystentingversusend- 42.Noordzij PG, Boersma E, Bax JJ, Feringa HH, Schreiner F, Schouten O, et al.
arterectomyfortreatmentofcarotidarterystenosis.CochraneDatabaseSystRev Prognosticvalueofroutinepreoperativeelectrocardiographyinpatientsundergo-
2020;2:CD000515. ingnoncardiacsurgery.AmJCardiol2006;97:1103–1106.
20.BendixenM,JørgensenOD,KronborgC,AndersenC,LichtPB.Postoperativepain 43.ChivulescuM,LieØ,PopescuBA,SkulstadH,EdvardsenT,JurcutRO,etal.High
andqualityoflifeafterlobectomyviavideo-assistedthoracoscopicsurgeryoran- penetranceandsimilardiseaseprogressioninprobandsandinfamilymemberswith
terolateralthoracotomyforearlystagelungcancer:arandomisedcontrolledtrial. arrhythmogeniccardiomyopathy.EurHeartJ2020;41:1401–1410.
LancetOncol2016;17:836–844. 44.HallqvistL,GranathF,BellM.Myocardialinfarctionafternoncardiacsurgeryin
21.FalcozPE,PuyraveauM,ThomasPA,DecaluweH,HürtgenM,PetersenRH,etal. Sweden:anational,retrospectiveobservationalcohortstudy.BrJAnaesth2020;
Video-assisted thoracoscopic surgery versus open lobectomy for primary 125:47–54.
non-small-celllungcancer:apropensity-matchedanalysisofoutcomefromthe 45.ChaudhryW,CohenMC.Cardiacscreeninginthenoncardiacsurgerypatient.Surg
EuropeanSocietyofThoracicSurgeondatabase.EurJCardiothoracSurg2016;49: ClinNorthAm2017;97:717–732.
602–609. 46.FordMK,BeattieWS,WijeysunderaDN.Systematicreview:predictionofperi-
22.MartinD,MantziariS,DemartinesN,HubnerM,StudyGroupESA.Definingmajor operativecardiaccomplicationsandmortalitybytheRevisedCardiacRiskIndex.
surgery:aDelphiconsensusamongEuropeanSurgicalAssociation(ESA)members. AnnInternMed2010;152:26–35.
WorldJSurg2020;44:2211–2219. 47.Duceppe E,Parlow J, MacDonald P,Lyons K,McMullenM, Srinathan S,et al.
23.BolligerM,KroehnertJA,MolineusF,KandiolerD,SchindlM,RissP.Experiences CanadianCardiovascularSocietyguidelinesonperioperativecardiacriskassess-
withthestandardizedclassificationofsurgicalcomplications(Clavien-Dindo)in ment and management for patients who undergo noncardiac surgery. Can J
generalsurgerypatients.EurSurg2018;50:256–261. Cardiol2017;33:17–32.
24.BjorckM,EarnshawJJ,AcostaS,BastosGoncalvesF,CochennecF,DebusES,etal. 48.YapMKC,AngKF,Gonzales-PorciunculaLA,EsposoE.ValidationoftheAmerican
Editor’s choice – European Society for Vascular Surgery (ESVS) 2020 Clinical CollegeofSurgeonsRiskCalculatorforpreoperativeriskstratification.HeartAsia
Practice Guidelines on the management of acute limb ischaemia. Eur J Vasc 2018;10:e010993.
EndovascSurg2020;59:173–218. 49.DakikHA,ChehabO,EldiraniM,SbeityE,KaramC,AbouHassanO,etal.Anew
25.HolteK,KehletH.Postoperativeileus:apreventableevent.BrJSurg2000;87: index for pre-operative cardiovascular evaluation. J Am Coll Cardiol 2019;73:
1480–1493. 3067–3078.
26.PopescuWM,BellR,DuffyAJ,KatzKH,PerrinoAC.Apilotstudyofpatientswith 50.DakikHA,SbaityE,MsheikA,KasparC,EldiraniM,ChehabO,etal.AUB-HAS2
clinicallysevereobesityundergoinglaparoscopicsurgery:evidenceforimpaired CardiovascularRiskIndex:performanceinsurgicalsubpopulationsandcomparison
cardiacperformance.JCardiothoracVascAnesth2011;25:943–949. totheRevisedCardiacRiskIndex.JAmHeartAssoc2020;9:e016228.
27.Lestar M, Gunnarsson L, Lagerstrand L, Wiklund P, Odeberg-Wernerman S. 51.DakikHA,EldiraniM,KasparC,ChehabO,MsheikA,MakkiM,etal.Prospective
Hemodynamicperturbationsduringrobot-assistedlaparoscopicradicalprostatec- validationoftheAUB-HAS2CardiovascularRiskIndex.EurHeartJQualCareClin
tomyin45°Trendelenburgposition.AnesthAnalg2011;113:1069–1075. Outcomes2022;8:96–97.
28.Hirvonen EA, Nuutinen LS, Kauko M. Hemodynamic changes due to 52.Duceppe E, Patel A, Chan MTV, Berwanger O, Ackland G, Kavsak PA, et al.
Trendelenburgpositioningandpneumoperitoneumduringlaparoscopichysterec- PreoperativeN-terminalpro-B-typenatriureticpeptideandcardiovascularevents
tomy.ActaAnaesthesiolScand1995;39:949–955. afternoncardiacsurgery:acohortstudy.AnnInternMed2020;172:96–104.
29.NguyenNT,WolfeBM.Thephysiologiceffectsofpneumoperitoneuminthemor- 53.Weber M, Luchner A, Seeberger M, Mueller C, Liebetrau C, Schlitt A, et al.
bidlyobese.AnnSurg2005;241:219–226. Incrementalvalueofhigh-sensitivetroponinTinadditiontotherevisedcardiacin-
30.KeusF,GooszenHG,vanLaarhovenCJ.Open,small-incision,orlaparoscopic dexforperi-operativeriskstratificationinnon-cardiacsurgery.EurHeartJ2013;34:
cholecystectomyforpatientswithsymptomaticcholecystolithiasis.Anoverview 853–862.
of Cochrane Hepato-BiliaryGroup reviews. Cochrane Database SystRev 2010; 54.KuehSH,PasleyT,WheelerM,PembertonJ.Thenotsoinnocentheartmurmur:a
2010:CD008318. 5-yearexperience.InternMedJ2017;47:199–205.
31.MamidannaR,BurnsEM,BottleA,AylinP,StonellC,HannaGB,etal.Reducedrisk 55.DouglasPS,GarciaMJ,HainesDE,LaiWW,ManningWJ,PatelAR,etal.ACCF/
ofmedicalmorbidityandmortalityinpatientsselectedforlaparoscopiccolorectal ASE/AHA/ASNC/HFSA/HRS/SCAI/SCCM/SCCT/SCMR 2011 Appropriate Use
resectioninEngland:apopulation-basedstudy.ArchSurg2012;147:219–227. CriteriaforEchocardiography.AReportoftheAmericanCollegeofCardiology
32.CirocchiR,FarinellaE,TrastulliS,SciannameoF,AudisioRA.Electivesigmoidcol- Foundation Appropriate Use Criteria Task Force, American Society of
ectomyfordiverticulardisease.Laparoscopicvsopensurgery:asystematicreview. Echocardiography, American Heart Association, American Society of Nuclear
ColorectalDis2012;14:671–683. Cardiology,HeartFailureSocietyofAmerica,HeartRhythmSociety,Societyfor
33.MurrMM,MartinT,HainesK,TorrellaT,DragottiR,KandilA,etal.Astate-wide CardiovascularAngiographyandInterventions,SocietyofCriticalCareMedicine,
reviewofcontemporaryoutcomesofgastricbypassinFlorida:doesprovidervol- Society of Cardiovascular Computed Tomography, Society for Cardiovascular
umeimpactoutcomes?AnnSurg2007;245:699–706. MagneticResonanceAmericanCollegeofChestPhysicians.JAmSocEchocardiogr
34.GraileyK,MarkarSR,KarthikesalingamA,AboudR,ZiprinP,FaizO.Laparoscopic 2011;24:229–267.
versusopencolorectalresectionintheelderlypopulation.SurgEndosc2013;27: 56.FriedmanJM,CousoR,KitchensM,VakhshoriV,HillinCD,WuCH,etal.Benign
19–30. heartmurmursasapredictorforcomplicationsfollowingtotaljointarthroplasty.
35.WanhainenA,VerziniF,VanHerzeeleI,AllaireE,BownM,CohnertT,etal. JOrthop2017;14:470–474.
Editor’s choice – European Society for Vascular Surgery (ESVS) 2019 Clinical 57.HipAttackInvestigators.Acceleratedsurgeryversusstandardcareinhipfracture
PracticeGuidelinesonthemanagementofabdominalaorto-iliacarteryaneurysms. (HIPATTACK):aninternational,randomised,controlledtrial.Lancet2020;395:
EurJVascEndovascSurg2019;57:8–93. 698–708.
36.PowellJT,SweetingMJ,UlugP,BlankensteijnJD,LederleFA,BecqueminJP,etal. 58.CowieB.Thepreoperativepatientwithasystolicmurmur.AnesthPainMed2015;5:
Meta-analysisofindividual-patientdatafromEVAR-1,DREAM,OVERandACE e32105.
trialscomparingoutcomesofendovascularoropenrepairforabdominalaortican- 59.AttenhoferJostCH,TurinaJ,MayerK,SeifertB,AmannFW,BuechiM,etal.
eurysmover5years.BrJSurg2017;104:166–178. Echocardiographyintheevaluationofsystolicmurmursofunknowncause.AmJ
37.LederleFA,KyriakidesTC,StroupeKT,FreischlagJA,PadbergFT,Jr.,MatsumuraJS, Med2000;108:614–620.
etal.Openversusendovascularrepairofabdominalaorticaneurysm.NEnglJMed 60.KobalSL,TrentoL,BaharamiS,TolstrupK,NaqviTZ,CercekB,etal.Comparison
2019;380:2126–2135. of effectiveness of hand-carried ultrasound to bedside cardiovascular physical
38.BauerSM,CayneNS,VeithFJ.Newdevelopmentsinthepreoperativeevaluation examination.AmJCardiol2005;96:1002–1006.
andperioperativemanagementofcoronaryarterydiseaseinpatientsundergoing 61.AbidovA,RozanskiA,HachamovitchR,HayesSW,Aboul-EneinF,CohenI,etal.
vascularsurgery.JVascSurg2010;51:242–251. Prognosticsignificanceofdyspneainpatientsreferredforcardiacstresstesting.
39.Antoniou GA, Chalmers N, Georgiadis GS, Lazarides MK, Antoniou SA, NEnglJMed2005;353:1889–1898.
Serracino-InglottF,etal.Ameta-analysisofendovascularversussurgicalrecon- 62.CajitaMI,CajitaTR,HanHR.Healthliteracyandheartfailure:asystematicreview.
structionoffemoropoplitealarterialdisease.JVascSurg2013;57:242–253. JCardiovascNurs2016;31:121–130.
40.VisserenFLJ,MachF,SmuldersYM,CarballoD,KoskinasKC,BackM,etal.2021 63.MagnaniJW,MujahidMS,AronowHD,CeneCW,DicksonVV,HavranekE,etal.
ESCGuidelinesoncardiovasculardiseasepreventioninclinicalpractice.EurHeartJ Healthliteracyandcardiovasculardisease.Fundamentalrelevancetoprimaryand
2021;42:3227–3337. secondary prevention: a scientific statement from the American Heart
41.Botto F, Alonso-Coello P, Chan MT, Villar JC, Xavier D, Srinathan S, et al. Association.Circulation2018;138:e48–e74.
Myocardialinjuryafternoncardiacsurgery:alarge,international,prospectiveco- 64.ShinkunasLA,KlipowiczCJ,CarlisleEM.Shareddecisionmakinginsurgery:ascop-
hortstudyestablishingdiagnosticcriteria,characteristics,predictors,and30-day ingreviewofpatientandsurgeonpreferences.BMCMedInformDecisMak2020;20:
outcomes.Anesthesiology2014;120:564–578. 190.
Downloaded
from
https://academic.oup.com/eurheartj/article/43/39/3826/6675076
by
guest
on
22
January
2026
--- Страница 85 ---
3910 ESCGuidelines
65. deMikSML,StubenrouchFE,BalmR,UbbinkDT.Systematicreviewofshared 86.TjeertesEKM,vanFessemJMK,Mattace-RasoFUS,HoofwijkAGM,StolkerRJ.
decision-makinginsurgery.BrJSurg2018;105:1721–1730. HoeksSE.Influenceoffrailtyonoutcomeinolderpatientsundergoingnon-cardiac
66. PhamC,LizarondoL,KarnonJ,AromatarisE,MunnZ,GibbC,etal.Strategiesfor surgery–asystematicreviewandmeta-analysis.AgingDis2020;11:1276–1290.
implementingshareddecisionmakinginelectivesurgerybyhealthcarepracti- 87.MosqueraC,SpaniolasK,FitzgeraldTL.Impactoffrailtyonsurgicaloutcomes:the
tioners:asystematicreview.JEvalClinPract2020;26:582–601. rightpatientfortherightprocedure.Surgery2016;160:272–280.
67. NiburskiK,GuadagnoE,Abbasgholizadeh-RahimiS,PoenaruD.Shareddecision 88.RockwoodK,SongX,MacKnightC,BergmanH,HoganDB,McDowellI,etal.A
makinginsurgery:ameta-analysisofexistingliterature.Patient2020;13:667–681. globalclinicalmeasureoffitnessandfrailtyinelderlypeople.CMAJ2005;173:
68. AbateSM,ChekoYA,BasuB.Globalprevalenceanddeterminantsofpreoperative 489–495.
anxietyamongsurgicalpatients:asystematicreviewandmeta-analysis.IntJSurg 89.FriedLP,TangenCM,WalstonJ,NewmanAB,HirschC,GottdienerJ,etal.Frailty
Open2020;25:6–16. inolderadults:evidenceforaphenotype.JGerontolABiolSciMedSci2001;56:
69. TakagiH,AndoT,UmemotoT,GroupALICE.Perioperativedepressionoranxiety M146–M156.
and postoperative mortality in cardiac surgery: a systematic review and 90.Alvarez-NebredaML,BentovN,UrmanRD,SetiaS,HuangJC,PfeiferK,etal.
meta-analysis.HeartVessels2017;32:1458–1468. RecommendationsforpreoperativemanagementoffrailtyfromtheSocietyfor
70. TullyPJ,BakerRA.Depression,anxiety,andcardiacmorbidityoutcomesaftercor- PerioperativeAssessmentandQualityImprovement(SPAQI).JClinAnesth2018;
onaryarterybypasssurgery:acontemporaryandpracticalreview.JGeriatrCardiol 47:33–42.
2012;9:197–208. 91.GrigoryanKV,JavedanH,RudolphJL.Orthogeriatriccaremodelsandoutcomesin
71. RosenbergerPH,JoklP,IckovicsJ.Psychosocialfactorsandsurgicaloutcomes:an hipfracturepatients:asystematicreviewandmeta-analysis.JOrthopTrauma2014;
evidence-basedliteraturereview.JAmAcadOrthopSurg2006;14:397–405. 28:e49–e55.
72. TheunissenM,PetersML,BruceJ,GramkeHF,MarcusMA.Preoperativeanxiety 92.BorsonS,ScanlanJM,ChenP,GanguliM.TheMini-Cogasascreenfordementia:
and catastrophizing: a systematic review and meta-analysis of the association validationinapopulation-basedsample.JAmGeriatrSoc2003;51:1451–1454.
withchronicpostsurgicalpain.ClinJPain2012;28:819–841. 93.BiccardBM.Relationshipbetweentheinabilitytoclimbtwoflightsofstairsandout-
73. SzeverenyiC,KekecsZ,JohnsonA,ElkinsG,CsernatonyZ,VargaK.Theuseof comeaftermajornon-cardiacsurgery:implicationsforthepre-operativeassess-
adjunctpsychosocialinterventionscandecreasepostoperativepainandimprove mentoffunctionalcapacity.Anaesthesia2005;60:588–593.
the quality of clinical care in orthopedic surgery: a systematic review and 94.LuratiBuseGAL,PuelacherC,MenosiGualandroD,GeniniAS,HidvegiR,Bolliger
meta-analysisofrandomizedcontrolledtrials.JPain2018;19:1231–1252. D,etal.Associationbetweenself-reportedfunctionalcapacityandmajoradverse
74. VillaG,LaniniI,AmassT,BoccieroV,ScireCalabrisottoC,ChelazziC,etal.Effects cardiaceventsinpatientsatelevatedriskundergoingnoncardiacsurgery:apro-
ofpsychologicalinterventionsonanxietyandpaininpatientsundergoingmajor spectivediagnosticcohortstudy.BrJAnaesth2020;126:102–110.
electiveabdominalsurgery:asystematicreview.PerioperMed(Lond)2020;9:38. 95.WijeysunderaDN,PearseRM,ShulmanMA,AbbottTEF,TorresE,AmbostaA,
75. Richards SH, Anderson L, Jenkinson CE, Whalley B, Rees K, Davies P, et al. etal.Assessmentoffunctionalcapacitybeforemajornon-cardiacsurgery:aninter-
Psychologicalinterventions forcoronaryheartdisease.CochraneDatabaseSyst national,prospectivecohortstudy.Lancet2018;391:2631–2640.
Rev2017;4:CD002902. 96.WijeysunderaDN,BeattieWS,HillisGS,AbbottTEF,ShulmanMA,AcklandGL,
76. BilimoriaKY,LiuY,ParuchJL,ZhouL,KmiecikTE,KoCY,etal.Developmentand etal.IntegrationoftheDukeActivityStatusIndexintopreoperativeriskevaluation:
evaluationoftheuniversalACSNSQIPsurgicalriskcalculator:adecisionaidand amulticentreprospectivecohortstudy.BrJAnaesth2020;124:261–270.
informedconsenttoolforpatientsandsurgeons.JAmCollSurg2013;217:833–- 97.Jeger RV, Probst C, Arsenic R, Lippuner T, Pfisterer ME, Seeberger MD, et al.
842.e831–833. Long-termprognosticvalueofthepreoperative12-leadelectrocardiogrambefore
76a. FronczekJ,PolokK,DevereauxPJ,etal.ExternalvalidationoftheRevisedCardiac majornoncardiacsurgeryincoronaryarterydisease.AmHeartJ2006;151:508–513.
Risk Index and National Surgical Quality Improvement Program Myocardial 98.ColletJP,ThieleH,BarbatoE,BarthelemyO,BauersachsJ,BhattDL,etal.2020
Infarction and Cardiac Arrest calculator in noncardiac vascular surgery. Br J ESCGuidelinesforthemanagementofacutecoronarysyndromesinpatientspre-
Anaesth.2019;123(4):421–429.doi:10.1016/j.bja.2019.05.02. sentingwithoutpersistentST-segmentelevation.EurHeartJ2021;42:1289–1367.
77. BertgesDJ,GoodneyPP,ZhaoY,SchanzerA,NolanBW,LikoskyDS,etal.The 99.HindricksG,PotparaT,DagresN,ArbeloE,BaxJJ,Blomstrom-LundqvistC,etal.
VascularStudyGroupofNewEnglandCardiacRiskIndex(VSG-CRI)predictscar- 2020ESCGuidelinesforthediagnosisandmanagementofatrialfibrillationdevel-
diaccomplicationsmoreaccuratelythantheRevisedCardiacRiskIndexinvascular opedincollaborationwiththeEuropeanAssociationforCardio-ThoracicSurgery
surgerypatients.JVascSurg2010;52:674–683.683.e1–683.e3. (EACTS).EurHeartJ2021;42:373–498.
78. ProtopapaKL,SimpsonJC,SmithNC,MoonesingheSR.Developmentandvalid- 100. GanguliI,LupoC,MainorAJ,RaymondS,WangQ,OravEJ,etal.Prevalenceand
ationoftheSurgicalOutcomeRiskTool(SORT).BrJSurg2014;101:1774–1783. costofcarecascadesafterlow-valuepreoperativeelectrocardiogramforcataract
79. WongDJN,HarrisS,SahniA,BedfordJR,CortesL,ShawyerR,etal.Developing surgery in fee-for-service medicare beneficiaries. JAMA Intern Med 2019;179:
andvalidatingsubjectiveandobjectiverisk-assessmentmeasuresforpredicting 1211–1219.
mortality after major surgery: an international prospective cohort study. PLoS 101. GualandroDM,PuelacherC,LuratiBuseG,LampartA,StrunzC,CardozoFA,etal.
Med2020;17:e1003253. Comparisonofhigh-sensitivitycardiactroponinIandTforthepredictionofcardiac
80. GuptaPK,GuptaH,SundaramA,KaushikM,FangX,MillerWJ,etal.Development complicationsafternon-cardiacsurgery.AmHeartJ2018;203:67–73.
and validation of a risk calculator for prediction of cardiac risk after surgery. 102. HumbleCAS,HuangS,JammerI,BjorkJ,ChewMS.Prognosticperformanceof
Circulation2011;124:381–387. preoperativecardiactroponinandperioperativechangesincardiactroponinfor
81. MsheikA,KasparC,MailhacA,HoballahJJ,TamimH,DakikHA.Performanceof thepredictionofmajoradversecardiaceventsandmortalityinnoncardiacsurgery:
theAUB-HAS2CardiovascularRiskIndexinvascularsurgerypatients.VascMed asystematicreviewandmeta-analysis.PLoSOne2019;14:e0215094.
2021;26:535–541. 103. ParkSJ,ChoiJH,ChoSJ,ChangSA,ChoiJO,LeeSC,etal.Comparisonoftrans-
82. GlanceLG,FadenE,DuttonRP,LustikSJ,LiY,EatonMP,etal.Impactofthechoice thoracic echocardiography with N-terminal pro-brain natriuretic peptide as a
ofriskmodelforidentifyinglow-riskpatientsusingthe2014AmericanCollegeof tool for risk stratification of patients undergoing major noncardiac surgery.
Cardiology/AmericanHeartAssociationPerioperativeGuidelines.Anesthesiology KoreanCircJ2011;41:505–511.
2018;129:889–900. 104. LeeG,SouSM,TwerenboldR,ReichlinT,OshimaS,HochgruberT,etal.B-type
83. RobinsonTN,WalstonJD,BrummelNE,DeinerS,BrownC,KennedyM,etal. natriureticpeptideandclinicaljudgmentinthedetectionofexercise-inducedmyo-
Frailtyforsurgeons:reviewofaNationalInstituteonAgingConferenceonfrailty cardialischemia.AmJMed2014;127:427–435.
forspecialists.JAmCollSurg2015;221:1083–1092. 105. WalterJ,deLavallazJdF,KoechlinL,ZimmermannT,BoeddinghausJ,HoneggerU,
84. RichterD,GuastiL,WalkerD,LambrinouE,LionisC,AbreuA,etal.Frailtyincar- etal.Usinghigh-sensitivitycardiactroponinfortheexclusionofinduciblemyocardial
diology: definition, assessment and clinical implications for general cardiology. ischemiainsymptomaticpatients:acohortstudy.AnnInternMed2020;172:175–185.
AconsensusdocumentoftheCouncilforCardiologyPractice(CCP),Association 106. WalterJE,HoneggerU,PuelacherC,MuellerD,WagenerM,SchaerliN,etal.
forAcuteCardioVascularCare(ACVC),AssociationofCardiovascularNursing Prospectivevalidationofabiomarker-basedruleoutstrategyforfunctionallyrele-
andAlliedProfessions(ACNAP),EuropeanAssociationofPreventiveCardiology vantcoronaryarterydisease.ClinChem2018;64:386–395.
(EAPC),EuropeanHeartRhythmAssociation(EHRA),CouncilonValvularHeart 107. MuellerD,PuelacherC,HoneggerU,WalterJE,BadertscherP,SchaerliN,etal.
Diseases(VHD),CouncilonHypertension(CHT),CouncilofCardio-Oncology DirectcomparisonofcardiactroponinTandIusingauniformandasex-specific
(CCO), Working Group (WG) Aorta and Peripheral Vascular Diseases, WG approachinthedetectionoffunctionallyrelevantcoronaryarterydisease.Clin
e-Cardiology,WGThrombosis,oftheEuropeanSocietyofCardiology,European Chem2018;64:1596–1606.
PrimaryCareCardiologySociety(EPCCS).EurJPrevCardiol2022;29:216–227. 108. Ackland GL, Abbott TEF, Cain D, Edwards MR, Sultan P, Karmali SN, et al.
85. HornorMA,MaM,ZhouL,CohenME,RosenthalRA,RussellMM,etal.Enhancing Preoperativesystemicinflammationandperioperativemyocardialinjury:prospect-
theAmericanCollegeofSurgeonsNSQIPSurgicalRiskCalculatortopredictgeri- iveobservationalmulticentrecohortstudyofpatientsundergoingnon-cardiacsur-
atricoutcomes.JAmCollSurg2020;230:88–100e101. gery.BrJAnaesth2019;122:180–187.
Downloaded
from
https://academic.oup.com/eurheartj/article/43/39/3826/6675076
by
guest
on
22
January
2026
--- Страница 86 ---
ESCGuidelines 3911
109.WritingCommitteefortheVisionStudyInvestigators,DevereauxPJ,BiccardBM, 131. HeibergJ,El-AnsaryD,CantyDJ,RoyseAG,RoyseCF.Focusedechocardiography:
SigamaniA,XavierD,ChanMTV,etal.Associationofpostoperativehigh-sensitivity asystematicreviewofdiagnosticandclinicaldecision-makinginanaesthesiaand
troponinlevelswithmyocardialinjuryand30-daymortalityamongpatientsunder- criticalcare.Anaesthesia2016;71:1091–1100.
goingnoncardiacsurgery.JAMA2017;317:1642–1651. 132. CantyDJ,RoyseCF.Auditofanaesthetist-performedechocardiographyonperi-
110.PuelacherC,GualandroDM,LuratiBuseG,BolligerD,MarbotS,KindlerC,etal. operativemanagementdecisionsfornon-cardiacsurgery.BrJAnaesth2009;103:
Etiologyofperi-operativemyocardialinfarction/injuryafternoncardiacsurgeryand 352–358.
associatedoutcome.JAmCollCardiol2020;76:1910–1912. 133. CantyDJ,HeibergJ,YangY,RoyseAG,MargaleS,NanjappaN,etal.One-yearre-
111.PuelacherC,LuratiBuseG,SeebergerD,SazgaryL,MarbotS,LampartA,etal. sultsofthepilotmulticentrerandomisedtrialofpreoperativefocusedcardiacultra-
Perioperative myocardial injury after noncardiac surgery: incidence, mortality, soundinhipfracturesurgery.AnaesthIntensiveCare2019;47:207–208.
andcharacterization.Circulation2018;137:1221–1232. 134. Matyal R, Hess PE, Subramaniam B, Mitchell J, Panzica PJ, Pomposelli F, et al.
112.Huelsmann M, Neuhold S, Resl M, Strunk G, Brath H, Francesconi C, et al. Perioperative diastolic dysfunction during vascular surgery and its association
PONTIAC(NT-proBNPselectedpreventionofcardiaceventsinapopulationof withpostoperativeoutcome.JVascSurg2009;50:70–76.
diabeticpatientswithoutahistoryofcardiacdisease):aprospectiverandomized 135. Saito S, Takagi A, Kurokawa F, Ashihara K, Hagiwara N. Usefulness of tissue
controlledtrial.JAmCollCardiol2013;62:1365–1372. Doppler echocardiography to predict perioperative cardiac events in patients
113.Ledwidge M, Gallagher J, Conlon C, Tallon E, O’Connell E, Dawkins I, et al. undergoingnoncardiacsurgery.HeartVessels2012;27:594–602.
Natriureticpeptide-basedscreeningandcollaborativecareforheartfailure:the 136. HigashiM,YamauraK,IkedaM,ShimauchiT,SaikiH,HokaS.Diastolicdysfunction
STOP-HFrandomizedtrial.JAMA2013;310:66–74. oftheleftventricleisassociatedwithpulmonaryedemaafterrenaltransplantation.
114.MuellerC,McDonaldK,deBoerRA,MaiselA,ClelandJGF,KozhuharovN,etal. ActaAnaesthesiolScand2013;57:1154–1160.
HeartFailureAssociationoftheEuropeanSocietyofCardiologypracticalguidance 137. BrecherO,GulatiH,RoistacherN,ZhangH,ShiW,ThalerHT,etal.Preoperative
ontheuseofnatriureticpeptideconcentrations.EurJHeartFail2019;21:715–731. echocardiographicindicesofdiastolicdysfunctionandbrainnatriureticpeptidein
115.DeHertSG,LuratiBuseGA.Cardiacbiomarkersforthepredictionanddetection predictingpostoperativeatrialfibrillationafternoncardiacsurgery.AnesthAnalg
ofadversecardiaceventsafternoncardiacsurgery:anarrativereview.AnesthAnalg 2017;124:1099–1104.
2020;131:187–195. 138. ZhouY,LiuL,ChengT,WangDX,YangHY,ZhangBW,etal.Grade3echocar-
116.MauermannE,BolligerD,SeebergerE,PuelacherC,CorbiereS,FilipovicM,etal. diographicdiastolicdysfunctionisassociatedwithincreasedriskofmajoradverse
Incrementalvalueofpreoperativecopeptinforpredictingmyocardialinjury.Anesth cardiovasculareventsaftersurgery:aretrospectivecohortstudy.AnesthAnalg
Analg2016;123:1363–1371. 2019;129:651–658.
117.BuseGL,MannsB,LamyA,GuyattG,PolanczykCA,ChanMTV,etal.TroponinT 139. FayadA,AnsariMT,YangH,RuddyT,WellsGA.Perioperativediastolicdysfunc-
monitoring to detect myocardial injury after noncardiac surgery: a cost- tioninpatientsundergoingnoncardiacsurgeryisanindependentriskfactorforcar-
consequenceanalysis.CanJSurg2018;61:185–194. diovascularevents:asystematicreviewandmeta-analysis.Anesthesiology2016;125:
118.Vascular Events In Noncardiac Surgery Patients Cohort Evaluation Study 72–91.
Investigators,DevereauxPJ,ChanMT,Alonso-CoelloP,WalshM,BerwangerO, 140. WillinghamM,AyoubiSA,DoanM,WingertT,ScovottiJ,Howard-QuijanoK,etal.
et al.Associationbetweenpostoperative troponinlevelsand30-daymortality Preoperativediastolicdysfunctionandpostoperativeoutcomesafternoncardiac
amongpatientsundergoingnoncardiacsurgery.JAMA2012;307:2295–2304. surgery.JCardiothoracVascAnesth2020;34:679–686.
119.ManthaS,FossJ,EllisJE,RoizenMF.Intensecardiactroponinsurveillanceforlong- 141. SougawaH,InoY,KitabataH,TanimotoT,TakahataM,ShimamuraK,etal.Impact
termbenefitsiscost-effectiveinpatientsundergoingopenabdominalaorticsur- ofleftventricularejectionfractionandpreoperativehemoglobinlevelonperi-
gery:adecisionanalysismodel.AnesthAnalg2007;105:1346–1356. operative adverse cardiovascular events in noncardiac surgery. Heart Vessels
120.Levitan EB, Graham LA, Valle JA, Richman JS, Hollis R, Holcomb CN, et al. 2021;36:1317–1326.
Pre-operativeechocardiographyamongpatientswithcoronaryarterydiseasein 142. HreybeH,ZahidM,SonelA,GoodCB,ShaverJ,SabaS.Noncardiacsurgeryand
theUnitedStatesVeteransAffairshealthcaresystem:aretrospectivecohortstudy. theriskofdeathandothercardiovasculareventsinpatientswithhypertrophiccar-
BMCCardiovascDisord2016;16:173. diomyopathy.ClinCardiol2006;29:65–68.
121.ChangHY,ChangWT,LiuYW.Applicationoftransthoracicechocardiographyin 143. KertaiMD,BountioukosM,BoersmaE,BaxJJ,ThomsonIR,SozziF,etal.Aortic
patientsreceivingintermediate-orhigh-risknoncardiacsurgery.PLoSOne2019;14: stenosis:anunderestimatedriskfactorforperioperativecomplicationsinpatients
e0215854. undergoingnoncardiacsurgery.AmJMed2004;116:8–13.
122.WijeysunderaDN,BeattieWS,KarkoutiK,NeumanMD,AustinPC,LaupacisA. 144. Marbach JA, Almufleh A, Di Santo P, Jung R, Simard T, McInnes M, et al.
Associationofechocardiographybeforemajorelectivenon-cardiacsurgerywith Comparativeaccuracyoffocusedcardiacultrasonographyandclinicalexamination
postoperativesurvivalandlengthofhospitalstay:populationbasedcohortstudy. forleftventriculardysfunctionandvalvularheartdisease:asystematicreviewand
BMJ2011;342:d3695. meta-analysis.AnnInternMed2019;171:264–272.
123.FarisJG,HartleyK,FullerCM,LangstonRB,RoyseCF,VeltmanMG.Auditofcar- 145. LuratiBuseGAL,PuelacherC,GualandroDM,KilincD,GlarnerN,HidvegiR,etal.
diacpathologydetectionusingacriteria-basedperioperativeechocardiography Adherence to the European Society of Cardiology/European Society of
service.AnaesthIntensiveCare2012;40:702–709. Anaesthesiologyrecommendationsonpreoperativecardiactestingandassociation
124.SteedsRP,GarbiM,CardimN,KasprzakJD,SadeE,NihoyannopoulosP,etal. withpositiveresultsandcardiacevents:acohortstudy.BrJAnaesth2021;127:
EACVIappropriatenesscriteriafortheuseoftransthoracicechocardiographyin 376–385.
adults:areportofliteratureandcurrentpracticereview.EurHeartJCardiovasc 146. KnuutiJ,WijnsW,SarasteA,CapodannoD,BarbatoE,Funck-BrentanoC,etal.
Imaging2017;18:1191–1204. 2019ESCGuidelinesforthediagnosisandmanagementofchroniccoronarysyn-
125.KertaiMD,BoersmaE,BaxJJ,Heijenbrok-KalMH,HuninkMG,L’TalienGJ,etal.A dromes.EurHeartJ2020;41:407–477.
meta-analysiscomparingtheprognosticaccuracyofsixdiagnostictestsforpredict- 147. WolkMJ,BaileySR,DohertyJU,DouglasPS,HendelRC,KramerCM,etal.ACCF/
ingperioperativecardiacriskinpatientsundergoingmajorvascularsurgery.Heart AHA/ASE/ASNC/HFSA/HRS/SCAI/SCCT/SCMR/STS2013multimodalityappro-
2003;89:1327–1334. priateusecriteriaforthedetectionandriskassessmentofstableischemicheart
126.HalmEA,BrownerWS,TubauJF,TateoIM,ManganoDT.Echocardiographyfor disease:areportoftheAmericanCollegeofCardiologyFoundationAppropriate
assessing cardiac risk in patients having noncardiac surgery. Study of Use Criteria Task Force, American Heart Association, American Society of
PerioperativeIschemiaResearchGroup.AnnInternMed1996;125:433–441. Echocardiography, American Society of Nuclear Cardiology, Heart Failure
127.RohdeLE,PolanczykCA,GoldmanL,CookEF,LeeRT,LeeTH.Usefulnessof Society of America, Heart Rhythm Society, Society for Cardiovascular
transthoracicechocardiographyasatoolforriskstratificationofpatientsundergo- Angiography and Interventions, Society of Cardiovascular Computed
ingmajornoncardiacsurgery.AmJCardiol2001;87:505–509. Tomography, Society for Cardiovascular Magnetic Resonance, and Society of
128.GalaskoGI,BarnesSC,CollinsonP,LahiriA,SeniorR.Whatisthemostcost- ThoracicSurgeons.JAmCollCardiol2014;63:380–406.
effectivestrategytoscreenforleftventricularsystolicdysfunction:natriureticpep- 148. PellikkaPA,Arruda-OlsonA,ChaudhryFA,ChenMH,MarshallJE,PorterTR,etal.
tides,theelectrocardiogram,hand-heldechocardiography,traditionalechocardiog- Guidelinesforperformance,interpretation,andapplicationofstressechocardiog-
raphy,ortheircombination?EurHeartJ2006;27:193–200. raphyinischemicheartdisease:fromtheAmericanSocietyofEchocardiography.
129.CardimN,DalenH,VoigtJU,IonescuA,PriceS,NeskovicAN,etal.Theuseof JAmSocEchocardiogr2020;33:1–41.e8.
handheldultrasounddevices:apositionstatementoftheEuropeanAssociation 149. KohAS,FloresJL,KengFY,TanRS,ChuaTS.Correlationbetweenclinicalout-
ofCardiovascularImaging(2018update).EurHeartJCardiovascImaging2019;20: comesandappropriatenessgradingforreferraltomyocardialperfusionimaging
245–252. forpreoperativeevaluationpriortonon-cardiacsurgery.JNuclCardiol2012;19:
130.CantyDJ,RoyseCF,KilpatrickD,BowmanL,RoyseAG.Theimpactoffocused 277–284.
transthoracicechocardiographyinthepre-operativeclinic.Anaesthesia2012;67: 150. NguyenP,PlotkinJ,FishbeinTM,LaurinJM,SatoskarR,ShettyK,etal.Dobutamine
618–625. stressechocardiographyinpatientsundergoingorthotopiclivertransplantation:a
Downloaded
from
https://academic.oup.com/eurheartj/article/43/39/3826/6675076
by
guest
on
22
January
2026
--- Страница 87 ---
3912 ESCGuidelines
pooledanalysisofaccuracy,perioperativeandlongtermcardiovascularprognosis. myocardial infarction in patients presenting with ST-segment elevation of the
IntJCardiovascImaging2013;29:1741–1748. EuropeanSocietyofCardiology(ESC).EurHeartJ2018;39:119–177.
151. Shaw LJ, Eagle KA, Gersh BJ, Miller DD. Meta-analysis of intravenous 172. IlluminatiG,RiccoJB,GrecoC,MangieriE,CalioF,CeccaneiG,etal.Systematic
dipyridamole-thallium-201imaging(1985to1994)anddobutamineechocardiog- preoperativecoronaryangiographyandstentingimprovespostoperativeresults
raphy (1991 to 1994) for risk stratification before vascular surgery. J Am Coll ofcarotidendarterectomyinpatientswithasymptomaticcoronaryarterydisease:
Cardiol1996;27:787–798. arandomisedcontrolledtrial.EurJVascEndovascSurg2010;39:139–145.
152. BeattieWS,AbdelnaemE,WijeysunderaDN,BuckleyDN.Ameta-analyticcom- 173. SorensenLT.Woundhealingandinfectioninsurgery.Theclinicalimpactofsmok-
parisonofpreoperativestressechocardiographyandnuclearscintigraphyimaging. ingandsmokingcessation:asystematicreviewandmeta-analysis.ArchSurg2012;
AnesthAnalg2006;102:8–16. 147:373–383.
153. BachDS,EagleKA.Dobutaminestressechocardiography.Stressingtheindications 174. GourgiotisS,AloizosS,AravositaP,MystakelliC,IsaiaEC,GakisC,etal.Theeffects
forpreoperativetesting.Circulation1997;95:8–10. oftobaccosmokingontheincidenceandriskofintraoperativeandpostoperative
154. EtchellsE,MeadeM,TomlinsonG,CookD.Semiquantitativedipyridamolemyo- complicationsinadults.Surgeon2011;9:225–232.
cardialstressperfusionimagingforcardiacriskassessmentbeforenoncardiacvas- 175. WorldHealthOrganization.WHOTobaccoandpostsurgicaloutcomes.https://
cularsurgery:ameta-analysis.JVascSurg2002;36:534–540. apps.who.int/iris/rest/bitstreams/1265388/retrieve.
155. BallalRS,KapadiaS,SecknusMA,RubinD,ArheartK,MarwickTH.Prognosisof 176. MillsE,EyawoO,LockhartI,KellyS,WuP,EbbertJO.Smokingcessationreduces
patientswithvasculardiseaseafterclinicalevaluationanddobutaminestressecho- postoperative complications: a systematic review and meta-analysis. Am J Med
cardiography.AmHeartJ1999;137:469–475. 2011;124:144–154.e8.
156. BoersmaE,PoldermansD,BaxJJ,SteyerbergEW,ThomsonIR,BangaJD,etal. 177. LeeSM,LandryJ,JonesPM,BuhrmannO,Morley-ForsterP.Long-termquitrates
Predictorsofcardiaceventsaftermajorvascularsurgery:roleofclinicalcharacter- afteraperioperativesmokingcessationrandomizedcontrolledtrial.AnesthAnalg
istics,dobutamineechocardiography,andbeta-blockertherapy.JAMA2001;285:
2015;120:582–587.
1865–1873. 178. WongJ,AbrishamiA,RiaziS,SiddiquiN,You-TenE,KormanJ,etal.Aperiopera-
157. CullenMW,McCullyRB,WidmerRJ,SchroederDR,SalonenBR,RaslauD,etal. tivesmokingcessationinterventionwithvarenicline,counseling,andfaxreferralto
Preoperativedobutaminestressechocardiographyandclinicalfactorsforassess- atelephonequitline versusabriefintervention: arandomizedcontrolled trial.
ment of cardiac risk after noncardiac surgery. J Am Soc Echocardiogr 2020;33:
AnesthAnalg2017;125:571–579.
423–432. 179. CavalheriV,GrangerC.Preoperativeexercisetrainingforpatientswithnon-small
158. VanDammeH,PierardL,GillainD,BenoitT,RigoP,LimetR.Cardiacriskassess- celllungcancer.CochraneDatabaseSystRev2017;6:CD012020.
180. TewGA,AyyashR,DurrandJ,DanjouxGR.Clinicalguidelineandrecommenda-
mentbeforevascularsurgery:aprospectivestudycomparingclinicalevaluation,do-
tionsonpre-operativeexercisetraininginpatientsawaitingmajornon-cardiacsur-
butamine stress echocardiography, and dobutamine Tc-99m sestamibi
tomoscintigraphy.CardiovascSurg1997;5:54–64.
gery.Anaesthesia2018;73:750–768.
181. MusallamKM,RosendaalFR,ZaatariG,SoweidA,HoballahJJ,SfeirPM,etal.
159. MetzLD,BeattieM,HomR,RedbergRF,GradyD,FleischmannKE.Theprognostic
Smokingandtheriskofmortalityandvascularandrespiratoryeventsinpatients
valueofnormalexercisemyocardialperfusionimagingandexerciseechocardiog-
raphy:ameta-analysis.JAmCollCardiol2007;49:227–237.
undergoingmajorsurgery.JAMASurg2013;148:755–762.
182. TuranA,MaschaEJ,RobermanD,TurnerPL,YouJ,KurzA,etal.Smokingandperi-
160. CohenMC,SiewersAE,DickensJD,Jr.,HillT,MullerJE.Perioperativeandlong-
operativeoutcomes.Anesthesiology2011;114:837–846.
termprognosticvalueofdipyridamoleTc-99msestamibimyocardialtomography
inpatientsevaluatedforelectivevascularsurgery.JNuclCardiol2003;10:464–472. 183. ImC,OhTK,SongIA.Associationbetweenuseofpreoperativeantihypertensive
medicationand90-daymortalityafternoncardiacsurgery:aretrospectivecohort
161. DowsleyTF,ShethT,ChowBJW.Complementarypre-operativeriskassessment
study.AmJHypertens2020;33:534–542.
usingcoronarycomputedtomographyangiographyandnuclearmyocardialperfu-
184. Clemente-MoragonA,GomezM,Villena-GutierrezR,LalamaDV,Garcia-PrietoJ,
sionimaginginnon-cardiacsurgery:aVISION-CTAsub-study.JNuclCardiol2020;
MartinezF,etal.Metoprololexertsanon-classeffectagainstischaemia-reperfusion
27:1331–1337.
injurybyabrogatingexacerbatedinflammation.EurHeartJ2020;41:4425–4440.
162. Das MK, Pellikka PA, Mahoney DW, Roger VL, Oh JK, McCully RB, et al.
185. PoiseStudyGroup,DevereauxPJ,YangH,YusufS,GuyattG,LeslieK,etal.Effects
Assessmentofcardiacriskbeforenonvascularsurgery:dobutaminestressechocar-
ofextended-releasemetoprololsuccinateinpatientsundergoingnon-cardiacsur-
diographyin530patients.JAmCollCardiol2000;35:1647–1653.
gery(POISEtrial):arandomisedcontrolledtrial.Lancet2008;371:1839–1847.
163. TorresMR,ShortL,BaglinT,CaseC,GibbsH,MarwickTH.Usefulnessofclinical
186. Alonso-CoelloP,PaniaguaP,MizeraR,DevereauxPJ.Shouldphysiciansinitiate
riskmarkersandischemicthresholdtostratifyriskinpatientsundergoingmajor
beta-blockertherapyinpatientsundergoingnon-cardiacsurgery?Insightsfrom
noncardiacsurgery.AmJCardiol2002;90:238–242.
thePOISEtrial.PolArchMedWewn2008;118:616–618.
164. LabibSB,GoldsteinM,KinnunenPM,SchickEC.Cardiaceventsinpatientswith
187. BlessbergerH,LewisSR,PritchardMW,FawcettLJ,DomanovitsH,SchlagerO,
negative maximal versus negative submaximal dobutamine echocardiograms
et al. Perioperative beta-blockers for preventing surgery-related mortality and
undergoingnoncardiacsurgery:importanceofrestingwallmotionabnormalities.
morbidityinadultsundergoingnon-cardiacsurgery.CochraneDatabaseSystRev
JAmCollCardiol2004;44:82–87.
2019;9:CD013438.
165. LancellottiP,PellikkaPA,BudtsW,ChaudhryFA,DonalE,DulgheruR,etal.The
188. FriedellML,VanWayCW,3rd,FreybergRW,AlmenoffPL.Beta-blockadeandop-
clinicaluseofstressechocardiographyinnon-ischaemicheartdisease:recommen- erativemortalityinnoncardiacsurgery:harmfulorhelpful?JAMASurg2015;150:
dations from the European Association of Cardiovascular Imaging and the 658–663.
AmericanSocietyofEchocardiography.EurHeartJCardiovascImaging2016;17: 189. WijeysunderaDN,DuncanD,Nkonde-PriceC,ViraniSS,WashamJB,Fleischmann
1191–1229.
KE,etal.Perioperativebetablockadeinnoncardiacsurgery:asystematicreviewfor
166. NandalurKR,DwamenaBA,ChoudhriAF,NandalurMR,CarlosRC.Diagnostic the2014ACC/AHAguidelineonperioperativecardiovascularevaluationandman-
performanceofstresscardiacmagneticresonanceimaginginthedetectionofcor- agementofpatientsundergoingnoncardiacsurgery:areportoftheAmerican
onaryarterydisease:ameta-analysis.JAmCollCardiol2007;50:1343–1353. CollegeofCardiology/AmericanHeartAssociationTaskForceonpracticeguide-
167. VavereAL,Arbab-ZadehA,RochitteCE,DeweyM,NiinumaH,GottliebI,etal. lines.JAmCollCardiol2014;64:2406–2425.
Coronaryarterystenoses:accuracyof64-detectorrowCTangiographyinseg- 190. LondonMJ,HurK,SchwartzGG,HendersonWG.Associationofperioperative
ments with mild, moderate, or severe calcification – a subanalysis of the beta-blockadewithmortalityandcardiovascularmorbidityfollowingmajornoncar-
CORE-64trial.Radiology2011;261:100–108. diacsurgery.JAMA2013;309:1704–1713.
168. ShethT,ChanM,ButlerC,ChowB,TandonV,NageleP,etal.Prognosticcapabil- 191. Angeli F, Verdecchia P, Karthikeyan G, Mazzotta G, Gentile G, Reboldi G.
itiesofcoronarycomputedtomographicangiographybeforenon-cardiacsurgery: ß-Blockersreducemortalityinpatientsundergoinghigh-risknon-cardiacsurgery.
prospectivecohortstudy.BMJ2015;350:h1907. AmJCardiovascDrugs2010;10:247–259.
169. KrievinsD,ZellansE,LatkovskisG,JegereS,KumsarsI,KaufmanisK,etal.Diagnosis 192. Lindenauer PK, Pekow P, Wang K, Mamidi DK, Gutierrez B, Benjamin EM.
andmanagementofsilentcoronaryischemiainpatientsundergoingcarotidend- Perioperativebeta-blockertherapyandmortalityaftermajornoncardiacsurgery.
arterectomy.JVascSurg2021;73:533–541. NEnglJMed2005;353:349–361.
170. Krievins D, Zellans E, Latkovskis G, Erglis A, Zvaigzne L, Kumsars I, et al. 193. WallaceAW,AuS,CasonBA.Perioperativebeta-blockade:atenololisassociated
Pre-operativediagnosisofsilentcoronaryischaemiamayreducepost-operative withreducedmortalitywhencomparedtometoprolol.Anesthesiology2011;114:
deathandmyocardialinfarctionandimprovesurvivalofpatientsundergoinglower 824–836.
extremitysurgicalrevascularisation.EurJVascEndovascSurg2020;60:411–420. 194. RedelmeierD,ScalesD,KoppA.Betablockersforelectivesurgeryinelderlypa-
171. IbanezB,JamesS,AgewallS,AntunesMJ,Bucciarelli-DucciC,BuenoH,etal.2017 tients:populationbased,retrospectivecohortstudy.BMJ2005;331:932.
ESCGuidelinesforthemanagementofacutemyocardialinfarctioninpatientspre- 195. Ashes C, Judelman S, Wijeysundera DN, Tait G, Mazer CD, Hare GM, et al.
sentingwithST-segmentelevation:theTaskForceforthemanagementofacute Selectivebeta1-antagonismwithbisoprololisassociatedwithfewerpostoperative
Downloaded
from
https://academic.oup.com/eurheartj/article/43/39/3826/6675076
by
guest
on
22
January
2026
--- Страница 88 ---
ESCGuidelines 3913
strokesthanatenololormetoprolol:asingle-centercohortstudyof44,092con- eventsIn noncardiacSurgery patIentscOhort evaluatioN Prospective Cohort.
secutivepatients.Anesthesiology2013;119:777–787. Anesthesiology2017;126:16–27.
196.ShammashJB,TrostJC,GoldJM,BerlinJA,GoldenMA,KimmelSE.Perioperative 217. HollmannC,FernandesNL,BiccardBM.Asystematicreviewofoutcomesasso-
beta-blockerwithdrawalandmortalityinvascularsurgicalpatients.AmHeartJ ciatedwithwithholdingorcontinuingangiotensin-convertingenzymeinhibitors
2001;141:148–153. andangiotensinreceptorblockersbeforenoncardiacsurgery.AnesthAnalg2018;
197.WallaceAW,AuS,CasonBA.Associationofthepatternofuseofperioperative 127:678–687.
beta-blockadeandpostoperativemortality.Anesthesiology2010;113:794–805. 218. McMurray JJ, Packer M, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, et al.
198.Kwon S, Thompson R, Florence M, Maier R, McIntyre L, Rogers T, et al. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med
Beta-blockercontinuationafternoncardiacsurgery:areportfromthesurgical 2014;371:993–1004.
careandoutcomesassessmentprogram.ArchSurg2012;147:467–473. 219. LegrandM,FutierE,LeoneM,DeniauB,MebazaaA,PlaudB,etal.Impactof
199.KertaiMD,CooterM,PollardRJ,BuhrmanW,AronsonS,MathewJP,etal.Is renin-angiotensinsysteminhibitorscontinuationversusdiscontinuationonout-
ComplianceWithSurgicalCareImprovementProjectCardiac(SCIP-Card-2)mea- comeaftermajorsurgery:protocolofamulticenterrandomized,controlledtrial
suresforperioperativebeta-blockersassociatedwithreducedincidenceofmortal- (STOP-or-NOTtrial).Trials2019;20:1–7.
ityandcardiovascular-relatedcriticalqualityindicatorsafternoncardiacsurgery? 220. WijeysunderaDN,BeattieWS.Calciumchannelblockersforreducingcardiac
AnesthAnalg2018;126:1829–1838.
morbidity after noncardiac surgery: a meta-analysis. Anesth Analg 2003;97:
200.Longrois D, Couffignal C, Ait-Hamou N, Amour J, Cholley B, Dilly M, et al. 634–641.
Indispensableoptimisationdelaréintroductiondesbêtabloquantsaprèschirurgie 221. KertaiMD,WesterhoutCM,VargaKS,AcsadyG,GalJ.Dihydropiridinecalcium-
cardiaque.Résultatsdel’étudeBêtabloquantsAvantetAprèsChirurgieCardiaque
channel blockers and perioperative mortality in aortic aneurysm surgery. Br J
(BBAACC).Anesthésie&Réanimation2015;1:A248. Anaesth2008;101:458–465.
201.OesterleA,WeberB,TungR,ChoudhryNK,SinghJP,UpadhyayGA.Preventing 222. OliverMF,GoldmanL,JulianDG,HolmeI.Effectofmivazerolonperioperativecar-
postoperativeatrialfibrillationafternoncardiacsurgery:ameta-analysis.AmJMed
diaccomplicationsduringnon-cardiacsurgeryinpatientswithcoronaryheartdis-
2018;131:795–804e795.
ease:theEuropeanMivazerolTrial(EMIT).Anesthesiology1999;91:951–961.
202.AokiY,KawasakiY,IdeK,ShimizuY,SatoS,YokoyamaJ.Landiololhydrochloride 223. DevereauxPJ,SesslerDI,LeslieK,KurzA,MrkobradaM,Alonso-CoelloP,etal.
forpreventionofatrialfibrillationduringesophagectomy:arandomizedcontrolled
Clonidine in patients undergoing noncardiac surgery. N Engl J Med 2014;370:
trial.JAClinRep2020;6:34. 1504–1513.
203.AoyamaH,OtsukaY,AoyamaY.Landiololinfusionduringgeneralanesthesiadoes
224. HagerB,BetschartM,KrapfR.Effectofpostoperativeintravenousloopdiureticon
notpreventpostoperativeatrialfibrillationinpatientsundergoinglungresection.
renalfunctionaftermajorsurgery.SchweizMedWochenschr1996;126:666–673.
GenThoracCardiovascSurg2016;64:735–741.
225. Arora P, Pourafkari L, Visnjevac O, Anand EJ, Porhomayon J, Nader ND.
204.Ojima T, Nakamori M, Nakamura M, Katsuda M, Hayata K, Kato T, et al.
Preoperativeserumpotassiumpredictstheclinicaloutcomeafternon-cardiacsur-
Randomizedclinicaltrialoflandiololhydrochlorideforthepreventionofatrialfib-
gery.ClinChemLabMed2017;55:145–153.
rillationandpostoperativecomplicationsafteroesophagectomyforcancer.BrJ
226. TagawaM,OgataA,HamanoT.Pre-and/orintra-operativeprescriptionofdiure-
Surg2017;104:1003–1009.
tics, butnot renin-angiotensin-system inhibitors,is significantlyassociated with
205.HorikoshiY,GoyagiT,KudoR,KodamaS,HoriguchiT,NishikawaT.Thesuppres-
acutekidneyinjuryafternon-cardiacsurgery:aretrospectivecohortstudy.PLoS
siveeffectsoflandiololadministrationontheoccurrenceofpostoperativeatrialfib-
One2015;10:e0132507.
rillation and tachycardia, and plasma IL-6 elevation in patients undergoing
227. LoSapioP,GensiniGF,BevilacquaS,ChitiE,PaperettiL,PratesiC,etal.Theroleof
esophagealsurgery:arandomizedcontrolledclinicaltrial.JClinAnesth2017;38:
ivabradineintheincidenceofperioperativecoronarycomplicationsinpatients
111–116.
206.O’BrienB,BurragePS,NgaiJY,PrutkinJM,HuangCC,XuX,etal.Societyof
undergoingvascularsurgery.IntJCardiol2013;168:4352–4353.
228. Thiruvenkatarajan V, Meyer EJ, Nanjappa N, Van Wijk RM, Jesudason D.
Cardiovascular Anesthesiologists/European Association of Cardiothoracic
AnaesthetistsPracticeAdvisoryforthemanagementofperioperativeatrialfibrilla- Perioperative diabetic ketoacidosis associated with sodium-glucose
co-transporter-2inhibitors:asystematicreview.BrJAnaesth2019;123:27–36.
tioninpatientsundergoingcardiacsurgery.JCardiothoracVascAnesth2019;33:
12–26. 229. Patoulias D, Manafis A, Mitas C, Avranas K, Lales G, Zografou I, et al.
Sodium-glucosecotransporter2inhibitorsandtheriskofdiabeticketoacidosis;
207.ZhuJ,WangC,GaoD,ZhangC,ZhangY,LuY,etal.Meta-analysisofamiodarone
versusbeta-blockerasaprophylactictherapyagainstatrialfibrillationfollowingcar- frompathophysiologytoclinicalpractice.CardiovascHematolDisordDrugTargets
diacsurgery.InternMedJ2012;42:1078–1087.
2018;18:139–146.
230. ManganoDT,LayugEL,WallaceA,TateoI.Effectofatenololonmortalityandcar-
208.AuerJ,WeberT,BerentR,PuschmannR,HartlP,NgCK,etal.Acomparisonbe-
tweenoralantiarrhythmicdrugsinthepreventionofatrialfibrillationaftercardiac diovascularmorbidityafternoncardiacsurgery.MulticenterStudyofPerioperative
IschemiaResearchGroup.NEnglJMed1996;335:1713–1720. surgery:thepilotStudyofPreventionofPostoperativeAtrialFibrillation(SPPAF),a
randomized,placebo-controlledtrial.AmHeartJ2004;147:636–643. 231. McGoryML,MaggardMA,KoCY.Ameta-analysisofperioperativebetablockade:
209.LondonMJ,SchwartzGG,HurK,HendersonWG.Associationofperioperative
whatistheactualriskreduction?Surgery2005;138:171–179.
232. WallaceA,LayugB,TateoI,LiJ,HollenbergM,BrownerW,etal.Prophylacticaten-
statin use with mortality and morbidity after major noncardiac surgery. JAMA
InternMed2017;177:231–242. olol reduces postoperative myocardial ischemia. McSPI Research Group.
210.LindenauerPK,PekowP,WangK,GutierrezB,BenjaminEM.Lipid-loweringther-
Anesthesiology1998;88:7–17.
apyandin-hospitalmortalityfollowingmajornoncardiacsurgery.JAMA2004;291: 233. BouriS,Shun-ShinMJ,ColeGD,MayetJ,FrancisDP.Meta-analysisofsecureran-
2092–2099. domisedcontrolledtrialsofbeta-blockadetopreventperioperativedeathinnon-
211.BerwangerO,deBarrosESPG,BarbosaRR,PrecomaDB,FigueiredoEL,HajjarLA,
cardiacsurgery.Heart2014;100:456–464.
etal.Atorvastatinforhigh-riskstatin-naivepatientsundergoingnoncardiacsurgery: 234. HajibandehS,HajibandehS,AntoniouSA,TorellaF,AntoniouGA.Effectofbeta-
theLoweringtheRiskofOperativeComplicationsUsingAtorvastatinLoading blockersonperioperativeoutcomesinvascularandendovascularsurgery:asys-
Dose(LOAD)randomizedtrial.AmHeartJ2017;184:88–96. tematicreviewandmeta-analysis.BrJAnaesth2017;118:11–21.
212.SandersRD,NicholsonA,LewisSR,SmithAF,AldersonP.Perioperativestatin 235. XiaJ,QuY,YinC,XuD.Preoperativerosuvastatinprotectspatientswithcoronary
therapy forimprovingoutcomesduringandafternoncardiacvascularsurgery.
arterydiseaseundergoingnoncardiacsurgery.Cardiology2015;131:30–37.
CochraneDatabaseSystRev2013;7:CD009971. 236. McEvoy MD, Gupta R, Koepke EJ, Feldheiser A, Michard F, Levett D, et al.
213.PutzuA,deCarvalhoESC,deAlmeidaJP,BellettiA,CassinaT,LandoniG,etal. PerioperativeQualityInitiativeConsensusStatementonpostoperativebloodpres-
Perioperativestatintherapyincardiacandnon-cardiacsurgery:asystematicreview
sure,riskandoutcomesforelectivesurgery.BrJAnaesth2019;122:575–586.
andmeta-analysisofrandomizedcontrolledtrials.AnnIntensiveCare2018;8:95. 237. EllenbergerC,TaitG,BeattieWS.Chronicbetablockadeisassociatedwithabet-
214.WesselinkEM,KappenTH,TornHM,SlooterAJC,vanKleiWA.Intraoperative teroutcomeafterelectivenoncardiacsurgerythanacutebetablockade:asingle-
hypotensionandtheriskofpostoperativeadverseoutcomes:asystematicreview. centerpropensity-matchedcohortstudy.Anesthesiology2011;114:817–823.
BrJAnaesth2018;121:706–721. 238. ZauggM,BestmannL,WackerJ,LucchinettiE,BoltresA,SchulzC,etal.Adrenergic
215.ShiffermillerJF,MonsonBJ,VokounCW,BeachyMW,SmithMP,SullivanJN,etal. receptorgenotypebutnotperioperativebisoprololtherapymaydeterminecar-
Prospective Randomized Evaluation of Preoperative Angiotensin-Converting diovascularoutcomeinat-riskpatientsundergoingsurgerywithspinalblock:the
EnzymeInhibition(PREOP-ACEI).JHospMed2018;13:661–667. SwissBetaBlockerinSpinalAnesthesia(BBSA)study:adouble-blinded,placebo-
216.RoshanovPS,RochwergB,PatelA,SalehianO,DuceppeE,Belley-CoteEP,etal. controlled,multicentertrialwith1-yearfollow-up.Anesthesiology2007;107:33–44.
Withholdingversuscontinuingangiotensin-convertingenzymeinhibitorsorangio- 239. FaloyeAO,GebreMA,BechtelAJ.Predictingcardiacriskinnoncardiacsurgery:a
tensinIIreceptorblockersbeforenoncardiacsurgery:ananalysisoftheVascular narrativereview.JAnesth2021;35:122–129.
Downloaded
from
https://academic.oup.com/eurheartj/article/43/39/3826/6675076
by
guest
on
22
January
2026
--- Страница 89 ---
3914 ESCGuidelines
240. SteffelJ,CollinsR,AntzM,CornuP,DestegheL,HaeuslerKG,etal.2021European cardiacandnon-cardiacsurgery:asystematicreviewandmeta-analysis.EurHeart
HeartRhythmAssociationPracticalGuideontheuseofnon-vitaminkantagonist JAcuteCardiovascCare2017;6:753–770.
oralanticoagulantsinpatientswithatrialfibrillation.Europace2021;23:1612–1676. 261. MehranR,BaberU,StegPG,AritiC,WeiszG,WitzenbichlerB,etal.Cessationof
241. ZhengSL,RoddickAJ.Associationofaspirinuseforprimarypreventionwithcar- dualantiplatelettreatmentandcardiaceventsafterpercutaneouscoronaryinter-
diovasculareventsandbleeding events: asystematicreviewand meta-analysis. vention(PARIS):2yearresultsfromaprospectiveobservationalstudy.Lancet
JAMA2019;321:277–287. 2013;382:1714–1722.
242. PiepoliMF,HoesAW,AgewallS,AlbusC,BrotonsC,CatapanoAL,etal.2016 262. SoDYF,WellsGA,LordkipanidzeM,RuelM,PerraultLP,YeongChongA,etal.A
EuropeanGuidelinesoncardiovasculardiseasepreventioninclinicalpractice:the randomizedstudyofearlyvs.delayedcoronaryarterybypasssurgeryamongpa-
Sixth Joint Task Force of the European Society of Cardiology and Other tientswithacutecoronarysyndromestreatedwithticagrelor:theRAPIDCABG
SocietiesonCardiovascularDiseasePreventioninClinicalPractice(constituted study. http://clinicaltrialresults.org/wp-content/uploads/2021/11/So_RAPID_
byrepresentativesof10societiesandbyinvitedexperts)developedwiththespe- CABG.pdf.
cialcontributionoftheEuropeanAssociationforCardiovascularPrevention& 263. GurbelPA,BlidenKP,ButlerK,TantryUS,GesheffT,WeiC,etal.Randomized
Rehabilitation(EACPR).EurHeartJ2016;37:2315–2381. double-blindassessmentoftheONSETandOFFSEToftheantiplateleteffectsof
243. DevereauxPJ,MrkobradaM,SesslerDI,LeslieK,Alonso-CoelloP,KurzA,etal. ticagrelorversusclopidogrelinpatientswithstablecoronaryarterydisease:the
Aspirin in patients undergoing noncardiac surgery. N Engl J Med 2014;370: ONSET/OFFSETstudy.Circulation2009;120:2577–2585.
1494–1503. 264. ValgimigliM,BuenoH,ByrneRA,ColletJP,CostaF,JeppssonA,etal.2017ESC
244. GrahamMM,SesslerDI,ParlowJL,BiccardBM,GuyattG,LeslieK,etal.Aspirinin focusedupdateondualantiplatelettherapyincoronaryarterydiseasedeveloped
patientswithpreviouspercutaneouscoronaryinterventionundergoingnoncardiac incollaborationwithEACTS:theTaskForcefordualantiplatelettherapyincoron-
surgery.AnnInternMed2018;168:237–244.
ary artery disease of the European Society of Cardiology (ESC) and of the
245. VahanianA,BeyersdorfF,PrazF,MilojevicM,BaldusS,BauersachsJ,etal.2021 EuropeanAssociationforCardio-ThoracicSurgery(EACTS).EurHeartJ2018;
ESC/EACTSGuidelinesforthemanagementofvalvularheartdisease.EurHeartJ 39:213–260.
2022;43:561–632.
265. ValgimigliM,FrigoliE,HegD,TijssenJ,JuniP,VranckxP,etal.Dualantiplateletther-
246. BrouwerJ,NijenhuisVJ,DelewiR,HermanidesRS,HolvoetW,DuboisCLF,etal. apyafterPCIinpatientsathighbleedingrisk.NEnglJMed2021;385:1643–1655.
Aspirinwithorwithoutclopidogrelaftertranscatheteraortic-valveimplantation.N 266. UrbanP,MeredithIT,AbizaidA,PocockSJ,CarrieD,NaberC,etal.Polymer-free
EnglJMed2020;383:1447–1457.
drug-coatedcoronarystentsinpatientsathighbleedingrisk.NEnglJMed2015;
247. KooBK,KangJ,ParkKW,RheeTM,YangHM,WonKB,etal.Aspirinversusclo- 373:2038–2047.
pidogrelforchronicmaintenancemonotherapyafterpercutaneouscoronaryinter-
267. Windecker S, Latib A, Kedhi E, Kirtane AJ, Kandzari DE, Mehran R, et al.
vention (HOST-EXAM): an investigator-initiated, prospective, randomised,
Polymer-basedorpolymer-freestentsinpatientsathighbleedingrisk.NEnglJ
open-label,multicentretrial.Lancet2021;397:2487–2496.
Med2020;382:1208–1218.
248. MehranR,BaberU,SharmaSK,CohenDJ,AngiolilloDJ,BriguoriC,etal.Ticagrelor
268. NeumannFJ,Sousa-UvaM,AhlssonA,AlfonsoF,BanningAP,BenedettoU,etal.
withorwithoutaspirininhigh-riskpatientsafterPCI.NEnglJMed2019;381:
2018ESC/EACTSGuidelinesonmyocardialrevascularization.EurHeartJ2019;40:
2032–2042.
87–165.
249. VranckxP,ValgimigliM,JuniP,HammC,StegPG,HegD,etal.Ticagrelorplusas-
269. WatanabeH,MorimotoT,NatsuakiM,YamamotoK,ObayashiY,OgitaM,etal.
pirinfor1month,followedbyticagrelormonotherapyfor23monthsvsaspirin
ComparisonofClopidogrelMonotherapyAfter1to2MonthsofDualAntiplatelet
plusclopidogrelorticagrelorfor12months,followedbyaspirinmonotherapy
Therapywith12MonthsofDualAntiplateletTherapyinPatientsWithAcute
for12monthsafterimplantationofadrug-elutingstent:amulticentre,open-label,
CoronarySyndrome:TheSTOPDAPT-2ACSRandomizedClinicalTrial.JAMA
randomisedsuperioritytrial.Lancet2018;392:940–949.
Cardiol2022;7:407–417.
250. WatanabeH,DomeiT,MorimotoT,NatsuakiM,ShiomiH,ToyotaT,etal.Effect
270. KimBK,HongMK,ShinDH,NamCM,KimJS,KoYG,etal.Anewstrategyfor
of1-monthdualantiplatelettherapyfollowedbyclopidogrelvs12-monthdualanti-
discontinuation of dual antiplatelet therapy: the RESET Trial (REal Safety and
platelettherapyoncardiovascularandbleedingeventsinpatientsreceivingPCI:the
STOPDAPT-2randomizedclinicaltrial.JAMA2019;321:2414–2427. Efficacy of 3-month dual antiplatelet Therapy following Endeavor
zotarolimus-elutingstentimplantation).JAmCollCardiol2012;60:1340–1348.
251. BergerPB,KleimanNS,PencinaMJ,HsiehWH,SteinhublSR,JeremiasA,etal.
271. FeresF,CostaRA,AbizaidA,LeonMB,Marin-NetoJA,BotelhoRV,etal.Threevs
Frequency of major noncardiacsurgeryandsubsequent adverseeventsin the
twelvemonthsofdualantiplatelettherapyafterzotarolimus-elutingstents:the
yearafterdrug-elutingstentplacementresultsfromtheEVENT(Evaluationof
OPTIMIZErandomizedtrial.JAMA2013;310:2510–2522.
Drug-ElutingStentsandIschemicEvents)Registry.JACCCardiovascInterv2010;3:
920–927. 272. Schulz-SchupkeS,ByrneRA,TenBergJM,NeumannFJ,HanY,AdriaenssensT,
etal.ISAR-SAFE:arandomized,double-blind,placebo-controlledtrialof6vs.12
252. SaiaF,BelottiLMB,GuastarobaP,BerardiniA,RossiniR,MusumeciG,etal.Riskof
monthsofclopidogreltherapyafterdrug-elutingstenting.EurHeartJ2015;36: adversecardiacandbleedingeventsfollowingcardiacandnoncardiacsurgeryinpa-
1252–1263.
tientswithcoronarystent:howimportantistheinterplaybetweenstenttypeand
timefromstentingtosurgery?CircCardiovascQualOutcomes2016;9:39–47. 273. GwonHC,HahnJY,ParkKW,SongYB,ChaeIH,LimDS,etal.Six-monthversus
12-monthdualantiplatelettherapyafterimplantationofdrug-elutingstents:the
253. HuberKC,EvansMA,BresnahanJF,GibbonsRJ,HolmesDR,Jr.Outcomeofnon- EfficacyofXience/PromusVersusCyphertoReduceLateLossAfterStenting
cardiacoperationsinpatientswithseverecoronaryarterydiseasesuccessfullytrea-
tedpreoperativelywithcoronaryangioplasty.MayoClinProc1992;67:15–21. (EXCELLENT)randomized,multicenterstudy.Circulation2012;125:505–513.
254. EgholmG,KristensenSD,ThimT,OlesenKK,MadsenM,JensenSE,etal.Riskas- 274. ValgimigliM,CampoG,MontiM,VranckxP,PercocoG,TumscitzC,etal.Short-
sociatedwithsurgerywithin12monthsaftercoronarydrug-elutingstentimplant- versuslong-termdurationofdual-antiplatelettherapyaftercoronarystenting:a
ation.JAmCollCardiol2016;68:2622–2632. randomizedmulticentertrial.Circulation2012;125:2015–2026.
255. HolcombCN,GrahamLA,RichmanJS,ItaniKMF,MaddoxTM,HawnMT.Thein- 275. HanY,XuB,XuK,GuanC,JingQ,ZhengQ,etal.Sixversus12monthsofdual
crementalriskofcoronarystentsonpostoperativeadverseevents:amatchedco- antiplatelettherapyafterimplantationofbiodegradablepolymersirolimus-eluting
hortstudy.AnnSurg2016;263:924–930. stent:randomizedsubstudyoftheI-LOVE-IT2Trial.CircCardiovascInterv2016;
256. MahmoudKD,SanonS,HabermannEB,LennonRJ,ThomsenKM,WoodDL,etal. 9:e003145.
Perioperativecardiovascularriskofpriorcoronarystentimplantationamongpa- 276. HongSJ,ShinDH,KimJS,KimBK,KoYG,ChoiD,etal.6-Monthversus12-month
tientsundergoingnoncardiacsurgery.JAmCollCardiol2016;67:1038–1049. dual-antiplatelettherapyfollowinglongeverolimus-elutingstentimplantation:the
257. Holcomb CN, Hollis RH, Graham LA, Richman JS, Valle JA, Itani KM, et al. IVUS-XPLrandomizedclinicaltrial.JACCCardiovascInterv2016;9:1438–1446.
Associationofcoronarystentindicationwithpostoperativeoutcomesfollowing 277. HahnJY,SongYB,OhJH,ChoDK,LeeJB,DohJH,etal.6-monthversus12-month
noncardiacsurgery.JAMASurg2016;151:462. orlongerdualantiplatelettherapyafterpercutaneouscoronaryinterventioninpa-
258. RodriguezA,GuileraN,MasesA,SierraP,OlivaJC,ColillesC,etal.Managementof tientswithacutecoronarysyndrome(SMART-DATE):arandomised,open-label,
antiplatelettherapyinpatientswithcoronarystentsundergoingnoncardiacsur- non-inferioritytrial.Lancet2018;391:1274–1284.
gery:associationwithadverseevents.BrJAnaesth2018;120:67–76. 278. KedhiE,FabrisE,vanderEntM,BuszmanP,vonBirgelenC,RoolvinkV,etal.Six
259. ArmstrongEJ,GrahamL,WaldoSW,ValleJA,MaddoxTM,HawnMT.Patientand monthsversus12monthsdualantiplatelettherapyafterdrug-elutingstentimplant-
lesion-specificcharacteristicspredictriskofmajoradversecardiovascularevents ationinST-elevationmyocardialinfarction(DAPT-STEMI):randomised,multicen-
among patients with previous percutaneous coronary intervention undergoing tre,non-inferioritytrial.BMJ2018;363:k3793.
noncardiacsurgery.CatheterCardiovascInterv2017;89:617–627. 279. WallentinL,BeckerRC, BudajA,CannonCP,EmanuelssonH,HeldC,etal.
260. Siller-MatulaJM,PetreA,Delle-KarthG,HuberK,AyC,LordkipanidzeM,etal. Ticagrelorversusclopidogrelinpatientswithacutecoronarysyndromes.NEngl
ImpactofpreoperativeuseofP2Y12receptorinhibitorsonclinicaloutcomesin JMed2009;361:1045–1057.
Downloaded
from
https://academic.oup.com/eurheartj/article/43/39/3826/6675076
by
guest
on
22
January
2026
--- Страница 90 ---
ESCGuidelines 3915
280.WiviottSD,BraunwaldE,McCabeCH,MontalescotG,RuzylloW,GottliebS,etal. 301. Chai-Adisaksopha C, Hillis C, Siegal DM, Movilla R, Heddle N, Iorio A, et al.
Prasugrelversusclopidogrelinpatientswithacutecoronarysyndromes.NEnglJ Prothrombincomplexconcentratesversusfreshfrozenplasmaforwarfarinrever-
Med2007;357:2001–2015. sal:asystematicreviewandmeta-analysis.ThrombHaemost2016;116:879–890.
281.YusufS,ZhaoF,MehtaSR,ChrolaviciusS,TognoniG,FoxKK,etal.Effectsofclo- 302. LevyJH,AgenoW,ChanNC,CrowtherM,VerhammeP,WeitzJI,etal.Whenand
pidogrelinadditiontoaspirininpatientswithacutecoronarysyndromeswithout howtouseantidotesforthereversalofdirectoralanticoagulants:guidancefrom
ST-segmentelevation.NEnglJMed2001;345:494–502. theSSCoftheISTH.JThrombHaemost2016;14:623–627.
282.SullivanAE,NannaMG,WangTY,BhattDL,AngiolilloDJ,MehranR,etal.Bridging 303. PollackCV,Jr.,ReillyPA,vanRynJ,EikelboomJW,GlundS,BernsteinRA,etal.
antiplatelettherapyafterpercutaneouscoronaryintervention:JACCreviewtopic Idarucizumabfordabigatranreversal-fullcohortanalysis.NEnglJMed2017;
oftheweek.JAmCollCardiol2021;78:1550–1563. 377:431–441.
283.AngheloiuGO,GugiuGB,RuseC,PandeyR,DasariRR,WhatlingC.Ticagrelorre- 304. ConnollySJ,CrowtherM,EikelboomJW,GibsonCM,CurnutteJT,LawrenceJH,
movalfromhumanblood.JACCBasicTranslSci2017;2:135–145. etal.FullstudyreportofandexanetalfaforbleedingassociatedwithfactorXain-
284.BhattDL,PollackCV,WeitzJI,JenningsLK,XuS,ArnoldSE,etal.Antibody-based hibitors.NEnglJMed2019;380:1326–1335.
ticagrelorreversalagentinhealthyvolunteers.NEnglJMed2019;380:1825–1833. 305. Majeed A, Ågren A, Holmström M, Bruzelius M, Chaireti R, Odeberg J, et al.
285.MahlaE,MetzlerH,Bornemann-CimentiH,PruellerF,RaggamR,PregartnerG, Management of rivaroxaban- or apixaban-associated major bleeding with pro-
etal.Plateletinhibitionandbleedinginpatientsundergoingnon-cardiacsurgery thrombincomplexconcentrates:acohortstudy.Blood2017;130:1706–1712.
—theBIANCAObservationalStudy.ThrombHaemost2018;118:864–872. 306. Healey JS, Eikelboom J, Douketis J, Wallentin L, Oldgren J, Yang S, et al.
286.MahlaE,TantryUS,PrullerF,GurbelPA.Istherearoleforpreoperativeplatelet Periproceduralbleedingandthromboemboliceventswithdabigatrancompared
functiontestinginpatientsundergoingcardiacsurgeryduringantiplatelettherapy? with warfarin: results from the Randomized Evaluation of Long-Term
Circulation2018;138:2145–2159. Anticoagulation Therapy (RE-LY) Randomized Trial. Circulation 2012;126:
287.MahlaE,SuarezTA,BlidenKP,RehakP,MetzlerH,SequeiraAJ,etal.Plateletfunc- 343–348.
tion measurement-based strategy to reduce bleeding and waiting time in 307. GarciaD,AlexanderJH,WallentinL,WojdylaDM,ThomasL,HannaM,etal.
clopidogrel-treatedpatientsundergoingcoronaryarterybypassgraftsurgery:the Managementandclinicaloutcomesinpatientstreatedwithapixabanvswarfarin
timingbasedonplateletfunctionstrategytoreduceclopidogrel-associatedbleed- undergoingprocedures.Blood2014;124:3692–3698.
ing related to CABG (TARGET-CABG) study. Circ Cardiovasc Interv 2012;5: 308. SherwoodMW,DouketisJD,PatelMR,PicciniJP,HellkampAS,LokhnyginaY,etal.
261–269. Outcomesoftemporaryinterruptionofrivaroxabancomparedwithwarfarinin
288.WindeckerS,LopesRD,MassaroT,Jones-BurtonC,GrangerCB,AronsonR,etal. patientswithnonvalvularatrialfibrillation:resultsfromtherivaroxabanoncedaily,
Antithrombotictherapyinpatientswithatrialfibrillationandacutecoronarysyn- oral,directfactorXainhibitioncomparedwithvitaminKantagonismforpreven-
drometreatedmedicallyorwithpercutaneouscoronaryinterventionorundergo- tionofstrokeandembolismtrialinatrialfibrillation(ROCKETAF).Circulation
ingelectivepercutaneouscoronaryintervention:insightsfromtheAUGUSTUS 2014;129:1850–1859.
trial.Circulation2019;140:1921–1932. 309. ShawJR,LiN,VanasscheT,CoppensM,SpyropoulosAC,SyedS,etal.Predictors
289.GenereuxP,RutledgeDR,PalmeriniT,CaixetaA,KedhiE,HermillerJB,etal.Stent ofpreproceduraldirectoralanticoagulantlevelsinpatientshavinganelectivesur-
thrombosis and dual antiplatelet therapy interruption with everolimus-eluting geryorprocedure.BloodAdvances2020;4:3520–3527.
stents:insightsfromtheXienceVCoronaryStentSystemTrials.CircCardiovasc 310. GodierA,DincqAS,MartinAC,RaduA,LeblancI,AntonaM,etal.Predictorsof
Interv2015;8:e001362. pre-proceduralconcentrationsofdirectoralanticoagulants:aprospectivemulti-
290.Beyer-WestendorfJ,GelbrichtV,ForsterK,EbertzF,KohlerC,WerthS,etal. centrestudy.EurHeartJ2017;38:2431–2439.
Peri-interventionalmanagementofnoveloralanticoagulantsindailycare:results 311. DouketisJD,SpyropoulosAC,DuncanJ,CarrierM,LeGalG,TafurAJ,etal.
fromtheprospectiveDresdenNOACregistry.EurHeartJ2014;35:1888–1896. Perioperative management of patients with atrial fibrillation receiving a direct
291.OttoCM,NishimuraRA,BonowRO,CarabelloBA,ErwinJP,3rd,GentileF,etal. oralanticoagulant.JAMAInternMed2019;179:1469–1478.
2020ACC/AHAGuidelineforthemanagementofpatientswithvalvularheartdis- 312. ColonnaP,vonHeymannC,SantamariaA,SaxenaM,VanasscheT,WolpertD,
ease. Executive summary: a report of the American College of Cardiology/ etal.Routineclinicalpracticeintheperiproceduralmanagementofedoxabanther-
American Heart Association Joint Committee on Clinical Practice Guidelines. apyisassociatedwithlowriskofbleedingandthromboemboliccomplications:the
Circulation2021;143:e35–e71. prospective, observational, and multinational EMIT-AF/VTE study. Clin Cardiol
292.DouketisJD,SpyropoulosAC,KaatzS,BeckerRC,CapriniJA,DunnAS,etal. 2020;43:769–780.
Perioperativebridginganticoagulationinpatientswithatrialfibrillation.NEnglJ 313. Albaladejo P, Pernod G, Godier A, de Maistre E, Rosencher N, Mas JL, et al.
Med2015;373:823–833. Managementofbleedingandemergencyinvasiveproceduresinpatientsondabiga-
293.KuoHC,LiuFL,ChenJT,CherngYG,TamKW,TaiYH.Thromboembolicand tran: updated guidelines from the French Working Group on Perioperative
bleedingriskofperiproceduralbridginganticoagulation:asystematicreviewand Haemostasis (GIHP) – September 2016. Anaesth Crit Care Pain Med 2018;37:
meta-analysis.ClinCardiol2020;43:441–449. 391–399.
294.KovacsMJ,WellsPS,AndersonDR,Lazo-LangnerA,KearonC,BatesSM,etal. 314. NarouzeS,BenzonHT,ProvenzanoDA,BuvanendranA,DeAndresJ,DeerTR,
Postoperativelowmolecularweightheparinbridgingtreatmentforpatientsat etal.Interventionalspineandpainproceduresinpatientsonantiplateletandanti-
highriskofarterialthromboembolism(PERIOP2):doubleblindrandomisedcon- coagulant medications: guidelines from the American Society of Regional
trolledtrial.BMJ2021;373:n1205. AnesthesiaandPainMedicine,theEuropeanSocietyofRegionalAnaesthesiaand
295.CaldeiraD,DavidC,SantosAT,CostaJ,PintoFJ,FerreiraJJ.Efficacyandsafetyof Pain Therapy, the American Academy of Pain Medicine, the International
lowmolecularweightheparininpatientswithmechanicalheartvalves:systematic NeuromodulationSociety,theNorthAmericanNeuromodulationSociety,and
reviewandmeta-analysis.JThrombHaemost2014;12:650–659. theWorldInstituteofPain.RegAnesthPainMed2015;40:182–212.
296.BirnieDH,HealeyJS,WellsGA,VermaA,TangAS,KrahnAD,etal.Pacemakeror 315. JohnstonS.Anevidencesummaryofthemanagementofpatientstakingdirectoral
defibrillatorsurgerywithoutinterruptionofanticoagulation.NEnglJMed2013; anticoagulants(DOACs)undergoingdentalsurgery.IntJOralMaxillofacSurg2016;
368:2084–2093. 45:618–630.
297.Sant’annaRT,LeiriaTL,NascimentoT,Sant’annaJR,KalilRA,LimaGG,etal. 316. SivolellaS,DeBiagiM,BrunelloG,BerengoM,PengoV.Managingdentoalveolar
Meta-analysisofcontinuousoralanticoagulantsversusheparinbridginginpatients surgicalproceduresinpatientstakingneworalanticoagulants.Odontology2015;
undergoing CIED surgery: reappraisal after the BRUISE study. Pacing Clin 103:258–263.
Electrophysiol2015;38:417–423. 317. OckermanA,VanhaverbekeM,MiclotteI,BelmansA,VanasscheT,PolitisC,etal.
298.Eichhorn W, Barsukov E, Al-Dam A, Gröbe A, Smeets R, Eichhorn M, et al. Tranexamicacidtoreducebleedingafterdentalextractioninpatientstreatedwith
Postoperativebleedingriskforcutaneoussurgeryintheheadandneckregion non-vitaminKoralanticoagulants:designandrationaleoftheEXTRACT-NOAC
with continued phenprocoumon therapy. J Cranio-Maxillofac Surg 2014;42: trial.BrJOralMaxillofacSurg2019;57:1107–1112.
608–611. 318. NijenhuisVJ,BrouwerJ,DelewiR,HermanidesRS,HolvoetW,DuboisCLF,etal.
299.NandoeTewarieRDS,BartelsRHMA.Theperioperativeuseoforalanticoagulants Anticoagulationwithorwithoutclopidogrelaftertranscatheteraortic-valveim-
duringsurgicalproceduresforcarpaltunnelsyndrome.Apreliminarystudy.Acta plantation.NEnglJMed2020;382:1696–1707.
Neurochirurgica2010;152:1211–1213. 319. XuK,ChanNC,IbrahimQ,KrugerP,SinhaS,BhagirathV,etal.Reductioninmor-
300.DohertyJU,GluckmanTJ,HuckerWJ,JanuzziJL,Jr.,OrtelTL,SaxonhouseSJ,etal. tality following elective major hip and knee surgery: a systematic review and
2017ACCExpertConsensusDecisionPathwayforperiproceduralmanagement meta-analysis.ThrombHaemost2019;119:668–674.
ofanticoagulationinpatientswithnonvalvularatrialfibrillation:areportofthe 320. SmilowitzNR,GuptaN,GuoY,MaldonadoTS,EikelboomJW,GoldhaberSZ,etal.
American College of Cardiology Clinical Expert Consensus Document Task Trendsinperioperativevenousthromboembolismassociatedwithmajornoncar-
Force.JAmCollCardiol2017;69:871–898. diacsurgery.THOpen2017;1:e82–e91.
Downloaded
from
https://academic.oup.com/eurheartj/article/43/39/3826/6675076
by
guest
on
22
January
2026
--- Страница 91 ---
3916 ESCGuidelines
321. KlemenND,FeingoldPL,HashimotoB,WangM,KleymanS,BrackettA,etal. 344. CassidyMR,RosenkranzP,McAnenyD.Reducingpostoperativevenousthrombo-
Mortality risk associated with venous thromboembolism: a systematic review embolismcomplicationswithastandardizedrisk-stratifiedprophylaxisprotocol
andBayesianmeta-analysis.LancetHaematol2020;7:e583–e593. andmobilizationprogram.JAmCollSurg2014;218:1095–1104.
322. GangireddyC,RectenwaldJR,UpchurchGR,WakefieldTW,KhuriS,Henderson 345. MusallamKM,TamimHM,RichardsT,SpahnDR,RosendaalFR,HabbalA,etal.
WG,etal.Riskfactorsandclinicalimpactofpostoperativesymptomaticvenous Preoperativeanaemiaandpostoperativeoutcomesinnon-cardiacsurgery:aretro-
thromboembolism.JVascSurg2007;45:335–341;discussion341–332. spectivecohortstudy.Lancet2011;378:1396–1407.
323. CapriniJA.Riskassessmentasaguideforthepreventionofthemanyfacesofven- 346. BaronDM,FranchiniM,GoobieSM,JavidrooziM,KleinAA,LasockiS,etal.Patient
ousthromboembolism.AmJSurg2010;199:S3–S10. blood management during the COVID-19 pandemic: a narrative review.
324. ObiAT,PannucciCJ,NackashiA,AbdullahN,AlvarezR,BahlV,etal.Validationof Anaesthesia2020;75:1105–1113.
theCaprinivenousthromboembolismriskassessmentmodelincriticallyillsurgical 347. MunozM,Gomez-RamirezS,CamposA,RuizJ,LiumbrunoGM.Pre-operativean-
patients.JAMASurg2015;150:941–948. aemia:prevalence,consequencesandapproachestomanagement.BloodTransfus
325. LobastovK,BarinovV,SchastlivtsevI,LaberkoL,RodomanG,BoyarintsevV. 2015;13:370–379.
ValidationoftheCapriniriskassessmentmodelforvenousthromboembolismin 348. vonHeymannC,KaufnerL,SanderM,SpiesC,SchmidtK,GombotzH,etal.Does
high-risksurgicalpatientsinthebackgroundofstandardprophylaxis.JVascSurg theseverityofpreoperativeanemiaorbloodtransfusionhaveastrongerimpacton
VenousLymphatDisord2016;4:153–160.
long-term survival after cardiac surgery? J Thorac Cardiovasc Surg 2016;152:
326. HacheyKJ,HewesPD,PorterLP,RidyardDG,RosenkranzP,McAnenyD,etal. 1412–1420.
Caprini venous thromboembolism risk assessment permits selection for post- 349. RosslerJ,SchoenrathF,SeifertB,KasererA,SpahnGH,FalkV,etal.Irondeficiency
discharge prophylactic anticoagulation in patients with resectable lung cancer. isassociatedwithhighermortalityinpatientsundergoingcardiacsurgery:apro-
JThoracCardiovascSurg2016;151:37–44e31. spectivestudy.BrJAnaesth2020;124:25–34.
327. SterblingHM,RosenAK,HacheyKJ,VellankiNS,HewesPD,RaoSR,etal.Caprini 350. AlthoffFC,NebH,HerrmannE,TrentinoKM,VernichL,FullenbachC,etal.
riskmodeldecreasesvenousthromboembolismratesinthoracicsurgerycancer Multimodalpatientbloodmanagementprogrambasedonathree-pillarstrategy: patients.AnnThoracSurg2018;105:879–885. asystematicreviewandmeta-analysis.AnnSurg2019;269:794–804.
328. Falck-YtterY,FrancisCW,JohansonNA,CurleyC,DahlOE,SchulmanS,etal. 351. MeybohmP,HerrmannE,SteinbickerAU,WittmannM,GruenewaldM,FischerD,
PreventionofVTEinorthopedicsurgerypatients:antithrombotictherapyandpre- etal.Patientbloodmanagementisassociatedwithasubstantialreductionofred
vention of thrombosis, 9th ed: American College of Chest Physicians bloodcellutilizationandsafeforpatient’soutcome:aprospective,multicenterco-
Evidence-BasedClinicalPracticeGuidelines.Chest2012;141:e278S–e325S.
hortstudywithanoninferioritydesign.AnnSurg2016;264:203–211.
329. FaraoniD,ComesRF,GeertsW,WilesMD,ESAVTEGuidelinesTaskForce.
352. FrewN,AlexanderD,HoodJ,AcornleyA.Impactofabloodmanagementproto-
European guidelines on perioperative venous thromboembolism prophylaxis:
colontransfusionratesandoutcomesfollowingtotalhipandkneearthroplasty.
neurosurgery.EurJAnaesthesiol2018;35:90–95.
AnnRCollSurgEngl2016;98:380–386.
330. Kozek-Langenecker S, Fenger-Eriksen C, Thienpont E, Barauskas G, ESA VTE
353. LeahyMF,HofmannA,TowlerS,TrentinoKM,BurrowsSA,SwainSG,etal.
GuidelinesTaskForce.Europeanguidelinesonperioperativevenousthrombo-
Improvedoutcomesandreducedcostsassociatedwithahealth-system-widepa-
embolismprophylaxis:surgeryintheelderly.EurJAnaesthesiol2018;35:116–122.
tientbloodmanagementprogram:aretrospectiveobservationalstudyinfourma-
331. VenclauskasL,MaleckasA,ArcelusJI,ESAVTEGuidelinesTaskForce.European joradulttertiary-carehospitals.Transfusion2017;57:1347–1358.
guidelinesonperioperativevenousthromboembolismprophylaxis:surgeryinthe
354. So-OsmanC,NelissenR,Koopman-vanGA,KluyverE,PöllR,OnstenkR,etal.
obesepatient.EurJAnaesthesiol2018;35:147–153.
Patientbloodmanagementinelectivetotalhip-andknee-replacementsurgery
332. AfshariA,AgenoW,AhmedA,DuranteauJ,FaraoniD,Kozek-LangeneckerS,etal.
(Part1):arandomizedcontrolledtrialonerythropoietinandbloodsalvageastrans-
Europeanguidelinesonperioperativevenousthromboembolismprophylaxis:ex-
ecutivesummary.EurJAnaesthesiol2018;35:77–83. fusionalternativesusingarestrictivetransfusionpolicyinerythropoietin-eligiblepa-
tients.Anesthesiology2014;120:839–851.
333. CimminielloC,PrandoniP,AgnelliG,DiMinnoG,PoloFrizH,ScaglioneF,etal.
355. TheusingerOM,KindSL,SeifertB,Borgeatl,GerberC,SpahnDR.Patientblood
Thromboprophylaxis with enoxaparin and direct oral anticoagulants in major
managementinorthopaedicsurgery:afour-yearfollow-upoftransfusionrequire-
orthopedicsurgeryandacutelyillmedicalpatients:ameta-analysis.InternEmerg
Med2017;12:1291–1305. mentsandbloodlossfrom2008to2011attheBalgristUniversityHospitalin
Zurich,Switzerland.BloodTransfus2014;12:195–203.
334. LassenMR,GallusA,RaskobGE,PineoG,ChenD,RamirezLM,etal.Apixaban
356. FroesslerB,PalmP,WeberI,HodylNA,SinghR,MurphyEM.Theimportantrole
versusenoxaparinforthromboprophylaxisafterhipreplacement.NEnglJMed
2010;363:2487–2498. forintravenousironinperioperativepatientbloodmanagementinmajorabdom-
inalsurgery:arandomizedcontrolledtrial.AnnSurg2016;264:41–46.
335. LassenMR,RaskobGE,GallusA,PineoG,ChenD,PortmanRJ.Apixabanoren-
357. Triphaus C, Judd L, Glaser P, Goehring MH, Schmitt E, Westphal S, et al.
oxaparinforthromboprophylaxisafterkneereplacement.NEnglJMed2009;361:
594–604. Effectiveness of preoperative iron supplementation in major surgical patients
336. LassenMR,AgenoW,BorrisLC,LiebermanJR,RosencherN,BandelTJ,etal. with iron deficiency: a prospective observational study. Ann Surg 2021;274:
Rivaroxabanversusenoxaparinforthromboprophylaxisaftertotalkneearthro-
e212–e219.
plasty.NEnglJMed2008;358:2776–2786. 358. CappelliniMD,Comin-ColetJ,deFranciscoA,DignassA,DoehnerW,LamCS,
337. Eriksson BI, Borris LC, Friedman RJ, Haas S, Huisman MV, Kakkar AK, et al.
etal.Irondeficiencyacrosschronicinflammatoryconditions:internationalexpert
Rivaroxabanversusenoxaparinforthromboprophylaxisafterhiparthroplasty.N opinion on definition, diagnosis, and management. Am J Hematol 2017;92:
EnglJMed2008;358:2765–2775. 1068–1078.
338. FriedmanRJ,DahlOE,RosencherN,CapriniJA,KurthAA,FrancisCW,etal. 359. AuerbachM,MacdougallIC.Safetyofintravenousironformulations:factsandfolk-
Dabigatranversusenoxaparinforpreventionofvenousthromboembolismafter
lore.BloodTransfus2014;12:296–300.
hiporkneearthroplasty:apooledanalysisofthreetrials.ThrombRes2010;126: 360. Richards T, Baikady RR, Clevenger B, Butcher A, Abeysiri S, Chau M, et al.
175–182. Preoperativeintravenousirontotreatanaemiabeforemajorabdominalsurgery
339. KawaiY,FujiT,FujitaS,KimuraT,IbusukiK,AbeK,etal.Edoxabanversusenox- (PREVENTT): a randomised, double-blind, controlled trial. Lancet 2020;396:
aparinforthepreventionofvenousthromboembolismaftertotalkneeorhipar-
1353–1361.
throplasty:pooledanalysisofcoagulationbiomarkersandprimaryefficacyand 361. KaufnerL,vonHeymannC,HenkelmannA,PaceNL,WeibelS,KrankeP,etal.
safetyendpointsfromtwophase3trials.ThrombJ2016;14:48. Erythropoietinplusironversuscontroltreatmentincludingplaceboorironforpre-
340. PetersenPB,KehletH,JorgensenCC.LundbeckFoundationCentreforFast-track, operativeanaemicadultsundergoingnon-cardiacsurgery.CochraneDatabaseSyst
Hip,GroupKRC.Safetyofin-hospitalonlythromboprophylaxisafterfast-trackto- Rev2020;8:CD012451.
talhipandkneearthroplasty:aprospectivefollow-upstudyin17,582procedures. 362. Munoz M, Acheson AG, Auerbach M, Besser M, Habler O, Kehlet H, et al.
ThrombHaemost2018;118:2152–2161. Internationalconsensusstatementontheperi-operativemanagementofanaemia
341. WilsonDG,PooleWE,ChauhanSK,RogersBA.Systematicreviewofaspirinfor andirondeficiency.Anaesthesia2017;72:233–247.
thromboprophylaxis in modern elective total hip and knee arthroplasty. Bone 363. WorldHealthAssembly.Availability,safetyandqualityofbloodproducts.http://
JointJ2016;98-B:1056–1061. apps.who.int/gb/ebwha/pdf_files/WHA63/A63_R12-en.pdf(27October2017).
342. JennyJY,PabingerI,SamamaCM,ESAVTEGuidelinesTaskForce.Europeanguide- 364. KotzeA,HarrisA,BakerC,IqbalT,LaviesN,RichardsT,etal.BritishCommittee
lines on perioperative venous thromboembolism prophylaxis: aspirin. Eur J forStandardsinHaematologyGuidelinesontheidentificationandmanagementof
Anaesthesiol2018;35:123–129. pre-operativeanaemia.BrJHaematol2015;171:322–331.
343. AndersonDR,DunbarM,MurnaghanJ,KahnSR,GrossP,ForsytheM,etal.Aspirin 365. Koch CG, Reineks EZ, Tang AS, Hixson ED, Phillips S, Sabik JF, 3rd, et al.
orrivaroxabanforVTEprophylaxisafterhiporkneearthroplasty.NEnglJMed Contemporary bloodletting in cardiac surgical care. Ann Thorac Surg 2015;99:
2018;378:699–707. 779–784.
Downloaded
from
https://academic.oup.com/eurheartj/article/43/39/3826/6675076
by
guest
on
22
January
2026
--- Страница 92 ---
ESCGuidelines 3917
366.RiessenR,BehmenburgM,BlumenstockG,GuenonD,EnkelS,SchaferR,etal.A 388. PeruzziWT,ParkerMA,LichtenthalPR,Cochran-ZullC,TothB,BlakeM.Aclinical
simple“blood-savingbundle”reducesdiagnosticbloodlossandthetransfusionrate evaluationofabloodconservationdeviceinmedicalintensivecareunitpatients.
inmechanicallyventilatedpatients.PLoSOne2015;10:e0138879. CritCareMed1993;21:501–506.
367.ShanderA,KaplanLJ,HarrisMT,GrossI,NagarshethNP,NemethJ,etal.Topical 389. KataifeED,SaidS,BraunJ,RocheTR,RosslerJ,KasererA,etal.TheHaemostasis
hemostatictherapyinsurgery:bridgingtheknowledgeandpracticegap.JAmColl TrafficLight,auser-centredcoagulationmanagementtoolforacutebleedingsitua-
Surg2014;219:570–579.e574. tions: a simulation-based randomised dual-centre trial. Anaesthesia 2021;76:
368.MenkisAH,MartinJ,ChengDC,FitzgeraldDC,FreedmanJJ,GaoC,etal.Drug, 902–910.
devices,technologies,andtechniquesforbloodmanagementinminimallyinvasive 390. GoodnoughLT,ShiehL,HadhazyE,ChengN,KhariP,MaggioP.Improvedblood
and conventional cardiothoracic surgery: a consensus statement from the utilizationusingreal-timeclinicaldecisionsupport.Transfusion2014;54:1358–1365.
International Society for Minimally Invasive Cardiothoracic Surgery (ISMICS) 391. OliverJC,GriffinRL,HannonT,MarquesMB.Thesuccessofourpatientblood
2011.Innovations(Phila)2012;7:229–241. managementprogramdependedonaninstitution-widechangeintransfusionprac-
369.AnastasiadisK,MurkinJ,AntonitsisP,BauerA,RanucciM,GygaxE,etal.Useof tices.Transfusion2014;54:2617–2624.
minimalinvasiveextracorporealcirculationincardiacsurgery:principles,definitions 392. KasererA,RösslerJ,BraunJ,FarokhzadF,PapeHC,DutkowskiP,etal.Impactofa
andpotentialbenefits.ApositionpaperfromtheMinimalinvasiveExtra-Corporeal
patientbloodmanagementmonitoringandfeedbackprogrammeonallogeneic
TechnologiesinternationalSociety(MiECTiS).InteractCardiovascThoracSurg2016; bloodtransfusionsandrelatedcosts.Anaesthesia2019;74:1534–1541.
22:647–662.
393. SardarM,AzharuddinM,SubediA,GhatageP,DuD,SzallasiA.Improvingblood
370.WeberCF,GörlingerK,MeiningerD,HerrmannE,BingoldT,MoritzA,etal. transfusionpracticesinacommunityhospitalsetting:ourexperiencewithreal-time
Point-of-caretesting:aprospective,randomizedclinicaltrialofefficacyincoagulo-
clinicaldecisionsupport.MedSci(Basel)2018;6.
pathiccardiacsurgerypatients.Anesthesiology2012;117:531–547.
394. JenkinsI,DoucetJJ,ClayB,KopkoP,FippsD,HemmenE,etal.Transfusingwisely:
371.Weber CF, Zacharowski K, Meybohm P, Adam EH, Hofer S, Brün K, et al. clinical decisionsupport improves blood transfusion practices. Jt Comm J Qual
Hemotherapy algorithms for coagulopathic cardiac surgery patients. Clin Lab PatientSaf2017;43:389–395.
2014;60:1059–1063.
395. StaplesS,SalisburyRA,KingAJ,PolzellaP,BakhishliG,StavesJ,etal.Howdoweuse
372.MuñozM,Gómez-RamírezS,Kozek-LangenekerS.Pre-operativehaematological electronicclinicaldecisionsupportandfeedbacktopromotegoodtransfusion
assessmentinpatientsscheduledformajorsurgery.Anaesthesia2016;71Suppl practice.Transfusion2020;60:1658–1665.
1:19–28.
396. DerzonJH,ClarkeN,AlfordA,GrossI,ShanderA,ThurerR.Restrictivetransfu-
373.Kozek-LangeneckerSA,AfshariA,AlbaladejoP,SantullanoCA,DeRobertisE, sionstrategyandclinicaldecisionsupportpracticesforreducingRBCtransfusion
Filipescu DC, et al. Management of severe perioperative bleeding: guidelines overuse.AmJClinPathol2019;152:544–557.
from the European Society of Anaesthesiology. Eur J Anaesthesiol 2013;30: 397. DawoodMM,GutpaDK,SouthernJ,WaliaA,AtkinsonJB,EagleKA.Pathologyof
270–382.
fatalperioperativemyocardialinfarction:implicationsregardingpathophysiology
374.MeybohmP,ZacharowskiK,WeberCF.Point-of-carecoagulationmanagementin andprevention.IntJCardiol1996;57:37–44.
intensivecaremedicine.CritCare2013;17:218.
398. EagleKA,RihalCS,MickelMC,HolmesDR,FosterED,GershBJ.Cardiacriskof
375.KerK,EdwardsP,PerelP,ShakurH,RobertsI.Effectoftranexamicacidonsurgical noncardiacsurgery:influenceofcoronarydiseaseandtypeofsurgeryin3368op-
bleeding:systematicreviewandcumulativemeta-analysis.BMJ2012;344:e3054.
erations. CASS Investigators and University of Michigan Heart Care Program.
376.DevereauxPJ,MarcucciM,PainterTW,ConenD,LomivorotovV,SesslerDI,etal. CoronaryArterySurgeryStudy.Circulation1997;96:1882–1887.
Tranexamicacidinpatientsundergoingnoncardiacsurgery.NEnglJMed2022.
399. McFalls EO, Ward HB, Moritz TE, Goldman S, Krupski WC, Littooy F, et al.
377.MeybohmP,ChoorapoikayilS,WesselsA,HerrmannE,ZacharowskiK,SpahnDR.
Coronary-arteryrevascularizationbeforeelectivemajorvascularsurgery.NEngl
Washedcellsalvageinsurgicalpatients:areviewandmeta-analysisofprospective JMed2004;351:2795–2804.
randomizedtrialsunderPRISMA.Medicine(Baltimore)2016;95:e4490.
400. WongEY,LawrenceHP,WongDT.Theeffectsofprophylacticcoronaryrevascu-
378.SantosAA,SilvaJP,SilvaLdaF,SousaAG,PiottoRF,BaumgratzJF.Therapeuticop- larizationormedicalmanagementonpatientoutcomesafternoncardiacsurgery–
tionstominimizeallogeneicbloodtransfusionsandtheiradverseeffectsincardiac
surgery:asystematicreview.RevBrasCirCardiovasc2014;29:606–621.
ameta-analysis.CanJAnaesth2007;54:705–717.
401. FengB,LinJ,JinJ,QianW,CaoS,WengX.Theeffectofpreviouscoronaryartery
379.Haensig M, Kempfert J, Kempfert PM, Girdauskas E, Borger MA, Lehmann S.
revascularizationontheadversecardiaceventsninetydaysaftertotaljointarthro-
Thrombelastometryguidedblood-componenttherapyaftercardiacsurgery:aran-
plasty.JArthroplasty2018;33:235–240.
domizedstudy.BMCAnesthesiol2019;19:201.
402. MaronDJ,HochmanJS,ReynoldsHR,BangaloreS,O’BrienSM,BodenWE,etal.
380.DiasJD,SauaiaA,AchneckHE,HartmannJ,MooreEE.Thromboelastography-
Initialinvasiveorconservativestrategyforstablecoronarydisease.NEnglJMed
guidedtherapyimprovespatientbloodmanagementandcertainclinicaloutcomes
2020;382:1395–1407.
inelectivecardiacandliversurgeryandemergencyresuscitation:asystematicre-
viewandanalysis.JThrombHaemost2019;17:984–994. 403. BaineyKR,AlemayehuW,WelshRC,KumarA,KingSB,3rd,KirtaneAJ.Long-term
clinicaloutcomesfollowingrevascularizationinhigh-riskcoronaryanatomypa-
381.ChutipongtanateA,YasaengC,VirankabutraT,ChutipongtanateS.Systematic
tientswithstableischemicheartdisease.JAmHeartAssoc2021;10:e018104.
comparisonoffourpoint-of-caremethodsversusthereferencelaboratorymeas-
404. WindeckerS,NeumannFJ,JuniP,Sousa-UvaM,FalkV.Considerationsforthe
urementofhemoglobininthesurgicalICUsetting:across-sectionalmethodcom-
choicebetweencoronaryarterybypassgraftingandpercutaneouscoronaryinter- parisonstudy.BMCAnesthesiol2020;20:92.
ventionasrevascularizationstrategiesinmajorcategoriesofpatientswithstable
382.Terada R, Ikeda T, Mori Y, Yamazaki S, Kashiwabara K, Yamauchi H, et al.
Comparisonoftwopointofcarewholebloodcoagulationanalysisdevicesand multivesselcoronaryarterydisease:anaccompanyingarticleofthetaskforceof
conventionalcoagulationtestsasapredictingtoolofperioperativebleedinginadult the 2018 ESC/EACTS guidelines on myocardial revascularization. Eur Heart J
cardiacsurgery–apilotprospectiveobservationalstudyinJapan.Transfusion2019; 2019;40:204–212.
59:3525–3535. 405. RaberL,MintzGS,KoskinasKC,JohnsonTW,HolmNR,OnumaY,etal.Clinical
383.CohenJ,ScorerT,WrightZ,StewartIJ,SosnovJ,PidcokeH,etal.Aprospective useofintracoronaryimaging.Part1:guidanceandoptimizationofcoronaryinter-
evaluationofthromboelastometry(ROTEM)toidentifyacutetraumaticcoagulo- ventions. An expert consensus document of the European Association of
pathyandpredictmassivetransfusioninmilitarytraumapatientsinAfghanistan.
PercutaneousCardiovascularInterventions.EuroIntervention2018;14:656–677.
Transfusion2019;59:1601–1607. 406. JohnsonTW,RaberL,DiMarioC,BourantasCV,JiaH,MattesiniA,etal.Clinical
384.YatesJ,PerelmanI,KhairS,TaylorJ,LampronJ,TinmouthA,etal.Exclusioncriteria useofintracoronaryimaging.Part2:acutecoronarysyndromes,ambiguouscoron-
andadverseeventsinperioperativetrialsoftranexamicacid:asystematicreview
aryangiographyfindings,andguidinginterventionaldecision-making:anexpertcon-
andmeta-analysis.Transfusion2019;59:806–824. sensusdocumentoftheEuropeanAssociationofPercutaneousCardiovascular
385.CRASH-2trialCollaborators.Effectsoftranexamicacidondeath,disability,vascu- Interventions.EuroIntervention2019;15:434–451.
larocclusiveeventsandothermorbiditiesinpatientswithacutetraumaticbrainin- 407. RichardtG,AbdelghaniM,AllaliA,ToelgR,AbdellaouiM,KrackhardtF,etal.
jury (CRASH-3): a randomised, placebo-controlled trial. Lancet 2019;394: Polymer-freedrug-coatedvs.bare-metalcoronarystentsinpatientsundergoing
1713–1723. non-cardiac surgery: a subgroup analysis of the LEADERS FREE trial. Clin Res
386.HALT-ITTrialCollaborators.Effectsofahigh-dose24-hinfusionoftranexamic Cardiol2021;110:162–171.
acidondeathandthromboemboliceventsinpatientswithacutegastrointestinal 408. CasseseS,BelleL,NdrepepaG,BossonJL,FusaroM,LonborgJ,etal.Deferredvs
bleeding(HALT-IT):aninternationalrandomised,double-blind,placebo-controlled immediatestentinginprimarypercutaneouscoronaryintervention:acollaborative
trial.Lancet2020;395:1927–1936. meta-analysisofrandomizedtrialswithcardiacmagneticresonanceimagingdata.
387.MukhopadhyayA,YipHS,PrabhuswamyD,ChanYH,PhuaJ,LimTK,etal.Theuse CanJCardiol2018;34:1573–1580.
ofabloodconservationdevicetoreduceredbloodcelltransfusionrequirements:a 409. BelleL,MotreffP,ManginL,RangeG,MarcaggiX,MarieA,etal.Comparisonof
beforeandafterstudy.CritCare2010;14:R7. immediate with delayed stenting using the minimalist immediate mechanical
Downloaded
from
https://academic.oup.com/eurheartj/article/43/39/3826/6675076
by
guest
on
22
January
2026
--- Страница 93 ---
3918 ESCGuidelines
interventionapproachinacuteST-segment-elevationmyocardialinfarction:the 432. HabibG,LancellottiP,AntunesMJ,BongiorniMG,CasaltaJP,DelZottiF,etal.
MIMIStudy.CircCardiovascInterv2016;9:e003388. 2015 ESC Guidelines for the management of infective endocarditis: the Task
410. HammillBG,CurtisLH,Bennett-GuerreroE,O’ConnorCM,JollisJG,Schulman ForcefortheManagementofInfectiveEndocarditisoftheEuropeanSocietyof
KA,etal.Impactofheartfailureonpatientsundergoingmajornoncardiacsurgery. Cardiology (ESC). Endorsed by: European Association for Cardio-Thoracic
Anesthesiology2008;108:559–567. Surgery(EACTS),theEuropeanAssociationofNuclearMedicine(EANM).Eur
411. GoldmanL,CalderaDL,NussbaumSR,SouthwickFS,KrogstadD,MurrayB,etal. HeartJ2015;36:3075–3128.
Multifactorialindexofcardiacriskinnoncardiacsurgicalprocedures.NEnglJMed 433. PolanczykCA,GoldmanL,MarcantonioER,OravEJ,LeeTH.Supraventricularar-
1977;297:845–850. rhythmiainpatientshavingnoncardiacsurgery:clinicalcorrelatesandeffecton
412. McDonaghTA,MetraM,AdamoM,GardnerRS,BaumbachA,BohmM,etal.2021 lengthofstay.AnnInternMed1998;129:279–285.
ESCGuidelinesforthediagnosisandtreatmentofacuteandchronicheartfailure. 434. vanDiepenS,BakalJA,McAlisterFA,EzekowitzJA.Mortalityandreadmissionof
EurHeartJ2021;42:3599–3726. patientswithheartfailure,atrialfibrillation,orcoronaryarterydiseaseundergoing
413. LeeTH,MarcantonioER,MangioneCM,ThomasEJ,PolanczykCA,CookEF,etal. noncardiacsurgery:ananalysisof38047patients.Circulation2011;124:289–296.
Derivationandprospectivevalidationofasimpleindexforpredictionofcardiacrisk 435. AlberteC,ZipesDP.Useofnonantiarrhythmicdrugsforpreventionofsuddencar-
ofmajornoncardiacsurgery.Circulation1999;100:1043–1049. diacdeath.JCardiovascElectrophysiol2003;14:S87–S95.
414. FluWJ,vanKuijkJP,HoeksSE,KuiperR,SchoutenO,GoeiD,etal.Prognosticim- 436. BrugadaJ,KatritsisDG,ArbeloE,ArribasF,BaxJJ,Blomstrom-LundqvistC,etal.
plicationsofasymptomaticleftventriculardysfunctioninpatientsundergoingvas- 2019ESCGuidelinesforthemanagementofpatientswithsupraventriculartachy-
cularsurgery.Anesthesiology2010;112:1316–1324. cardia.EurHeartJ2020;41:655–720.
415. CohnSL.Preoperativeevaluationfornoncardiacsurgery.AnnInternMed2016; 437. CalkinsH,YongP,MillerJM,OlshanskyB,CarlsonM,SaulJP,etal.Catheterabla-
165:ITC81–ITC96.
tionofaccessorypathways,atrioventricularnodalreentranttachycardia,andthe
416. SmilowitzNR,BancoD,KatzSD,BeckmanJA,BergerJS.Associationbetween atrioventricularjunction:finalresultsofaprospective,multicenterclinicaltrial.
heartfailureandperioperativeoutcomesinpatientsundergoingnon-cardiacsur- TheAtakrMulticenterInvestigatorsGroup.Circulation1999;99:262–270.
gery.EurHeartJQualCareClinOutcomes2021;7:68–75.
438. ChenSA,ChiangCE,YangCJ,ChengCC,WuTJ,WangSP,etal.Sustainedatrial
417. LermanBJ,PopatRA,AssimesTL,HeidenreichPA,WrenSM.Associationbetween tachycardiainadultpatients.Electrophysiologicalcharacteristics,pharmacological
heartfailureandpostoperativemortalityamongpatientsundergoingambulatory
response,possiblemechanisms,andeffectsofradiofrequencyablation.Circulation
noncardiacsurgery.JAMASurg2019;154:907–914.
1994;90:1262–1278.
418. DhillonA,KhannaA,RandhawaMS,CywinskiJ,SaagerL,ThamilarasanM,etal.
439. KatritsisDG,ZografosT,KatritsisGD,GiazitzoglouE,VachliotisV,PaxinosG,etal.
Perioperativeoutcomesofpatientswithhypertrophiccardiomyopathyundergoing
Catheterablationvs.antiarrhythmicdrugtherapyinpatientswithsymptomatic
non-cardiacsurgery.Heart2016;102:1627–1632.
atrioventricular nodal re-entrant tachycardia: a randomized, controlled trial.
419. NaguehSF,BierigSM,BudoffMJ,DesaiM,DilsizianV,EidemB,etal.American Europace2017;19:602–606.
SocietyofEchocardiographyclinicalrecommendationsformultimodalitycardio-
440. Pappone C, Vicedomini G, Manguso F, Saviano M, Baldi M, Pappone A, et al.
vascularimagingofpatientswithhypertrophiccardiomyopathy.Endorsedbythe
Wolff-Parkinson-Whitesyndromeintheeraofcatheterablation:insightsfroma
American Society of Nuclear Cardiology, Society for Cardiovascular Magnetic registrystudyof2169patients.Circulation2014;130:811–819.
Resonance, and Society of Cardiovascular Computed Tomography. J Am Soc
441. SpectorP,ReynoldsMR,CalkinsH,SondhiM,XuY,MartinA,etal.Meta-analysisof
Echocardiogr2011;24:473–498.
ablationofatrialflutterandsupraventriculartachycardia.AmJCardiol2009;104:
420. KormosRL,CowgerJ,PaganiFD,TeutebergJJ,GoldsteinDJ,JacobsJP,etal.The 671–677.
SocietyofThoracicSurgeonsIntermacsdatabaseannualreport:evolvingindica-
442. PotparaTS,PolovinaMM,MarinkovicJM,LipGY.Acomparisonofclinicalcharac-
tions, outcomes, and scientific partnerships. J Heart Lung Transplant 2019;38:
teristicsandlong-termprognosisinasymptomaticandsymptomaticpatientswith
114–126.
first-diagnosedatrialfibrillation:theBelgradeAtrialFibrillationStudy.IntJCardiol
421. RobertsSM,HovordDG,KodavatigantiR,SathishkumarS.Ventricularassistde-
2013;168:4744–4749.
vicesandnon-cardiacsurgery.BMCAnesthesiol2015;15:185.
443. MujovicN,DobrevD,MarinkovicM,RussoV,PotparaTS.Theroleofamiodarone
422. RodsethRN,BiccardBM,LeManachY,SesslerDI,LuratiBuseGA,ThabaneL,etal.
in contemporary management of complex cardiac arrhythmias. Pharmacol Res
Theprognosticvalueofpre-operativeandpost-operativeB-typenatriureticpep-
2020;151:104521.
tidesinpatientsundergoingnoncardiacsurgery:B-typenatriureticpeptideand
444. DanGA,Martinez-RubioA,AgewallS,BorianiG,BorggrefeM,GaitaF,etal.
N-terminalfragmentofpro-B-typenatriureticpeptide:asystematicreviewandin-
dividualpatientdatameta-analysis.JAmCollCardiol2014;63:170–180. Antiarrhythmicdrugs-clinicaluseandclinicaldecisionmaking:aconsensusdocu-
ment from the European Heart Rhythm Association (EHRA) and European
423. KarthikeyanG,MoncurRA,LevineO,Heels-AnsdellD,ChanMT,Alonso-CoelloP,
SocietyofCardiology(ESC)WorkingGrouponCardiovascularPharmacology,en-
etal.Isapre-operativebrainnatriureticpeptideorN-terminalpro-B-typenatri-
dorsedbytheHeartRhythmSociety(HRS),Asia-PacificHeartRhythmSociety
ureticpeptidemeasurementanindependentpredictorofadversecardiovascular
(APHRS)andInternational Societyof CardiovascularPharmacotherapy (ISCP).
outcomes within 30 days of noncardiac surgery? A systematic review and
meta-analysisofobservationalstudies.JAmCollCardiol2009;54:1599–1606. Europace2018;20:731–732an.
424. AgarwalS,RajamanickamA,BajajNS,GriffinBP,CatacutanT,SvenssonLG,etal. 445. EllenbogenKA,DiasVC,PlumbVJ,HeywoodJT,MirvisDM.Aplacebo-controlled
Impactofaorticstenosisonpostoperativeoutcomesafternoncardiacsurgeries. trialofcontinuousintravenousdiltiazeminfusionfor24-hourheartratecontrol
CircCardiovascQualOutcomes2013;6:193–200. duringatrialfibrillationandatrialflutter:amulticenterstudy.JAmCollCardiol
425. TaniguchiT,MorimotoT,ShiomiH,AndoK,ShiraiS,KanamoriN,etal.Elective
1991;18:891–897.
non-cardiacsurgeryinpatientswithsevereaorticstenosis–observationsfrom 446. PhillipsBG,GandhiAJ,SanoskiCA,JustVL,BaumanJL.Comparisonofintravenous
theCURRENTASRegistry.CircJ2020;84:1173–1182. diltiazemandverapamilfortheacutetreatmentofatrialfibrillationandatrialflutter.
426. LuisSA,DohaeiA,ChandrashekarP,ScottCG,PadangR,LokineniS,etal.Impact
Pharmacotherapy1997;17:1238–1245.
ofaorticvalvereplacementforsevereaorticstenosisonperioperativeoutcomes 447. PlatiaEV,MichelsonEL,PorterfieldJK,DasG.Esmololversusverapamilintheacute
followingmajornoncardiacsurgery.MayoClinProc2020;95:727–737. treatmentofatrialfibrillationoratrialflutter.AmJCardiol1989;63:925–929.
427. OkunoT,YahagiK,HoriuchiY,SatoY,TanakaT,KosekiK,etal.Theroleoftrans- 448. SethiNJ,NielsenEE,SafiS,FeinbergJ,GluudC,JakobsenJC.Digoxinforatrialfib-
catheteraorticvalvereplacementinthepatientswithsevereaorticstenosisrequir-
rillationandatrialflutter:asystematicreviewwithmeta-analysisandtrialsequential
ingmajornon-cardiacsurgery.CardiovascIntervTher2019;34:345–351. analysisofrandomisedclinicaltrials.PLoSOne2018;13:e0193924.
428. CallejaAM,DommarajuS,GaddamR,ChaS,KhandheriaBK,ChalikiHP.Cardiac 449. KarthGD,GeppertA,NeunteuflT,PriglingerU,HaumerM,GschwandtnerM,
riskinpatientsaged.75yearswithasymptomatic,severeaorticstenosisundergo- etal.Amiodaroneversusdiltiazemforratecontrolincriticallyillpatientswithatrial
ingnoncardiacsurgery.AmJCardiol2010;105:1159–1163. tachyarrhythmias.CritCareMed2001;29:1149–1153.
429. SohrabiB,KazemiB,MehryarA,Teimouri-DereshkiA,ToufanM,AslanabadiN. 450. VosMA,GolitsynSR,StanglK,RudaMY,VanWijkLV,HarryJD,etal.Superiorityof
Correlationbetweenpulmonaryarterypressuremeasuredbyechocardiography ibutilide(anewclassIIIagent)overDL-sotalolinconvertingatrialflutterandatrial
andrightheartcatheterizationinpatientswithrheumaticmitralvalvestenosis(a fibrillation. The Ibutilide/Sotalol Comparator Study Group. Heart 1998;79:
prospectivestudy).Echocardiography2016;33:7–13. 568–575.
430. BajajNS,AgarwalS,RajamanickamA,ParasharA,PoddarKL,GriffinBP,etal. 451. SinghS,ZobleRG,YellenL,BrodskyMA,FeldGK,BerkM,etal.Efficacyandsafety
Impactofseveremitralregurgitationonpostoperativeoutcomesafternoncardiac oforaldofetilideinconvertingtoandmaintainingsinusrhythminpatientswith
surgery.AmJMed2013;126:529–535. chronicatrialfibrillationoratrialflutter:thesymptomaticatrialfibrillationinvesti-
431. Stone GW, Lindenfeld J, Abraham WT, Kar S, Lim DS, Mishell JM, et al. gativeresearchondofetilide(SAFIRE-D)study.Circulation2000;102:2385–2390.
Transcatheter mitral-valve repair in patients with heart failure. N Engl J Med 452. VolgmanAS,CarberryPA,StamblerB,LewisWR,DunnGH,PerryKT,etal.
2018;379:2307–2318. Conversionefficacyandsafetyofintravenousibutilidecomparedwithintravenous
Downloaded
from
https://academic.oup.com/eurheartj/article/43/39/3826/6675076
by
guest
on
22
January
2026
--- Страница 94 ---
ESCGuidelines 3919
procainamideinpatientswithatrialflutterorfibrillation.JAmCollCardiol1998;31: 473. BonfantiL,AnnoviA,Sanchis-GomarF,SaccentiC,MeschiT,TicinesiA,etal.
1414–1419. Effectivenessandsafetyofelectricalcardioversionforacute-onsetatrialfibrillation
453.Bianconi L, Castro A, Dinelli M, Alboni P, Pappalardo A, Richiardi E, et al. intheemergencydepartment:areal-world10-yearsinglecenterexperience.Clin
Comparisonofintravenouslyadministereddofetilideversusamiodaroneinthe ExpEmergMed2019;6:64–69.
acute termination of atrial fibrillation and flutter. A multicentre, randomized, 474. Kheiri B, Barbarawi M, Zayed Y, Hicks M, Osman M, Rashdan L, et al.
double-blind,placebo-controlledstudy.EurHeartJ2000;21:1265–1273. Antiarrhythmicdrugsorcatheterablationinthemanagementofventricularta-
454.Kerola T, Dewland TA, Vittinghoff E, Heckbert SR, Stein PK, Marcus GM. chyarrhythmiasinpatientswithimplantablecardioverter-defibrillators:asystemat-
Modifiablepredictorsofventricularectopyinthecommunity.JAmHeartAssoc ic review and meta-analysis of randomized controlled trials. Circ Arrhythm
2018;7:e010078. Electrophysiol2019;12:e007600.
455.YangJ,DudumR,MandyamMC,MarcusGM.Characteristicsofunselectedhigh- 475. SantangeliP,MuserD,MaedaS,FiltzA,ZadoES,FrankelDS,etal.Comparative
burden premature ventricular contraction patients. Pacing Clin Electrophysiol effectivenessofantiarrhythmicdrugsandcatheterablationforthepreventionof
2014;37:1671–1680. recurrent ventricular tachycardia in patients with implantable cardioverter-
456.ParreiraL,MarinheiroR,AmadorP,MesquitaD,FarinhaJ,LopesA,etal.Frequent defibrillators: a systematic review and meta-analysis of randomized controlled
prematureventricularcontractions.Associationofburdenandcomplexitywith trials.HeartRhythm2016;13:1552–1559.
prognosisaccordingtothepresenceofstructuralheartdisease.AnnNoninvasive 476. MartinezBK,BakerWL,KonopkaA,GiannelliD,ColemanCI,KlugerJ,etal.
Electrocardiol2021;26:e12800. Systematicreviewandmeta-analysisofcatheterablationofventriculartachycardia
457.Agarwal V, Vittinghoff E, Whitman IR, Dewland TA, Dukes JW, Marcus GM.
inischemicheartdisease.HeartRhythm2020;17:e206–e219.
Relation between ventricular premature complexes and incident heart failure. 477. ReddyVY,ReynoldsMR,NeuzilP,RichardsonAW,TaborskyM,JongnarangsinK,
AmJCardiol2017;119:1238–1242. etal.Prophylacticcatheterablationforthepreventionofdefibrillatortherapy.N
458.DukesJW,DewlandTA,VittinghoffE,MandyamMC,HeckbertSR,SiscovickDS,
EnglJMed2007;357:2657–2665.
etal.Ventricularectopyasapredictorofheartfailureanddeath.JAmCollCardiol 478. SappJL,WellsGA,ParkashR,StevensonWG,BlierL,SarrazinJF,etal.Ventricular
2015;66:101–109. tachycardiaablationversusescalationofantiarrhythmicdrugs.NEnglJMed2016;
459.Marcus GM. Evaluation and management of premature ventricular complexes.
375:111–121.
Circulation2020;141:1404–1418. 479. KuckKH,SchaumannA,EckardtL,WillemsS,VenturaR,DelacretazE,etal.
460.MukharjiJ,RudeRE,PooleWK,GustafsonN,ThomasLJ,Jr.,StraussHW,etal.Risk
Catheterablationofstableventriculartachycardiabeforedefibrillatorimplantation
factorsforsuddendeathafteracutemyocardialinfarction:two-yearfollow-up.AmJ inpatientswithcoronaryheartdisease(VTACH):amulticentrerandomisedcon-
Cardiol1984;54:31–36. trolledtrial.Lancet2010;375:31–40.
461.ChenJ,JohnsonG,HellkampAS,AndersonJ,MarkDB,LeeKL,etal.Rapid-rate 480. BricenoDF,GuptaT,RomeroJ,KolteD,KheraS,VillablancaPA,etal.Catheter
nonsustained ventricular tachycardia found on implantable cardioverter- ablationofventriculartachycardiainnonischemiccardiomyopathy:apropensity
defibrillatorinterrogation:relationshiptooutcomesintheSCD-HeFT(Sudden score-matchedanalysisofin-hospitaloutcomesintheUnitedStates.JCardiovasc
CardiacDeathinHeartFailureTrial).JAmCollCardiol2013;61:2161–2168.
Electrophysiol2018;29:771–779.
462.MakimotoH,ZielkeS,ClasenL,LinT,GerguriS,MullerP,etal.Clinicalsignificance 481. GliksonM,NielsenJC,KronborgMB,MichowitzY,AuricchioA,BarbashIM,etal.
2021ESCGuidelinesoncardiacpacingandcardiacresynchronizationtherapy.Eur
ofprecedentasymptomaticnon-sustainedventriculartachycardiasonsubsequent
HeartJ2021;42:3427–3520.
ICDinterventionsandheartfailurehospitalizationinprimarypreventionICDpa-
482. Marti-AlmorJ,CladellasM,BazanV,DelclosJ,AltabaC,GuijoMA,etal.Novelpre-
tients.EurJMedRes2020;25:5.
463.Sanchez Munoz JJ, Garcia-Alberola A, Martinez-Sanchez J, Penafiel-Verdu P, dictorsofprogressionofatrioventricularblockinpatientswithchronicbifascicular
block.RevEspCardiol2010;63:400–408.
Caro-MartinezC,Manzano-FernandezS,etal.Prematureventricularcomplexes
asatriggerforventricularfibrillation.RevEspCardiol2010;63:798–801. 483. SantiniM,CastroA,GiadaF,RicciR,InamaG,GaggioliG,etal.Preventionofsyn-
copethroughpermanentcardiacpacinginpatientswithbifascicularblockandsyn-
464.KakishitaM,KuritaT,MatsuoK,TaguchiA,SuyamaK,ShimizuW,etal.Modeof
onsetofventricularfibrillationinpatientswithBrugadasyndromedetectedbyim- copeofunexplainedorigin:thePRESSstudy.CircArrhythmElectrophysiol2013;6:
plantablecardioverterdefibrillatortherapy.JAmCollCardiol2000;36:1646–1653.
101–107.
465.SrivathsanK,GamiAS,AckermanMJ,AsirvathamSJ.Treatmentofventricularfib- 484. StoneME,SalterB,FischerA.Perioperativemanagementofpatientswithcardiac
implantableelectronicdevices.BrJAnaesth2011;107:i16–i26.
rillationinapatientwithpriordiagnosisoflongQTsyndrome:importanceofpre-
485. Cardiac implantable electronic device management (corrected). Anesthesiology
ciseelectrophysiologicdiagnosistosuccessfullyablatethetrigger.HeartRhythm 2020;132:225–252.
2007;4:1090–1093.
486. GiffordJ,LarimerK,ThomasC,MayP.ICD-ONRegistryforperioperativeman-
466.AlmendralJ,VillacastinJP,ArenalA,TercedorL,MerinoJL,DelcanJL.Evidencefa-
agementofCIEDs:mostrequirenochange.PacingClinElectrophysiol2017;40:
voringthehypothesisthatventriculararrhythmiashaveprognosticsignificancein
128–134.
left ventricular hypertrophy secondary to systemic hypertension. Am J Cardiol
487. MahlowWJ,CraftRM,MisuliaNL,CoxJW,Jr.,HirshJB,SniderCC,etal.Aperi-
1995;76:60D–63D.
operative managementalgorithm forcardiacrhythm managementdevices:the
467.PrioriSG,Blomstrom-LundqvistC,MazzantiA,BlomN,BorggrefeM,CammJ,etal. PACED-OPprotocol.PacingClinElectrophysiol2013;36:238–248.
2015ESCGuidelinesforthemanagementofpatientswithventriculararrhythmias 488. NeubauerH,WellmannM,Herzog-NiesceryJ,WutzlerA,WeberTP,MuggeA,
andthepreventionofsuddencardiacdeath:theTaskForcefortheManagementof
etal.ComparisonofperioperativestrategiesinICDpatients:theperioperative
PatientswithVentricularArrhythmiasandthePreventionofSuddenCardiacDeath ICDmanagementstudy(PIMstudy).PacingClinElectrophysiol2018;41:1536–1542.
of the European Society of Cardiology (ESC). Endorsed by: Association for 489. FeldmanJB,StoneME.AnesthesiateamsmanagingpacemakersandICDsforthe
European Paediatric and Congenital Cardiology (AEPC). Eur Heart J 2015;36: perioperative period: enhanced patient safety and improved workflows. Curr
2793–2867. OpinAnaesthesiol2020;33:441–447.
468.ConnollySJ,DorianP,RobertsRS,GentM,BailinS,FainES,etal.Comparisonof 490. MickusGJ,SolimanGI,ReedRR,MartinAK.Perioperativemanagementofalead-
beta-blockers,amiodaroneplusbeta-blockers,orsotalolforpreventionofshocks lesspacemaker:thepaucityofevidence-basedguidelines.JCardiothoracVascAnesth
fromimplantablecardioverterdefibrillators:theOPTICStudy:arandomizedtrial. 2016;30:1594–1598.
JAMA2006;295:165–171.
491. KaruppiahS,PrielippR,BanikRK.Anestheticconsiderationforpatientswithmicra
469.BrodineWN,TungRT,LeeJK,HockstadES,MossAJ,ZarebaW,etal.Effectsof leadlesspacemaker.AnnCardAnaesth2020;23:493–495.
beta-blockersonimplantablecardioverterdefibrillatortherapyandsurvivalinthe
492. GiffordJ,LarimerK,ThomasC,MayP,StanhopeS,GamiA.Randomizedcon-
patients with ischemic cardiomyopathy (from the Multicenter Automatic trolledtrialofperioperativeICDmanagement:magnetapplicationversusrepro-
DefibrillatorImplantationTrial-II).AmJCardiol2005;96:691–695. gramming.PacingClinElectrophysiol2014;37:1219–1224.
470.TilzRR,LenarczykR,ScherrD,HaugaaKH,IliodromitisK,PurerfellnerH,etal. 493. Winter J, Kohlmeier A, Shin DI, O’Connor S. Subcutaneous implantable
Management of ventricular tachycardia in the ablation era: results of the cardioverter-defibrillators and sternal wires: a cautionary tale. Circ Arrhythm
EuropeanHeartRhythmAssociationSurvey.Europace2018;20:209–213. Electrophysiol2014;7:986–987.
471.CroninEM,BogunFM,MauryP,PeichlP,ChenM,NamboodiriN,etal.2019HRS/ 494. SchulmanPM,TreggiariMM,YanezND,HenriksonCA,JesselPM,DewlandTA,
EHRA/APHRS/LAHRSexpertconsensusstatementoncatheterablationofven- et al. Electromagnetic interference with protocolized electrosurgery dispersive
triculararrhythmias.Europace2019;21:1143–1144. electrode positioning in patients with implantable cardioverter defibrillators.
472.ScheuermeyerFX,GrafsteinE,StenstromR,InnesG,HeslopC,MacPheeJ,etal. Anesthesiology2019;130:530–540.
Thirty-dayand1-yearoutcomesofemergencydepartmentpatientswithatrialfib- 495. BaegMK,KimSW,KoSH,LeeYB,HwangS,LeeBW,etal.Endoscopicelectrosur-
rillation and no acute underlying medical cause. Ann Emerg Med 2012;60: geryinpatientswithcardiacimplantableelectronicdevices.ClinEndosc2016;49:
755–765.e752. 176–181.
Downloaded
from
https://academic.oup.com/eurheartj/article/43/39/3826/6675076
by
guest
on
22
January
2026
--- Страница 95 ---
3920 ESCGuidelines
496. MangarD,AtlasGM,KanePB.Electrocautery-inducedpacemakermalfunctiondur- 519. BowkerD,BanksD.Pulmonaryhypertensioninnoncardiacsurgicalpatients.In:
ingsurgery.CanJAnaesth1991;38:616–618. KaplanJA Cronin B andMaus TM, editors. Essentialsof Cardiac Anesthesia for
497. RoznerMA.Reviewofelectricalinterferenceinimplantedcardiacdevices.Pacing NoncardiacSurgery.Philadelphia,PA:Elsevier;2019.p138–164.
ClinElectrophysiol2003;26:923–925. 520. MeyerS,McLaughlinVV,SeyfarthHJ,BullTM,VizzaCD,Gomberg-MaitlandM,
498. deCockCC,SpruijtHJ,vanCampenLM,PluAW,VisserCA.Electromagnetic etal.Outcomesofnoncardiac,nonobstetricsurgeryinpatientswithPAH:aninter-
interferenceofanimplantablelooprecorderbycommonlyencounteredelectronic nationalprospectivesurvey.EurRespirJ2013;41:1302–1307.
devices.PacingClinElectrophysiol2000;23:1516–1518. 521. Price LC, Montani D, Jais X, Dick JR, Simonneau G, Sitbon O, et al.
499. Suarez-FusterL,OhC,BaranchukA.Transcutaneouselectricalnervestimulation Noncardiothoracicnonobstetricsurgeryinmild-to-moderatepulmonaryhyper-
electromagneticinterferenceinanimplantablelooprecorder.JArrhythm2018; tension.EurRespirJ2010;35:1294–1302.
34:96–97. 522. Olsson KM, Halank M, Egenlauf B, Fistera D, Gall H, Kaehler C, et al.
500. GilboaSM,SalemiJL,NembhardWN,FixlerDE,CorreaA.Mortalityresultingfrom Decompensatedrightheartfailure,intensivecareandperioperativemanagement
congenitalheartdiseaseamongchildrenandadultsintheUnitedStates,1999to inpatientswithpulmonaryhypertension:updatedrecommendations fromthe
2006.Circulation2010;122:2254–2263. CologneConsensusConference2018.IntJCardiol2018;272S:46–52.
501. MarelliAJ,Ionescu-IttuR,MackieAS,GuoL,DendukuriN,KaouacheM.Lifetime 523. PilkingtonSA,TaboadaD,MartinezG.Pulmonaryhypertensionanditsmanage-
prevalenceofcongenitalheartdiseaseinthegeneralpopulationfrom2000to2010.
mentinpatientsundergoingnon-cardiacsurgery.Anaesthesia2015;70:56–70.
Circulation2014;130:749–756. 524. ESC. 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary
502. MaxwellBG,WongJK,KinC,LobatoRL.Perioperativeoutcomesofmajornon-
hypertension.EurHeartJ2022;43:3618–3731.
cardiacsurgeryinadultswithcongenitalheartdisease.Anesthesiology2013;119: 525. ThunbergCA,GaitanBD,GrewalA,RamakrishnaH,StansburyLG,GrigoreAM.
762–769. Pulmonaryhypertensioninpatientsundergoingcardiacsurgery:pathophysiology,
503. BaumgartnerH,DeBackerJ,Babu-NarayanSV,BudtsW,ChessaM,DillerGP,etal. perioperativemanagement,andoutcomes.JCardiothoracVascAnesth2013;27:
2020ESCGuidelinesforthemanagementofadultcongenitalheartdisease.Eur
551–572.
HeartJ2021;42:563–645. 526. HaywardCS,KellyRP,MacdonaldPS.Inhalednitricoxideincardiologypractice.
504. Regitz-Zagrosek V, Roos-Hesselink JW, Bauersachs J, Blomström-Lundqvist C,
CardiovascRes1999;43:628–638.
CífkováR,DeBonisM,etal.2018ESCGuidelinesforthemanagementofcardio- 527. ChowCK,TeoKK,RangarajanS,IslamS,GuptaR,AvezumA,etal.Prevalence,
vasculardiseasesduringpregnancy.EurHeartJ2018;39:3165–3241. awareness,treatment,andcontrolofhypertensioninruralandurbancommunities
505. Ammash NM, Connolly HM, Abel MD, Warnes CA. Noncardiac surgery in
inhigh-,middle-,andlow-incomecountries.JAMA2013;310:959–968.
Eisenmengersyndrome.JAmCollCardiol1999;33:222–227. 528. FutierE,LefrantJY,GuinotPG,GodetT,LorneE,CuvillonP,etal.Effectofindi-
vidualizedvsstandardbloodpressuremanagementstrategiesonpostoperativeor-
506. Faraoni D, Zurakowski D, Vo D, Goobie SM, Yuki K, Brown ML, et al.
gandysfunctionamonghigh-riskpatientsundergoingmajorsurgery:arandomized
Post-operativeoutcomesinchildrenwithandwithoutcongenitalheartdisease
undergoingnoncardiacsurgery.JAmCollCardiol2016;67:793–801.
clinicaltrial.JAMA2017;318:1346–1357.
529. WilliamsB,ManciaG,SpieringW,AgabitiRoseiE,AziziM,BurnierM,etal.2018
507. Alonso-GonzalezR,BorgiaF,DillerGP,InuzukaR,KempnyA,Martinez-Naharro
ESC/ESHGuidelinesforthemanagementofarterialhypertension.EurHeartJ2018;
A,etal.Abnormallungfunctioninadultswithcongenitalheartdisease:prevalence,
39:3021–3104.
relationtocardiacanatomy,andassociationwithsurvival.Circulation2013;127:
882–890. 530. HowellSJ,SearJW,FoexP.Hypertension,hypertensiveheartdiseaseandperi-
operativecardiacrisk.BrJAnaesth2004;92:570–583.
508. MaxwellBG,PosnerKL,WongJK,OakesDA,KellyNE,DominoKB,etal.Factors
531. MessinaA,RobbaC,CalabroL,ZambelliD,IannuzziF,MolinariE,etal.Association
contributingtoadverseperioperativeeventsinadultswithcongenitalheartdisease:
betweenperioperativefluidadministrationandpostoperativeoutcomes:a20-year
astructuredanalysisofcasesfromtheclosedclaimsproject.CongenitHeartDis
systematicreviewandameta-analysisofrandomizedgoal-directedtrialsinmajor
2015;10:21–29.
visceral/noncardiacsurgery.CritCare2021;25:43.
509. LuiGK,SaidiA,BhattAB,BurchillLJ,DeenJF,EaringMG,etal.Diagnosisandman-
532. JorgensenME,HlatkyMA,KoberL,SandersRD,Torp-PedersenC,GislasonGH,
agementofnoncardiaccomplicationsinadultswithcongenitalheartdisease:asci-
etal.Beta-blocker-associatedrisksinpatientswithuncomplicatedhypertension
entific statement from the American Heart Association. Circulation 2017;136: undergoingnoncardiacsurgery.JAMAInternMed2015;175:1923–1931.
e348–e392.
533. WekslerN,KleinM,SzendroG,RozentsveigV,SchilyM,BrillS,etal.Thedilemma
510. AdlerY,CharronP,ImazioM,BadanoL,Baron-EsquiviasG,BogaertJ,etal.2015
ofimmediatepreoperativehypertension:totreatandoperate,ortopostponesur-
ESCGuidelinesforthediagnosisandmanagementofpericardialdiseases:theTask gery?JClinAnesth2003;15:179–183.
ForcefortheDiagnosisandManagementofPericardialDiseasesoftheEuropean
534. PerkJ,DeBackerG,GohlkeH,GrahamI,ReinerZ,VerschurenM,etal.European
Society of Cardiology (ESC). Endorsed by: the European Association for Guidelinesoncardiovasculardiseasepreventioninclinicalpractice(version2012).
Cardio-ThoracicSurgery(EACTS).EurHeartJ2015;36:2921–2964. The Fifth Joint Task Force of the European Society of Cardiology and Other
511. TuckBC,TownsleyMM.Clinicalupdateinpericardialdiseases.JCardiothoracVasc SocietiesonCardiovascularDiseasePreventioninClinicalPractice(constituted
Anesth2019;33:184–199.
byrepresentativesofninesocietiesandbyinvitedexperts).EurHeartJ2012;33:
512. RisticAD,ImazioM,AdlerY,AnastasakisA,BadanoLP,BrucatoA,etal.Triage 1635–1701.
strategyforurgentmanagementofcardiactamponade:apositionstatementof 535. AboyansV,RiccoJB,BartelinkMEL,BjorckM,BrodmannM,CohnertT,etal.2017
the European Society of Cardiology Working Group on Myocardial and ESCGuidelinesontheDiagnosisandTreatmentofPeripheralArterialDiseases,in
PericardialDiseases.EurHeartJ2014;35:2279–2284. collaborationwiththeEuropeanSocietyforVascularSurgery(ESVS).Document
513. SinDD,WuL,ManSF.Therelationshipbetweenreducedlungfunctionandcar- coveringatheroscleroticdiseaseofextracranialcarotidandvertebral,mesenteric,
diovascularmortality:apopulation-basedstudyandasystematicreviewofthelit- renal, upper andlower extremity arteries. Endorsed by: the European Stroke
erature.Chest2005;127:1952–1959.
Organization (ESO). The Task Force for the Diagnosis and Treatment of
514. CanetJ,GallartL,GomarC,PaluzieG,VallesJ,CastilloJ,etal.Predictionofpost- PeripheralArterialDiseasesoftheEuropeanSocietyofCardiology(ESC)andof
operative pulmonary complications in a population-based surgical cohort. theEuropeanSocietyforVascularSurgery(ESVS).EurHeartJ2018;39:763–816.
Anesthesiology2010;113:1338–1350.
536. Bonaca MP, Nault P, Giugliano RP, Keech AC, Pineda AL, Kanevsky E, et al.
515. EdrichT,SadovnikoffN.Anesthesiaforpatientswithseverechronicobstructive Low-densitylipoproteincholesterolloweringwithevolocumabandoutcomesin
pulmonarydisease.CurrOpinAnaesthesiol2010;23:18–24.
patientswithperipheralarterydisease:insightsfromtheFOURIERTrial(Further
516. ChauEH,LamD,WongJ,MokhlesiB,ChungF.Obesityhypoventilationsyndrome: Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With
a review of epidemiology, pathophysiology, and perioperative considerations. ElevatedRisk).Circulation2018;137:338–350.
Anesthesiology2012;117:188–205. 537. Anand SS, Bosch J, Eikelboom JW, Connolly SJ, Diaz R, Widimsky P, et al.
517. KawR,GaliB,CollopNA.Perioperativecareofpatientswithobstructivesleepap- Rivaroxabanwithorwithoutaspirininpatientswithstableperipheralorcarotid
nea.CurrTreatOptionsNeurol2011;13:496–507.
arterydisease:aninternational,randomised,double-blind,placebo-controlledtrial.
518. GalieN,HumbertM,VachieryJL,GibbsS,LangI,TorbickiA,etal.2015ESC/ERS Lancet2018;391:219–229.
Guidelinesforthediagnosisandtreatmentofpulmonaryhypertension:theJoint 538. AshtonCM,PetersenNJ,WrayNP,KiefeCI,DunnJK,WuL,etal.Theincidenceof
TaskForcefortheDiagnosisandTreatmentofPulmonaryHypertensionofthe perioperativemyocardialinfarctioninmenundergoingnoncardiacsurgery.Ann
European Society of Cardiology (ESC) and the European Respiratory Society InternMed1993;118:504–510.
(ERS). Endorsed by: Association for European Paediatric and Congenital 539. ConteMS,BradburyAW,KolhP,WhiteJV,DickF,FitridgeR,etal.Globalvascular
Cardiology (AEPC), International Society for Heart and Lung Transplantation guidelinesonthemanagementofchroniclimb-threateningischemia.EurJVasc
(ISHLT).EurHeartJ2016;37:67–119. EndovascSurg2019;58:S1–S109.e33.
Downloaded
from
https://academic.oup.com/eurheartj/article/43/39/3826/6675076
by
guest
on
22
January
2026
--- Страница 96 ---
ESCGuidelines 3921
540.BrownLC,PowellJT,ThompsonSG,EpsteinDM,SculpherMJ,GreenhalghRM. 568. RomanM,MonaghanA,SerrainoGF,MillerD,PathakS,LaiF,etal.Meta-analysisof
The UK EndoVascular Aneurysm Repair (EVAR) trials: randomised trials of theinfluenceoflifestylechangesforpreoperativeweightlossonsurgicaloutcomes.
EVARversusstandardtherapy.HealthTechnolAssess2012;16:1–218. BrJSurg2019;106:181–189.
541.ParavastuSC,JayarajasingamR,CottamR,PalfreymanSJ,MichaelsJA,ThomasSM. 569. McCulloughPA,GallagherMJ,DejongAT,SandbergKR,TrivaxJE,AlexanderD,
Endovascularrepairofabdominalaorticaneurysm.CochraneDatabaseSystRev etal.Cardiorespiratoryfitnessandshort-termcomplicationsafterbariatricsur-
2014:CD004178.doi:10.1002/14651858.CD004178.pub2. gery.Chest2006;130:517–525.
542.StatherPW,SidloffD,DattaniN,ChokeE,BownMJ,SayersRD.Systematicreview 570. SmithTB,StonellC,PurkayasthaS,ParaskevasP.Cardiopulmonaryexercisetesting
andmeta-analysisoftheearlyandlateoutcomesofopenandendovascularrepair asariskassessmentmethodinnoncardio-pulmonarysurgery:asystematicreview.
ofabdominalaorticaneurysm.BrJSurg2013;100:863–872. Anaesthesia2009;64:883–893.
543.EslamiMH,RybinDV,DorosG,SiracuseJJ,FarberA.ExternalvalidationofVascular 571. EmergingRiskFactorsCollaboration,SarwarN,GaoP,SeshasaiSR,GobinR,
StudyGroupofNewEnglandriskpredictivemodelofmortalityafterelectiveab- KaptogeS,etal.Diabetesmellitus,fastingbloodglucoseconcentration,andrisk
dominalaortaaneurysmrepairintheVascularQualityInitiativeandcomparison of vascular disease: a collaborative meta-analysis of 102 prospective studies.
againstestablishedmodels.JVascSurg2018;67:143–150. Lancet2010;375:2215–2222.
544.BonacaMP,BauersachsRM,AnandSS,DebusES,NehlerMR,PatelMR,etal. 572. KadoiY.Anestheticconsiderationsindiabeticpatients.PartII:intraoperativeand
Rivaroxaban in peripheral artery disease after revascularization. N Engl J Med postoperativemanagementofpatientswithdiabetesmellitus.JAnesth2010;24:
2020;382:1994–2004. 748–756.
545.CutlipDE,PintoDS.Extracranialcarotiddiseaserevascularization.Circulation2012; 573. CosentinoF,GrantPJ,AboyansV,BaileyCJ,CerielloA,DelgadoV,etal.2019ESC
126:2636–2644. Guidelinesondiabetes,pre-diabetes,andcardiovasculardiseasesdevelopedincol-
546.Herzog CA, Asinger RW, Berger AK, Charytan DM, Diez J, Hart RG, et al. laborationwiththeEASD.EurHeartJ2020;41:255–323.
Cardiovasculardiseaseinchronickidneydisease.AclinicalupdatefromKidney 574. AmericanDiabetesAssociation.15.Diabetescareinthehospital:standardsof
Disease:ImprovingGlobalOutcomes(KDIGO).KidneyInt2011;80:572–586. medicalcareindiabetes-2020.DiabetesCare2021;44:S211–S220.
547.Section3:PreventionandTreatmentofAKI.KidneyIntSuppl(2011)2012;2:37–68. 575. ShahNJ,LeisA,KheterpalS,EnglesbeMJ,KumarSS.Associationofintraoperative
548.RomagnoliS,RicciZ,RoncoC.Perioperativeacutekidneyinjury:prevention,early hyperglycemiaandpostoperativeoutcomesinpatientsundergoingnon-cardiac
recognition,andsupportivemeasures.Nephron2018;140:105–110. surgery:amulticenterretrospectivestudy.BMCAnesthesiol2020;20:106.
549.KheterpalS,TremperKK,HeungM,RosenbergAL,EnglesbeM,ShanksAM,etal. 576. AharazA,PottegardA,HenriksenDP,HallasJ,Beck-NielsenH,LassenAT.Riskof
Developmentandvalidationofanacutekidneyinjuryriskindexforpatientsunder- lacticacidosisintype2diabetespatientsusingmetformin:acasecontrolstudy.PLoS
goinggeneralsurgery:resultsfromanationaldataset.Anesthesiology2009;110: One2018;13:e0196122.
505–515. 577. VogtAP,BallyL.Perioperativeglucosemanagement:currentstatusandfuturedi-
550.RebholzCM,InkerLA,ChenY,LiangM,FosterMC,EckfeldtJH,etal.RiskofESRD rections.BestPractResClinAnaesthesiol2020;34:213–224.
andmortalityassociatedwithchangeinfiltrationmarkers.AmJKidneyDis2017;70: 578. PasquelFJ,Gomez-HuelgasR,AnzolaI,OyedokunF,HawJS,VellankiP,etal.
551–560. PredictivevalueofadmissionhemoglobinA1coninpatientglycemiccontroland
551.McCulloughPA,ChoiJP,FeghaliGA,SchusslerJM,StolerRM,VallabahnRC,etal. responsetoinsulintherapyinmedicineandsurgerypatientswithtype2diabetes.
Contrast-inducedacutekidneyinjury.JAmCollCardiol2016;68:1465–1473. DiabetesCare2015;38:e202–e203.
552.Section2:AKIDefinition.KidneyIntSuppl(2011)2012;2:19–36. 579. CarpenterDL,GreggSR,XuK,BuchmanTG,CoopersmithCM.Prevalenceand
553.GorenO,MatotI.Perioperativeacutekidneyinjury.BrJAnaesth2015;115:ii3–ii14. impactofunknowndiabetesintheICU.CritCareMed2015;43:e541–e550.
554.ZealleyI,WangH,DonnanPT,BellS.Exposuretocontrastmediaintheperiopera- 580. vandenBoomW,SchroederRA,ManningMW,SetjiTL,FiestanGO,DunsonDB.
tiveperiodconfersnoadditionalriskofacutekidneyinjuryinsurgicalpatients. EffectofA1Candglucoseonpostoperativemortalityinnoncardiacandcardiac
NephrolDialTransplant2018;33:1751–1756. surgeries.DiabetesCare2018;41:782–788.
555.STARSurgCollaborative.Perioperativeintravenouscontrastadministrationand 581. DhatariyaK,LevyN,KilvertA,WatsonB,CousinsD,FlanaganD,etal.NHS
theincidenceofacutekidneyinjuryaftermajorgastrointestinalsurgery:prospect- Diabetesguidelinefortheperioperativemanagementoftheadultpatientwithdia-
ive,multicentrecohortstudy.BrJSurg2020;107:1023–1032. betes.DiabetMed2012;29:420–433.
556.MeerschM,SchmidtC,ZarbockA.Patientwithchronicrenalfailureundergoing 582. BergqvistD,AgnelliG,CohenAT,EldorA,NilssonPE,LeMoigne-AmraniA,etal.
surgery.CurrOpinAnaesthesiol2016;29:413–420. Durationofprophylaxisagainstvenousthromboembolismwithenoxaparinafter
557.NCDRiskFactorCollaboration.Worldwidetrendsinbody-massindex,under- surgeryforcancer.NEnglJMed2002;346:975–980.
weight,overweight,andobesityfrom1975to2016:apooledanalysisof2416 583. KirschnerM,doOHN,ParmentierS,HartC,HenzeL,BispingG,etal.Primary
population-based measurement studies in 128.9 million children, adolescents, thromboprophylaxisinpatientswithmalignancies:DailyPracticerecommenda-
andadults.Lancet2017;390:2627–2642. tionsbytheHemostasisWorkingPartyoftheGermanSocietyofHematology
558.LavieCJ,ArenaR,AlpertMA,MilaniRV,VenturaHO.Managementofcardiovas- and Medical Oncology (DGHO), the Society of Thrombosis and Hemostasis
culardiseasesinpatientswithobesity.NatRevCardiol2018;15:45–56. Research (GTH), and the Austrian Society of Hematology and Oncology
559.OrtegaFB,LavieCJ,BlairSN.Obesityandcardiovasculardisease.CircRes2016; (OGHO).Cancers(Basel)2021;13:2905.
118:1752–1770. 584. ESC.2022ESCGuidelinesoncardio-oncology.EurHeartJ2022;XX:XX–XX.
560.De Hert S, Staender S, Fritsch G, Hinkelbein J, Afshari A, Bettelli G, et al. 585. COVIDSurgCollaborative,GlobalSurgCollaborative.Timingofsurgeryfollowing
Pre-operativeevaluationofadultsundergoingelectivenoncardiacsurgery:updated SARS-CoV-2 infection: an international prospective cohort study. Anaesthesia
guidelinefromtheEuropeanSocietyofAnaesthesiology.EurJAnaesthesiol2018;35: 2021;76:748–758.
407–465. 586. COVIDSurgCollaborative,GlobalSurgCollaborative.SARS-CoV-2infectionand
561.LavieCJ,DeSchutterA,PartoP,JahangirE,KokkinosP,OrtegaFB,etal.Obesity venousthromboembolismaftersurgery:aninternationalprospectivecohortstudy.
andprevalenceofcardiovasculardiseasesandprognosis–theobesityparadoxup- Anaesthesia2022;77:28–39.
dated.ProgCardiovascDis2016;58:537–547. 587. GuzikTJ,MohiddinSA,DimarcoA,PatelV,SavvatisK,Marelli-BergFM,etal.
562.ElagiziA,KachurS,LavieCJ,CarboneS,PandeyA,OrtegaFB,etal.Anoverview COVID-19andthecardiovascularsystem:implicationsforriskassessment,diagno-
andupdateonobesityandtheobesityparadoxincardiovasculardiseases.Prog sis,andtreatmentoptions.CardiovascRes2020;116:1666–1687.
CardiovascDis2018;61:142–150. 588. Puntmann VO, Carerj ML, Wieters I, Fahim M, Arendt C, Hoffmann J, et al.
563.ValentijnTM,GalalW,TjeertesEK,HoeksSE,VerhagenHJ,StolkerRJ.Theobesity Outcomesofcardiovascularmagneticresonanceimaginginpatientsrecentlyre-
paradoxinthesurgicalpopulation.Surgeon2013;11:169–176. covered from coronavirus disease 2019 (COVID-19). JAMA Cardiol 2020;5:
564.Hidvegi R, Puelacher C, Gualandro DM, Lampart A, Lurati Buse G, 1265–1273.
Hammerer-LerchnerA,etal.Obesityparadoxandperioperativemyocardialinfarc- 589. RohatgiN,SmilowitzNR,ReejhsinghaniR.Perioperativecardiovascularconsidera-
tion/injuryinnon-cardiacsurgery.ClinResCardiol2020;109:1140–1147. tionspriortoelectivenoncardiacsurgeryinpatientswithahistoryofCOVID-19.
565.RossR,BlairSN,ArenaR,ChurchTS,DespresJP,FranklinBA,etal.Importanceof JAMASurg2022;157:187–188.
assessingcardiorespiratoryfitnessinclinicalpractice:acaseforfitnessasaclinical 590. DengJZ,ChanJS,PotterAL,ChenYW,SandhuHS,PandaN,etal.Theriskofpost-
vitalsign:ascientificstatementfromtheAmericanHeartAssociation.Circulation operative complications after major elective surgery in active or resolved
2016;134:e653–e699. COVID-19intheUnitedStates.AnnSurg2022;275:242–246.
566.McAuleyPA,ArteroEG,SuiX,LeeDC,ChurchTS,LavieCJ,etal.Theobesity 591. AnesthesiaPatientSafetyFoundation.AmericanSocietyofAnesthesiologistsand
paradox, cardiorespiratory fitness, and coronary heart disease. Mayo Clin Proc Anesthesia Patient Safety Foundation Joint Statement on Elective Surgery and
2012;87:443–451. Anesthesia for Patients after COVID-19 Infection. https://www.apsf.org/news-
567.PedersenBK.Bodymassindex-independenteffectoffitnessandphysicalactivity updates/asa-and-apsf-joint-statement-on-elective-surgery-and-anesthesia-for-
forall-causemortality.ScandJMedSciSports2007;17:196–204. patients-after-covid-19-infection/(30March2022).
Downloaded
from
https://academic.oup.com/eurheartj/article/43/39/3826/6675076
by
guest
on
22
January
2026
--- Страница 97 ---
3922 ESCGuidelines
592. Mellin-OlsenJ,StaenderS,WhitakerDK,SmithAF.TheHelsinkiDeclarationon 616. CecconiM,CorredorC,ArulkumaranN,AbuellaG,BallJ,GroundsRM,etal.
patientsafetyinanaesthesiology.EurJAnaesthesiol2010;27:592–597. Clinicalreview:goal-directedtherapy–whatistheevidenceinsurgicalpatients?
593. DeHertS.Perioperativemonitoring:anaesthesiology.In:CammAJLüscherTF Theeffectondifferentriskgroups.CritCare2013;17:209.
Maurer G and Serruys PW, editors. ESC CardioMed. 3rd ed. Oxford: Oxford 617. ArulkumaranN,CorredorC,HamiltonMA,BallJ,GroundsRM,RhodesA,etal.
UniversityPress;2018.p2683–2686. Cardiaccomplicationsassociatedwithgoal-directedtherapyinhigh-risksurgical
594. Hamilton-DaviesC,MythenMG,SalmonJB,JacobsonD,ShuklaA,WebbAR. patients:ameta-analysis.BrJAnaesth2014;112:648–659.
Comparisonofcommonlyusedclinicalindicatorsofhypovolaemiawithgastro- 618. NicklasJY,DienerO,LeistenschneiderM,SellhornC,SchonG,WinklerM,etal.
intestinaltonometry.IntensiveCareMed1997;23:276–281. Personalisedhaemodynamicmanagementtargetingbaselinecardiacindexinhigh-
595. MarikPE,CavallazziR.Doesthecentralvenouspressurepredictfluidresponsive- riskpatientsundergoingmajorabdominalsurgery:arandomisedsingle-centreclin-
ness?Anupdatedmeta-analysisandapleaforsomecommonsense.CritCareMed icaltrial.BrJAnaesth2020;125:122–132.
2013;41:1774–1781. 619. TaenzerAH,PykeJB,McGrathSP.Areviewofcurrentandemergingapproachesto
596. Gaba DM. Improving anesthesiologists’ performance by simulating reality. addressfailure-to-rescue.Anesthesiology2011;115:421–431.
Anesthesiology1992;76:491–494. 620. PykeJ,TaenzerAH,RenaudCE,McGrathSP.Developingacontinuousmonitoring
597. RuncimanWB.Commentaryonequipmentrecommendations.EurJAnaesthesiol infrastructurefordetectionofinpatientdeterioration.JtCommJQualPatientSaf
Suppl1993;7:16–18. 2012;38:428–431.
598. BlockFE,Jr.,NuutinenL,BallastB.Optimizationofalarms:astudyonalarmlimits, 621. McGrathSP,TaenzerAH,KaronN,BlikeG.Surveillancemonitoringmanagement
alarmsounds,andfalsealarms,intendedtoreduceannoyance.JClinMonitComput forgeneralcareunits:strategy,design,andimplementation.JtCommJQualPatient
1999;15:75–83. Saf2016;42:293–302.
599. DeHertS,MoermanA.Anestheticpreconditioning:havewefoundtheholygrailof 622. TaenzerAH,SpenceBC.Theafferentlimbofrapidresponsesystems:continuous
perioperativecardioprotection?JCardiothoracVascAnesth2018;32:1135–1136. monitoringongeneralcareunits.CritCareClin2018;34:189–198.
600. BijkerJB,vanKleiWA,KappenTH,vanWolfswinkelL,MoonsKG,KalkmanCJ. 623. LiuSS,WuCL.Theeffectofanalgesictechniqueonpostoperativepatient-reported Incidenceofintraoperativehypotensionasafunctionofthechosendefinition:lit- outcomesincludinganalgesia:asystematicreview.AnesthAnalg2007;105:789–808.
eraturedefinitionsappliedtoaretrospectivecohortusingautomateddatacollec- 624. WhitePF,KehletH.Postoperativepainmanagementandpatientoutcome:timeto
tion.Anesthesiology2007;107:213–220. returntowork!.AnesthAnalg2007;104:487–489.
601. VernooijLM,vanKleiWA,MachinaM,PasmaW,BeattieWS,PeelenLM.Different 625. TuranA,LeungS,BajracharyaGR,BabazadeR,BarnesT,SchachamYN,etal.Acute
methodsofmodellingintraoperativehypotensionandtheirassociationwithpost- postoperativepainisassociatedwithmyocardialinjuryafternoncardiacsurgery.
operativecomplicationsinpatientsundergoingnon-cardiacsurgery.BrJAnaesth
AnesthAnalg2020;131:822–829.
2018;120:1080–1089. 626. OlsenAM,FosbolEL,LindhardsenJ,FolkeF,CharlotM,SelmerC,etal.Long-term
cardiovascularriskofnonsteroidalanti-inflammatorydruguseaccordingtotime
602. Sessler DI, Bloomstone JA, Aronson S, Berry C, Gan TJ, Kellum JA, et al.
passed after first-time myocardial infarction: a nationwide cohort study.
PerioperativeQualityInitiativeconsensusstatementonintraoperativebloodpres-
sure,riskandoutcomesforelectivesurgery.BrJAnaesth2019;122:563–574.
Circulation2012;126:1955–1963.
627. SchmidtM,SorensenHT,PedersenL.Diclofenacuseandcardiovascularrisks:ser-
603. SesslerDI,MeyhoffCS,ZimmermanNM,MaoG,LeslieK,VasquezSM,etal.
iesofnationwidecohortstudies.BMJ2018;362:k3426.
Period-dependentassociationsbetweenhypotensionduringandforfourdaysafter
628. FarkouhME,GreenbergBP.Anevidence-basedreviewofthecardiovascularrisks
noncardiacsurgeryandacompositeofmyocardialinfarctionanddeath:asubstudy
ofthePOISE-2trial.Anesthesiology2018;128:317–327.
ofnonsteroidalanti-inflammatorydrugs.AmJCardiol2009;103:1227–1237.
629. RayWA,Varas-LorenzoC,ChungCP,CastellsagueJ,MurrayKT,SteinCM,etal.
604. LadhaKS,BeattieWS,TaitG,WijeysunderaDN.Associationbetweenpreopera-
Cardiovascularrisksofnonsteroidalantiinflammatorydrugsinpatientsafterhospi-
tiveambulatoryheartrateandpostoperativemyocardialinjury:aretrospectiveco-
hortstudy.BrJAnaesth2018;121:722–729. 1ta 5li 5z –at 1i 6o 3n .forseriouscoronaryheartdisease.CircCardiovascQualOutcomes2009;2:
605. Abbott TE, Ackland GL, Archbold RA, Wragg A, Kam E, Ahmad T, et al.
630. AntmanEM,BennettJS,DaughertyA,FurbergC,RobertsH,TaubertKA,etal.Use
Preoperativeheartrateandmyocardialinjuryafternon-cardiacsurgery:results ofnonsteroidalantiinflammatorydrugs:anupdateforclinicians:ascientificstate-
ofapredefinedsecondaryanalysisoftheVISIONstudy.BrJAnaesth2016;117:
mentfromtheAmericanHeartAssociation.Circulation2007;115:1634–1642.
172–181.
631. Schug SA, Joshi GP, Camu F, Pan S, Cheung R. Cardiovascular safety of the
606. AbbottTEF,MintoG,LeeAM,PearseRM,AcklandGL.,POM-HR,POMO-Oand
cyclooxygenase-2 selective inhibitors parecoxib and valdecoxib in the post-
OPTIMISEstudygroups.Elevatedpreoperativeheartrateisassociatedwithcardio- operativesetting:ananalysisofintegrateddata.AnesthAnalg2009;108:299–307.
pulmonaryandautonomicimpairmentinhigh-risksurgicalpatients.BrJAnaesth
632. LiuSS,BaeJJ,BieltzM,MaY,MemtsoudisS.Associationofperioperativeuseof
2017;119:87–94.
nonsteroidal anti-inflammatory drugs with postoperative myocardial infarction
607. Ruetzler K, Yilmaz HO, Turan A, Zimmerman NM, Mao G, Hung MH, et al. aftertotaljointreplacement.RegAnesthPainMed2012;37:45–50.
Intra-operativetachycardiaisnotassociatedwithacompositeofmyocardialinjury
633. Schmidt M, Lamberts M, Olsen AM, Fosboll E, Niessner A, Tamargo J, et al.
and mortality after noncardiac surgery: a retrospective cohort analysis. Eur J Cardiovascularsafetyofnon-aspirinnon-steroidalanti-inflammatorydrugs:review
Anaesthesiol2019;36:105–113.
andpositionpaperbytheworkinggroupforCardiovascularPharmacotherapyof
608. StraarupTS,HausenloyDJ,RolighedLarsenJK.Cardiactroponinsandvolatile theEuropeanSocietyofCardiology.EurHeartJ2016;37:1015–1023.
anaesthetics in coronary artery bypass graft surgery: a systematic review, 634. GregoryA,StapelfeldtWH,KhannaAK,SmischneyNJ,BoeroIJ,ChenQ,etal.
meta-analysisandtrialsequentialanalysis.EurJAnaesthesiol2016;33:396–407.
Intraoperativehypotensionisassociatedwithadverseclinicaloutcomesafternon-
609. LandoniG,LomivorotovVV,NigroNetoC,MonacoF,PasyugaVV,BradicN,etal. cardiacsurgery.AnesthAnalg2021;132:1654–1665.
Volatileanestheticsversustotalintravenousanesthesiaforcardiacsurgery.NEnglJ 635. AldingtonS,ShirtcliffeP,WeatherallM,BeasleyR.Increasedriskofcardiovascular
Med2019;380:1214–1225.
eventswithparecoxib/valdecoxib:asystematicreviewandmeta-analysis.NZMedJ
610. LuratiBuseGA,SchumacherP,SeebergerE,StuderW,SchumanRM,FasslJ,etal. 2005;118:U1755.
Randomizedcomparisonofsevofluraneversuspropofoltoreduceperioperative
636. DevereauxPJ,SesslerDI.Cardiaccomplicationsinpatientsundergoingmajornon-
myocardialischemiainpatientsundergoingnoncardiacsurgery.Circulation2012; cardiacsurgery.NEnglJMed2015;373:2258–2269.
126:2696–2704.
637. SabateS,MasesA,GuileraN,CanetJ,CastilloJ,OrregoC,etal.Incidenceandpre-
611. RodgersA,WalkerN,SchugS,McKeeA,KehletH,vanZundertA,etal.Reduction dictorsofmajorperioperativeadversecardiacandcerebrovasculareventsinnon-
ofpostoperativemortalityandmorbiditywithepiduralorspinalanaesthesia:re- cardiacsurgery.BrJAnaesth2011;107:879–890.
sultsfromoverviewofrandomisedtrials.BMJ2000;321:1493. 638. SmilowitzNR,Redel-TraubG,HausvaterA,ArmaniousA,NicholsonJ,Puelacher
612. BosEME,HollmannMW,LirkP.Safetyandefficacyofepiduralanalgesia.CurrOpin C, et al. Myocardial injury after noncardiac surgery: a systematic review and
Anaesthesiol2017;30:736–742. meta-analysis.CardiolRev2019;27:267–273.
613. GogartenW,VandermeulenE,VanAkenH,KozekS,LlauJV,SamamaCM,etal. 639. SmilowitzNR,GuptaN,GuoY,BergerJS,BangaloreS.Perioperativeacutemyo-
Regional anaesthesia and antithrombotic agents: recommendations of the cardial infarction associated with non-cardiac surgery. Eur Heart J 2017;38:
EuropeanSocietyofAnaesthesiology.EurJAnaesthesiol2010;27:999–1015. 2409–2417.
614. HamiltonMA,CecconiM,RhodesA.Asystematicreviewandmeta-analysisonthe 640. MasterAM,DackS,JaffeHL.Postoperativecoronaryarteryocclusion.JAMA1938;
useofpreemptivehemodynamicinterventiontoimprovepostoperativeoutcomes 110:1415–1418.
inmoderateandhigh-risksurgicalpatients.AnesthAnalg2011;112:1392–1402. 641. Devereaux PJ, Xavier D, Pogue J, Guyatt G, Sigamani A, Garutti I, et al.
615. GrocottMP,DushianthanA,HamiltonMA,MythenMG,HarrisonD,RowanK, Characteristicsandshort-termprognosisofperioperativemyocardialinfarction
etal.Perioperativeincreaseinglobalbloodflowtoexplicitdefinedgoalsandout- inpatientsundergoingnoncardiacsurgery:acohortstudy.AnnInternMed2011;
comesfollowingsurgery.CochraneDatabaseSystRev2012;11:CD004082. 154:523–528.
Downloaded
from
https://academic.oup.com/eurheartj/article/43/39/3826/6675076
by
guest
on
22
January
2026
--- Страница 98 ---
ESCGuidelines 3923
642.BorgesFK,DevereauxPJ.Physiciansshouldobtainperioperativecardiactroponin 666. Arsenault KA, Yusuf AM, Crystal E, Healey JS, Morillo CA, Nair GM, et al.
measurementsinat-riskpatientsundergoingnoncardiacsurgery.ClinChem2021; Interventionsforpreventingpost-operativeatrialfibrillationinpatientsundergoing
67:50–53. heartsurgery.CochraneDatabaseSystRev2013;2013:CD003611.
643.ThygesenK,AlpertJS,JaffeAS,ChaitmanBR,BaxJJ,MorrowDA,etal.Fourth 667. OzaydinM,IcliA,YucelH,AkcayS,PekerO,ErdoganD,etal.Metoprololvs.car-
Universal Definition of Myocardial Infarction (2018). Circulation 2018;138: vedilolorcarvedilolplusN-acetylcysteineonpost-operativeatrialfibrillation:a
e618–e651. randomized,double-blind,placebo-controlledstudy.EurHeartJ2013;34:597–604.
644.TodaH,NakamuraK,ShimizuK,EjiriK,IwanoT,MiyoshiT,etal.Effectsofbiso- 668. O’NealJB,BillingsF,LiuX,ShotwellMS,LiangY,ShahAS,etal.Effectofpreopera-
prololtransdermalpatchesforpreventionofperioperativemyocardialinjuryin tivebeta-blockeruseonoutcomesfollowingcardiacsurgery.AmJCardiol2017;
high-riskpatientsundergoingnon-cardiacsurgery:multicenterrandomizedcon- 120:1293–1297.
trolledstudy.CircJ2020;84:642–649. 669. Buckley MS, Nolan PE, Jr., Slack MK, Tisdale JE, Hilleman DE, Copeland JG.
645.DevereauxPJ,SzczeklikW.Myocardialinjuryafternon-cardiacsurgery:diagnosis Amiodaroneprophylaxisforatrialfibrillationaftercardiacsurgery:meta-analysis
andmanagement.EurHeartJ2020;41:3083–3091. ofdoseresponseandtimingofinitiation.Pharmacotherapy2007;27:360–368.
646.RuetzlerK,SmilowitzNR,BergerJS,DevereauxPJ,MaronBA,NewbyLK,etal. 670. RiberLP,ChristensenTD,JensenHK,HoejsgaardA,PilegaardHK.Amiodarone
Diagnosisandmanagementofpatientswithmyocardialinjuryafternoncardiacsur- significantlydecreasesatrialfibrillationinpatientsundergoingsurgeryforlungcan-
gery:AscientificstatementfromtheAmericanHeartAssociation.Circulation2021; cer.AnnThoracSurg2012;94:339–344;discussion345–336.
144:e287–e305. 671. TisdaleJE,WroblewskiHA,WallDS,RiegerKM,HammoudZT,YoungJV,etal.A
647.BorgesFK,ShethT,PatelA,MarcucciM,YungT,LangerT,etal.Accuracyofphy- randomizedtrialevaluatingamiodaroneforpreventionofatrialfibrillationafterpul-
siciansindifferentiatingtype1andtype2myocardialinfarctionbasedonclinical monaryresection.AnnThoracSurg2009;88:886–893;discussion894–885.
information.CJCOpen2020;2:577–584. 672. YuanX,DuJ,LiuQ,ZhangL.Definingtheroleofperioperativestatintreatmentin
648.GualandroDM,PuelacherC,LuratiBuseG,GlarnerN,CardozoFA,VogtR,etal. patientsaftercardiacsurgery:ameta-analysisandsystematicreviewof20rando-
Incidenceandoutcomesofperioperativemyocardialinfarction/injurydiagnosedby mizedcontrolledtrials.IntJCardiol2017;228:958–966.
high-sensitivitycardiactroponinI.ClinResCardiol2021;110:1450–1463.
673. ZhengZ,JayaramR,JiangL,EmbersonJ,ZhaoY,LiQ,etal.Perioperativerosuvas-
649.ParkJ,OhAR,KwonJH,KimS,KimJ,YangK,etal.Associationbetweencardiologist tatinincardiacsurgery.NEnglJMed2016;374:1744–1753.
evaluationandmortalityinmyocardialinjuryafternon-cardiacsurgery.Heart2021. 674. FairleyJL,ZhangL,GlassfordNJ,BellomoR.Magnesiumstatusandmagnesium
650.Devereaux PJ, Duceppe E,Guyatt G, TandonV, Rodseth R, Biccard BM, et al.
therapyincardiacsurgery:asystematicreviewandmeta-analysisfocusingonar-
Dabigatraninpatientswithmyocardialinjuryafternon-cardiacsurgery(MANAGE): rhythmiaprevention.JCritCare2017;42:69–77.
aninternational,randomised,placebo-controlledtrial.Lancet2018;391:2325–2334.
675. TabbalatRA,HamadNM,AlhaddadIA,HammoudehA,AkashehBF,KhaderY.
651.PonikowskiP,VoorsAA,AnkerSD,BuenoH,ClelandJGF,CoatsAJS,etal.2016 EffectofColchiciNeontheInciDenceofatrialfibrillationinopenheartsurgerypa-
ESCGuidelinesforthediagnosisandtreatmentofacuteandchronicheartfailure: tients:END-AFtrial.AmHeartJ2016;178:102–107.
theTaskForceforthediagnosisandtreatmentofacuteandchronicheartfailureof 676. WangW,MeiYQ,YuanXH,FengXD.Clinicalefficacyofepicardialapplicationof
theEuropeanSocietyofCardiology(ESC)developedwiththespecialcontribution drug-releasing hydrogels to prevent postoperative atrial fibrillation. J Thorac
oftheHeartFailureAssociation(HFA)oftheESC.EurHeartJ2016;37:2129–2200.
CardiovascSurg2016;151:80–85.
652.KonstantinidesSV,MeyerG,BecattiniC,BuenoH,GeersingGJ,HarjolaVP,etal. 677. DielemanJM,NierichAP,RosseelPM,vanderMaatenJM,HoflandJ,DiephuisJC,
2019ESCGuidelinesforthediagnosisandmanagementofacutepulmonaryem-
etal.Intraoperativehigh-dosedexamethasoneforcardiacsurgery:arandomized
bolismdevelopedincollaborationwiththeEuropeanRespiratorySociety(ERS). controlledtrial.JAMA2012;308:1761–1767.
EurHeartJ2020;41:543–603.
678. Whitlock RP, Devereaux PJ, Teoh KH, Lamy A, Vincent J, Pogue J, et al.
653.MartiC,JohnG,KonstantinidesS,CombescureC,SanchezO,LankeitM,etal.
Methylprednisoloneinpatientsundergoingcardiopulmonarybypass(SIRS):aran-
Systemicthrombolytictherapyforacutepulmonaryembolism:asystematicreview
andmeta-analysis.EurHeartJ2015;36:605–614.
domised,double-blind,placebo-controlledtrial.Lancet2015;386:1243–1253.
679. KoweyPR,DorianP,MitchellLB,PrattCM,RoyD,SchwartzPJ,etal.Vernakalant
654.NeelyRC,ByrneJG,GosevI,CohnLH,JavedQ,RawnJD,etal.Surgicalembolec-
hydrochloridefortherapidconversionofatrialfibrillationaftercardiacsurgery:a
tomyforacutemassiveandsubmassivepulmonaryembolisminaseriesof115pa-
tients.AnnThoracSurg2015;100:1245–1251;discussion1251–1242. randomized, double-blind, placebo-controlled trial. Circ Arrhythm Electrophysiol
2009;2:652–659.
655.ConenD,Alonso-CoelloP,DouketisJ,ChanMTV,KurzA,SigamaniA,etal.Riskof
strokeandotheradverseoutcomesinpatientswithperioperativeatrialfibrillation 680. GillinovAM,BagiellaE,MoskowitzAJ,RaitenJM,GrohMA,BowdishME,etal.Rate
1yearafternon-cardiacsurgery.EurHeartJ2020;41:645–651.
controlversusrhythmcontrolforatrialfibrillationaftercardiacsurgery.NEnglJ
656.AlTurkiA,MarafiM,ProiettiR,CardinaleD,BlackwellR,DorianP,etal.Majorad-
Med2016;374:1911–1921.
versecardiovasculareventsassociatedwithpostoperativeatrialfibrillationafter 681. SaxenaA,DinhDT,SmithJA,ShardeyGC,ReidCM,NewcombAE.Usefulnessof
postoperativeatrialfibrillationasanindependentpredictorforworseearlyandlate noncardiac surgery: a systematic review and meta-analysis. Circ Arrhythm
outcomesafterisolatedcoronaryarterybypassgrafting(multicenterAustralian Electrophysiol2020;13:e007437.
657.ChebboutR,HeywoodEG,DrakeTM,WildJRL,LeeJ,WilsonM,etal.Asystem-
studyof19,497patients).AmJCardiol2012;109:219–225.
aticreviewoftheincidenceofandriskfactorsforpostoperativeatrialfibrillation 682. Gialdini G, Nearing K, Bhave PD, Bonuccelli U, Iadecola C, Healey JS, et al.
followinggeneralsurgery.Anaesthesia2018;73:490–498. Perioperativeatrialfibrillationandthelong-termriskofischemicstroke.JAMA
658.AlbiniA,MalavasiVL,VitoloM,ImbertiJF,MariettaM,LipGYH,etal.Long-term
2014;312:616–622.
outcomesofpostoperativeatrialfibrillationfollowingnoncardiacsurgery:asys- 683. HorwichP,ButhKJ,LegareJF.Newonsetpostoperativeatrialfibrillationisasso-
tematicreviewandmetanalysis.EurJInternMed2021;85:27–33. ciated with a long-term risk for stroke and death following cardiac surgery.
659.HyunJ,ChoMS,NamGB,KimM,DoU,KimJ,etal.Naturalcourseofnew-onset
JCardSurg2013;28:8–13.
postoperativeatrialfibrillationafternoncardiacsurgery.JAmHeartAssoc2021;10: 684. AhlssonA,FengsrudE,BodinL,EnglundA.Postoperativeatrialfibrillationinpa-
e018548. tientsundergoingaortocoronarybypasssurgerycarriesaneightfoldriskoffuture
660.HeywoodEG,DrakeTM,BradburnM,LeeJ,WilsonMJ,LeeMJ.Atrialfibrillation atrialfibrillationandadoubledcardiovascularmortality.EurJCardiothoracSurg
aftergastrointestinalsurgery:incidenceandassociatedriskfactors.JSurgRes2019; 2010;37:1353–1359.
238:23–28. 685. ButtJH,XianY,PetersonED,OlsenPS,RorthR,GundlundA,etal.Long-term
661.LinMH,KamelH,SingerDE,WuYL,LeeM,OvbiageleB.Perioperative/post- thromboembolicriskinpatientswithpostoperativeatrialfibrillationaftercoronary
operativeatrialfibrillationandriskofsubsequentstrokeand/ormortality.Stroke arterybypassgraftsurgeryandpatientswithnonvalvularatrialfibrillation.JAMA
2019;50:1364–1371. Cardiol2018;3:417–424.
662.DobrevD,AguilarM,HeijmanJ,GuichardJB,NattelS.Postoperativeatrialfibrillation: 686. ButtJH,OlesenJB,Havers-BorgersenE,GundlundA,AnderssonC,GislasonGH,
mechanisms,manifestationsandmanagement.NatRevCardiol2019;16:417–436. etal.Riskofthromboembolismassociatedwithatrialfibrillationfollowingnoncar-
663.MathewJP,FontesML,TudorIC,RamsayJ,DukeP,MazerCD,etal.Amulticenter diacsurgery.JAmCollCardiol2018;72:2027–2036.
riskindexforatrialfibrillationaftercardiacsurgery.JAMA2004;291:1720–1729. 687. SelimM.Perioperativestroke.NEnglJMed2007;356:706–713.
664.VillarealRP,HariharanR,LiuBC,KarB,LeeVV,ElaydaM,etal.Postoperativeatrial 688. MacellariF,PaciaroniM,AgnelliG,CasoV.Perioperativestrokeriskinnonvascular
fibrillationandmortalityaftercoronaryarterybypasssurgery.JAmCollCardiol surgery.CerebrovascDis2012;34:175–181.
2004;43:742–748. 689. MashourGA,ShanksAM,KheterpalS.Perioperativestrokeandassociatedmortal-
665.CardinaleD,SandriMT,ColomboA,SalvaticiM,TedeschiI,BacchianiG,etal. ityafternoncardiac,nonneurologicsurgery.Anesthesiology2011;114:1289–1296.
Preventionofatrialfibrillationinhigh-riskpatientsundergoinglungcancersurgery: 690. NgJL,ChanMT,GelbAW.Perioperativestrokeinnoncardiac,nonneurosurgical
thePRESAGETrial.AnnSurg2016;264:244–251. surgery.Anesthesiology2011;115:879–890.
Downloaded
from
https://academic.oup.com/eurheartj/article/43/39/3826/6675076
by
guest
on
22
January
2026
--- Страница 99 ---
3924 ESCGuidelines
691. WalickaM,TuszynskaA,ChlebusM,SanchakY,SliwczynskiA,BrzozowskaM,etal. 699. MinchinM,RolandM,RichardsonJ,RowarkS,GuthrieB.QualityofcareintheUnited
Predictorsofin-hospitalmortalityinsurgicalwards:amultivariableretrospective Kingdomafterremovaloffinancialincentives.NEnglJMed2018;379:948–957.
cohortanalysisof2,800,069hospitalizations.WorldJSurg2021;45:480–487. 700. SongZ,JiY,SafranDG,ChernewME.Healthcarespending,utilization,andquality
692. MattinglyAS,LermanBJ,PopatR,WrenSM.Associationofsexwithpostoperative 8yearsintoglobalpayment.NEnglJMed2019;381:252–263.
mortalityamongpatientswithheartfailurewhounderwentelectivenoncardiacop- 701. ArbeloE,AktaaS,BollmannA,D’AvilaA,DrossartI,DwightJ,etal.Qualityindi-
erations.JAMANetwOpen2019;2:e1914420. catorsforthecareandoutcomesofadultswithatrialfibrillation.Europace2021;23:
693. WorldHealthOrganization.Prevalenceofanaemiainwomenofreproductiveage 494–495.
(aged15–49)(%).In:GlobalHealthObservatory.Geneva:WorldHealthOrganiziation; 702. SchieleF,AktaaS,RosselloX,AhrensI,ClaeysMJ,ColletJP,etal.2020Updateof
2022.https://www.who.int/data/gho/data/indicators/indicator-details/GHO/prevalence- the quality indicators for acute myocardial infarction: a position paper of the
of-anaemia-in-women-of-reproductive-age-(-) AssociationforAcuteCardiovascularCare:thestudygroupforqualityindicators
694. GombotzH,SchreierG,NeubauerS,KastnerP,HofmannA.Genderdisparitiesin fromtheACVCandtheNSTE-ACSguidelinegroup.EurHeartJAcuteCardiovasc
redbloodcelltransfusioninelectivesurgery:aposthocmulticentrecohortstudy. Care2021;10:224–233.
BMJOpen2016;6:e012210. 703. AktaaS,AbdinA,ArbeloE,BurriH,VernooyK,Blomstrom-LundqvistC,etal.
695. RiesenhuberM,SpannbauerA,RauschaF,SchmidingerH,BoszottaA,PezawasT, EuropeanSocietyofCardiologyQualityIndicatorsforthecareandoutcomesof
etal.Sexdifferencesandlong-termoutcomeinpatientswithpacemakers.Front cardiac pacing: developed by the Working Group for Cardiac Pacing Quality
CardiovascMed2020;7:569060. IndicatorsincollaborationwiththeEuropeanHeartRhythmAssociationofthe
696. VarmaN,MittalS,PrillingerJB,SnellJ,DalalN,PicciniJP.Survivalinwomenversus EuropeanSocietyofCardiology.Europace2022;24:165–172.
menfollowingimplantationofpacemakers,defibrillators,andcardiacresynchroniza- 704. Corrigendumto:2020ESCGuidelinesforthemanagementofacutecoronarysyn-
tiontherapydevicesinalarge,nationwidecohort.JAmHeartAssoc2017;6:e005031. dromesinpatientspresentingwithoutpersistentST-segmentelevation:theTask
697. FangMC,SingerDE,ChangY,HylekEM,HenaultLE,JensvoldNG,etal.Gender Forceforthemanagementofacutecoronarysyndromesinpatientspresenting
differencesintheriskofischemicstrokeandperipheralembolisminatrialfibrilla- withoutpersistentST-segmentelevationoftheEuropeanSocietyofCardiology
tion: the AnTicoagulation and Risk factors In Atrial fibrillation (ATRIA) study. (ESC).EurHeartJ2021;42:2298.
Circulation2005;112:1687–1691. 705. Batra G, Aktaa S, Wallentin L, Maggioni AP, Wilkinson C, Casadei B, et al.
698. AktaaS,BatraG,WallentinL,BaigentC,ErlingeD,JamesS,etal.EuropeanSociety Methodologyforthedevelopmentofinternationalclinicaldatastandardsforcom-
ofCardiologymethodologyforthedevelopmentofqualityindicatorsforthequan- mon cardiovascular conditions: European Unified Registries for Heart Care
tificationofcardiovascularcareandoutcomes.EurHeartJQualCareClinOutcomes Evaluation and Randomised Trials (EuroHeart). Eur Heart J Qual Care Clin
2022;8:4–13. Outcomes2021:qcab052.
Downloaded
from
https://academic.oup.com/eurheartj/article/43/39/3826/6675076
by
guest
on
22
January
2026
